TW202311292A - Cdh3與cd3之雙特異性抗體構築體 - Google Patents
Cdh3與cd3之雙特異性抗體構築體 Download PDFInfo
- Publication number
- TW202311292A TW202311292A TW111129622A TW111129622A TW202311292A TW 202311292 A TW202311292 A TW 202311292A TW 111129622 A TW111129622 A TW 111129622A TW 111129622 A TW111129622 A TW 111129622A TW 202311292 A TW202311292 A TW 202311292A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- cdr
- cancer
- cdh3
- human
- Prior art date
Links
- 101100004988 Caenorhabditis elegans cdh-3 gene Proteins 0.000 title description 4
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims abstract description 281
- 241000282414 Homo sapiens Species 0.000 claims abstract description 267
- 230000027455 binding Effects 0.000 claims abstract description 258
- 210000004027 cell Anatomy 0.000 claims abstract description 226
- 238000000034 method Methods 0.000 claims abstract description 118
- 102000048587 human CDH3 Human genes 0.000 claims abstract description 78
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 74
- 239000013598 vector Substances 0.000 claims abstract description 22
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 20
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 20
- 239000002157 polynucleotide Substances 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 102100024153 Cadherin-15 Human genes 0.000 claims description 202
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims description 202
- 206010028980 Neoplasm Diseases 0.000 claims description 124
- 201000011510 cancer Diseases 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 65
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 65
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 32
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 13
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 241001515942 marmosets Species 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 241000282695 Saimiri Species 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010000830 Acute leukaemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006143 Brain stem glioma Diseases 0.000 claims description 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 4
- 208000024207 chronic leukemia Diseases 0.000 claims description 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 201000002575 ocular melanoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000003708 skin melanoma Diseases 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 3
- 230000002183 duodenal effect Effects 0.000 claims description 2
- 210000001198 duodenum Anatomy 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 2
- 241000288950 Callithrix jacchus Species 0.000 claims 1
- 241000288960 Saguinus oedipus Species 0.000 claims 1
- 241000282696 Saimiri sciureus Species 0.000 claims 1
- 208000037959 spinal tumor Diseases 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 141
- 102000004169 proteins and genes Human genes 0.000 description 122
- 235000018102 proteins Nutrition 0.000 description 117
- 108090000765 processed proteins & peptides Proteins 0.000 description 99
- 235000001014 amino acid Nutrition 0.000 description 87
- 108091007433 antigens Proteins 0.000 description 80
- 102000036639 antigens Human genes 0.000 description 80
- 239000000427 antigen Substances 0.000 description 79
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 78
- 239000000203 mixture Substances 0.000 description 74
- 229940024606 amino acid Drugs 0.000 description 69
- 150000001413 amino acids Chemical class 0.000 description 62
- 241000282553 Macaca Species 0.000 description 58
- 102000004196 processed proteins & peptides Human genes 0.000 description 57
- 239000003814 drug Substances 0.000 description 52
- 125000005647 linker group Chemical group 0.000 description 45
- 238000003556 assay Methods 0.000 description 44
- 229920001184 polypeptide Polymers 0.000 description 43
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 42
- 229940079593 drug Drugs 0.000 description 40
- 238000009472 formulation Methods 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 34
- 108060003951 Immunoglobulin Proteins 0.000 description 34
- 239000012636 effector Substances 0.000 description 34
- 102000018358 immunoglobulin Human genes 0.000 description 34
- -1 oxaliplatin Chemical compound 0.000 description 32
- 238000006467 substitution reaction Methods 0.000 description 32
- 231100000491 EC50 Toxicity 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 239000012634 fragment Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 241000282412 Homo Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 27
- 241000282567 Macaca fascicularis Species 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 239000011230 binding agent Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 150000007523 nucleic acids Chemical group 0.000 description 23
- 241000894007 species Species 0.000 description 23
- 239000000539 dimer Substances 0.000 description 22
- 239000000178 monomer Substances 0.000 description 21
- 230000004048 modification Effects 0.000 description 20
- 238000012986 modification Methods 0.000 description 20
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 19
- 239000011651 chromium Substances 0.000 description 19
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 210000004602 germ cell Anatomy 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 230000001472 cytotoxic effect Effects 0.000 description 18
- 238000002784 cytotoxicity assay Methods 0.000 description 18
- 231100000263 cytotoxicity test Toxicity 0.000 description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 17
- 241000283984 Rodentia Species 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 17
- 230000004927 fusion Effects 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 239000003755 preservative agent Substances 0.000 description 17
- 230000003013 cytotoxicity Effects 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 16
- 229940000406 drug candidate Drugs 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000004071 biological effect Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002502 liposome Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 14
- 108091006905 Human Serum Albumin Proteins 0.000 description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 14
- 241000288906 Primates Species 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 102000008100 Human Serum Albumin Human genes 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 241001529936 Murinae Species 0.000 description 13
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229910052804 chromium Inorganic materials 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 230000013595 glycosylation Effects 0.000 description 11
- 238000006206 glycosylation reaction Methods 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 230000036515 potency Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- 241000282560 Macaca mulatta Species 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 229920005862 polyol Polymers 0.000 description 8
- 150000003077 polyols Chemical class 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102100025805 Cadherin-1 Human genes 0.000 description 7
- 102100036364 Cadherin-2 Human genes 0.000 description 7
- 102100029758 Cadherin-4 Human genes 0.000 description 7
- 102100029761 Cadherin-5 Human genes 0.000 description 7
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 101000794580 Homo sapiens Cadherin-4 Proteins 0.000 description 7
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 241000282577 Pan troglodytes Species 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 235000004400 serine Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 101000777071 Homo sapiens Chromodomain-helicase-DNA-binding protein 3 Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 241000235649 Kluyveromyces Species 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229960003646 lysine Drugs 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 235000013930 proline Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 102100031266 Chromodomain-helicase-DNA-binding protein 3 Human genes 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102000003839 Human Proteins Human genes 0.000 description 5
- 108090000144 Human Proteins Proteins 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 238000012867 alanine scanning Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 235000004554 glutamine Nutrition 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229940068965 polysorbates Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000008521 threonine Nutrition 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000255789 Bombyx mori Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 238000012452 Xenomouse strains Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000012537 formulation buffer Substances 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 235000006109 methionine Nutrition 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 238000013391 scatchard analysis Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
- 244000285963 Kluyveromyces fragilis Species 0.000 description 3
- 241001138401 Kluyveromyces lactis Species 0.000 description 3
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 101100268518 Mus musculus Serpina1e gene Proteins 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108010086890 R-cadherin Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000009831 antigen interaction Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 238000009781 safety test method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 239000012443 tonicity enhancing agent Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 241000256118 Aedes aegypti Species 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101000984015 Homo sapiens Cadherin-1 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101100004990 Mus musculus Cdh3 gene Proteins 0.000 description 2
- 101100268514 Mus musculus Serpina1a gene Proteins 0.000 description 2
- 101100268515 Mus musculus Serpina1b gene Proteins 0.000 description 2
- 101100268516 Mus musculus Serpina1c gene Proteins 0.000 description 2
- 101100268517 Mus musculus Serpina1d gene Proteins 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006043 T cell recruitment Effects 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009583 bone marrow aspiration Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- ZACLXWTWERGCLX-MDUHGFIHSA-N dom-1 Chemical compound O([C@@H]1C=C(C([C@@H](O)[C@@]11CO)=O)C)[C@@H]2[C@H](O)C[C@@]1(C)C2=C ZACLXWTWERGCLX-MDUHGFIHSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 102000047933 human CDH1 Human genes 0.000 description 2
- 102000048721 human CDH2 Human genes 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000009938 salting Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- SPSSULHKWOKEEL-UHFFFAOYSA-N 2,4,6-trinitrotoluene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O SPSSULHKWOKEEL-UHFFFAOYSA-N 0.000 description 1
- RLFZYIUUQBHRNV-UHFFFAOYSA-N 2,5-dihydrooxadiazole Chemical compound C1ONN=C1 RLFZYIUUQBHRNV-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- CRTWOYOCILXSSX-UHFFFAOYSA-N 2-bromo-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)C(Br)CC1=CN=CN1 CRTWOYOCILXSSX-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- VIIIJFZJKFXOGG-UHFFFAOYSA-N 3-methylchromen-2-one Chemical compound C1=CC=C2OC(=O)C(C)=CC2=C1 VIIIJFZJKFXOGG-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100279566 Arabidopsis thaliana EMB514 gene Proteins 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 101000968267 Drosophila melanogaster Protein dachsous Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101000847522 Escherichia coli F7-1 fimbrial protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000943088 Homo sapiens Choline dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091062154 Mir-205 Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000024306 antigen processing and presentation of peptide antigen Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000017484 calcium-dependent cell-cell adhesion Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 102000049207 human CHD3 Human genes 0.000 description 1
- 108700005872 human Fv Proteins 0.000 description 1
- 102000056549 human Fv Human genes 0.000 description 1
- 102000049018 human NCAM1 Human genes 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000011294 monotherapeutic Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940063137 norditropin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002384 proinvasive effect Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 102200055464 rs113488022 Human genes 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 239000000015 trinitrotoluene Substances 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本發明是有關於一種雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3的第一人類結合域以及結合至T細胞表面上之人類CD3的第二結合域。此外,本發明提供一種編碼該抗體構築體的聚核苷酸、包含該聚核苷酸的載體以及經該聚核苷酸或載體轉形或轉染的宿主細胞。另外,本發明提供一種用於生產本發明抗體構築體的方法、一種該抗體構築體的醫學用途以及一種包含該抗體構築體的套組。
Description
本發明是有關於一種雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3的第一人類結合域以及結合至T細胞表面上之人類CD3的第二結合域。此外,本發明提供一種編碼該抗體構築體的聚核苷酸、包含該聚核苷酸的載體以及經該聚核苷酸或載體轉形或轉染的宿主細胞。另外,本發明提供一種用於生產本發明抗體構築體的方法、一種該抗體構築體的醫學用途以及一種包含該抗體構築體的套組。
在人類中,黏附蛋白(cadherin)超家族含括超過100個成員,包括所謂的典型黏附蛋白P黏附蛋白、E黏附蛋白、N黏附蛋白以及R黏附蛋白,其每一者在一組獨立組織中是活化的(Takeichi M. Development, 102:639-55(1988)、van Roy F., Nature Rev., V14:121-134 (2014))。黏附蛋白尤其在成體組織與器官發育時,還有在各種組織的穩態中扮演不可或缺的角色(Conacci-Sorrell M, et al., J Clin Invest, 109:987-91, (2002))。黏附蛋白是穿膜醣蛋白,透過形成鈣依賴性接合還有透過將機械刺激轉化成電化學活性(一種稱為機械傳導的過程)來調節細胞-細胞黏附過程(Gumbiner J. Cell. Biol., 148:399-404 (2000);Yagi, et al., Genes Dev., 14:1169-1180 (2000, Parades et al. Biochimica et Biophysica Acta 1826, 297-311 (2012))。
胎盤黏附蛋白(P黏附蛋白),又已知為鈣依賴性細胞-細胞黏附蛋白3 (CDH3),是一個118 kDa的蛋白質,具有一個約800個胺基酸的大胞外域(ECD)。CDH3 ECD包含五個黏附蛋白重複序列,在本文中命名為(胞外)域1-5/ Dom1-Dom5 / D1-D5,各自由約110個胺基酸所組成。與P黏附蛋白具有最高序列同源性的蛋白質是E黏附蛋白(序列同源性為53%)以及N黏附蛋白(序列同源性為39%)。
在健康成年個體中的P黏附蛋白表現位準被認為是低的,且在層狀上皮的基底或較低層的表現有限,層狀上皮包括前列腺及皮膚、乳房肌上皮細胞(Takeichi M. J Cell Biol 103:2649-58, (1986)與Shimoyama Y, et al., Cancer Res, 49:2128-33(1989))。在基因剔除小鼠中,儘管P黏附蛋白功能喪失並不會致死,但已顯示與發育缺陷,還有乳房上皮的增生及發育不良有關聯(G.L. Radice et al. J. Cell Biol. 139: 1025–1032 (1997))。
相對於P黏附蛋白在健康個體中的基因表現低,P黏附蛋白在一些疾病中的表現上調,這些疾病包括免疫疾病,像是克隆氏病及結腸炎(Hardy, et al., Gut 50:513-519 (2002))。此外,就癌細胞的前侵襲性特性來說,P黏附蛋白被認為是扮演重大角色(Furukawa, et al., Microscopy Res. Technique 38 (4):343-352 (1997)、Parades et al. Clin Cancer Res. 11(16), 5869-5877 (2005)、Parades et al. Biochimica et Biophysica Acta 1826, 297-311 (2012))。在各種腫瘤中已描述過P黏附蛋白上調,這些腫瘤包括結腸直腸癌、肺癌(NSCLC)、乳癌(三陰性)、胰臟癌、頭頸癌、甲狀腺癌、子宮頸癌、卵巢癌及胃癌(Milic et al. Cancer Res 68: (19) 7760-7768 (2008)、Imai et al. Clin Cancer Res 14(20) 6487-6495 (2008)、Paredes et al Clin Cancer Res 11 (16) 5869-5877 (2005)、Dasgupta et al. Oral Oncology 42, 306–316 (2006)、Jarzab et al. Cancer Res; 65: (4) 1587-1597 (2005)、Patel et al. Int. J. Cancer: 106, 172–177 (2003)、Kim et al. Human Pathology 41, 877–885 (2010))。此外,發現到P黏附蛋白表現增加與各種類型癌症患者的低存活率相關聯(Sun L et al. Am J Pathol. 2011; 179:380-90;Gamallo, Modern Pathology, 14:650-654, (2001);Stefansson, et al., J. Clin. Oncol. 22(7):1242-1252 (2004)、Parades et al. Cancer Res. 64, 8309-8317 (2004))、Taniuchi K et al. Cancer Res. 2005; 65:3092-9;Paredes J et al. Clin Cancer Res. 2005; 11:5869-77;Hardy RG et al. Gut. 2002; 50:513-9;Peralta Soler A et al. Cancer. 1999; 86:1263-72)。
在非傳染性疾病分類中,贅瘤在致死疾病中排名第二,排在心血管疾病之後,於2013年造成全球有830萬例死亡(GBD 2013 Lancet 2015; 385: 117–71)。自1990年起,癌症病例的實際數目增加達45.6%,可能是因為全球人口增加,人類變得更老且已確立的風險因子的盛行(例如吸菸、過重、體能活動不足)也增加所致(GBD 2013 Lancet 2015; 385: 117–71、Torre LA et al. CA Cancer J Clin. 2015; 65:87-108)。在男性中,肺癌是主要死因,每年估計約有110萬個病例,接著是肝癌與胃癌。在女性中,乳癌是主要死因,每年約有50萬個病例,接著是肺癌與結腸癌。在2012年,全世界估計有一千四百萬個新增癌症病例,男性肺癌有約120萬個病例,而女性乳癌約170萬個病例(Torre LA et al. CA Cancer J Clin. 2015; 65:87-108)。總而言之,癌症在全世界對於社會造成極大負擔,且對於要對抗這個疾病的治療選項有高度需求。
治療癌症的常見策略涉及外科手術,然後是化學療法、放射線療法或最近的標靶療法或其組合(例如腫瘤學的NCCN指引)。化療劑含括核苷酸類似物(像是5-氟尿嘧啶(5-FU))、DNA損傷劑(諸如奧沙利鉑)以及拓樸異構酶抑制劑(像是依立替康(irinotecan))或微管抑制劑(諸如歐洲紫杉醇(docetaxel)),它們全都會抑制腫瘤細胞增生。標靶療法包括例如小分子化合物,其選擇性抑制突變的致癌激酶,像是BRAF V600E選擇性化合物維羅非尼(vemurafenib) (Garbe C. et al Recent Results Cancer Res. 2014;201:215-25)經核准用於治療黑色素瘤,或者是退行性淋巴瘤激酶(ALK)抑制劑克唑替尼(crizotinib)與色瑞替尼(ceritinib)經核准用於治療肺癌(Pall G. Curr Opin Oncol. 2015; 27:118-24)。此外,有像是以抗體為基礎的化合物,例如西妥昔單抗(cetuximab)以及帕尼單抗(panitumumab),它們辨識並不活化上皮生長因子受體(EGFR)且其經核准用於治療KRAS野生型結腸癌(Tol J, Punt CJ. Clin Ther. 2010; 32:437-53);或曲妥珠單抗(trastuzumab),其辨識Her2並經核准用於乳癌療法 (Ahmed S. et al. Breast Cancer. 2015; 22:101-16)。
儘管開發了廣泛範圍的治療干涉手段,但除了偶發病例以外,這種異質性疾病並無對策可用。個別腫瘤的異質性造成僅僅有限數目的患者會對某些療法有反應,並且進一步在腫瘤進展期間對治療劑產生抗性(Jamal-Hanjani M. et al Clin Cancer Res. 2015; 21:1258-1266)。最後,儘管新近開發的標靶療法似乎耐受更好,但藥物副作用也會造成治療中斷或終止(http://www.cancer.net/navigating-cancer-care/how-cancer-treated/chemotherapy/side-effects-chemotherapy;Sun GC et al. Anticancer Agents Med Chem. 2015 Mar 17. [印刷前線上公開])。
因此,對於開發新藥物仍然有高度醫學需求。
CDH3在腫瘤細胞中的過度表現為治療癌症的新方法提供了一個基礎,透過使用雙特異性抗體,其辨識過度表現CDH3之腫瘤細胞並藉由使被此抗體之CD3結合部分所辨識之細胞毒性T細胞重新改向來殺滅它們。
已在RNA層次或在蛋白質層次使用初步免疫組織化學進行表現分析,證明CDH3在廣泛範圍的不同癌症類型中以高度且可充分偵測的位準表現,癌症類型包括結腸癌(Milic et al.、Kita et al、Imai et al.、http://www.proteinatlas.org/)、肺癌(包括非小細胞肺癌與小細胞肺癌) (Imai et al, human protein atlas)、乳癌(較佳為三陰性乳癌) (Perou et al、Paredes et al、Turashvili et al、Imai et al.)、胰臟癌(Imai et al.、Taniuchi et al )、頭頸癌(包括鱗狀細胞癌或舌癌) (Dasgupta et al;本身未公開數據)、甲狀腺癌(Jarzab et al、Rocha et al.、human protein atlas)、子宮頸癌(Imai et al.、Han et al.)、卵巢癌(較佳為第II期或以上) (Patel et al human proeion atlas)、胃癌(Kim et al;Imai et al )、子宮內膜癌(Sugiyama Y et al. Clin Cancer Res. 2003; 9:5589-600;human protein atlas)、膽管癌(Baek S et al. Anat Cell Biol. 2010; 43:110-7;Imai et al)、膀胱癌(Imai et al,本身未公開數據)、前列腺癌(Imai et al;本身未公開數據)、睪丸癌(Imai et al)、軟組織肉瘤(Imai et al )、食道癌(本身未公開數據)、腎臟癌(本身未公開數據)。
將來的分析可能會證明,在其他腫瘤或其子類中的表現升高,然後對這樣的一種療法來說也可能變得意義重大。舉例而言,Fotouhi等人證明,在小腸神經內分泌腫瘤中的CDH3啟動子甲基化降低可能會使得CDH3蛋白表現升高(Fotouhi O et al. Epigenetics. 2014; 9:987-97)。在CDH3與miR-205 (一種微RNA,似乎是鱗狀肺細胞癌的一個特異性標記)的表現升高間觀察到正向相關性(Huang W et al. Chin Med J (Engl). 2014; 127:272-8)。
相對於CDH3在腫瘤組織中的表現升高,CDH3在正常組織中的表現是低的或不能被偵測到(Milic et al.、Imai et al、Taniuchi et al、Rocha et al、Dasgupta et al、Han et al、Patel.、Kim et al、Sugiyma et al、Jarzab et al.、human protein atlas)。總結來說,就所提議的雙特異性抗體方法來說,此為CDH3是適宜目標的證據。
在以下專利中已描述過各種結合至P黏附蛋白的抗體且大多經充分特徵鑑定並已公開:WO9919477、WO02/097395、WO04/110345、WO06/114704、WO07/102525、WO2010/001585、WO2010126137;WO2010054007、WO2011056997、WO2011080796、WO2011071541。
在技藝中已知一些抗體(諸如抗CDH3抗體PF-03732010)會阻斷CDH3的功能,例如是透過干擾CDH3的黏附特性(Zhang CC et al. Clin Cancer Res. 2010; 16:5177-88)。這個抗體在活體外會造成3D球狀體瓦解,伴隨著胞內信號傳遞改變,諸如β-鏈蛋白在奈莫耳濃度下解離,但不會抑制增生。於10 mg/kg劑量下且依照這個方式,在臨床前模型中觀察到抑制活體內腫瘤生長與形成轉移還有存活期延長,這取決於CDH3的表現位準。在機械上,不能排除活體內抗腫瘤效用是受到抗體依賴性細胞之細胞毒性(ADCC)的過程所媒介,而ADCC涉及了透過細胞毒性T細胞結合至免疫球蛋白之Fc域來殺滅細胞。這樣的一個作用機制歸因於一些已提出請求的抗CDH3抗體。雖然已描述過阻斷P黏附蛋白活性作為抑制表現P黏附蛋白之腫瘤生長的一個方法,但所達到的結果經常不盡如人意,因為它們延遲腫瘤生長或充其量只是促使腫瘤停滯,但不會消除腫瘤。
為了增進抗體對腫瘤生長的抑制效用,可將抗體結合至細胞毒性或細胞生長抑制劑(例如化療劑、毒素、放射性同位素或類似物),產生抗體藥物結合物(ADC)或廣義為免疫結合物(immunoconjugates)。免疫結合物容許將藥物部分靶定投遞至腫瘤,並在細胞內累積。就殺滅腫瘤細胞來說,此等免疫結合物的效力大部分取決於各種參數,像是目標分子的內化行為還有個別免疫結合物的作用模式,而目標分子通常是位在細胞膜內且具有胞外域。總而言之,已顯示偶接至免疫結合物會明顯提高各種抗體的抗腫瘤效力。
更新近之結合至目標分子還有T細胞的雙特異性分子已顯示有令人滿意的結果,規避上述缺點中的許多者。這些藥物分子不依賴於完全阻斷目標功能或目標細胞增生狀態,因為它們採用T細胞之相當有效的天然殺滅效用。此類雙特異性分子的一個實例為雙特異性抗目標x抗-CD3單鏈抗體構築體,其先前已顯示會媒介目標細胞之高效率T細胞相關殺滅,參見例如布林度莫單抗(Blinatumomab)。
為了區別雙特異性scFv分子,必須滿足最終有助於治癒患者的良好藥品的不同標準。這些標準的組合及嚴苛程度使得能滿足這些要求的分子微乎其微且無法預測。最明顯的標準是藥物候選物的效率。
此等分子的效率取決於雙特異性分子之目標結合域還有T細胞招募部分上的多種參數。尤其是雙特異性scFv分子的目標結合部分無法預測,因為它們改變非常大,端視目標分子的本質而定,包括其三級與四級結構。在效率限制參數中,目標與雙特異性結合分子之間還有實際結合區的結合動力學(所謂結合表位)扮演主要角色。
抗-CDH3單株抗體(通常亦適用於任何其他單株抗體)是以高特異性辨識其目標分子的方式發生作用。它們只會辨識其目標CDH3分子上的單一位點或表位。此外,已發現許多抗體以物種特異性的方式展現其功能。但是,這個物種特異性不只是CDH3單株抗體(及其片段)所固有的,單株抗體大體上都有,對於其開發作為用以治療人類疾病的治療劑來說是一個明顯阻礙。為了要獲得上市核准,任一種新的候選醫藥必須通過嚴格測試。這個測試分成臨床前階段以及臨床階段;而後者是在人類患者體內進行,前者是在動物體內進行。臨床前測試之目的在於證明藥物候選物具有所需活性且最重要是安全。只有當在臨床前測試時已確立在動物體內的安全性還有藥物候選物的可行有效性,這個藥物候選物才最有可能被個別管理機關獲准用於人類臨床測試。可以依照以下三種方式針對安全性在動物體內測試藥物候選物:(i)在相關物種(亦即藥物候選物可辨識異種同源抗原的物種中)、(ii)在含有人類抗原的基因轉殖動物中,以及(iii)透過使用藥物候選物的代用品,其可結合動物體內存在的異種同源抗原。基因轉殖動物的限制條件在於這個技術通常僅限於囓齒動物。囓齒動物與人類之間在生理學上有明顯差異,而安全性結果可能無法輕易就推演至人類。藥物候選物之代用品的限制條件在於物質組成與實際藥物候選物不同,且所使用的動物通常為囓齒動物,有如上述的限制條件。因此,在囓齒動物中所產生的臨床前數據對藥物候選物的預測有效度有限。
針對安全性測試選用的方法是使用相關物種,較佳為靈長動物,且因為遺傳相似性較佳為黑猩猩。但是,黑猩猩被認為是瀕危物種且因為牠們與人類相似的特質,在歐洲已禁止將這些動物用於藥物安全性測試且在其他地方也受到高度限制。
儘管技藝中所述之接合T細胞的雙特異性單鏈抗體在治療惡性疾病方面有很高的治療潛力,但大多數的這些雙特異性分子具有限制性,因為它們具有物種特異性且僅會辨識人類抗原,還可能會辨識靈長動物抗原(亦即獼猴對應物)。此外,大多數該等雙特異性分子進一步受到限制,因為它們無法跨過物種界線發揮其所需功能,使得它們可辨識人類與靈長動物異種同源物,但無法展現出例如T細胞媒介細胞毒性。
因為對於有更多可利用選擇以供治療本文揭示之各種癌症類型仍有需求,故提供用於解決這個問題的手段及方法,其呈雙特異性抗體構築體的形式,具有一個針對CDH3的結合域以及一個針對T細胞上之CD3的第二結合域。
在第一態樣中,本發明提供雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3表位簇的第一較佳人類結合域,並包含結合至T細胞表面上之人類CD3的第二較佳人類結合域,其中人類CDH3的表位簇內含在人類CDH3的胺基酸位置291-363 (SEQ ID NO: 36)中。
在本發明的一個較佳具體例中,雙特異性抗體構築體的特徵在於該第一結合域也結合至獼猴CDH3,較佳結合至食蟹獼侯CDH3。
這個橫跨物種的功能性代表相同分子可用於臨床前動物研究還有人類的臨床研究中。相較於物種特異性代用品分子,這在動物研究中產生高度相當的結果還有大幅增加預測有效性。因為本發明CDH3xCD3雙特異性抗體構築體的CD3與CDH3結合域具有跨物種特異性及功能性(亦即與人類抗原及獼猴抗原反應展現出相當的T細胞媒介細胞毒性效用),可用於在臨床前評估這些結合域在靈長動物與(以相同形式)人類體內作為藥物的安全性、活性及/或藥動學概況。應理解,在較佳具體例中,本發明抗體構築體的第一結合域及第二結合域的跨物種特異性相同。
以上文觀點來說,對於構築代用品CDH3xCD3雙特異性抗體構築體以供在種系距離(始於人類)物種中測試的需求消失了。因此,相同分子可用於動物臨床前測試,如同要在臨床測試還有後續上市核准和治療藥物投與被投與給人類者相同。如同在之後投與給人類般,在臨床前動物測試使用相同分子的能力實際上消除或至少大幅減少在臨床前動物測試中獲得之數據在人類病例中之實用性有限的危險。簡言之,在動物體內使用相同分子獲得如同實際投與給人類的臨床前安全性數據更確認數據對人類相關譜系的實用性。相反來說,在使用代用品分子的習知方法中,該代用品分子必須在分子上調整成臨床前全性評估使用的動物測試系統。因此,要在人類療法中使用的分子事實上就序列來說不同於臨床前測試的藥動學參數及/或生物活性中使用之代用品分子,而且還可能在結構上不同,結果在臨床前動物測試中所得數據至人類病例實用性I可轉移性有限。使用代用品分子需要構築、生產、純化並特徵鑑定一個嶄新的構築體。這產生了獲得那個分子所需的額外開發成本與時間。總結來說,除了用於人類療法的實際藥物以外,必須個別開發出代用品,必須進行兩種分子的兩條開發線。因此,表現本文所述跨物種特異性與功能性(亦即反應性)之本發明人類CDH3xCD3雙特異性抗體構築體的一個主要優點是,相同分子可用於人類及臨床前測試中的治療劑。
使用本發明跨物種特異性CDH3xCD3雙特異性抗體構築體,不再需要使測試動物適應要被投與給人類的藥物候選物,諸如例如創造基因轉殖動物。較佳地,依據本發明用途及方法,表現跨物種特異性及反應性之本發明CDH3xCD3雙特異性抗體構築體可直接用於非黑猩猩靈長動物(像是獼猴)的臨床前測試,而不需要任何動物基因操作。如習於技藝者所熟知,要使測試動物適應藥物候選物的方法總是會有在臨床前安全性測試所得到的結果對人類來說較不具代表性與預測性的風險,因為動物的修改。例如,在基因轉殖動物中,由轉基因所編碼的蛋白質通常會過度表現。因此,抗體對這個蛋白抗原的生物活性所得到的數據就其人類預測值有限,其中蛋白質在人類體內以更低、更為生理學的位準表現。
較佳地,本發明人類CDH3xCD3雙特異性抗體構築體的又一個優點在於,當使用該抗體做為動物臨床前測試的一部分時(例如在藥動學動物研究的過程中),能夠抽取多個血液樣品。使用非黑猩猩靈長動物比使用低等動物(例如小鼠)要更容易獲得多次抽血。抽取多個血液樣品容許連續測試血液參數,以供測定本發明CDH3xCD3雙特異性抗體構築體所引起的生物學效用。此外,抽取多個血液樣品能夠讓研究人員評估如本文定義之本發明(較佳為人類) CDH3xCD3雙特異性抗體構築體的藥動學概況。另外,可在投與本發明CDH3xCD3雙特異性抗體構築體期間抽取的不同血液樣品中測量潛在副作用,而潛在副作用是由該抗體引起並反映在血液參數中。
展現跨物種特異性之如本文所定義的本發明CDH3xCD3雙特異性抗體構築體的優點可簡要歸納如下:
首先,在臨床前測試中使用的如本文所定義之本發明CDH3xCD3雙特異性抗體構築體與在人類療法中使用者相同。因此,不再需要開發兩種在藥動學特徵及生物學活性上有所差異的獨立分子。這非常有利,因為例如藥動學結果可以比例如習知代用品方法更為直接轉換並應用至人類狀態。
其次,使用如本文定義之本發明CDH3xCD3雙特異性抗體構築體來製備人類治療劑比代用品方法省錢且不費工。
第三,如本文定義之本發明CDH3xCD3雙特異性抗體構築體不但可用於一種靈長動物物種的臨床前測試,還可用於一系列不同靈長動物物種的臨床前測試,從而限制不同靈長動物與人類的潛在物種差異性風險。
第四,若需要的話,動物測試可避免使用黑猩猩,因為黑猩猩是瀕危物種。
第五,可抽取多個血液樣品用於大規模藥動學研究。
第六,有鑑於依據本發明之一個較佳具體例的抗體構築體為人類來源,當被投與給人類患者時產生對抗該結合分子的免疫反應被降至最低。排除用對衍生自非人類物種(例如小鼠)之藥物候選物具有專一性之抗體誘發的免疫反應,其產生對抗鼠類來源之治療分子的人類抗小鼠抗體(HAMA)。
本發明CDH3xCD3雙特異性抗體構築體的治療用途提供一種新穎且具開創性的治療方法,其用於癌症,較佳為實體腫瘤,更佳為如下所列的癌瘤與其他癌症徵象。如下面實例中所示,本發明CDH3xCD3雙特異性抗體構築體提供一種有利工具以便殺滅表現CDH3的人類癌細胞。更甚者,相較於典型(單專一性)IgG分子或ADC,本發明CDH3xCD3雙特異性抗體構築體的細胞毒性活性提供一種有益的作用模式。
關於在動物模型中的藥物候選物特徵鑑定,對相關動物物種的物種交叉反應性是必要的且物種間親和力差距應維持在10倍親和力差異以下,以確保預測性動物模型配置。就效力與毒性測試來說,獼猴(且尤其是食蟹獼猴)是最為相關的物種且具有最高預測值。為分析抗體構築體能否滿足效率標準,必須開發出個別細胞毒性分析並予以量化。
為了防止不良反應,必須確認雙特異性抗體構築體的目標結合部分特異地結合至P黏附蛋白,且其上述最接近之同源物或體內存在的其他蛋白質沒有一者會結合至P黏附蛋白。
本發明抗體構築體較佳地不結合至CHD3胞外域D1 (SEQ ID NO: 1的位置108-215),它們較佳地不結合至CHD3胞外域D4 (SEQ ID NO: 1的位置441-546),且它們較佳地不結合至CDH3胞外域D5 (SEQ ID NO: 1的位置547-650)。
依據本發明的最佳具體例,雙特異性抗體構築體的特徵在於第一結合域結合至內含在人類CHD3胺基酸位置291-327 (SEQ ID NO: 34)的一個表位中。特異性結合至胺基酸位置291-327 (SEQ ID NO: 34)的抗體較佳地不結合至人類CDH3的CHD3胞外域D3 (SEQ ID NO: 1的位置328-440)。
依據本發明的一個較佳抗體構築體亦可定義為雙特異性抗體構築體,其較佳地包含第一人類結合域及較佳地包含第二人類結合域,該第人類一結合域結合至目標細胞表面上的人類CDH3之表位,而該第二人類結合域結合至T細胞表面上的人類CD3,其中該人類構築體結合至與命名為CDH3-11、CDH3-12、CDH3-13或CDH3-14之抗體結合至相同表位,或競爭結合至CDH3,亦即該抗體包含:
• 如SEQ ID NO: 155中所示的VH區以及如SEQ ID NO: 156中所示的VL區,
• 如SEQ ID NO: 165中所示的VH區以及如SEQ ID NO: 166中所示的VL區,
• 如SEQ ID NO: 175中所示的VH區以及如SEQ ID NO: 176中所示的VL區;或
• 如SED NO: 185中所示的VH區以及如SEQ ID NO: 186中所示的VL區。
在本發明的另一個態樣中,雙特異性抗體構築體的特徵在於該第一結合域結合至內含在人類CDH3胺基酸位置328-363 (SEQ ID NO: 35)的一個表位中。
依據本發明的一個較佳抗體構築體亦可定義為一種雙特異性抗體構築體,其較佳地包含第一人類結合域以及較佳地包含第二人類結合域,第一人類結合域結合至目標細胞表面上的人類CDH3之表位,而第二人類結合域結合至T細胞表面上的人類CD3,其中該抗體構築體與被命名為CDH3-24的抗體結合至相同表位,並競爭結合至CDH3,該抗體CDH3-24亦即包含如SEQ ID NO: 285中所示VH區以及如SEQ ID NO: 286中所示VL區的抗體。
依據本發明的另一個較佳抗體構築體亦可定義為一種雙特異性抗體構築體,其較佳地包含第一人類結合域以及較佳地包含第二人類結合域,第一人類結合域結合至目標細胞表面上的人類CDH3之表位,而第二人類結合域結合至T細胞表面上的人類CD3,其中該抗體構築體與被命名為CDH3-25、CDH3-26或CDH3-27的抗體結合至相同表位,並競爭結合至CDH3,該等抗體CDH3-25、CDH3-26及CDH3-27亦即包含下列的抗體:
• 如SEQ ID NO: 295中所示VH區以及如SEQ ID NO: 296中所示VL區,
• 如SEQ ID NO: 305中所示VH區以及如SEQ ID NO: 306中所示VL區,或
• 如SEQ ID NO: 315中所示VH區以及如SEQ ID NO: 316中所示VL區。
可在競爭分析中測定一個抗體構築體會否與另一個給定抗體構築體競爭結合,競爭分析為諸如競爭性ELISA或基於細胞的競爭分析。亦可使用偶合卵白素的微粒(珠粒)。與塗覆卵白素的ELISA盤相似,當與經生物素化的蛋白質反應時,這些珠粒的每一者可用作為能在其上進行分析的受質。抗原塗覆在珠粒上並且接著經第一抗體預塗覆。添加第二抗體並測定任何額外結合。經由流動式細胞測量術產生讀數。
在本發明的另一個具體例中,雙特異性抗體構築體的特徵在於第一結合域結合至人類CDH3胺基酸位置328-363 (SEQ ID NO: 35)內含的一個表位,並且結合至人類CDH3胺基酸位置404-440 (SEQ ID NO: 390)內含的一個表位。
此外,本發明抗體構築體較佳地不結合至如SEQ ID NO: 1中所示之人類CDH3胺基酸位置216-252或253-290內含的一個表位。
此外,本發明抗體構築體較佳地不結合至如SEQ ID NO: 1中所示之人類CDH3胺基酸位置364-403內含的一個表位。
特異地結合至胺基酸位置328-363 (SEQ ID NO: 35)內含之一個表位的抗體構築體較佳地不結合至人類CDH3的CHD3胞外域D2 (SEQ ID NO: 1的位置216-327)。
本發明的一個優點在於提供一種雙特異性抗體構築體,其包含一個結合至CD3的結合域以及一個能夠結合至CDH3的結合域,而兩個結合域均對人類以及獼猴CDH3展現出跨物種特異性。出乎意料發現到,本發明CDH3xCD3雙特異性抗體構築體在人類與獼猴CDH3分析系統中不但特異性地結合至CDH3的人類與獼猴CDH3同源物及CD3,還展現T細胞媒介的細胞毒性。有利地,本發明提供CDH3xCD3雙特異性抗體構築體,其在人類及獼猴體內顯示T細胞媒介的細胞毒性。這個優點是透過結合至一個由人類CDH3胺基酸位置291-363 (SEQ ID NO: 36)內含之表位簇而達成。
必須注意到,如本文所用,除非另有清楚指明,否則單數形式「一(a、an以及the)」包括複數個指涉對象。因此,舉例而言,提到「一種試劑」包括一或多種此等不同試劑,而提到「方法」包括技藝中具有通常技術者熟知的相同步驟與方法,且可經過修飾或取代如本文所述方法。
除非另有指明,否則在一連串元件之前的術語「至少」要理解為指該系列中的每一個元件。習於技藝者應認知到或能夠在無需過度實驗的情況下確認,如本文所述本發明之特定具體例的許多等效方式。這些等效方式希望是受本發明所含括。
術語「及/或」使用於本文中時包括「及」、「或」以及「該術語有關元件的全部或任何其他組合」。
術語「約」或「大約」如本文所用表示在給定數值或範圍的±20%內,較佳±15%內,更佳±10%內,且最佳±5%內。
除非另有需要,否則通篇說明書及之後的申請專利範圍中,用語「包含(comprise)」及變化形式(諸如comprises以及comprising)應理解為意指包括所述整數或步驟或整數或步驟的群組,但不排除任何其他整數或步驟或整數或步驟的群組。當在本文使用時,術語「包含(comprising)」可置換成術語「含有(containing)」或「包括(including)」,或有時當在本文中使用時置換成術語「具有(having)」。
當在本文中使用時,「由…組成」排除在請求元件中未具體指明的任何元件、步驟或組成。當在本文中使用時,「大體上由…組成」不排除實質上不影響申請專利範圍基本與新穎特徵的材料或步驟。
在本文的各種情況中,任一術語「包含」、「大體上由…組成」以及「由…組成」可替換成其他兩種術語中的另一者。
術語「抗體構築體」意指一種分子,其中結構及/或功能是以抗體(例如全長或完全免疫球蛋白分子)的結構及/或功能為基礎。抗體構築體因而能夠結合至其特異性目標或抗原。此外,依據本發明的抗體構築體包含容許目標結合之抗體最小結構標準。這個最小結構標準可以是例如由至少三個輕鏈CDR (亦即VL區的CDR1、CDR2與CDR3)及/或三個重鏈CDR (亦即VH區的CDR1、CDR2與CDR3)的存在,較佳全部六個CDR所界定。本發明據以構築的抗體包括例如單株抗體、重組抗體、嵌合抗體、去免疫抗體、人類化抗體以及人類抗體。
在依據本發明「抗體構築體」的定義中,全長或完整抗體包括駱駝科抗體及其他藉由生物技術或蛋白質工程方法或過程產生的免疫球蛋白抗體。這些全長抗體可以是例如單株抗體、重組抗體、嵌合抗體、去免疫抗體、人類化抗體以及人類抗體。亦在「抗體構築體」的定義中的是全長抗體的片段,諸如VH、VHH、VL、(s)dAb、Fv、Fd、Fab、Fab’、F(ab')2或「r IgG」 (「半抗體」)。依據本發明之抗體構築體亦可為抗體的經修飾片段,又稱為抗體變異體,諸如scFv、二-scFv或二(s)-scFv、scFv-Fc、scFv-拉鍊、scFab、Fab2、Fab3、雙功能抗體、單鏈雙功能抗體、串聯雙功能抗體(Tandab’s)、串聯di-scFv、串聯tri-scFv、「微抗體」(實例為以下結構:(VH-VL-CH3)2、(scFv-CH3)2、((scFv)2-CH3 + CH3)、((scFv)2-CH3)或(scFv-CH3-scFv)2)、多鏈抗體(諸如三鏈抗體或四鏈抗體),以及單域抗體(諸如奈米抗體或單可變域抗體,僅包含一個可變域,可以是VHH、VH或VL,特異地結合其他V區或結構域的不同抗原或表位)。
此外,術語「抗體構築體」的定義包括單價、二價及多價(polyvalent/multivalent)構築體,且因此單特異性構築體特異地結合至單一個抗原結構,雙特異性與多特異性構築體透過不同結合域特異地結合超過一個抗原結構,例如兩個、三個或更多個。另外,術語「抗體構築體」的定義包括僅有一條多肽鏈組成的分子還有由超過一條多肽鏈組成的分子,鏈可以是相同的(同型二聚體、同型三聚體或同型寡聚體),或不同的(雜二聚體、雜三聚體或雜寡聚體)。上面述明的抗體及其變異體或衍生物的實例尤其描述於Harlow and Lane, Antibodies a laboratory manual, CSHL Press (1988) and Using Antibodies: a laboratory manual, CSHL Press (1999)、Kontermann and Dübel, Antibody Engineering, Springer, 2nd ed. 2010以及Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009中。
本發明抗體構築體較佳為「活體外產生的抗體構築體」。這個術語意指依據上文定義的抗體構築體,其中所有或部分可變區(例如至少一個CDR)是在非免疫細胞篩選(例如活體外噬菌體展示、蛋白質晶片或任何其他方法)中產生,其中可針對候選序列結合至抗原的能力來進行測試。因此,這個術語較佳地排除僅透過遺傳重組在動物體內的免疫細胞中產生的序列。「重組抗體」是一種透過使用重組DNA技術或遺傳工程製造的抗體。
術語「單株抗體」(mAb)或單株抗體構築體如本文所用意指獲自一群實質上均質的抗體群的抗體,實質上均質的抗體群意即組成該群的個別抗體相同,除了可能的天然突變及/或轉譯後修飾(例如異構化、醯胺化)以微量存在。單株抗體具有高度特異性,被導向對抗抗原上的單一抗原位點或決定子,相對於習知(多株)抗體製品,多株抗體製品通常包括被導向對抗不同決定子(或表位)的不同抗體。除了其特異性以外,單株抗體有利之處在於它們是由融合瘤培養物所合成,因此不會被其他免疫球蛋白汙染。修飾用語「單株」指抗體是由實質上均質的抗體群獲得的特徵,且不會被認為是需要透過任何特定方法來製造抗體。
關於製備單株抗體,可使用提供經由連續細胞株培養產生抗體的任何技術。例如,要使用的單株抗體可以是藉由首先由Koehler et al., Nature, 256: 495 (1975)描述的融合瘤方法製得,或可藉由重組DNA方法製得(參見例如美國專利第4,816,567號)。製造人類單株抗體的更多技術實例包括三源雜交瘤(trioma)技術、人類B細胞融合瘤技術(Kozbor, Immunology Today 4 (1983), 72)以及EBV-融合瘤技術(Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96)。
接著可使用標準方法來篩選融合瘤,以便鑑定出一或多個生產與指定抗原特異地結合之抗體的融合瘤,標準方法為諸如酶聯免疫吸附分析(ELISA)以及表面電漿共振(BIACORE™)分析。可使用任何形式的相關抗原作為免疫原,例如重組抗原、天然形式、其任何變異體或片段,還有其抗原性肽。EIAcore系統中採用的表面電漿共振可用來增加結合至目標抗原(諸如CDH3或CD3ε)之表位的噬菌體抗體的效率(Schier, Human Antibodies Hybridomas 7 (1996), 97-105;Malmborg, J. Immunol. Methods 183 (1995), 7-13)。
製造單株抗體的另一種例示性方法包括篩選蛋白表現庫,例如噬菌體呈現庫或核糖體呈現庫。噬菌體呈現庫描述於例如Ladner et al., 美國專利第5,223,409號;Smith (1985) Science 228:1315-1317、Clackson et al., Nature, 352: 624-628 (1991)與Marks et al., J. Mol. Biol., 222: 581-597 (1991)中。
除了使用呈現庫以外,可使用相關抗原來免疫人類動物,例如囓齒動物(諸如小鼠、倉鼠、兔或大鼠)。在一個具體例中,非人類動物包括至少一部分的人類免疫球蛋白基因。舉例來說,可以使用大的人類Ig (免疫球蛋白)基因座片段對缺乏小鼠抗體生產的小鼠品系進行工程化。使用融合瘤技術,可生產並選擇衍生自具有所需特異性之基因的抗原特異性單株抗體。參見例如XENOMOUSE™、Green et al. (1994) Nature Genetics 7:13-21、US 2003-0070185、WO 96/34096與WO 96/33735。
也可以從非人類動物獲得單株抗體,並接著使用技藝內熟知的重組DNA技術予以修飾(例如人類化、去免疫化、使其成為嵌合等)。經修飾抗體構築體的實例包括非人類抗體的人類化變異體、「親和力經成熟」的抗體(參見例如Hawkins et al. J. Mol. Biol. 254, 889-896 (1992)與Lowman et al., Biochemistry 30, 10832- 10837 (1991))以及具有效應功能已改變的抗體變異體(參見例如美國專利5,648,260、Kontermann and Dübel (2010),上文與Little (2009),上文)。
在免疫學中,親和力成熟是在免疫反應過程期間,B細胞生產對抗原親和力增加之抗體的過程。隨著對相同抗原的暴露增加,宿主將會生產親和力逐漸變大的抗體。如同天然原型,活體外親和力成熟是基於突變以及選擇的原理。活體外親和力成熟已經成功用來將抗體、抗體構築體以及抗體片段最佳化。使用放射線、化學突變劑或易錯PCR在CDR內引進隨機突變。此外,可以透過鏈改組來增加遺傳多樣性。使用像是噬菌體呈現之呈現方法進行兩回合或三回合的突變與選擇會產生親和力在低奈莫耳範圍內的抗體片段。
抗體構築體的胺基酸置換變異的一個較佳類型是關於替換親本抗體(例如人類化或人類抗體)的一或多個超變區殘基。一般來說,選出用於進一步開發的所得變異體將的生物特性相對於它們自其所生的親本抗體將有所增進。用於產生此等置換變異體的習知方法涉及使用噬菌體呈現的親和力成熟。簡言之,數個超變區位點(例如6-7個位點)經突變而在各個位點處產生所有可能的胺基酸置換。由此生成的抗體變異體如與M13基因III產物的融合物包裝於每個顆粒中呈現在絲狀噬菌體顆粒的單價形式。接著如本文所揭示針對其生物活性(例如結合親和力)篩選噬菌體呈現變異體。為了鑑別用於修飾的候選超變區位點,可進行丙胺酸掃描誘變來鑑別明顯有助於抗原結合的超變區殘基。或者或另外,分析抗原-抗體複合物好有利於鑑別結合域與例如人類CDH3之間之接觸點的結晶結構。依據本文所精心計畫的技術,這些接觸殘基與相鄰殘基是置換候選者。在產生此等變異體之後,如本文所述對一組變異體進行篩選,且可選出在一或多個相關分析中具有優越特性的抗體用於進一步開發。
本發明之單株抗體及抗體構築體特別包括「嵌合」抗體(免疫球蛋白)或此等抗體的片段,其中一部分重鏈及/或輕鏈與衍生自特定物種或屬於特定抗體類型或亞型的抗體中的對應序列相同或同源,而重鏈及/或輕鏈的其餘部分與衍生自另一物種或屬於另一抗體類型或亞型的抗體之對應序列相同或同源,只要它們展現出期望的生物活性即可(美國專利第4,816,567號;Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984))。在本文中,感興趣的嵌合抗體包括「靈長動物化(primitized)」抗體,其包含衍生自非人類靈長動物(例如舊世界猴、猿等)的可變域抗原結合序列以及人類恆定區序列。已描述過各種用於製造嵌合抗體的不同方法。參見例如Morrison et al., Proc. Natl. Acad. ScL U.S.A. 81:6851 , 1985;Takeda et al., Nature 314:452, 1985、Cabilly et al.,美國專利第4,816,567號;Boss et al.,美國專利第4,816,397號;Tanaguchi et al., EP 0171496;EP 0173494;以及GB 2177096。
也可以藉由例如在WO 98/52976或WO 00/34317中揭示的方法,透過刪除特定人類T細胞表位來修飾抗體、抗體構築體或抗體片段(一種稱為「去免疫化」的方法)。簡言之,可針對結合至第II類MHC的肽來分析抗體的重鏈與輕鏈可變域;這些肽代表可能的T細胞表位(如WO 98/52976與WO 00/34317中所定義)。關於偵測可能的T細胞表位,可應用一種稱為「肽穿線(peptide threading)」的電腦模型化方法,而另外可針對出現在VH與VL序列中的模組來搜尋人類第II類MHC結合肽資料庫,如WO 98/52976及WO 00/34317中所述。這些模組結合至18個主要第II類MHC DR異型的任一者,並因此構成可能的T細胞表位。所偵測到的可能T細胞表位可以透過置換可變域中的少數胺基酸殘基,或者較佳單一胺基酸置換而消除。通常,進行保守置換。通常但不排除可使用在人類生殖系抗體序列的位置中所共有的胺基酸。例如於Tomlinson, et al. (1992) J. MoI. Biol. 227:776-798;Cook, G.P. et al. (1995) Immunol. Today Vol. 16 (5): 237-242;以及Tomlinson et al. (1995) EMBO J. 14: 14:4628-4638中揭示人類生殖系序列。V BASE指南提供一個全面性的人類免疫球蛋白可變區序列指南(由Tomlinson, LA. Et al. MRC Centre for Protein Engineering, Cambridge, UK)彙整。這些序列可用做為人類序列來源,例如用於框架區或CDR。也可以使用一致人類框架區,例如如美國專利第6,300,064號中所述。
「人類化」抗體、抗體構築體或其片段(諸如Fv、Fab、Fab'、F(ab')2或抗體的其他抗原結合亞序列)是大多數為人類序列的抗體或免疫球蛋白,其含有衍生自非人類免疫球蛋白的最少序列。人類化抗體多半是人類免疫球蛋白(受體抗體),其中受體超變區(CDR)的殘基替換成非人類(例如囓齒動物)物種(諸如具有期望特異性、親和力與能力的小鼠、大鼠、倉鼠或兔)(供體抗體)之超變區的殘基。在一些情況下,人類免疫球蛋白的Fv框架區(FR)殘基替換成對應非人類殘基。此外,「人類化抗體」如本文所用亦可包含在受體抗體或供體抗體中都不會發現到的殘基。進行這些修飾好進一步將抗體效能予以改善並最佳化。人類化抗體也可以包含至少一部分免疫球蛋白恆定區(Fc),通常是人類免疫球蛋白的恆定區。更多詳情參見Jones et al., Nature, 321: 522-525 (1986);Reichmann et al., Nature, 332: 323-329 (1988);以及Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992)。
可藉由將不直接參與抗原結合的Fv可變域序列替換成人類Fv可變域的相同序列來產生人類化抗體或其片段。產生人類化抗體或其片段的例示性方法是由下列所提供:Morrison (1985) Science 229:1202-1207;Oi et al. (1986) BioTechniques 4:214;以及US 5,585,089;US 5,693,761;US 5,693,762;US 5,859,205;與US 6,407,213。那些方法包括分離、操作以及表現核酸序列,該等核酸序列編碼重鏈或輕鏈之至少一者的全部或部分免疫球蛋白Fv可變域。此等核酸如上所述可由產生抗體對抗預定目標的融合瘤以及其他來源獲得。編碼人類化抗體分子的重組DNA接而可被選殖至適當表現載體中。
也可以使用基因轉殖動物(諸如表現人類重鏈與輕鏈基因,但無法表現內源性小鼠免疫球蛋白重鏈與輕鏈基因的小鼠)生產人類化抗體。Winter描述一種例示性CDR移植方法,其可用來製備本文所述的人類化抗體(美國專利第5,225,539號)。特定人類抗體的全部CDR可替換成非人類CDR的至少一部分,或只有一些CDR被替換成非人類CDR。只需要替換人類化抗體結合至預定抗原所需的CDR數目即可。
可透過引入保守置換、一致序列置換、生殖系置換及/或回復突變將人類化抗體最佳化。此等經改變的免疫球蛋白分子可以透過技藝中熟知之數種技術中的任一者來進行(例如Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80: 7308-7312, 1983;Kozbor et al., Immunology Today, 4: 7279, 1983;Olsson et al., Meth. Enzymol., 92: 3-16, 1982以及EP 239 400)。
術語「人類抗體」、「人類抗體構築體」及「人類結合域」包括抗體、抗體構築體以及結合域,該等結合域具有諸如可變區與恆定區或技藝中熟知實質上對應於人類生殖系免疫球蛋白序列之域的抗體區,包括例如那些Kabat et al. (1991)(上文)所述者。本發明之人類抗體、抗體構築體或結合域可包括不被人類生殖系免疫球蛋白序列所編碼的胺基酸殘基(例如因為在活體外隨機或定點誘變或因為在活體內體突變引入的突變),例如在CDR中,且尤其是在CDR3中。人類抗體、抗體構築體或結合域可具有至少一個、兩個、三個、四個、五個或更多個位置替換成不被人類生殖系免疫球蛋白序列所編碼的胺基酸殘基。人類抗體、抗體構築體與結合域的定義如本文所用也含括完全人類抗體,其只包括非人工及/或遺傳修改的人類抗體序列,如那些透過使用諸如Xenomouse的技術或系統衍生者。
在一些具體例中,本發明抗體構築體為「經分離」或為「實質上純的」抗體構築體。當用來描述本文揭示的抗體構築體時,「經分離」或「實質上純的」表示抗體構築體已經過鑑定、分離及/或自其生產環境的組分回收。較佳地,抗體構築體不或實質上不與其生產環境的所有其他組分締合。其生產環境的汙染組分是通常會干擾多肽的診斷或治療用途的材料,諸如由重組轉染細胞產生者,並可能包括酶、激素及其他蛋白質或非蛋白質溶質。抗體構築體在給定樣品中可例如佔總蛋白質重量的至少約5%,或至少約50%。應理解,以總蛋白質含量的重量為準,經分離蛋白質可佔5%至99.9%,視情況而定。透過使用誘導性啟動子或高表現啟動子,可以明顯更高的濃度製造多肽,使得其以濃度含量增加的方式製造。定義包括在技藝中所熟知的廣泛不同生物體及/或宿主細胞中生產抗體構築體。在較佳具體例中,抗體將被純化(1)至足以藉由使用例如旋杯式定序儀獲得N端或內部胺基酸序列之至少15個殘基的程度,或(2)至均質,此係藉由使用例如庫馬斯藍或較佳銀染劑,在非還原或還原條件下進行SDS-PAGE所達成。然而,經分離抗體通常將藉由至少一個純化步驟來製備。
術語「結合域」的特徵在於就本發明來說,一種分別(特異地)結合至目標分子(抗原) CDH3與CD3上的目標表位或給定目標表位/與其交互作用/辨識其的結構域。第一結合域(辨識CDH3)的結構與功能,以及較佳地第二結合域(CD3)的結構及/或功能是基於抗體(例如全長或完全免疫球蛋白分子)的結構及/或功能。依據本發明,第一結合域特徵在於存在三個輕鏈CDR (亦即VL區的CDR1、CDR2與CDR3)以及三個重鏈CDR (亦即VH區的CDR1、CDR2與CDR3)。第二結合域較佳地亦包含允許目標結合之抗體最小結構標準。更佳地,第二節合域包含至少三個輕鏈CDR (亦即VL區的CDR1、CDR2與CDR3)以及三個重鏈CDR (亦即VH區的CDR1、CDR2與CDR3)。預期第一結合域及/或第二節合域是噬菌體呈現或庫篩選方法生產或者是獲得,而不是藉由將現存(單株)抗體的CDR序列移植到框架中。
依據本發明,結合域較佳呈多肽形式。此等多肽可包括蛋白質部分以及非蛋白質部分(例如化學連接子或化學交聯劑,諸如戊二醛)。蛋白質(包括其片段,較佳為生物活性片段,以及通常具有少於30個胺基酸的肽)包含兩個或更多個經由一個共價肽鍵彼此偶合的胺基酸(產生胺基酸鏈)。術語「多肽」如本文所用描述一群分子,它們通常由超過30個胺基酸所組成。多肽可進一步形成多聚體,諸如二聚體、三聚體以及更高的寡聚體,亦即由超過一個多肽分子組成。形成此等二聚體、三聚體等的多肽分子可以相同或不相同。因此,此等多聚體的對應更高級結構稱為同二聚體或雜二聚體、同三聚體或雜三聚體等。雜多聚體的一個實例為抗體分子,就其天然形式來說是由兩個相同多肽輕鏈以及兩個相同多肽重鏈組成。術語「肽」、「多肽」以及「蛋白質」也指經天然修飾的肽/多肽/蛋白質,其中修飾是例如透過轉譯後修飾(像是糖基化、乙醯基化、磷酸化與類似者)來進行。在本文中提到時,「肽」、「多肽」或「蛋白質」也可以是經化學修飾(諸如經聚乙二醇化)。此等修飾為技藝中所熟知並且描述於以下本文。
如上所提,結合域通常可包含抗體輕鏈可變區(VL)以及抗體重鏈可變區(VH);但是,不必然同時包含兩者。舉例而言,Fd片段具有兩個VH區且通常保有完整抗原結合域的一些抗原結合功能。(經修飾)抗原結合抗體片段的實例包括(1)Fab片段,具有VL、VH、CL與CH1域的單價片段;(2) F(ab')2片段,具有兩個在絞鍊區透過一個雙硫橋連結之Fab片段的二價片段;(3)Fd片段,具有兩個VH與CH1域;(4)Fv片段,具有抗體之一臂的VL與VH域;(5)dAb片段(Ward et al., (1989) Nature 341 :544-546),其具有VH域;(6)經分離互補決定區(CDR),以及(7)單鏈Fv (scFv),偏好後者(例如衍生自scFV-庫)。依據本發明之抗體構築體的具體例實例例如描述於以下:WO 00/006605、WO 2005/040220、WO 2008/119567、WO 2010/037838、WO 2013/026837、WO 2013/026833、US 2014/0308285、US 2014/0302037、WO 2014/144722、WO 2014/151910以及WO 2015/048272。
較佳地,結合至CDH3的結合域及/或結合至CD3的結合域為人類結合域。包含至少一個人類結合域的抗體與抗體構築體免去了與具有非人類(諸如囓齒動物,例如鼠類、大鼠、倉鼠或兔)可變及/或恆定區之抗體或抗體構築體有關的一些問題。存在此等囓齒動物來源的蛋白質可能會導致抗體或抗體構築體被快速清除或者患者可能產生對抗抗體或抗體構築體的免疫反應。為了避免使用囓齒動物來源的抗體或抗體構築體,可透過將人類抗體功能引入囓齒動物來生成人類或完全人類抗體/抗體構築體,使得囓齒動物生產完全人類抗體。
在YAC中選殖以及重建大小有百萬鹼基的人類基因座並且將它們引入小鼠生殖系的能力提供一個強效方法,以說明極大的功能組分或粗略定位之基因座還有產生可供使用的人類疾病模型。此外,使用將小鼠基因座替換成其人類相等基因座的技術能夠特別洞悉人類基因產物在發育、其與其他系統溝通,及其參與疾病誘發與進展期間的表現及調節。
這樣一個策略的重要實際應用是小鼠體液性免疫系統的「人類化」。將人類免疫球蛋白(Ig)基因座引入內源性Ig基因已被不活化的小鼠體內提供了一個機會,以便研究抗體的程式化表現以及組裝的基本機制,還有其在B細胞發育時的角色。此外,此一策略可提供一個用於製造完全人類單株抗體(mAb)的理想來源-在人類疾病中滿足抗體療法前景的重要里程碑。完全人類抗體或抗體構築體預期將小鼠mAb或源自小鼠之mAb所固有的免疫原性反應以及過敏反應降至最低,並因而增加投與抗體/抗體構築體的效力與安全性。使用完全人類抗體或抗體構築體預期在治療慢性與反覆性人類疾病(諸如發炎、自體免疫與癌症,其需要重複化合物投藥)上可提供實質益處。
用於此目標的一個方法是預先將缺乏小鼠抗體生產的小鼠品系進行工程化而帶有人類Ig基因座的片段,使得小鼠能在不存在小鼠抗體的情況下生產一個大的人類抗體組庫(repertoire)。大的人類Ig片段將能保有多數可變基因多樣性並且適當調節抗體生產與表現。透過探究抗體多樣化與選擇的小鼠機制以及缺乏對人類蛋白質的免疫耐受性,在這些小鼠品系中所重現的人類抗體組庫應產生高親和力抗體對抗感興趣的任一種抗原,包括人類抗原。使用融合瘤技術,可容易生產並選擇帶有所需特異性的抗原特異性人類mAb。這個一般性策略經證實與產生第一個XenoMouse小鼠品系有關(參見Green et al. Nature Genetics 7:13-21 (1994))。XenoMouse品系經酵母菌人工染色體(YAC)改造,該YAC分別含有245 kb與190 kb大小的生殖系構型片段的人類重鏈基因座與κ輕鏈基因座,其含有核心可變區與恆定區序列。含有YAC的人類Ig證明與用於重排及表現抗體的小鼠系統相容且能夠替換不活化的小鼠Ig基因。這個受到其引起B細胞發育、產生完全人類抗體之成體樣人類庫組,以及產生抗原特異性人類mAb的能力證實。這些結果也暗示著,引入含有更多數目的V基因、額外調節性元素以及人類Ig恆定區的更大人類Ig基因座部分基本上能再現完全庫組,其為人類體液性對感染與免疫接種產生反應的特徵。Green等人的成果最近擴展至透過分別引入人類重鏈基因座與κ輕鏈基因座之百萬鹼基大小的生殖系構型YAC片段而引入超過約80%人類抗體庫組。參見Mendez et al. Nature Genetics 15:146-156 (1997)以及U.S.美國專利申請案序號第08/759,620號。
於下列中進一步討論並描述XenoMouse小鼠的生成:美國專利申請案序號第07/466,008號、第07/610,515號、第07/919,297號、第07/922,649號、第08/031,801號、第08/112,848號、第08/234,145號、第08/376,279號、第08/430,938號、第08/464,584號、第08/464,582號、第08/463,191號、第08/462,837號、第08/486,853號、第08/486,857號、第08/486,859號、第08/462,513號、第08/724,752號和第08/759,620號;以及美國專利第6,162,963號;第6,150,584號;第6,114,598號;第6,075,181號和第5,939,598號以及日本專利第3 068 180 B2號、第3 068 506 B2號和第3 068 507 B2。亦參見Mendez et al. Nature Genetics 15:146-156 (1997)與Green and Jakobovits J. Exp. Med. 188:483-495 (1998)、EP 0 463 151 B1、WO 94/02602、WO 96/34096、WO 98/24893、WO 00/76310和WO 03/47336。
在一個替代方法中,其他人(包括GenPharm International, Inc.)採用一種「迷你基因座(minilocus)」方法。在迷你基因座方法中,透過納入Ig基因座的片段(個別基因)模擬Ig基因座。因此,一或多個VH基因、一或多個DH基因、一或多個JH基因、mu恆定區,以及第二恆定區(較佳為γ恆定區)形成至用以插入至動物體內的構築體中。於下列中描述這個方法:發予Surani等人的美國專利第5,545,807號與各自發予Lonberg and Kay的美國專利第5,545,806號;第5,625,825號;第5,625,126號;第5,633,425號;第5,661,016號;第5,770,429號;第5,789,650號;第5,814,318號;第5,877,397號;第5,874,299號;和第6,255,458號,發予Krimpenfort和Berns的美國專利第5,591,669號和第6,023.010號、發予Berns等人的美國專利第5,612,205號;第5,721,367號;和第5,789,215號,以及發予Choi and Dunn的美國專利第5,643,763號,以及GenPharm International美國專利申請序號第07/574,748號、第07/575,962號、第07/810,279號、第07/853,408號、第07/904,068號、第07/990,860號、第08/053,131號、第08/096,762號、第08/155,301號、第08/161,739號、第08/165,699號、第08/209,741號。亦參見EP 0 546 073 B1、WO 92/03918、WO 92/22645、WO 92/22647、WO 92/22670、WO 93/12227、WO 94/00569、WO 94/25585、WO 96/14436、WO97/13852與WO 98/24884和美國專利第5,981,175號。進一步參見Taylor
et al.(1992)、Chen
et al. (1993)、Tuaillon
et al. (1993)、Choi
et al. (1993)、Lonberg
et al.(1994)、Taylor
et al.(1994)與Tuaillon
et al.(1995)、Fishwild
et al.(1996)。
Kirin亦已證實,從小鼠生成人類抗體,於小鼠中已透過微細胞融合引入染色體大片段或整個染色體。參見歐洲專利申請第773 288號與第843 961號。Xenerex Biosciences正在開發一種用於有效生成人類抗體的技術。在這個技術中,SCID小鼠經人類淋巴細胞(例如B細胞及/或T細胞)重建。然後用抗原免疫小鼠且可產生對抗該抗原的免疫反應。參見美國專利第5,476,996號;第5,698,767號;以及第5,958,765號。
人類抗小鼠抗體(HAMA)反應引領業界製備嵌合或其他人類化抗體。但是,預期會觀察到某些人類抗嵌合抗體(HACA)反應,尤其是在臨床上或在多劑量使用抗體時。因此,提供包含對抗CDH3的完全人類結合域以及對抗CD3的完全人類結合域的抗體構築體以使得HAMA或HACA反應的擔心及/或作用消弭會是合乎需要的。
依據本發明,術語「(特異地)結合至」、「(特異地)辨識」、「(特異地)指向」以及「特異地與…反應」表示結合域與目標蛋白質或抗原(CDH3/CD3)上之表位的一或多個胺基酸(較佳至少兩個,更佳至少三個且最佳至少四個胺基酸)反應或特異地反應。
術語「表位」意指抗原上的一個位點,結合域(諸如抗體或免疫球蛋白,或抗體或免疫球蛋白的衍生物或片段)特異地結合至該位點。「表位」具有抗原性且該術語表位因而有時在本文中被稱為「抗原性結構」或「抗原性決定子」。因而,結合域是一個「抗原交互作用位點」。該結合/交互作用也理解成定義「特異性辨識」。
「表位」可以透過連續胺基酸或因為蛋白質三級褶疊而接近的非連續胺基酸所形成。「線性表位」是一種表位,其中胺基酸一級序列包含所辨識之表位。線性表位通常包括至少3個或至少4個,且更常至少5個或至少6個或至少7個,例如約8個至約10個呈獨特序列胺基酸,且亦可更長並包含至少15個或20個胺基酸,至少25個或30個胺基酸,或甚至更多。
相對於線性表位,「構型表位」是一種表位,其中包含該表位之一級胺基酸序列不是所辨識之表位的唯一限定構成要素(例如,一級胺基酸序列不必然被結合域所辨識的表位)。通常構型表位相對於線性表位包含數目較多的胺基酸。關於辨識構型表位,結合域辨識抗原的三維結構,較佳為肽或蛋白質或其片段(在本文中,結合域之一的抗原包含在CDH3蛋白中)的三維結構。例如,當蛋白分子褶疊而形成三維結構時,形成構型表位的某些胺基酸及/或多肽骨架變得相鄰,使得抗體能辨識表位。測定表位構型的方法包括,但不限於X射線結晶學、二維核磁共振(2D-NMR)、光譜以及定向自旋標記與電子順磁共振(EPR)光譜。
所提供的實例說明又一個鑑定給定結合域的方法,其包括給定結合域是否結合至給定蛋白質(尤其是CDH3)的一或多個表位的測試。
如本文所用,術語「表位簇」表示位在抗原之限定連續延續段中的表位。表位簇可包含一個、兩個或更多個表位。除了在表位簇以外的一個表位(對應於不連續表位)以外,抗體構築體也可以結合至表位簇中的一個表位。不連續表位的特徵通常在於其含括抗原的不連續胺基酸延續段。例如,抗體構築體可結合至胞外子域D3A與D3C,但不結合至D3B。「表位簇」的概念也用於鑑定本發明抗體構築體的特性。在上文說明CDH3胞外域中的表位簇以及表位(本發明中所定義者)並描示於圖1中。
當一個胞外域(D1-D5)或其子域(A、B、C)在人類CDH3蛋白中交換成非人類和非靈長動物(例如,雞或小鼠) CDH3抗原的胞外域(D1-D5)或其子域(A、B、C)(產生一個包含人類CDH3的構築體,其中一個人類胞外域或其子域替換成對應非人類胞外域或其子域),將使得結合結構域的結合降低。相較於在人類CDH3蛋白的個別表位簇,該降低較佳為至少10%、20%、30%、40%、50%;更佳為至少60%、70%、80%、90%、95%或甚至100%,因此結合至人類CDH3蛋白之個別胞外域(D1-D5)或其子域被設定為100%。設想前述人類CDH3/非人類CDH3嵌合體在上述CHO細胞中表現。也設想人類CDH3/非人類CDH3嵌合體與具有不同膜結合蛋白(諸如EpCAM)的跨膜域及/或細胞質域融合。
在實例2中描述一種測試因為與非人類(例如,小鼠,但其他像是大鼠、倉鼠、兔、雞等) CDH3抗原的個別胞外域(D1-D5)或其子域交換而喪失結合的方法。一個確定一個目標抗原的特定殘基對於被一個抗體構築體或結合域辨識之貢獻度的方法是丙胺酸掃描(參見例如Morrison KL & Weiss GA. Cur Opin Chem Biol. 2001 Jun;5(3):302-7),其中每個待分析殘基被丙胺酸替換,例如經由位點定向誘發突變。因為丙胺酸的體積不大、在化學上為惰性、模擬許多其他胺基酸具有之二級結構參考物的甲基官能基而使用丙胺酸。有時可以在希望保留突變殘基的大小的情況下使用大體積胺基酸(諸如纈胺酸或白胺酸)。丙胺酸掃描是已經長時間使用的一項成熟技術。
結合域和表位或表位簇之間的交互作用暗示,結合域對特定蛋白質或抗原(在此分別為DH3和CD3)的表位或表位簇展現出可預見的親和力,且通常與CDH3或CD3以外的蛋白質或抗原不展現顯著反應性。「可預見的親和力」包括具有約10-6M (KD)或更強親和力的結合。較佳地,當結合親和力為約10 -12至10 -8 M、10-12到10-9 M、10-12到10-9 M,10-11至10 -8 M,較佳約10-11至10M時,結合被認為是具有特異性。結合域是否與目標特異性地反應或結合可以容易地被測試,尤其是透過比較該結合域與目標蛋白或抗原之反應與該結合域與CDH3或CD3以外之蛋白質或抗原的反應。較佳地,本發明的結合域實質上或基本上不結合至CDH3或CD3以外的蛋白質或抗原(即,第一結合域是不能夠結合CDH3以外的蛋白質而第二結合域不能夠結合CD3以外的蛋白質)。
術語「基本上不結合/基本上結合」或「不能夠結合」表示本發明的結合域不結合至CDH3或CD3以外的蛋白質或抗原,亦即顯示對CDH3或CD3以外的蛋白質或抗原的反應性不超過30%、較佳不超過20%、更佳不超過10%、尤佳不超過9%、8%、7%、6%或5%,而對CDH3或CD3的結合分別被設定為100%。
咸信特異性結合是由結合域和抗原的胺基酸序的特定模組來實現。因此,因為其一級、二級及/或三級結構還有該結構的二級修飾而達到結合。抗原交互作用位點與其特異性抗原的特異性交互作用可能導致該位點與抗原的簡單結合。此外,抗原交互作用位點與其特異性抗原的特異性交互作用可此外或另外導致一個信號起始,例如因為抗原的構型改變,抗原寡聚化等所引起。
在另一個態樣中,本發明提供雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3的第一較佳人類結合域,以及結合至T細胞表面上之人類CD3的第二較佳人類結合域,其中第一結合域包含含有CDR-H1、CDR-H2和CDR-H3的VH區以及含有CDR-L1、CDR-L2和CDR-L3的VL區,其是選自由下列組成之群:
a) 如SEQ ID NO: 149中所示的CDR-H1、如SEQ ID NO: 150中所示的CDR-H2、如SEQ ID NO: 151中所示的CDR-H3、如SEQ ID NO: 152中所示的CDR-L1、如SEQ ID NO: 153中所示的CDR-L2以及如SEQ ID NO: 154中所示的CDR-L3;
b) 如SEQ ID NO: 159中所示的CDR-H1、如SEQ ID NO: 160中所示的CDR-H2、如SEQ ID NO: 161中所示的CDR-H3、如SEQ ID NO: 162中所示的CDR-L1、如SEQ ID NO: 163中所示的CDR-L2以及如SEQ ID NO: 164中所示的CDR-L3;
c) 如SEQ ID NO: 169中所示的CDR-H1、如SEQ ID NO:170中所示的CDR-H2、如SEQ ID NO: 171中所示的CDR-H3、如SEQ ID NO: 172中所示的CDR-L1、如SEQ ID NO: 173中所示的CDR-L2以及如SEQ ID NO: 174中所示的CDR-L3;
d) 如SEQ ID NO:179中所述的CDR-H1、如SEQ ID NO: 180中所述的CDR-H2、如SEQ ID NO: 181中所述的CDR-H3、如SEQ ID NO:182中所述的CDR-L1、如SEQ ID NO: 183中所述的CDR-L2以及如SEQ ID NO:184中所述的CDR-L3;
e) 如SEQ ID NO:189中所述的CDR-H1、如SEQ ID NO: 190中所述的CDR-H2、如SEQ ID NO: 191中所述的CDR-H3、如SEQ ID NO: 192中所述的CDR-L1、如SEQ ID NO: 193中所述的CDR-L2以及如SEQ ID NO: 194中所述的CDR-L3;
f) 如SEQ ID NO: 199中所述的CDR-H1、如SEQ ID NO: 200中所述的CDR-H2、如SEQ ID NO: 201中所述的CDR-H3、如SEQ ID NO: 202中所述的CDR-L1、如SEQ ID NO: 203中所述的CDR-L2以及如SEQ ID NO: 204中所述的CDR-L3;
g) 如SEQ ID NO: 209中所述的CDR-H1、如SEQ ID NO: 210中所述的CDR-H2、如SEQ ID NO: 211中所述的CDR-H3、如SEQ ID NO:212中所述的CDR-L1、如SEQ ID NO:213中所述的CDR-L2以及如SEQ ID NO: 214中所述的CDR-L3;
h) 如SEQ ID NO: 219中所述的CDR-H1、如SEQ ID NO: 220中所述的CDR-H2、如SEQ ID NO: 221中所述的CDR-H3、如SEQ ID NO:222中所述的CDR-L1、如SEQ ID NO: 223中所述的CDR-L2以及如SEQ ID NO: 224中所述的CDR-L3;
i) 如SEQ ID NO: 229中所述的CDR-H1、如SEQ ID NO: 230中所述的CDR-H2、如SEQ ID NO: 231中所述的CDR-H3、如SEQ ID NO: 232中所述的CDR-L1、如SEQ ID NO: 233中所述的CDR-L2以及如SEQ ID NO: 234中所述的CDR-L3;以及
j) 如SEQ ID NO: 239中所述的CDR-H1、如SEQ ID NO: 240中所述的CDR-H2、如SEQ ID NO: 241中所述的CDR-H3、如SEQ ID NO: 242中所述的CDR-L1、如SEQ ID NO: 243中所述的CDR-L2以及如SEQ ID NO: 244中所述的CDR-L3。
在另一個態樣中,本發明提供雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3的第一較佳人類結合域,以及結合至T細胞表面上之人類CD3的第二較佳人類結合域,其中第一結合域包含含有CDR-H1、CDR-H2和CDR-H3的VH區和含有CDR-L1、CDR-L2和CDR-L3的VL區,其是選自由下列組成之群:
a) 如SEQ ID NO: 279中所述的CDR-H1、如SEQ ID NO: 280中所述的CDR-H2、如SEQ ID NO: 281中所述的CDR-H3、如SEQ ID NO: 282中所述的CDR-L1、如SEQ ID NO: 283中所述的CDR-L2以及如SEQ ID NO: 284中所述的CDR-L3;
b) 如SEQ ID NO: 289中所述的CDR-H1、如SEQ ID NO: 290中所述的CDR-H2、如SEQ ID NO: 291中所述的CDR-H3、如SEQ ID NO: 292中所述的CDR-L1、如SEQ ID NO: 293中所述的CDR-L2以及如SEQ ID NO: 294中所述的CDR-L3;
c) 如SEQ ID NO: 299中所述的CDR-H1、如SEQ ID NO: 300中所述的CDR-H2、如SEQ ID NO: 301中所述的CDR-H3、如SEQ ID NO: 302中所述的CDR-L1、如SEQ ID NO: 303中所述的CDR-L2以及如SEQ ID NO: 304中所述的CDR-L3;
d) 如SEQ ID NO: 309中所述的CDR-H1、如SEQ ID NO: 310中所述的CDR-H2、如SEQ ID NO: 311中所述的CDR-H3、如SEQ ID NO: 312中所述的CDR-L1、如SEQ ID NO: 313中所述的CDR-L2以及如SEQ ID NO: 314中所述的CDR-L3;
e) 如SEQ ID NO: 319中所述的CDR-H1、如SEQ ID NO: 320中所述的CDR-H2、如SEQ ID NO: 321中所述的CDR-H3、如SEQ ID NO: 322中所述的CDR-L1、如SEQ ID NO: 323中所述的CDR-L2以及如SEQ ID NO: 324中所述的CDR-L3;
f) 如SEQ ID NO: 329中所述的CDR-H1、如SEQ ID NO: 330中所述的CDR-H2、如SEQ ID NO: 331中所述的CDR-H3、如SEQ ID NO: 332中所述的CDR-L1、如SEQ ID NO: 333中所述的CDR-L2以及如SEQ ID NO: 334中所述的CDR-L3;
g) 如SEQ ID NO: 339中所述的CDR-H1、如SEQ ID NO: 340中所述的CDR-H2、如SEQ ID NO: 341中所述的CDR-H3、如SEQ ID NO: 342中所述的CDR-L1、如SEQ ID NO: 343中所述的CDR-L2以及如SEQ ID NO: 344中所述的CDR-L3;以及
h) 如SEQ ID NO: 349中所述的CDR-H1、如SEQ ID NO: 350中所述的CDR-H2、如SEQ ID NO: 351中所述的CDR-H3、如SEQ ID NO: 352中所述的CDR-L1、如SEQ ID NO: 353中所述的CDR-L2以及如SEQ ID NO: 354中所述的CDR-L3。
術語「可變的」意指抗體或免疫球蛋白結構域的一部分,其序列表現出變異性且涉入決定特定抗體的特異性和結合親和力(亦即,「可變域」)。可變重鏈(VH)和可變輕鏈(VL)的配對一起形成一個抗原結合位點。最鄰近VH的CH域被指定為CH1。各輕(L)鏈透過一個共價二硫鍵連接到重(H)鏈,而兩個H鏈透過一個或更多個二硫鍵彼此連接,端視H鏈同型而定。
變異性並非平均分佈於抗體的整個可變域;它集中在各重鏈和輕鏈可變區的子域中。這些子域被稱為「超變區」或「互補決定區」(CDR)。可變域中更加保守的(亦即,非超變)的部分稱為「框架」區(FRM或FR),並在三維空間中為六個CDR提供支架而形成抗原結合表面。天然重鏈和輕鏈的可變域各自包含四個FRM區(FR1、FR2、FR3,和FR4),主要採取β折片構型,透過三個超變區連接,其形成環路連接相連,並且在某些情況中形成β折片結構的一部分。每條鏈中的超變區經由FRM而非常接近地保持在一起,並與來自另一條鏈的超變區一起促成抗原結合位點的形成(參見Kabat等人,上文)。恆定域不直接參與抗原結合,但展現出多種效應功能,諸如例如,抗體-依賴性、細胞媒介的細胞毒性和補體活化。
術語「CDR」,及其複數形式「CDRs」意指它的三個互補決定區構成了一個輕鏈可變區(CDR-L1、CDR-L2和CDR-L3)的結合特性而三個互補決定區構成了一個重鏈可變區(CDR-H1、CDR-H2和CDR-H3)。CDR含有負責抗體與抗原特異性交互作用的大多數殘基,並因而貢獻抗體分子的功能活性:它們是抗原特異性的主要決定子。
將確切定義CDR邊界和長度進行不同的分類和編號系統。CDR可因此參照Kabat、Chothia,接觸或任何其他邊界(包括本文中所描述的編號系統)予以引用。儘管邊界不同,這些系統的每一者都具有一定程度的重疊,其中在可變序列內構成了所謂的「超變區」。根據這些系統,CDR定義可以在長度和邊界區域相對於相鄰的框架區而不同。參見例如Kabat (一種基於跨物種序列變異性的方法)、Chothia(一種基於抗原-抗體複合物的結晶學研究的方法),及/或MacCallum (Kabat et al.,上文;Chothia et al., J. MoI. Biol, 1987, 196: 901-917;與MacCallum et al., J. MoI. Biol, 1996, 262: 732)。用於特徵鑑定抗原結合位點的又另一個標準是依據Oxford Molecular的AbM抗體模型化軟體使用的AbM定義。參見,例如Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg)。到兩個殘基鑑定技術定義區域重疊,但不是相同的區域的程度內,可以將它們組合以限定雜交CDR。然而,較佳是根據所謂Kabat系統的編號。
通常,CDR形成可被歸類為典型結構的環結構。術語「典型結構」意指抗原結合(CDR)環所採用主鏈構型。從比較的結構研究已發現,六個抗原結合環中,有5個只有一個有限組庫的可用構型。每個典型結構可以透過多肽骨架的扭轉角度來進行特徵鑑定。因而抗體之間的對應環可能具有非常相似的三維結構,儘管在環的大多數部分中有高胺基酸序列變異性(Chothia and Lesk, J. MoI. Biol., 1987, 196: 901;Chothia et al., Nature, 1989, 342: 877;Martin and Thornton, J. MoI. Biol, 1996, 263: 800)。此外,在採用的環結構和其周圍的胺基酸序列之間有關聯性。特定典型類別的構型是由環長度,和位在環內關鍵位置處還有守恆框架內的胺基酸殘基(亦即,環的外側)所決定。因此,可基於這些關鍵胺基酸殘基的存在來分配一個特定典型類別。
術語「典型結構」也包括考慮到抗體的線性序列,例如依據Kabat所分類(Kabat et al.,上文)。Kabat編號方案(系統)是一種廣泛採用的標準,用於以一致的方式將抗體可變域的胺基酸殘基編號,並且如本文他處提到的本發明中應用的較佳方案。附加的結構方面考量也可以用於決定抗體的典型結構。例如,那些並非完全由Kabat編號所反映的差異可透過Chothia等人的編號系統加以說明,及/或透過其他技術(例如,結晶學及二維或三維計算模型化)揭示。因此,一個給定的抗體序列可以放在典型類別中,其允許除其他事項外鑑定合適的框架序列(例如,基於需要納入在庫中的各種典型結構)。於文獻中描述抗體胺基酸序列的Kabat編號以及如Chothia等人,上文所述的結構考量,還有它們用於解釋抗體結構的典型態樣的涵義。不同類別免疫球蛋白的次單位結構及三維構型在本領域中是充分熟知的。關於抗體結構的回顧,參見Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988。
輕鏈的CDR3,以及特別是重鏈的CDR3可在抗原結合時於輕鏈及重鏈可變區內構成最重要的決定子。在一些抗體構築體,重鏈CDR3似乎構成抗原和抗體之間的主要接觸區域。可使用活體外選擇方案(其中單獨CDR3改變)來改變抗體的結合特性或確定哪些殘基貢獻了與抗原的結合。因此,CDR3通常是抗體結合位點內分子多樣性的最大來源。例如,H3可以是短到兩個胺基酸殘基或大於26個胺基酸。
抗體基因的序列在組裝後和體細胞突變後是高度變異的,並且這些變異的基因估計編碼1010種不同抗體分子(Immunoglobulin Genes, 2nd ed., eds. Jonio et al., Academic Press, San Diego, CA, 1995)。因此,免疫系統提供一個免疫球蛋白組庫。術語「組庫」意指完全或部分衍生自至少一個編碼至少一個免疫球蛋白之序列的至少一個核苷酸序列。可透過在活體內重排重鏈的V、D和J片段,以及輕鏈的V和J片段來產生序列。或者,可以從對發生重排(例如活體外刺激)有反應的細胞產生序列。或者,部分或全部序列可以透過DNA剪接、核苷酸合成、誘變,和其它方法獲得,參見,例如美國專利5,565,332。組庫可以只包括一種序列,或者可以包括多個序列,包括那些在遺傳多樣性集合中的序列。
在一個具體例中,本發明抗體構築體的第一結合域包含選自如下所述VH區組成之群的VH區:SEQ ID NO: 155、SEQ ID NO: 165、SEQ ID NO: 175、SEQ ID NO: 185、SEQ ID NO: 195、SEQ ID NO: 205、SEQ ID NO: 215、SEQ ID NO: 225、SEQ ID NO: 235,以及SEQ ID NO: 245。
在本發明抗體構築體的另一個具體例中,第一結合域包含選自如下所述VL區組成之群的VL區:SEQ ID NO: 156、SEQ ID NO: 166、SEQ ID NO: 176、SEQID NO: 186、SEQ ID NO: 196、SEQ ID NO: 206、SEQ ID NO: 216、SEQ ID NO: 226、SEQ ID NO: 236,和SEQ ID NO: 246。
在本發明抗體構築體的另一個具體例中,第一結合結構域包含選自如下所述之成對VH區與VL區組成之群的VH區及VL區:SEQ ID NO: 155+156、SEQID NO: 165+166、SEQ ID NO: 175+176、SEQ ID NO: 185+186、SEQ ID NO: 195+196、SEQ ID NO: 205+206、SEQ ID NO: 215+216、SEQ ID NO: 225+226、SEQ ID NO: 235+236,和SEQ ID NO: 245+246。
在另一個具體例中,本發明抗體構築體的第一結合域包含選自如下所述之VH區組成之群的VH區:SEQ ID NO: 285、SEQ ID NO: 295、SEQ ID NO: 305、SEQ ID NO: 315、SEQ ID NO: 325、SEQ ID NO: 335、SEQ ID NO: 345,以及SEQ ID NO: 355。
在本發明抗體構築體的又一個具體例中,第一結合域包含選自如下所述之VL區組成之群的VL區:SEQ ID NO: 286、SEQ ID NO: 296、SEQ ID NO: 306、SEQID NO: 316、SEQ ID NO: 326、SEQ ID NO: 336、SEQ ID NO: 346,以及SEQ ID NO: 356。
在本發明抗體構築體的另一個具體例中,第一結合域包含選自如下所述之成對VH區與VL區組成之群的VH區及VL區:SEQ ID NO: 285+286、SEQID NO: 295+296、SEQ ID NO: 305+306、SEQ ID NO: 315+316、SEQ ID NO: 325+326、SEQ ID NO: 335+336、SEQ ID NO: 345+346,和SEQ IDNO: 355+356。
術語「雙特異性」如本文所用意指抗體構築體是「至少雙特異性」,亦即它包含至少一個第一結合域和第二結合域,其中第一結合域結合至一個抗原或目標(在此為CDH3),而第二結合域結合至另一個抗原或目標(在此為CD3)。因此,根據本發明的抗體構築體包含對至少兩種不同抗原或目標的特異性。術語本發明的「雙特異性抗體構築體」還含括多特異性抗體構築體,例如三特異性抗體構築體,後者包括具有超過三種(例如四種,五種…)特異性的三個結合域或構築體。
鑑於根據本發明的抗體構築體(至少)是雙特異性,它們不自然地發生,且它們與天然產品明顯不同。因此,「雙特異性」抗體構築體或免疫球蛋白是具有至少兩個有不同特異性的獨特結合部位的人工雜交抗體或免疫球蛋白。雙特異性抗體可以透過多種方法(包括融合瘤的融合或連接Fab'片段)產生。見,例如Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990)。
本發明抗體構築體的至少兩個結合域以及可變域可以或可以不包括肽連接子(間隔肽)。術語「肽連接子」依據本發明定義胺基酸序列,本發明抗體構築體的一個(可變及/或結合)域與另一個(可變及/或結合)域的胺基酸序列藉其互相連接。這種肽連接子的一個必要技術特徵在於,它不包含任何聚合活性。合適的肽連接子描述於美國專利4,751,180和4,935,233或WO88/09344中。
在使用連接子的情況下,連接子較佳具有足以確保第一及第二結構域各自可以彼此獨立保有其差異性結合特異性的長度與序列。對於在本發明抗體構築體(或兩個可變域)中連接至少兩個結合域的肽連接子來說,那些肽連接子較佳是包含只有數個胺基酸殘基的肽連接子,例如12個胺基酸殘基或更少。因此,具有12個、11個、10個、9個、8個、7個、6個或5個胺基酸殘基的連接子較佳。少於5個胺基酸的預想肽連接子包含4個、3個、2個或一個胺基酸,其中富含甘胺酸的連接子較佳。在該「肽連接子」中尤佳的「單一」胺基酸是Gly。因此,該肽連接子可以由單個胺基酸Gly所組成。肽連接子的另一較佳具體例的特徵在於胺基酸序列Gly-Gly-Gly-Gly-Ser,亦即Gly
4Ser (SEQ ID NO: 393),或其聚合物,亦即(Gly
4Ser)x,其中x是1或更大的一個整數。該肽連接子的特性(包括不存在促進二級結構)在本技藝中是已知的並且例如描述Dall’Acqua et al. (Biochem. (1998) 37, 9266-9273)、Cheadle et al. (Mol Immunol (1992) 29, 21-30)與Raag and Whitlow (FASEB (1995) 9(1), 73-80)中。也不促進任何二級結構的肽連接子較佳。可提供該等結構域彼此的鍵聯,例如藉由遺傳工程,如實例中所述。在本技藝中熟知用於製備融合且可操作地連接之雙特異性單鏈構築體並在哺乳動物細胞或細菌中表現它們的方法(如WO99/54440 Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001))。
因此,本發明提供一個較佳具體例,其中抗體構築體呈選自以下組成之群的形式:(scFv)2、scFv-單域mAb、雙功能抗體或任一前述形式的寡聚體。術語「呈一種形式」不排除構築體可進一步修飾,例如透過附接或融合至其它部分,如本文所述。
根據一個尤佳的具體例,本發明抗體構築體為「雙特異性單鏈抗體構築體」,更佳為雙特異性「單鏈Fv」(scFv)。儘管Fv片段的兩個結構域(VL和VH)由個別的基因編碼,可以使用重組方法經由合成連接子將它們接合,使得它們能夠製備成單蛋白質鏈,其中VL區和VH區配對以形成單價分子;參見例如,Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883)。這些抗體片段是使用習於技藝者所熟知的習知技術獲得,並且以與完全或全長抗體相同的方式來評估片段的功能。單鏈可變片段(scFv)因此是免疫球蛋白的重鏈(VH)可變區與輕鏈(VL)可變區的融合蛋白,通常是用大約十個至約25個胺基酸,較佳約15至20個胺基酸的短肽連接子予以連結。連接子通常是富含甘胺酸以提供可撓性,還有絲胺酸或蘇胺酸以提供溶解度,並且可將VH的N端與VL的C端連接,或反之亦然。這個蛋白質保留了原有免疫球蛋白的特異性,儘管已移除恆定區並且引入連接子。
在本技藝中已熟知雙特異性單鏈分子,並且描述於WO 99/54440、Mack, J. Immunol. (1997), 158, 3965-3970、Mack, PNAS, (1995), 92, 7021-7025、Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197、Löffler, Blood, (2000), 95, 6, 2098-2103、Brühl, Immunol., (2001), 166, 2420-2426、Kipriyanov, J. Mol. Biol., (1999), 293, 41-56中。可採用生產單鏈抗體的技術(參見,尤其是美國專利4,946,778、Kontermann and Dübel (2010),上文以及Little (2009),上文)產生特異性辨識選定目標的單鏈抗體構築。
二價(bivalent)(也稱為二價(divalent))或雙特異性單鏈可變片段(二scFv或二scFv具有形式(scFv)2,可以透過將兩個scFv分子連接而被工程化。如果這兩個scFv分子具有相同的結合特異性,所得(scFv)2分子較佳被稱為二價(亦即它對同一個目標表位具有兩個價數)。如果兩個scFv分子具有不同的結合特異性,則所得(scFv)2分子較佳被稱為雙特異性。可以藉由產生具有兩個VH區和兩個VL區的單一肽鏈而產生連結,產生串聯的scFv (參見例如Kufer P. et al., (2004) Trends in Biotechnology 22(5):238-244)。另一種可能性是產生具有短到兩個可變區無法一起摺疊之連接子肽(例如約五個胺基酸)的scFv分子,迫使scFv二聚體化。這種類型已知為雙功能抗體(參見例如Hollinger, Philipp et al., (July 1993) Proceedings of the National Academy of Sciences of the United States of America 90 (14): 6444-8)。
根據本發明抗體構築體的另一個較佳具體例,結合域(結合至目標抗原CDH3或CD3)的重鏈(VH)和輕鏈(VL)不直接經由如上所述的肽連接子連接,而是結合域形成所述的雙功能抗體。因此,CD3結合域的VH可以經由肽連接子融合至CDH3結合域的VL,而CDH3結合域的VH經由此等肽連接子融合至CD3結合域的VL。
單域抗體包含僅僅一個(單體)抗體可變域,其能夠選擇性地結合至獨立於其它V區或結構域的一個特定抗原。第一單域抗體是由在駱駝中發現的重鏈抗體工程化而來,且這些被稱為VHH片段。軟骨魚也具有從其中可以得到單域抗體(稱為VNAR片段)的重鏈抗體(IgNAR)。另一種方法是將常見免疫球蛋白(例如人類或囓齒動物)的二聚可變域分裂成單體,因而得到VH或VL作為單域抗體。雖然大多數的單域抗體研究目前是基於重鏈可變域,但衍生自輕鏈的奈米抗體也已經顯示會特異性地結合到目標表位。單域抗體的實例稱為sdAb,奈米抗體或單可變域抗體。
(單域mAb)2因而是一種由(至少)兩個單域單株抗體組成的單株抗體構築體,其分別選自包含VH、VL的VHH和VNAR的群。連接子較佳呈肽連接子的形式。同樣地,「scFv-單域mAb」是一種單株抗體構築體,由至少一個如上所述的單域抗體以及一個如上所述的scFv分子組成。再次,連接子較佳呈肽連接子的形式。
在一個具體例中,第一結合域包含選自那些如下所述序列組成之群的胺基酸序列:如SEQ ID NO: 157、SEQ ID NO: 167、SEQ ID NO: 177、SEQ ID NO: 187、SEQ ID NO: 197、SEQ ID NO: 207、SEQ ID NO: 217、SEQ ID NO: 227、SEQ ID NO: 237,和SEQ ID NO: 247。
在另一個具體例中,第一結合域包含選自那些如下所述序列組成之群的胺基酸序列:SEQ ID NO:287、SEQ ID NO: 297、SEQ ID NO: 307、SEQ ID NO: 317、SEQ ID NO: 327、SEQ ID NO: 337、SEQ ID NO: 347,和SEQ ID NO: 357。
亦預想,本發明抗體構築體除了它結合至目標分子CDH3和CD3的功能以外,還有另一個功能。在這種形式中,抗體構築體因為結合至CDH3而靶向目標細胞、透過CD3結合而媒介細胞毒性T細胞活性,並提供進一步的功能(諸如透過招募像是NK細胞的效應細胞、一個標記(螢光等)、治療劑(諸如毒素或放射性核種),及/或提高血清半衰期等的裝置),而為一種三功能或多功能抗體構築體。
擴展本發明抗體構築體的血清半衰期的實例包括肽、蛋白質或蛋白質結構域,其融合或以其它方式附接至抗體構築體。肽,蛋白質或蛋白質結構域的群組包括結合至在人類體內具有較佳藥動學概況的其他蛋白質(諸如血清白蛋白)之肽(參見WO 2009/127691)。其中的一個實例已SEQ ID NO: 437表示。此等半衰期延長(HLE)肽的替代性概念包括結合至新生兒Fc受體的肽(FcRn,參見WO 2007/098420),其亦用於本發明的一些構築體中。附接較大的蛋白質結構域或完整蛋白質的概念包括例如人類血清白蛋白、人類血清白蛋白之變異體或突變體的融合物(參見WO 2011/051489、WO 2012/059486、WO 2012/150319、WO 2013/135896、WO 2014/072481、WO 2013/075066)或其結構域還有免疫球蛋白恆定區(Fc域)及其變異體的融合物。Fc域的此等變異體可以被最佳化/修改,以允許二聚體或多聚體的期望配對、消除Fc受體結合(例如Fcγ受體)或其他原因。如果上述HLE分子是由僅單一條多肽鏈組成,則它們具有以下優點:(ⅰ)不需要兩個獨立的表現系統,以及(ii)它們可被分離具有高純度的,由於沒有一個「虛擬鏈(dummy chain)」。技藝中已知另一種在人類體內延長小蛋白質化合物半衰期的概念是將那些化合物聚乙二醇化,那些化合物為諸如本發明抗體構築體。
在一個較佳具體例中,根據本發明的雙特異性抗體構築體可以與融合伴侶(諸如蛋白質或多肽或肽)連結(例如,經由肽鍵),例如出於擴展構築體的血清半衰期之目的。這些融合伴侶可以從人類血清白蛋白(「HSA」或「HALB」)還有其序列變異體、結合至HSA的肽、結合至FcRn的肽(「FcRn BP」),或含有(抗體衍生之) Fc區之構築體選出。這些融合夥伴的例示性序列分別示於SEQ ID NO: 406-421和437-444中。大體上,融合伴侶可以連接至本發明雙特異性抗體構築體的N端或C端,無論是直接(例如經由肽鍵)或經由肽連接子(諸如GGGGS)n (其中「n」是2或更大的整數,如2或3或4)。合適的肽連接子示於SEQ ID NO: 392-400中。
出於延伸構築體血清半衰期之目的,命名為CDH3-13 (如SEQ ID NO: 178中所示的雙特異性分子的全長序列)的抗體構築體在框架內與選擇的融合蛋白或融合肽連結(參見例如SEQ ID NO: 437-444)。這些融合構築體的個別序列示於SEQ ID NO: 379-389中。這些融合夥伴相對於「裸」雙特異性抗體構築體的序列也可被連結(C端或N端,以它對應且顯示為CDH3-13的方式)到任何其他本文所揭示的抗體構築體。
因此,預想本發明雙特異性抗體構築體進一步包含如SEQ ID NO: 437中所示的多肽或白蛋白,較佳為人類白蛋白或其變異體(具有改善的特性,例如對FcRn受體的親和力以及擴展血漿半衰期),最佳為如SEQ ID NO: 443或444所示的白蛋白。這些部分較佳是在框架內融合至雙特異性抗體構築體的C端。
實例15另外顯示了一個意想不到的優點,即白蛋白的C-末端融合到本發明雙特異性抗體構築體牽涉其中。關於那些對人類與狨、獠狨或松鼠猴CD3ε鏈具有特異性之結合域的雙特異性T細胞接合分子來說(其中表位是由WO 2008/119567之SEQ ID NO: 2、4、6或8組成之群包含的胺基酸序列的一部分,且包含至少胺基酸序列Gln-Asp-Gly-Asn-Glu),觀察到那些分子-以非常高的濃度使用時-顯示T細胞細胞毒性,甚至在不存在目標細胞的情況下。這種高濃度的問題可能與特定給藥途徑或與特定目標設置和所需化合物濃度組合有關。結合至T細胞表面上之人類CD3的此等第二結合域的較佳實例描述於下文並示於SEQ ID NO: 445-537中。當血清白蛋白融合至此雙特異性構築體的C端時,得以避免T細胞細胞毒性,參見圖13。在不希望受理論的囿限的情況下,在高濃度T細胞接合雙特異性抗體構築體的存在下以及在目標細胞不存在下,抗體構築體經由CD3結合域而二聚體化或多聚體化可解釋T細胞活化。此二聚體化或多聚體化在空間上受到白蛋白或其變異體融合至抗體構築體之C端而被削弱,同時維持該抗體構築體對其T細胞接合作用模式的特徵。
因此,根據本發明一個較佳抗體構築體自N端到C端順序包含:
• 一結合域,具有選自由SEQ ID NO: 157、SEQ ID NO: 167、SEQ ID NO: 177、SEQ ID NO: 187、SEQ ID NO: 197、SEQ ID NO: 207、SEQ ID NO: 217、SEQ ID NO: 227、SEQ ID NO: 237、SEQ ID NO: 247、SEQ ID NO: 287、SEQ ID NO: 297、SEQ ID NO: 307、SEQ ID NO: 317、SEQ ID NO: 327、SEQ ID NO: 337、SEQ ID NO: 347,和SEQ ID NO: 357組成之群的胺基酸序列;
• 肽連接子,具有選自由SEQ ID NO: 392-400組成之群的胺基酸序列;
• 第二結合域,具有選自由SEQ ID NO: 453、SEQ ID NO: 462、SEQ ID NO: 471、SEQ ID NO: 480、SEQ ID NO: 489、SEQ ID NO: 498、SEQ ID NO: 507、SEQ ID NO: 516、SEQ ID NO: 525、SEQ ID NO: 534,和SEQ ID NO: 537組成之群的胺基酸序列;以及
• 視情況選用的肽連接子,具有選自由SEQ ID NO: 392-400組成之群的胺基酸序列;以及
• 多肽,具有選自由SEQ ID NO: 437、443和444組成之群的胺基酸序列。
根據另一個較佳具體例,本發明雙特異性抗體構築體包含(除了兩個結合域以外)第三域,其包含兩條多肽單體,各自包含鉸鏈、CH2和CH3域,其中該兩條多肽(或多肽單體)經由肽連接子彼此融合。較佳地,該第三域以N端至C端順序包含:鉸鏈-CH2-CH3-連接子-鉸鏈-CH2-CH3。該第三域的較佳胺基酸序列示於SEQ ID NO: 414-421中。該多肽單體的每一者較佳具有一個胺基酸序列,其選自由SEQ ID NO: 406-413組成之群,或與那些序列為至少90%一致。在另一個較佳具體例中,本發明的特異性抗體構築體的第一和第二結合域經由肽連接子融合至第三域,肽連接子例如是選自由SEQ ID NO: 392-400中任一者組成之群,較佳選自由SEQ ID NO: 392、393、395、396、397、399,和400中任一者組成之群。
與本發明相符,「鉸鏈」是IgG鉸鏈區。該區可以透過類推使用Kabat編號予以識別,參見Kabat位置223-243。在與上文相符,「鉸鏈」的最低標準是依照Kabat編號對應於IgG1序列之D231至P243延伸段的胺基酸殘基。術語CH2和CH3意指免疫球蛋白重鏈恆定區2和3。這些區域也可以透過類推使用Kabat編號予以識別,參見CH2的Kabat位置244-360和CH3的Kabat位置361-478。應理解,免疫球蛋白在IgG1 Fc區、IgG2 Fc區、IgG3 Fc區、IgG4 Fc區、IgM Fc區、IgA Fc區、IgD Fc區和IgE Fc區之間有一些變化(參見,例如Padlan, Molecular Immunology, 31(3), 169-217 (1993))。術語Fc單體意指IgA、IgD和IgG的最後兩個重鏈恆定區,以及IgE和IgM的最後三個重鏈恆定區。Fc單體亦可包括可撓性鉸鏈N端朝向這些域。就IgA和IgM而言,Fc單體可包括J鏈。就IgG而言,Fc部分包括免疫球蛋白結構域CH2和CH3和前兩個結構域和CH2之間的鉸鏈。雖然免疫球蛋白的Fc部分邊界可以改變,但包含功能性鉸鏈、CH2與CH3域之人類IgG重鏈Fc部分的一個實例可分別定義成,例如包含(鉸鏈域)的殘基D231至(CH3域的C端)的P476,或D231至L476 (就IgG4而言),其中編號是根據Kabat。
因此,本發明抗體構築體以N端至C端順序包含:
(a) 第一結合域;
(b) 肽連接子,具有選自由SEQ ID NO: 393、399及400組成之群的胺基酸序列;
(c) 第二結合域;
(d) 肽連接子,具有選自由SEQ ID NO: 392、393、395、396、397、399,及400組成之群的胺基酸序列;
(e) 第三域的第一多肽單體(包含鉸鏈、CH2及CH3域);
(f) 肽連接子,具有選自由SEQ ID NO: 402、403、404及405組成之群的胺基酸序列;以及
(g) 第三域的第二多肽單體(包含鉸鏈、CH2及CH3域)。
較佳是本發明抗體構築體以N端至C端順序包含:
(a) 第一結合域,具有選自由SEQ ID NO: 157、SEQ ID NO: 167、SEQ ID NO: 177、SEQ ID NO: 187、SEQ ID NO: 197、SEQ ID NO: 207、SEQ ID NO: 217、SEQ ID NO: 227、SEQ ID NO: 237、SEQ ID NO: 247、SEQ ID NO: 287、SEQ ID NO: 297、SEQ ID NO: 307、SEQ ID NO: 317、SEQID NO: 327、SEQ ID NO: 337、SEQ ID NO: 347,和SEQ ID NO: 357組成之群的胺基酸序列;
(b) 肽連接子,具有選自由SEQ ID NO: 393、399和400組成之群的胺基酸序列;
(c) 第二結合域、具有選自由SEQ ID NO: 453、SEQ ID NO: 462、SEQ ID NO: 471、SEQ ID NO: 480、SEQ ID NO: 489、SEQ ID NO: 498、SEQ ID NO: 507、SEQ ID NO: 516、SEQ ID NO: 525、SEQ ID NO: 534,和SEQ ID NO: 537組成之群的胺基酸序列;
(d) 肽連接子,具有選自由SEQ ID NO: 392、393、395、396、397、399,和400組成之群的胺基酸序列;以及
(e) 第三域,具有選自由SEQ ID NO: 414-421組成之群的胺基酸序列。
因此,在一個較佳具體例中,本發明抗體構築體包含選自由SEQ ID NO: 422、SEQ ID NO: 423、SEQ ID NO: 424、SEQ ID NO: 425、SEQ ID NO: 426、SEQ ID NO: 427、SEQ ID NO: 428、SEQ ID NO: 429、SEQ ID NO: 430、SEQ ID NO: 431、SEQ ID NO: 432、SEQ ID NO: 433、SEQ ID NO: 434,和SEQ ID NO: 435中所示者組成之群的多肽或由其組成。
參照實例15,顯示上述Fc構築體之一及其在小鼠異種移植模型中的抗腫瘤活性。
抗體構築體的共價修飾也包括在本發明的範疇之內,並且通常但不總是在轉譯後完成。例如,多種類型的抗體構築體共價修飾是透過使該抗體構築體的特定胺基酸殘基與有機衍生化試劑(能夠與選定側鏈或N-或C-端殘基反應)反應而被引入分子中。
半胱胺醯基殘基最常見與α-鹵代乙酸(和對應的胺)(諸如氯乙酸或氯乙醯胺)反應,以得到羧甲基或羧基醯胺甲基衍生物。半胱胺醯基殘基也可以透過與溴代三氟丙酮,α-溴-β-(5-咪唑基)丙酸、氯乙醯基磷酸鹽、N-烷基馬來醯亞胺、3-硝基-2-吡啶基二硫化物、甲基2-吡啶基二硫化物、對氯汞基苯甲酸、2-氯汞基-4-硝基苯酚,或氯-7-硝基苯并-2-氧雜-1,3-二唑反應而被衍生化。
組胺醯基殘基是透過在pH5.5-7.下0與焦碳酸二乙酯反應而被衍生化,因為此試劑對組胺醯基側鏈有相對特異性。對-溴苯甲醯甲基溴也可供使用;該反應較佳在0.1M二甲胂酸鈉、pH 6.0下進行。離胺醯基和胺基端殘基與琥珀酸酐或其他羧酸酐反應。用這些試劑進行的衍生化具有反轉離胺醯基殘基電荷的效用。用於衍生含α-胺基殘基的其他適宜試劑包括亞胺酸酯,諸如甲基吡啶亞胺甲酯;磷酸吡哆醛;吡哆醛;硼氫化氯;三硝基苯磺酸;O-甲基異脲;2,4-戊二酮;以及使用乙醛酸的轉胺酶催化反應。
精胺醯基殘基透過與一種或數種習知試劑反應而被修飾,其中苯甲醯甲醛、2,3-丁二酮、1,2-環己二酮,和茚三酮。精胺酸殘基的衍生化需要在鹼性條件下進行反應,因為胍官能基具有高pKa。此外,這些試劑可以與離胺酸的基團以及精胺酸ε-胺基反應。
可以進行酪胺醯基殘基的特異性修飾,其中尤其感興趣的是透過與芳香族重氮化合物或四硝基甲烷反應將光譜標記引入酪胺醯基殘基。最常見的是使用N-二乙醯基咪唑和四硝基甲烷以分別形成O-乙醯基酪胺醯基物質和3-硝基衍生物。使用125I或131I將酪胺醯基殘基碘化以製備用於上述適宜之放射免疫分析、氯胺T法的標記蛋白質。
藉由與碳二亞胺(R'-N=C=N-R')反應而選擇性地修飾羧基側基(天冬胺醯基或麩胺醯基),其中R和R是視情況選用的不同烷基,諸如1-環己基-3-(2-嗎啉基-4-乙基)碳二亞胺或1-乙基-3-(4-氮鎓-4,4-二甲基戊基)碳二亞胺。此外,天冬胺醯基和麩胺醯基殘基是透過與銨離子反應而被轉化為天冬醯胺醯基和麩醯胺醯基殘基。
衍生化與雙功能試劑是用於將本發明抗體構築體交聯至水不溶性支撐持基質或表面以供用於各種方法中。常用的交聯劑包括,例如1,1-雙(重氮乙醯基)-2-苯乙烷、戊二醛、N-羥基琥珀醯亞胺酯(例如與4-疊氮基水楊酸)、同雙功能亞胺酸酯(包括二琥珀醯亞胺酯,諸如3,3'-二硫代雙(琥珀醯亞胺基丙酸酯),和雙功能馬來醯亞胺(諸如雙-N-馬來醯亞胺基-1,8-辛烷)。衍生劑(諸如甲基-3-[(對-疊氮基苯基)二硫代]丙醯亞胺)產生可光活化的中間體,其能夠在光的存在下形成交聯。或者,反應性水不溶性基質(諸如溴化氰活化的碳水化合物)和反應基質(如美國專利第3,969,287號;第3,691,016號;第4,195,128號;第4,247,642號;第4,229,537號;以及第4,330,440號中所述)被用於蛋白質固定。
麩胺醯胺基和天冬醯胺醯基殘基常常分別脫醯胺成對應的麩胺醯基和天冬胺醯基殘基。或者,這些殘基在溫和的酸性條件下脫醯胺。這些殘基的任一種形式屬於本發明的範疇之內。
其它修飾包括脯胺酸和離胺酸的羥基化、絲胺醯基或蘇胺醯基殘基之羥基的磷酸化、離胺酸、精胺酸與組胺酸側鏈的α胺基的甲基化(T. E. Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, 1983, pp. 79-86)、N端胺的乙醯化,以及任何C端羧基的醯胺化。
包括在本發明範疇內的抗體構築體的另一類型共價修飾包含改變蛋白質的糖基化模式。如本技藝中已知的,糖基化模式可取決於蛋白質序列(例如,存在或不存在的特定的糖基化胺基酸殘基,在下面討論),或生產該蛋白質的宿主細胞或生物。在下面討論具體的表現系統。
多肽的糖基化通常是N-連接型或O-連接型。N-連接型意指碳水化合物部分與天冬醯胺酸殘基的側鏈附接。三肽序列天冬醯胺酸-X-絲胺酸和天冬醯胺酸-X-蘇胺酸,其中X是除脯胺酸外的任何胺基酸,是碳水化合物部分與天冬醯胺酸側鏈的酶促附接的辨識序列。因此,這些三肽序列的存在在一條多肽中產生了潛在的糖基化位點。O-連接型糖基化意指將糖N-乙醯基半乳糖胺、半乳糖或木糖之一附接到羥基胺基酸,最常見的是絲胺酸或蘇胺酸,儘管也可以使用5-羥基脯胺酸或5-羥基離胺酸。
便利地透過改變胺基酸序列,使其包含一或多個上述三肽序列(用於N-連接型糖基化位點)來實現將糖基化位點添加至抗體構築體。還可透過加入或替代一個或多個絲胺酸或蘇胺酸殘基至起始序列(用於O-連接型糖基化位點)來產生改變。為方便起見,抗體構築體的胺基酸序列較佳是透過在DNA層次上的改變,特別是透過讓編碼多肽的DNA在預選鹼基處突變,使得產生的密碼子將轉譯成所需胺基酸。
增加抗體構築體的碳水化合物部分數量的另一種方法是藉由使糖苷與蛋白質化學或酶促偶合。這些程序的優點在於它們不需要在具有N-和O-連接型糖基化的糖基化能力的宿主細胞內生產蛋白質。根據所使用的偶合模式,糖可以附接至(a)精胺酸和組胺酸、(b)游離羧基、(c)游離巰基,諸如半胱胺酸的游離巰基、(d)游離羥基基團,諸如絲胺酸、蘇胺酸,或羥基脯胺酸的游離羥基基團、(e)芳香族殘基,諸如苯丙胺酸、酪胺酸或色胺酸的芳香族殘基,或(f)麩胺醯胺酸的醯胺基。這些方法描述於WO 87/05330中,以及在Aplin and Wriston, 1981, CRC Crit. Rev. Biochem., pp. 259-306中。
可透過以化學或酶促方式移除存在於起始抗體構築體的碳水化合物部分。化學去糖基化需要蛋白質暴露於化合物三氟甲磺酸或等效化合物。這個處理導致除了連接糖(N-乙醯基葡糖胺或N-乙醯基半乳糖胺)外的大部分或全部糖的裂解,同時使多肽保持完整。化學去糖基化由Hakimuddin et al., 1987, Arch. Biochem. Biophys. 259:52與Edge et al., 1981, Anal. Biochem. 118:131描述。關於多肽上碳水化合物部分的酶促裂解可以透過使用多種內切和外切糖苷酶如Thotakura et al., 1987, Meth. Enzymol. 138:350所述來實現。在潛在糖基化位點的糖基化可藉由使用如Duskin et al., 1982, J. Biol. Chem. 257:3105所述化合物衣黴素來防止。衣黴素阻斷蛋白質-N-糖苷鍵聯的形成。
本文亦預想抗體構築體的其他修飾。例如,另一類型的抗體構築體共價修飾包含將抗體構築體連接至各種非蛋白質聚合物,非蛋白質聚合物包括,但不限於多元醇(諸如聚乙二醇、聚丙二醇、聚氧化烯,或聚乙二醇和聚丙二醇的共聚物),以在美國專利案第4,640,835號;第4,496,689號;第4,301,144號;第4,670,417號;第4,791,192號或第4,179,337號中所述的方式。此外,如技藝中已知,胺基酸置換可以在抗體構築體中的各種位置進行,例如為了便於添加聚合物(諸如PEG)。
在一些具體例中,本發明抗體構築體的共價修飾包含添加一或多種標記。該標記基團可以經由各種長度的間隔臂偶合至抗體構築體,以減少潛在的空間位阻。用於標記蛋白質的各種方法在技藝中是已知的,並且可以用來實施本發明。術語「標記」或「標記基團」意指任何可檢測的標記。一般而言,標記落入各種類,這取決於它們是待檢測的分析-以下實施例包括,但不限於:
a) 同位素標記,其可以是放射性或重同位素,諸如放射性同位素或放射性核種(例如,
3H、
14C、
15N、
35S、
89Zr、
90Y、
99Tc、
111In、
125I、
131I)
b) 磁性標記(例如磁性粒子)
c) 氧化還原活性部分
d) 光學染料(包括,但不限於發色團、磷光體和螢光團),例如螢光基團(例如FITC、羅丹明、鑭系磷光體)、化學發光基團,和可以是「小分子」螢光或蛋白質螢光的螢光團
e) 酶基團(例如辣根過氧化物酶、β-半乳糖苷酶、螢光素酶、鹼性磷酸酶)
f) 生物素化基團
g) 由次級報導分子識別之預先確定的多肽表位(例如,白胺酸拉鍊對序列、二級抗體的結合位點、金屬結合域、表位標籤等)。
「螢光標記」表示可經由其固有的螢光特性而被檢測的任何分子。合適的螢光標記包括但不限於螢光素、羅丹明、四甲基羅丹明、伊紅、藻紅、香豆素、甲基香豆素、芘、孔雀石綠、芪、螢光黃、瀑布藍、德州紅、IAEDANS、EDANS、BODIPY FL、LC紅640、Cy 5、Cy 5.5、LC紅705、俄勒岡綠、Alexa-Fluor染料(Alexa Fluor350、Alexa Fluor430、Alexa Fluor488、Alexa Fluor 546、Alexa Fluor 568、Alexa Fluor 594、Alexa Fluor 633、Alexa Fluor 660、Alexa Fluor 680)、瀑布藍、瀑布黃和R-藻紅蛋白(PE)( Molecular Probes, Eugene, OR)、FITC、羅丹明和德州紅(Pierce, Rockford, IL)、Cy5、Cy5.5、Cy7 (Amersham Life Science, Pittsburgh, PA)。合適的光學染料(包括螢光團)描述於Richard P. Haugland的Molecular Probes Handbook中。
合適的蛋白質螢光標記還包括但不限於,綠色螢光蛋白(包括海腎、海筆或水母物種的GFP(Chalfie
et al., 1994,
Science263:802-805)、EGFP (Clontech Laboratories, Inc.,Genbank登錄號U55762)、藍色螢光蛋白(BFP,Quantum Biotechnologies, Inc. 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H 1J9; Stauber, 1998,
Biotechniques24:462-471;Heim
et al., 1996,
Curr. Biol.6:178-182)、增強的黃色螢光蛋白(EYFP,Clontech Laboratories, Inc.)、螢光素酶(Ichiki
et al., 1993,
J. Immunol.150:5408-5417)、β半乳糖苷酶(Nolan
et al., 1988,
Proc. Natl. Acad. Sci. U.S.A. 85:2603-2607),和海腎(WO92 /15673、WO95 /07463、WO98/14605、WO98/26277、WO99/49019、美國專利第5,292,658號;第5,418,155號;第5,683,888號;第5,741,668號;第5,777,079號;第5,804,387號;第5,874,304號;第5,876,995號;第5,925,558號)。
白胺酸拉鍊結構域是促進它們被發現的蛋白質寡聚化。白胺酸拉鍊最初是在幾個DNA結合蛋白中被鑑定(Landschulz
et al., 1988,
Science240:1759),且從那時起已在各種不同的蛋白質中被發現。已知白胺酸拉鍊是天然存在的肽及其衍生物,它們是二聚體化或三聚體化。適於生產可溶性寡聚蛋白質的白胺酸拉鍊結構域的實例描述於PCT申請案WO 94/10308,而衍生自肺表面蛋白質D (SPD)的白胺酸拉鍊描述於Hoppe
et al., 1994,
FEBS Letters344:191中。使用經修飾的白胺酸拉鍊,允許與其融合的異源蛋白質穩定三聚體化描述於Fanslow
et al., 1994, Semin. Immunol. 6:267-78。在一種方法中,包含融合至一個白胺酸拉鍊肽之CDH3抗體片段或衍生物的重組融合蛋白在適當的宿主細胞中表現,以及從培養上清液回收形成之可溶性寡聚CDH3抗體片段或衍生物。
本發明的抗體構築體也可包含額外結構域,例如有助於分離分子或者語分子所採用的藥動學概況有關。有助於分離抗體構築體的結構域可選自肽模組或其次被引入的部分,它可以在一個分離方法(例如分離管柱)中被捕獲。此等額外結構域的非限制性具體例包括已知為Myc-標籤、HAT-標籤、HA-標籤、TAP-標籤、GST-標籤、幾丁質結合域(CBD-標籤)、麥芽糖結合蛋 (MBP-標籤)、Flag-標籤、Strep-標籤及其變體(如StrepII-標籤)和His-標籤的肽柱體(peptide motives)。依據所識別的CDR進行特徵鑑定之本文揭示的所有抗體構築體較佳包含His-標籤結構域,其通常已知為分子之胺基酸序列中的連續His殘基重複序列,較佳為五個,且更佳為六個His殘基(六組胺酸,參見SEQ ID NO: 436)。His-標籤可以例如位於在抗體構築體的N-或C-端處,較佳它位於C-端。最佳地,六組胺酸標籤(HHHHHH)是經由肽鍵連結至根據本發明的抗體構築體的C-端。
本發明的抗體構築體的第一結合域結合至目標細胞表面上的人類CDH3。人類CDH3的胺基酸序列由SEQ ID NO: 1表示。應了解,術語「表面上」,在本發明的上下文中,表示結合域特異性地結合至包含在CDH3胞外域(CDH3 ECD)之內的表位或表位簇。因此,當根據本發明的第一結合域是由天然表現細胞或細胞株,及/或由經轉形或經CDH3 (穩定/瞬時)轉染的細胞或細胞株表現時,其較佳結合至CDH3。在一個較佳具體例中,當CDH3在活體外結合分析(諸如BIAcore或斯卡查德(Scatchard))中用作為「目標」或「配體」時,第一結合域也結合至CDH3。「目標細胞」可以是在其表面上表現CDH3的任何原核或真核細胞;目標細胞較佳是人類或動物體一部分的細胞,如腫瘤或癌症細胞。
術語「CDH3 ECD」意指CDH3的一種形式,其基本上不含CDH3的跨膜和細胞質結構域。習於技藝者將能理解,依據技藝中慣常用於鑑別疏水性結構域的標準來鑑定本發明CDH3多肽鑑定的跨膜域。跨膜域的精確邊界可能會改變,但在本文中具體提及的結構域任一端處不超過約5個胺基酸的可能性最大。較佳的人類CDH3 ECD顯示於SEQ ID NO: 3中。
人類CDH3的第一結合域的親和力較佳≤15 nM、更佳≤10 nM,甚至更佳≤5 nM,甚至更佳≤1 nM,甚至更佳≤0.5 nM,甚至更佳≤0.1 nM,和最佳≤0.05 nM。親和力例如可以在BIAcore分析中或在斯卡查德分析中(例如實例中所述)進行測量。測定親和力的其他方法是技術人員所熟知的。
T細胞或T淋巴細胞是一種類型的淋巴細胞(本身類型白血球),它們在細胞媒介的免疫中扮演關鍵角色。有數種T細胞的子集,各自具有不同的功能。T細胞可以與其他淋巴細胞(諸如B細胞和NK細胞)區分開來,依據細胞表面上存在的T細胞受體(TCR)。TCR負責辨識結合至主要組織相容性複合物(MHC)分子的抗原和由兩種不同的蛋白質鏈組成。在95%的T細胞中,TCR由一個α鏈和β鏈組成。當TCR與抗原肽和MHC (肽/MHC複合物)接合時,T淋巴細胞是透過一系列由相關的酶、共受體、特化轉接分子媒介之生化事件所活化,並活化或釋放轉錄因子。
CD3受體複合物是一種蛋白質複合物,並且是由四條鏈組成。在哺乳動物中,該複合物含有一條CD3γ鏈、一條CD3δ鏈和兩條CD3ε鏈。 這些鏈與T細胞受體(TCR)和所謂的ζ鏈締合以形成T細胞受體CD3複合物,並在T淋巴細胞中產生活化信號。CD3γ、CD3δ,和CD3ε)鏈是高度相關的免疫球蛋白超家族的細胞表面蛋白,包含單一胞外免疫球蛋白結構域。CD3分子的胞內尾部包含稱為基於免疫受體酪胺酸的活化模組或簡稱ITAM的單個守恆模組,這對於TCR的信號傳導能力至關重要。該CD3ε分子在人類中是由駐留在11號染色體的
CD3E基因所編碼的多肽。最佳的CD3結合表位對應於人類CD3ε胞外域的胺基酸殘基1-27。
經由T細胞的招募,目標細胞受到多特異性(至少是雙特異性)抗體構築體的重新定向溶解涉及細胞溶解突觸形成和穿孔蛋白及顆粒酶的遞送。接合的T細胞能夠連續溶解目標細胞,並且不會受到免疫逃逸機制干擾肽抗原加工和呈遞,或單株T細胞分化所影響。參見,例如WO 2007/042261。
透過CDH3/CD3雙特異性抗體構築體媒介的細胞毒性可以用各種方式來測定。效應細胞可以是例如經刺激的富集(人類)CD8陽性T細胞或未經刺激的(人類)周邊血液單核細胞(PBMC)。如果目標細胞是獼猴來源或表現或用獼猴CDH3轉染,則效應細胞也應是獼猴來源的,諸如獼猴T細胞株,例如4119LnPx。目標細胞應表現CDH3 (的至少胞外域),例如人類或獼猴CDH3。目標細胞可以是經CDH3穩定或瞬時轉染的細胞株(諸如CHO),例如人類或獼猴CDH3。或者,目標細胞可以是CDH3陽性自然表現者細胞株。在目標細胞株在細胞表面上表現較高位準的CDH3時,通常預期EC50值較低。效應細胞對目標細胞(E:T)的比率通常為約10:1,但也可以會改變。可以在51鉻釋放分析(約18小時的培育時間)或在基於FACS的細胞毒性分析(約48小時的培育時間)中測定CDH3/CD3雙特異性抗體構築體的細胞毒性活性。也可以修改分析培育時間(細胞毒性反應)。測量細胞毒性的其他方法是習於技藝者所熟知,並包含MTT或MTS分析、基於ATP的分析(包括生物發光分析)、磺基羅丹明B (SRB)分析、WST分析、成株分析和ECIS技術。
由本發明CDH3/CD3雙特異性抗體構築體所媒介的細胞毒性活性較佳在基於細胞的細胞毒性分析中進行測量。它也可以在一個51-鉻釋放分析中進行測定。它是由EC
50值表示,其對應於半數最大有效濃度(抗體構築體在基線與最大反應之間誘發半細胞毒性反應的濃度)。較佳地,CDH3xCD3雙特異性抗體構築體的EC
50值是≤5000 pg/ml或≤4000 pg/ml,更佳≤3000 pg/ml或≤2000 pg/ml,甚至更佳≤1000 pg/ml或≤500 pg/ml,甚至更佳≤400 pg/ml或 ≤300 pg/ml,甚至更佳≤200 pg/ml,甚至更佳≤100 pg/ml,甚至更佳≤50 pg/ml,甚至更佳≤20 pg/ml或≤10 pg/ml,以及最佳≤5 pg/ml。
上面提供的EC
50值可以在不同分析中進行測量。習於技藝者知道,相較於未經刺激的PBMC,當使用經刺激/富集CD8+ T細胞作為效應細胞時,預期EC50可能較低。可進一步預期,相較於低目標表現大鼠,當目標細胞表現大量目標抗原時,EC50值較低。例如,當經刺激/富集的人類CD8 + T細胞用作為效應細胞(與任一經CDH3轉染的細胞,諸如CHO細胞或CDH3陽性自然表現者細胞株,諸如A431被用作目標細胞),CDH3xCD3雙特異性抗體構築體的EC
50值較佳≤1000 pg/ml,更佳≤500 pg/ml,甚至更佳≤250 pg/ml,甚至更佳≤100 pg/ml,甚至更佳≤50 pg/ml,甚至更佳≤10 pg/ml,以及最佳≤5 pg/ml。當人類PBMC用作為效應細胞時,CDH3xCD3雙特異性抗體構築體的EC
50值較佳為≤5000 pg/ml或≤4000 pg/ml (特別是當目標細胞是CDH3陽性自然表現者細胞株時,諸如A431),更佳≤2000 pg/ml (特別是當目標細胞是經CDH3轉染的細胞,諸如CHO細胞),更佳≤1000 pg/ml或≤500 pg/ml,甚至更佳≤200 pg/ml,甚至更佳≤150 pg/ml,甚至更佳≤100 pg/ml,以及最佳≤50 pg/ml或更低。當獼猴T細胞株(諸如LnPx4119)用作為效應細胞,還有經獼猴CDH3轉染的細胞株(諸如CHO細胞)用作為目標細胞株時,CDH3xCD3雙特異性抗體構築體的EC
50值較佳≤2000 pg/ml或≤1500 pg/ml,更佳≤1000 pg/ml或≤500 pg/ml,甚至更佳≤300 pg/ml或≤250 pg/ml,甚至更佳≤100 pg/ml,以及最佳≤50 pg/ml。
較佳地,本發明CDH3/CD3雙特異性抗體構築體不誘導/媒介CDH3陰性細胞(諸如CHO細胞)的溶解或基本上不誘導/媒介CDH3陰性細胞(諸如CHO細胞)的溶解。術語「不誘導溶解」、「基本上不誘導溶解」、「不媒介溶解」或「基本上不媒介溶解」表示本發明抗體構築體不誘導或媒介CDH3陰性細胞的超過30%,較佳不超過20%,更佳不超過10%,尤佳不超過9%、8%、7%、6%或5%溶解,而CDH3陽性細胞株(諸如A431)的溶解被設定為100%。這通常適用於高達500 nM的抗體構築體濃度。習於技藝者知道如何測量細胞溶解而不費力。此外,本說明書中教導如何測量細胞溶解的具體說明。
個別CDH3/CD3雙特異性抗體構築體在單體和二聚體同型之間的細胞毒性活性差異被稱為「效力差」。此效力差可以例如被計算成在分子的單體和二聚體形式的EC
50值之間的比率。本發明的CDH3/CD3雙特異性抗體構築體的效力差較佳≤5,更佳≤4,甚至更佳≤3,甚至更佳≤2,以及最佳≤1。作為一個實例,對於CDH3-13的效力差測定為0.5,CDH3-13xCD3-HLE(Fc)的效力差測定為0.9,CDH3-25的效力差測定為0.7,而CDH3-25xCD3-HALB的效力差測定為0.7。
本發明抗體構築體的第一及/或第二(或任何其他)結合域較佳是對靈長動物的哺乳動物目成員具有跨物種特異性。跨物種特異性CD3結合域例如廟述於WO 2008/119567中。根據一個具體例,第一及/或第二結合域除了分別結合至人類CDH3和人類CD3以外,也結合至靈長動物CDH3/CD3(靈長動物包括但不限於新世界靈長動物(如狨、獠狨或松鼠猴)、舊世界靈長動物(例如狒狒和獼猴)、長臂猿和非人類人亞科。
在本發明的一個態樣中,第一結合域結合至人類CDH3並進一步結合至獼猴CDH3,諸如食蟹獼猴的CDH3 (SEQ ID NO: 5),且更佳地,結合至獼猴CDH3 ECD。對獼猴CDH3來說,第一結合域的親和力較佳≤15 nM,更佳≤10 nM,甚至更佳≤5 nM,甚至更佳≤1 nM,甚至更佳≤0.5 nM,甚至更佳≤0.1 nM,以及最佳≤0.05 nM或甚至≤0.01 nM。
根據本發明的用於結合獼猴CDH3相對人類CDH3[ma CDH3:hu CDH3]的抗體構築體的親和力差(如例如藉由BiaCore或透過斯卡查德分析所測定,參見實例)較佳在0.1和10之間,更佳在0.2和5之間,甚至更佳0.3和2.5之間,甚至更佳0.4和2之間,以及最佳0.5和1之間。
在本發明抗體構築體的一個具體例中,第二結合域結合至人類與狨、獠狨或松鼠猴CD3ε。較佳地,第二結合域結合至這些的CD3ε鏈的胞外表位。也設想,第二結合域結合至人類與獼猴CD3ε鏈的胞外表位。CD3ε的最佳表位是由人CD3ε胞外域的胺基酸殘基1-27所內含。甚至更具體地,表位包含至少胺基酸序列Gln-Asp-Gly-Asn-Glu。狨及獠狨均是屬於狨科的新世界靈長動物,而松鼠猴是屬於捲尾猴科的新世界靈長動物。
對本發明抗體構築體尤佳的是,結合T細胞表面上之人類CD3的第二結合域包含含有選自下列之CDR-L1、CDR-L2和CDR-L3的VL區:
(a) 如WO 2008/119567之SEQ ID NO: 27所示的CDR-L1、如WO 2008/119567之SEQ ID NO: 28所示的CDR-L2,及如WO 2008/119567之SEQ ID NO: 29所示的CDR-L3;
(b) 如WO 2008/119567之SEQ ID NO: 117所示的CDR-L1、如WO 2008/119567之SEQ ID NO: 118所示的CDR-L2,及如WO 2008/119567之SEQ ID NO: 119所示的;以及
(c) 如WO 2008/119567之SEQ ID NO: 153所示的CDR-L1、如WO 2008/119567之SEQ ID NO: 154所示的CDR-L2,及如WO 2008/119567之SEQ ID NO: 155所示的CDR-L3。
在本發明抗體構築體的一個替代性較佳具體例中,結合至T細胞表面上之人類CD3的第二結合域包含含有選自下列之CDR-H1、CDR-H2和CDR-H3的VH區;
(a) 如WO 2008/119567之SEQ ID NO: 12中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 13中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 14中所示的CDR-H3;
(b) 如WO 2008/119567之SEQ ID NO: 30中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 31中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 32中所示的CDR-H3;
(c) 如WO 2008/119567之SEQ ID NO: 48中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 49中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 50中所示的CDR-H3;
(d) 如WO 2008/119567之SEQ ID NO: 66中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 67中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 68中所示的CDR-H3;
(e) 如WO 2008/119567之SEQ ID NO: 84中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 85中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 86中所示的CDR-H3;
(f) 如WO 2008/119567之SEQ ID NO: 102中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 103中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 104中所示的CDR-H3;
(g) 如WO 2008/119567之SEQ ID NO: 120中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 121中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 122中所示的CDR-H3;
(h) 如WO 2008/119567之SEQ ID NO: 138中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 139中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 140中所示的CDR-H3;
(i) 如WO 2008/119567之SEQ ID NO: 156中所示的CDR-H、如WO 2008/119567之SEQ ID NO: 157中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 158中所示的CDR-H3;以及
(j) 如WO 2008/119567之SEQ ID NO: 174中所示的CDR-H1、如WO 2008/119567之SEQ ID NO: 175中所示的CDR-H2,及如WO 2008/119567之SEQ ID NO: 176中所示的CDR-H3。
對本發明抗體構築體又更佳的是,結合T細胞表面上之人類CD3的第二結合域包含選自由下列所示之VL區組成之群的VL區:WO 2008/119567的SEQ ID NO: 5、39、125、129、161或165。
可替代地較佳的是,結合至T細胞表面上之人類CD3的第二結合域包含選自由下列所示之VL區組成之群的VL區:WO 2008/119567的SEQ ID NO: 15、19、33、37、51、55、69、73、87、91、105、109、123、127、141、145、159、163、177或181。
更佳地,本發明抗體構築體的特徵在於結合至T細胞表面上之人類CD3的第二結合域包含選自下列組成之群中的VL區和VH區:
(a) 如WO 2008/119567之SEQ ID NO: 17或21中所示的VL區及如WO 2008/119567之NO: 15或19中所示的VH區;
(b) 如WO 2008/119567之SEQ ID NO:35或39中所示的VL區及如WO 2008/119567之SEQ ID NO: 33或37中所示的VH區;
(c) 如WO 2008/119567之SEQ ID NO: 53或57中所示的VL區及如WO 2008/119567之SEQ ID NO: 51或55中所示的VH區;
(d) 如WO 2008/119567之SEQ ID NO: 71或75中所示的VL區及如WO 2008/119567之SEQ ID NO: 69或73中所示的VH區;
(e) 如WO 2008/119567之SEQ ID NO: 89或93中所示的VL區及如WO 2008/119567之SEQ ID NO: 87或91中所示的VH區;
(f) 如WO 2008/119567之SEQ ID NO: 107或111中所示的VL區及如WO 2008/119567之SEQ ID NO: 105或109中所示的VH區;
(g) 如WO 2008/119567之SEQ ID NO: 125或129中所示的VL區及如WO 2008/119567之SEQ ID NO: 123或127中所示的VH區;
(h) 如WO 2008/119567之SEQ ID NO: 143或147中所示的VL區及如WO 2008/119567之SEQ ID NO: 141或145中所示的VH區;
(i) 如WO 2008/119567之SEQ ID NO: 161或165中所示的VL區及如之WO 2008/119567SEQ ID NO: 159或163中所示的VH區;以及
(j) 如WO 2008/119567之SEQ ID NO: 179或183中所示的VL區及如WO 2008/119567之SEQ ID NO: 177或181中所示的VH區。
結合至人類CD3並描述於WO 2008/119567中的以上結合域也示於SEQ ID NO: 445-537中。
根據本發明抗體構築體的一個較佳具體例,結合域且尤其是第二結合域(其結合至T細胞表面上的人類CD3)具有以下的形式:VH區和VL區的配對是呈單鏈抗體(scFv)的形式。VH區和VL區被安排呈VH-VL或VL-VH的順序。較佳是VH區位於連接子序列的N端,而VL區位於連接子序列的C端。
上述本發明抗體構築體的一個較佳具體例的特徵在於,結合至T細胞表面上之人類CD3的第二結合域包含選自由下列組成之群的胺基酸序列:WO 2008/119567的SEQ ID NO: 23、25、41、43、59、61、77、79、95、97、113、115、131、133、149、151、167、169,185或187。
在本發明的一個具體例中,抗體構築物具有選自如下列所示序列組成之群的胺基酸序列:SEQ ID NO: 158、SEQ ID NO: 168、SEQ ID NO: 178、SEQ ID NO: 188、SEQ ID NO: 198、SEQ ID NO: 208、SEQ ID NO: 218、SEQ ID NO: 228、SEQ ID NO: 238,和SEQ ID NO: 248。
在本發明的另一個具體例中,抗體構築物具有選自如下列所示序列組成之群的胺基酸序列:SEQID NO: 379、SEQID NO: 380、SEQ ID NO: 381、SEQ ID NO: 382、SEQ ID NO: 383、SEQ ID NO: 384、SEQ ID NO: 385、SEQ ID NO: 386、SEQ ID NO: 387、SEQ ID NO: 388和SEQ ID NO: 389。
在本發明的另一具體例中,抗體構築物具有選自如下列所示序列組成之群的胺基酸序列:SEQID NO: 288,SEQ ID NO: 298、SEQID NO: 308、SEQID NO: 318、SEQID NO: 328、SEQ ID NO: 338、SEQ ID NO: 348,和SEQ ID NO: 358。
也可以預期到本文所述抗體構築體的胺基酸序列修飾。例如,可能需要增進抗體構築體的結合親和力及/或其他生物學特性。抗體構築體的胺基酸序列變異體是透過將適宜核苷酸變化引入抗體構築體核酸,或透過肽合成來製備。所有下面描述的胺基酸序列修飾應產生仍保留了未修飾親本分子之期望生物學活性(結合至CDH3和CD3)的抗體。
術語「胺基酸」或「胺基酸殘基」通常意指一個具有其技藝中公認定義的胺基酸,諸如選自由下列組成之群的胺基酸:丙胺酸(Ala或A);精胺酸(Arg或R);天冬醯胺酸(Asn或N);天冬胺酸(Asp或D);半胱胺酸(Cys或C);麩胺醯胺酸(Gln或Q);麩胺酸(Glu或E);甘胺酸(Gly或G);組胺酸(His或H);異白胺酸(Ile或I):白胺酸(Leu或L);離胺酸(Lys或K);甲硫胺酸(Met或M);苯丙胺酸(Phe或F);脯胺酸(Pro或P);絲胺酸(Ser或S);蘇胺酸(Thr或T);色胺酸(Trp或W) 酪胺酸(Tyr或Y);和纈胺酸(Val或V),儘管可以根據需要使用經過修飾、合成或罕見胺基酸。大體上胺基酸可以依據下列來分組:具有非極性側鏈(例如,Ala、Cys、He、Leu、Met、Phe、Pro、VaI);帶負電荷的側鏈(例如,Asp、GIu);帶正電荷的側鏈(例如,Arg、His、Lys);或無電荷極性側鏈(例如,Asn、Cys、GIn、GIy、His、Met、Phe、Ser、Thr、Trp,與Tyr)
胺基酸修飾包括,例如抗體構築體的胺基酸序列內的殘基缺失及/或插入,及/或置換。可進行缺失、插入和置換的任何組合以獲得最終的構築體,前提為最終構築體具有期望的特徵。胺基酸變化還可改變抗體構築體的轉譯後過程,諸如改變糖基化位點的數目或位置。
例如,每個CDR中可插入或刪除1、2、3、4、5,或6個胺基酸(當然,這取決於其長度),且每個FR中可插入或刪除1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20,或25個胺基酸。較佳地,胺基酸序列插入包括將長度為1、2、3、4、5、6、7、8、9或10個殘基的胺基及/或羧基端融合物插入至含有一百個或更多個殘基的多肽,還有單胺基酸殘基或多胺基酸殘基的序列內插入。本發明抗體構築體的插入變異體包括融合至酶的抗體構築體之N端或C端,或融合至增加抗體構築體的血清半衰期的多肽。
置換型誘變最感興趣的位點包括重鏈及/或輕鏈中的CDR,特別是超變區,但是也可預期重鏈及/或輕鏈中的FR改變。置換較佳是如本文所述的保守取代。較佳地,1、2、3、4、5、6、7、8、9或10個胺基酸可在一個CDR中被置換,而1、2、3、4、5、6、7、8、9、 10、11、12、13、14、15、16、17、18、19、20,或25個胺基酸可在框架區(FR)中被置換的,這取決於CDR或FR的長度。例如,如果一個CDR序列含括6個胺基酸,則預想這些胺基酸有一個、兩個或三個被置換。同樣地,如果一個CDR序列含括15個胺基酸,則預想這些胺基酸有一個、兩個、三個、四個,五個或六個被置換。
用於鑑定較佳誘變位置之抗體構築體的某些殘基或區域的可用方法被稱為「丙胺酸掃描誘變」,如Cunningham and Wells in Science, 244: 1081-1085 (1989)所述。在此,抗體構築體內的殘基或一群目標殘基經鑑定(例如帶電荷殘基,諸如arg、asp、his、lys,與glu)並替換成中性或帶負電荷的胺基酸(最佳為丙胺酸或聚丙胺酸),以影響與表位的胺基酸交互作用。
之後,對置換顯示功能敏感性的那些胺基酸位置透過在置換位點或針對置換位點引入更多或其他變異體而被進一步改善。因此,儘管用於引入胺基酸序列變化的位點或區域是預定的,但本身不需要預先確定突變的性質。例如,為了分析或者最佳化在給定位點處的突變性能,在目標密碼子或區域處進行丙胺酸掃描或隨機誘變,並且針對期望活性的最佳組合來篩選所表現的抗體構築體。在具有已知序列之DNA中的預定位點進行置換突變的技術是眾所周知的,例如M13引子誘變和PCR誘變。使用抗原結合活性(例如CDH3或CD3結合)完成突變體的篩選。
一般來說,若在重鏈及/或輕鏈的一或多個或全部CDR中置換胺基酸,較佳是所得到的「經置換」序列與「原始」CDR序列至少60%、更佳65%、甚至更佳70%、特佳75%,更特別佳為80%一致。這意味著,它是取決CDR的長度,其與「經置換」序列的程度相同。例如,具有5個胺基酸的CDR較佳與其經置換序列為80%一致,以便有至少一個胺基酸置換。因此,抗體構築體的CDR與其經置換序列可具有不同程度的一致性,例如CDRL1可具有80%,而CDRL3可具有90%。
較佳的置換(或取代)是保守置換。但是,預期有任何置換(包括非保守置換或下面表1列出的「例示置換」的一或多者),只要抗體構築體維持其經由第一結合域結合至,以及經由第二結合域及/或其與經置換序列具有一致性的CDR(與「原始」CDR序列至少60%、更佳65%、甚至更佳70%、特別佳75%、更特別佳80%一致)結合至CD3或CD3ε。
保守置換顯示於表1「較佳置換」的標題下。如果此類置換導致生物學活性改變,那麼可以引入更實質性的改變(在表1中命名為「例示性置換」,或進一步如下所述參照胺基酸類別),並針對所期望的特徵篩選產品。
表1:胺基酸置換
在本發明抗體構築體的生物學特性方面的實質修飾是透過其在維持以下效用顯著不同來選擇置換:(a)多肽主鏈的結構在置換區域內,例如如同褶片或螺旋構型、(b)分子於目標位點處的電荷或疏水性,或(c)側鏈體積。基於共同的側鏈特性,天然存在的殘基分成數群:(1)疏水性:正白胺酸、met、ala、val、leu、i;(2)中性親水性:cys、ser、thr;(3)酸性:asp、glu;(4)鹼性:asn、gin、his、lys、arg;(5)影響鏈位向的殘基:gly、pro;以及(6)芳香族:trp、tyr、phe。
非保守置換將涉及到將這些類別之一的成員換成另一類別。不參與維持抗體構築體正確構型的任何半胱胺酸殘基通常可以用絲胺酸置換,以增進分子的氧化穩定性並防止異常交聯。相反地,半胱胺酸鍵可以加入至該抗體以增進其穩定性(特別是當抗體是抗體片段,諸如Fv片段)。
關於胺基酸序列、序列一致性及/或相似性是透過使用技藝中已知的標準技術來測定,標準技術包括但不限於Smith and Waterman, 1981,
Adv. Appl. Math.2:482的局部序列一致性演算、Needleman and Wunsch, 1970,
J. Mol. Biol.48:443的序列一致性排比演算、Pearson and Lipman, 1988,
Proc. Nat. Acad. Sci. U.S.A.85:2444的相似性方法研究、這些演算法的電腦實施(GAP、BESTFIT、FASTA,與TFASTA,在Wisconsin Genetics Software Package中,Genetics Computer Group, 575 Science Drive, Madison, Wis.)、Devereux
et al., 1984,
Nucl. Acid Res.12:387-395所述的最佳擬合序列程式、較佳使用預設或透過檢驗。較佳地,一致性百分率是依照FastDB基於下列參數算出:失配罰分為1;空位罰分為1;空位大小罰分為0.33;以及連接罰分為30,「Current Methods in Sequence Comparison and Analysis,」 Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp 127-149 (1988), Alan R. Liss, Inc.。
可用算法的一個實例是PILEUP。PILEUP從一組相關序列使用漸進、成對排比來創造多重序列排比。它也可以繪製表示用於創造排比的集簇關係的樹。PILEUP使用Feng & Doolittle, 1987,
J. Mol. Evol.35:351-360的漸進式排比法;該方法類似於Higgins and Sharp, 1989,
CABIOS5:151-153所述的方法
。可用的PILEUP參數包括預設空位為權重為3.00、預設空位長度權重為0.10,而加權末端空位。
可用演算法的另一個實例是BLAST演算法,描述於:
Altschul et al., 1990, J. Mol. Biol. 215:403-410;
Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402;及
Karin et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5787。特別可用的BLAST程式是從Altschul
et al., 1996,
Methods in Enzymology266:460-480獲得的WU-BLAST-2程式。WU-BLAST-2使用幾個檢索參數,其中大多數都被設定為預設值。可調參數設定具有以下值:重疊跨度= 1、重疊分數= 0.125、字閾值(T)=II。HSP S和HSP S2參數是動態值,根據特定序列的組成和針對正被檢索的感興趣序列的特定數據庫的組成由程式本身建立;然而,可調整這些值以提高靈敏度。
如Altschul
et al., 1993,
Nucl. Acids Res.25:3389-3402報導,另一個可用的演算法是空位BLAST。空位BLAST使用BLOSUM-62置換計分;閾值T參數設為9;雙擊法觸發無間隙擴展、k的空位長度值10+k;Xu設為16,且Xg設為40用於數據庫檢索階段和67用於演算法輸出階段。空位排比是由計分對應於約22位元的得分觸發。
一般來說,個別變異體CDR之間的胺基酸同源性、相似性或一致性為與本文所示序列至少60%,且更典型同源性或一致性較佳增加至少65%或70%,更佳至少75%或80%,甚至更佳至少85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%以及幾乎100%。以類似的方式,「百分率(%)核酸序列同一性」相對於本文鑑定之結合蛋白的核酸序列被定義為,候選序列中的核苷酸殘基與抗體構築體編碼序列中的核苷酸殘基相同的百分比。具體方法採用設定成預定參數之WU-BLAST-2的BLASTN模組,其中重疊跨度和重疊分數分別設為1和0.125。
大體上,編碼個別變異體CDR之核苷酸序列及本文所示核苷酸序列之間的核酸序列同源性、相似性或一致性為至少60%,並且更典型同源性或一致性較佳增加至少65%、70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95% 、96%、97%、98%或99%,以及幾乎100%。因此,「變異體CDR」是一個與本發明之親本CDR具有指定同源性,相似性或一致性,並共有生物學功能的CDR,包括但不限於親本CDR之特異性及/或活性的至少60%、65%、70%、75 %、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%。
在一個具體例中,本發明雙特異性抗體構築體顯示出在標準研究規模條件下有高單體產量,例如在標準兩步純化方法中。較佳地,根據本發明的抗體構築體的單體產量≥0.25 mg/L上清液,更佳≥0.5 mg/L,甚至更佳≥1 mg/L,且最佳≥3 mg / L上清液。
同樣地,可測定抗體構築體的二聚抗體構築體同型還有單體百分率(意即,單體:(單體+二聚體))的產量。單體和二聚抗體構築體的生產率和所計算的單體百分率可以例如從標準化研究規模生產的滾瓶培養物上清液的SEC純化步驟獲得。在一個具體例中,抗體構築體的單體百分率為≥80%,更佳≥85%,甚至更佳≥90%,且最佳≥95%。
在又一個具體例中,與本發明抗體構築體之人類生殖系的一致性百分率為≥70%或≥75%,更佳≥80%或≥85%,甚至更佳≥90%,且最佳≥ 95%。參見實例7。與人類抗體生殖系基因產物的一致性被認為是在治療期間於患者體內減少治療性蛋白質引發針對該藥物的免疫反應的重要特徵。Hwang & Foote (「Immunogenicity of engineered antibodies」; Methods 36 (2005) 3-10)證明,藥物抗體構築體的非人類部分減少會在治療期間於患者體內導致引發抗藥物抗體的風險降低。透過比較詳盡數目的臨床評估抗體藥物與個別免疫原性數據,趨勢顯示抗體V區的人類化使得比帶有未改變的非人類V區的抗體(患者平均23.59%)的蛋白質免疫原性更低(患者平均5.1%)。與人類序列同一性較高對於呈抗體構築體形式之基於V-區的蛋白質療法是需要的。出於確認生殖系同一性之目的,使用Vector NTI軟體以及透過將一致胺基酸殘基除以VL之胺基酸殘基總數(呈百分率)算出的胺基酸序列,VL的V區可以與人類生殖系V區段和J區段的胺基酸序列排比(http://vbase.mrc-cpe.cam.ac.uk/)。同樣可以用於VH區段(http://vbase.mrc-cpe.cam.ac.uk/),不同在於VH CDR3被排除在外,因為其多樣性高和缺乏現有人類生殖系VH CDR3排比夥伴。接著可使用重組技術來增加與人類抗體生殖系基因的序列一致性。
在一個具體例中,抗體構築體具有較佳的血漿穩定性(血漿與EC50 w/o血漿的EC50比率0) ≤5,更佳≤4或≤3.5,甚至更佳≤3或≤2.5,且最佳≤ 2或≤1.5或≤1。可以透過在人類血漿中於37℃下培育構築體24小時,接著經由在51鉻釋放細胞毒性分析中測定EC50來測試抗體構築體的血漿穩定性。在細胞毒性分析中的效應細胞可以是經刺激的富集人類CD8陽性T細胞。目標細胞可以是例如經人類CDH3轉染的CHO細胞。效應細胞對目標細胞(E:T)的比率可以選定為10:1。用於此目的之人類血漿庫是衍生自經由EDTA塗覆的注射器採集的健康供體的血液。經由離心除去細胞組分,並回收上方血漿相且隨後合併。作為對照,抗體構築體是在細胞毒性分析之前才稀釋於RPMI-1640培養基中。血漿穩定性計算為(血漿培育後)EC50對EC50(對照)的比率。參見實例11。
較佳的是本發明抗體構築體的單體轉換成二聚體不多。轉換可在不同條件下進行測量並透過高效尺寸排阻層析進行分析。例如,可在37℃、例如100 μg/ml或250 μg/ml濃度下於培養箱中培育抗體構築體的單體同型歷時7天。在這些條件下,較佳的是本發明抗體構築體顯示二聚體百分率為≤5%,更佳≤4%,甚至更佳≤3%,甚至更佳≤2.5%,甚至更佳≤2%,甚至更佳≤1.5%,及最佳≤1%。參見實例9。
也較佳的是本發明雙特異性抗體構築體在數個冷凍/解凍循環之後以極低的二聚體轉換存在。例如,抗體構築體單體在通用緩衝液被調整為250 μg/ml的濃度,並進行至三個冷凍/解凍循環(在-80℃下冷凍30分鐘,然後在室溫下解凍30分鐘),接著進行高效SEC來確定已轉變成二聚體抗體構築體之初始單體抗體構築體的百分率。較佳雙特異性抗體構築體的二聚體百分率為≤5%,更佳≤4%,甚至更佳≤3%,甚至更佳≤2.5%,甚至更佳≤2%,甚至更佳≤1.5%,及最佳≤1%,例如經過三個冷凍/解凍循環之後。
本發明雙特異性抗體構築體較佳地顯示聚集溫度高出50℃或高出52℃,更佳高出54℃或高出55℃,甚至更佳高出56℃或高出57℃,及最佳高出58℃或高出59℃的有利的熱穩定性。熱穩定性參數可以針對抗體聚集溫度如下測定:將濃度250 μg/ml的抗體溶液轉移到一個單次使用比色管中,並置於動態光散射裝置中。將樣品從40℃以0.5℃/min的加熱速率加熱至70℃,同時恆定採集所測量的半徑。半徑增加表示蛋白熔融和聚集,用於計算抗體的聚集溫度。參見實例10。
或者,溫度熔融曲線可以透過差示掃描量熱法(DSC)來測定,以確定抗體構築體的固有生物物理蛋白質穩定性。這些實驗使用MicroCal LLC (Northampton, MA, U.S.A) VP-DSC裝置進行。含有抗體構築體的樣品的能量吸收是從20℃記錄到90℃,與僅含有調配緩衝液的樣品相比較。將抗體構築體調整至250 μg/ml的最終濃度(例如在SEC運行緩衝液中)。關於各個熔解曲線的記錄,總體樣本溫度逐步增加。在每個溫度T下,紀錄樣品及調配緩衝液參考物的能量吸收。對應個別溫度樣品繪製減去參考物的能量吸收Cp差異(kcal/mole/℃)。熔融溫度被定義為在第一次最大吸收能量時的溫度。
進一步預想,本發明CDH3xCD3雙特異性抗體不與人類CDH3旁系同源物CDH1、CDH2、CDH4和CDH5交叉反應(意即不與其結合)。此外,預想本發明CDH3xCD3雙特異性抗體不與獼猴/獼猴CDH3旁系同源物CDH1、CDH2、CDH4和CDH5交叉反應(意即不與其結合)。參見實例6。
本發明CDH3xCD3雙特異性抗體也可預想具有濁度(在將經純化單體抗體濃縮至2.5 mg/ml並培育隔夜之後,依據OD340測量)為≤0.1,最佳≤0.05。參見實例12。
在另一個具體例中,本發明抗體構築體在酸性pH下是穩定的。在諸如pH 5.5的非生理學pH下,抗體構築體表現地越有耐受性(pH 5.5是運行所需pH,例如陽離子交換層析),則相對於加載蛋白質重量,從離子交換管柱洗下的抗體構築體回收率越高。在pH 5.5下由離子(例如陽離子)交換管柱的抗體構築體回收率較佳是≥30%,更佳≥40%,更佳≥50%,甚至更佳≥60%,甚至更佳≥70%,甚至更佳≥80%,及最佳≥90%。
進一步預想,本發明雙特異性抗體構築體顯示出治療效力或抗腫瘤活性。這可以例如在實例14中揭示的研究進行評估。
習於技藝者知道如何修改或改動本研究的某些參數,例如注射腫瘤細胞的數目、注射的部位、移植人類T細胞的數量、待投與雙特異性抗體構築體的數量,以及時間表,同時還達到一個有意義的和可再現的結果。較佳的是,腫瘤生長抑制T/C [%]≤70或≤60,更佳≤50或≤40,甚至更佳≤30或≤20,及最佳≤10或≤5或甚至≤2.5。
本發明進一步提供編碼本發明抗體構築體的聚核苷酸/核酸分子。
聚核苷酸是13或更多個在鏈中共價鍵結之核苷酸單體組成的生物聚合物。DNA (諸如cDNA的)和RNA(諸如mRNA)是具有不同生物功能的聚核苷酸的實例。核苷酸是有機分子,充當像DNA或RNA的核酸分子的單體或次單位。核酸分子或聚核苷酸可以雙鏈和單鏈、線性和環形。它較佳包含在其較佳包括在一個宿主細胞中的載體內。該宿主細胞是,例如在用本發明載體或聚核苷酸轉形或轉染後,能夠表現抗體構築體。為此目的,聚核苷酸或核酸分子可操作地與調控序列相連。
遺傳密碼子是一組規則,遺傳物質(核酸)內依據這個規則所編碼的信息被翻譯成蛋白質。在活細胞中的生物解碼是核糖體所達到,其以mRNA所指明的順序連接胺基酸,使用tRNA分子攜帶胺基酸和一次讀取mRNA的三個核苷酸。密碼子定義了這些核苷酸三聯(稱為密碼子)序列如何在蛋白質合成期間指定哪些胺基酸接下來要被添加。有一些例外,在核酸序列中的三核苷酸密碼子指定了一個單一胺基酸。因為絕大多數的基因是以完全相同的密碼子編碼,這種特殊的密碼子通常被稱為規範或標準遺傳密碼子。儘管遺傳密碼子確定用於一個給定編碼區的蛋白質序列,但其他基因組區域也可能影響這些蛋白質何時與在何處生產。
此外,本發明提供了一種包含本發明的聚核苷酸/核酸分子的載體。
載體是用作將(外來)遺傳物質轉移到細胞中之運載工具的核酸分子。術語「載體」包括-但並不限於-質體、病毒、黏粒和人工染色體。一般而言,工程化載體包含複製起點、多選殖位點和可選擇標記。載體本身通常是一個核苷酸序列,通常是DNA序列,包含一個插入物(轉基因)和作為載體的「骨架」的較大序列。最新的載體可含括轉基因插入物和骨架以外的其他功能:啟動子、遺傳標記、抗生素抗性、報告基因、靶向序列、蛋白質純化標誌。稱為表現載體(表達構築體)的載體特別是在目標細胞中用於表現的轉基因,並且通常具有控制序列。
術語「控制序列」意指在特定宿主生物體中可操作連接編碼序列表現所需的DNA序列。適於原核生物的控制序列包括例如啟動子、視情況選用的操縱子序列,和核糖體結合位點。已知真核細胞利用啟動子,多腺苷酸化信號,和增強子。
當核酸與另一核酸序列在功能上相關聯時,它被「可操作地連接」。例如,若前序列或分泌前導序列的DNA被表現為參與多肽分泌的前蛋白,則它可操作地連接至多肽的DNA;若啟動子或增強子影響序列的轉錄,則它可操作地連接至編碼序列;或核糖體結合位點經定位而促進轉譯,則它可操作地連接到一個編碼序列。大體上,「可操作地連接」表示被連接的DNA序列是鄰接的,而且在分泌前導序列的情況下是連續並在閱讀相(reading phase)內。然而,增強子不必然是連續的。透過接合在習知限制位點來達成連結。如果不存在此等位點,則合成的寡核苷酸轉接子或連接子是根據習知實施來使用。
「轉染」是將核酸分子或聚核苷酸(包括載體)精心引入目標細胞的過程。術語主要用於在真核細胞中的非病毒方法。轉導通常用於描述核酸分子或聚核苷酸的病毒媒介轉移。動物細胞的轉染通常涉及在細胞膜打開瞬態孔或「洞」,以允許物質的吸收。轉染可以使用磷酸鈣,透過電穿孔、透過細胞擠壓或透過混合陽離子脂質與材料以產生脂質體(其與細胞膜融合並將它們的貨物沉積在內部)來進行。
術語「轉形」用來描述核酸分子或聚核苷酸(包括載體)的非病毒性轉移至細菌,並且也轉移至非動物的真核細胞(包括植物細胞)。轉形因此是由於從其環境直接攝取穿過細胞膜且異源性遺傳物質(核酸分子)併入而在遺傳上改變細菌或非動物真核生物細胞。轉形可以藉由人工方法進行。為讓轉形發生,細胞或細菌必須處在勝任狀態下,可能會產生對環境條件(如飢餓和細胞密度)的時間限制性反應。
此外,本發明提供一種經聚核苷酸/核酸分子或本發明的載體轉形或轉染的宿主細胞。
如本文中所用,術語「宿主細胞」或「受體細胞」意欲包括任何個體細胞或細胞培養物,其可以是或已經是編碼本發明抗體構築體之載體、異源性核酸分子和聚核苷酸的受體。將各材料引入細胞內可以借助轉形、轉染與類似方式進行。術語「宿主細胞」也意欲包括後代或單個細胞的潛在後代。因為在後代因為天然、偶然的或有意的突變,或因為環境影響可能發生某些修飾,這些後代(實際上)可能不會(在形態學或基因組或總DNA配對物上)與親本細胞完全相同,但仍包括在如本文所用術語範圍內。合適的宿主細胞包括原核或真核細胞,並且還包括但不限於細菌、酵母細胞、真菌細胞、植物細胞和動物細胞(諸如昆蟲細胞和哺乳動物細胞,例如鼠類、大鼠、獼猴或人類)。
可以在細菌中生產本發明抗體構築體。在表現後,本發明抗體構築體是從大腸桿菌細胞糊呈可溶性部分的形式被分離,並且可以經由例如親和力層析及/或尺寸排阻予以純化。最終純化可以類似於用以純化(例如在CHO細胞中)所表現之抗體的方法來進行。
除了原核生物外,真核微生物(諸如絲狀真菌或酵母)也是本發明抗體構築體的合適選殖或表現宿主。釀酒酵母或普通烘焙酵母在低等真核宿主微生物中最為常用。然而,許多其它屬,種,和菌株通常是可用於本發明,諸如粟酒裂殖酵母(
Schizosaccharomyces pombe)、克魯維酵母宿主(如乳酸克魯維酵母(
K. lactis)、脆壁克魯維酵母(
K. fragilis)(ATCC 12424)、保加利亞克魯維酵母(
K. bulgaricus)(ATCC 16045)、威克克魯維酵母(
K. wickeramii)(ATCC 24178)、克魯雄酵母(
K. waltii)(ATCC 56500)、果蠅克魯維酵母(
K. drosophilarum)(ATCC 36906)、耐熱克魯維酵母(
K. thermotolerans)與馬克斯克魯維酵母(
K. marxianus);耶氏酵母(EP 402 226);畢斥酵母(EP 183 070);念珠菌;木黴(
Trichoderma reesei)(EP 244 234);紅麵包黴(
Neurospora crassa);許旺酵母,諸如西方許旺酵母;以及絲狀真菌,諸如紅黴屬(Neurospora)、青黴屬(Penicillium)、彎頸黴屬(Tolypocladium)和麴菌屬宿主,諸如如小巢狀麴菌(
A. nidulans)和黑麴菌(
A. niger)。
用於表現本發明糖基化抗體構築體的合適宿主細胞衍生自多細胞生物。無脊椎動物細胞的實例包括植物和昆蟲細胞。已鑑定了許多桿狀病毒株和變異體以及諸如來自以下宿主的對應容許昆蟲宿主細胞:秋行軍蟲(
Spodoptera frugiperda)(毛蟲)、埃及斑蚊(
Aedes aegypti)(蚊)、白線斑蚊(
Aedes albopictus)(蚊)、黑腹果蠅(
Drosophila melanogaster)(果蠅),以及家蠶(
Bombyx mori)。多種用於轉染的病毒株是公眾可獲得的,例如銀紋夜蛾核型多角體病毒(
Autographa californica) NPV的L-1變異體和蠶(
Bombyx mori) NPV的Bm-5病毒株,而且此等病毒依據本發明在本文可以用作病毒,特別用於轉染秋行軍蟲細胞。
棉花、玉米、馬鈴薯、大豆、矮牽牛、番茄的、芥菜與菸草的植物細胞培養物也可以用作為宿主。習於技藝者熟知用於在植物細胞培養物中生產蛋白質的選殖與表現載體。參見例如
Hiatt et al., Nature (1989) 342: 76-78 、 Owen et al. (1992) Bio/Technology 10: 790-794 、 Artsaenko et al. (1995) The Plant J 8: 745-750,以及
Fecker et al. (1996) Plant Mol Biol 32: 979-986。
但是,得到最多關注的是脊椎動物細胞,且在培養(組織培養)時繁衍脊椎動物細胞已經成為常規流程。可用哺乳動物宿主細胞株的實例是經SV40轉形的猴腎CV1細胞株(COS-7,ATCC CRL 1651);人類胚腎細胞株(293或293細胞,經次選殖以供在懸浮培養物中生長,Graham et al. , J. Gen Virol. 36 : 59 (1977));幼倉鼠腎細胞(BHK,ATCC CCL 10);中國倉鼠卵巢細胞/-DHFR (CHO,Urlaub
et al., Proc. Natl. Acad. Sci. USA 77: 4216 (1980));小鼠賽特利細胞(TM4,Mather, Biol. Reprod. 23: 243-251 (1980));猴腎細胞(CVI ATCC CCL 70);非洲綠猴腎細胞(VERO-76,ATCC CRL1587);人類子宮頸癌細胞(HELA,ATCC CCL 2);犬腎細胞(MDCK,ATCC CCL 34);水牛鼠肝細胞(BRL 3A,ATCC CRL 1442);人類肺細胞(W138,ATCC CCL 75);人類肝臟細胞(Hep G2,1413 8065);小鼠乳腺腫瘤(MMT 060562,ATCC CCL5 1);TRI細胞(Mather
et al., Annals N. Y Acad. Sci. (1982) 383: 44-68);MRC 5細胞;FS4細胞;以及人類肝腫瘤細胞株(Hep G2)。
在又一個具體例中,本發明提供一種用於生產本發明抗體構築體的方法,該方法包含在容許本發明抗體構築體表現的條件下培養本發明的宿主細胞,以及從培養物回收生產的抗體。
如本文中所用,術語「培養」意指於合適的條件下在培養基中活體外維持、分化、生長、增生及/或繁衍細胞。術語「表現」包括涉及生產本發明抗體構築體的任何步驟,包括但不限於轉錄、轉錄後修飾、轉譯、轉譯後修飾和分泌。
當使用重組技術時,抗體構築體可以在細胞內生產,在周質空間或直接分泌到培養基中。若抗體構築體在細胞內生產,則第一個步驟是例如透過離心或超濾移除微粒碎片,不論是宿主細胞或是溶解的片段。Carter
et al., Bio/Technology 10: 163-167 (1992)描述了用於分離被分泌到大腸桿菌周質空間的抗體的程序。簡言之,在乙酸鈉(pH 3.5)、EDTA和苯甲基磺醯氟(PMSF)存在下在約30分鐘內將細胞糊解凍。細胞碎片可透過離心去除。若抗體分泌到培養基中,則這個表現系統的上清液通常先使用商用蛋白質濃縮濾器(例如Amicon或Millipore Pellicon超濾單元)予以濃縮。蛋白酶抑制劑(諸如PMSF)可以被納入任何上述步驟中以抑制蛋白水解,而且可包括抗生素以防止外來污染物的生長。
從宿主細胞製備的本發明抗體構築體可以使用例如羥基磷灰石層析、凝膠電泳、透析和親和力層析加以回收或純化。用於蛋白質純化的其他技術(諸如在離子交換管柱上分離、乙醇沉澱、逆相HPLC、矽膠層析、肝素SEPHAROSE
TM上的層析、陰離子或陽離子交換樹脂上的層析(如聚天冬胺酸管柱)、層析聚焦、SDS-PAGE,和硫酸銨沉澱也可根據待回收的抗體來運用。若本發明抗體構築體包含CH3域,則可使用Bakerbond ABX樹脂((J.T. Baker, Phillipsburg, NJ)進行純化。
親和力層析是較佳的純化技術。親和力配體所附接的基質最常是瓊脂糖,但是也可使用其他基質。機械穩定的基質(諸如可控孔徑玻璃或聚(苯乙烯二乙烯)苯)容許比使用瓊脂糖可以實現的流速更快且處理時間更短。
此外,本發明提供包含本發明抗體構築體或根據本發明方法產生的抗體構築體的醫藥組成物。
如本文中所用,術語「醫藥組成物」是關於適於投與給患者(較佳為人類患者)的組成物。本發明的特佳醫藥組成物包含一或多種本發明抗體構築體,較佳呈治療有效量。較佳地,該醫藥組成物進一步包含一或多種(醫藥學上有效的)載劑、穩定劑、賦形劑、稀釋劑、增溶劑、界面活性劑、乳化劑、防腐劑及/或佐劑的合適調配物。組成物的可接受成分較佳在所採用的劑量與濃度下對接受者是無毒的。本發明的醫藥組成物包括,但不限於液體、冷凍與凍乾組成物。
本發明組成物可包含醫藥學上可接受的載劑。一般來說,如本文所用,「醫藥上可接受的載劑」表示任何與全部水性和非水性溶液、無菌溶液、溶劑、緩衝劑(例如,磷酸鹽緩衝鹽水(PBS)溶液)、水、懸浮劑、乳劑(諸如油/水乳液)、各種類型的潤濕劑、脂質體、分散介質和塗料,這是與藥物施用相容,尤其是與非經腸給藥相容。在醫藥組成物中使用這些介質和試劑在本領域中是已知的,且包含這些載劑的組成物可通過熟知的常規方法來調配。
某些具體例提供包含本發明抗體構築體且進一步包含一或多種賦形劑的醫藥組成物,諸如那些在本節中和本文其他地方說明性地描述。賦形劑在本發明中可以使用在這方面用於各種目的,例如調節調配物的物理、化學,或生物學特性,諸如調整黏度及或本發明的流程以增進有效性及或穩定此等調配物與方法對抗因為例如在製造、運輸、儲存、使用前準備、投要與之後期間發生的壓力所導致的分解與耗損。
在某些具體例中,醫藥組成物可以含有調配物材料用於修飾、維持或保存例如組成物的pH值、滲透度、黏度、透明度、顏色、等滲性、氣味、無菌性、穩定性、溶解率或釋放率、吸收或穿透(參見,REMINGTON'S PHARMACEUTICAL SCIENCES, 18" Edition, (A.R. Genrmo, ed.), 1990, Mack Publishing Company)。在這些具體例中,合適的調配物材料可包括,但穿透不限於:
• 基酸,諸如甘胺酸、丙胺酸、麩胺醯胺酸、天冬醯胺酸、蘇胺酸、脯胺酸、2-苯丙胺酸,包括帶電荷的胺基酸,較佳為離胺酸、離胺酸乙酸鹽、精胺酸,麩胺酸及/或組胺酸
• 抗微生物劑,諸如抗菌劑和抗真菌劑
• 抗氧化劑,諸如抗壞血酸、甲硫胺酸、亞硫酸鈉或亞硫酸氫鈉;
• 緩衝劑、緩衝系統及緩衝試劑,其用於將組成物維持在生理學pH下或在稍低的pH下,pH範圍通常為約5至約8或9;緩衝劑的實例為硼酸鹽、碳酸氫鹽、Tris-HCl、檸檬酸鹽、磷酸鹽或其他有機酸、琥珀酸鹽、磷酸鹽、組胺酸和乙酸鹽;例如Tris緩衝劑為約pH 7.0-8.5,或乙酸鹽緩衝劑違約pH 4.0-5.5;
• 非水性溶劑,諸如丙二醇、聚乙二醇、植物油(諸如橄欖油),以及如油酸乙酯的可注射有機酯;
• 水性載體,包括水、醇姓/水性溶液、乳液或懸浮液(包括鹽水和緩衝介質);
• 可生物降解的聚合物,諸如聚酯;
• 增積劑,諸如甘露醇或甘胺酸;
• 螯合劑,諸如乙二胺四乙酸(EDTA);
• 等滲劑和吸收延遲劑;
• 複合劑,諸如咖啡因、聚乙烯吡咯啶酮、β-環糊精或羥丙基-β-環糊精)
• 填料;
• 單糖;雙糖;和其他碳水化合物(例如葡萄糖、甘露糖或糊精);碳水化合物可以是非還原性糖,較佳是海藻糖、蔗糖、八硫酸鹽、山梨醇或木糖醇;
• (低分子量)蛋白質、多肽或蛋白質載劑,諸如人類或牛血清白蛋白、明膠或免疫球蛋白,較佳為人類來源;
• 著色劑和調味劑;
• 含硫還原劑,諸如穀胱甘肽、硫辛酸、巰基乙酸鈉、硫代甘油、α-單硫代甘油和硫代硫酸鈉
• 稀釋劑;
• 乳化劑;
• 親水聚合物,諸如聚乙烯吡咯啶酮)
• 形成鹽的相對離子,諸如鈉;
• 防腐劑,諸如抗微生物劑、抗氧化劑、螯合劑、惰性氣體與類似物;實例是:苯扎氯銨、苯甲酸、水楊酸、硫柳汞、苯乙醇、對羥基苯甲酸甲酯、對羥基苯甲酸丙酯、氯己定、山梨酸或過氧化氫);
• 金屬錯合物,諸如鋅-蛋白質錯合物;
• 溶劑和共溶劑(諸如甘油、丙二醇或聚乙二醇);
• 糖和糖醇,諸如海藻糖、蔗糖、八硫酸鹽、甘露醇、山梨醇或木糖醇水蘇糖、甘露糖、山梨糖、木糖、核糖,肌糖(myoinisitose)、半乳糖、乳糖醇、核糖醇、肌醇、半乳糖醇、甘油、環多醇(例如,肌醇)、聚乙二醇;以及多元糖醇;
• 懸浮劑;
• 界面活性劑或濕潤劑,諸如普朗尼克、PEG、脫水山梨醇酯、聚山梨醇酯(例如聚山梨醇酯20)、聚山梨醇酯、三硝基甲苯、緩血酸胺、卵磷脂、膽固醇、泰洛沙泊(tyloxapal);界面活性劑可以是洗滌劑,較佳分子量為> 1.2 KD及/或聚醚,較佳分子量為> 3 KD;較佳洗滌劑的非限制性實例是Tween 20、Tween 40、Tween 60、Tween 80和Tween 85;較佳聚醚的非限制性實例是PEG 3000、PEG 3350、PEG 4000和PEG 5000;
• 穩定性增強劑,諸如蔗糖或山梨醇;
• 張力增強劑,諸如鹼金屬鹵化物,較佳為氯化鈉或氯化鉀、甘露醇山梨醇;
• 非經腸遞送載劑,包括氯化鈉溶液、林格氏葡萄糖、葡萄糖和氯化鈉、乳酸林格氏或不揮發性油;
• 靜脈內遞送載劑,包括液體和營養補充劑、電解質補充劑(諸如基於林格葡萄糖的補充劑)。
很明顯對習於技藝者來說,醫藥組成物的不同組分(例如,上面列出的組分)可具有不同的效果,例如,胺基酸可以作為緩衝劑、穩定劑及/或抗氧化劑;甘露醇可以充當增積劑及/或張力增強劑;氯化鈉可以作為遞送載劑及/或張力增強劑;等等。
除了本文定義的本發明多肽以外,預想本發明組成物還可包含更多生物活性劑,這取決於組成物的期望用途。此類試劑可以是作用於胃腸系統的藥物、作為細胞抑制劑(cytostatica)的藥物、預防高尿酸血症的藥物、抑制免疫反應的藥物(例如皮質類固醇)、調節發炎反應的藥物、作用於循環系統的藥物及/或在技藝中已知的藥劑,諸如細胞激素。也可以預想的是,本發明抗體構築體應用在一個共同療法中,亦即與另一抗癌藥物組合。
在某些具體利中,最佳醫藥組成物將由習於技藝者根據例如下列因素而確定:期望投藥路徑、遞送形式和所需劑量。參見例如,REMINGTON'S PHARMACEUTICAL SCIENCES,上文。在某些具體例中,此等組成物可以影響本發明抗體構築體的物理狀態、穩定性、在活體內的清除率。在某些具體例中,醫藥組成物中的主要載劑或載體可以是天然水性或非水性。例如,合適的載劑或載體可以是注射用水、生理鹽水溶液或人工腦脊液,可能補充有在用於非經腸給藥組成物時組成物中常見的其他材料。與血清白蛋白混合的中性緩衝鹽水或鹽水是進一步的例示性載劑。在某些具體例中,本發明組成物的抗體構築體可以透過將具有期望純度的選定組成物與最佳調配劑混合來進行製備以供儲存,呈凍乾餅或水溶液的形式(REMINGTON'S PHARMACEUTICAL SCIENCES,上文)。此外,在某些具體例中,本發明抗體構築體可以使用適當賦形劑(如蔗糖)調配為凍乾物。
當預想是非經腸投藥時,可以呈無熱原、非經腸可接受的水溶液形式提供用於本發明的治療性組成物,其包含在醫藥上可接受載劑中的所需本發明抗體構築體。特別合適用於非經腸注射的載劑是無菌蒸餾水,其中本發明抗體構築物被調配成無菌、等滲溶液,經適當保存。在某些具體例中,該製劑可以涉及用試劑(諸如可注射微球體、生物可侵蝕顆粒、聚合化合物(諸如聚乳酸或聚乙醇酸),珠粒或脂質體)調配所需分子,提供產物可經由貯器注射遞送之受控或持續釋放。在某些具體例中,也可以使用透明質酸,具有在循環中促進持續的持續時間的效果。在某些具體例中,可植入的藥物遞送裝置可以被用於引入所需的抗體構築體。
其他醫藥組成物對於習於技藝者將是明顯的,包括涉及本發明抗體構築體呈持續遞送或受控遞送/釋放調配物的調配物。用於調配多種其他持續遞送或控制遞送裝置(諸如脂質體載體、生物可侵蝕微粒或多孔珠粒)和貯器注射技術的技術也是習於技藝者所熟知的。參見,例如,國際專利申請案第PCT/US93/00829,它描述了多孔聚合微粒的控制釋放用於遞送醫藥組成物。持續釋放製劑可包括呈有形製品(例如薄膜或微膠囊)形式的半通透性聚合物基質。持續釋放基質可包括聚酯、水凝膠、聚交酯(如美國專利第3,773,919號和歐洲專利申請公開號EP 058481中所揭示)、L-麩胺酸與γ-L-麩胺酸乙酯的共聚物(Sidman et al., 1983, Biopolymers 2:547-556)、聚(2-羥乙基-甲基丙烯酸酯) (Langer
et al., 1981, J. Biomed. Mater. Res. 15:167-277與Langer, 1982, Chem. Tech. 12:98-105)、乙烯醋酸乙烯酯(Langer et al., 1981, supra)或聚-D(-)-3-羥基丁酸(歐洲專利申請公開號No. EP 133,988)。持續釋放組成物亦可包括脂質體,其可透過數種技藝中已知的方法之一來製備。參見,例如Eppstein et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:3688-3692;歐洲專利申請公開號No. EP 036,676;EP 088,046與EP 143,949。
抗體構築體也可以包封在製備好的微膠囊中,例如透過凝聚技術或透過界面聚合(例如,分別為羥甲基纖維素或明膠微膠囊和聚(甲基丙烯酸甲酯)微膠囊)、在膠狀藥物投遞系統(例如,脂質體、白蛋白、微球體、微乳液、奈米顆粒和奈米膠囊),或在巨乳液中。這些揭示於Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980)。
用於活體內投藥的醫藥組成物通常是以無菌製劑提供。可以經由濾過無菌濾膜而實現。當該組成物被凍乾時,可以在凍乾與還原之前或之後使用這個方法進行滅菌。用於非經腸給藥的組成物可儲存成凍乾形式或在溶液中。非經腸組成物通常置於具有無菌存取口的容器中,例如具有可被皮下注射針刺穿的塞子的靜脈內溶液袋或小瓶。
本發明的另一個態樣包括本發明調配物的自緩衝抗體構築體,其可以用作醫藥組成物,如國際專利申請案WO 06138181A2 (PCT/US2006/022599)所述。各種說明都可應用在關於這方面的蛋白質穩定性和調配物材料以及方法,諸如Arakawa et al., 「Solvent interactions in pharmaceutical formulations,」 Pharm Res. 8(3): 285-91 (1991);Kendrick et al., “Physical stabilization of proteins in aqueous solution” in: RATIONAL DESIGN OF STABLE PROTEIN FORMULATIONS: THEORY AND PRACTICE, Carpenter and Manning, eds. Pharmaceutical Biotechnology. 13: 61-84 (2002),與Randolph et al., “Surfactant-protein interactions”, Pharm Biotechnol. 13: 159-75 (2002),特別參見關於賦形劑與賦形劑依據本發明用於自緩衝蛋白質調配物的方法的部分,尤其是蛋白質醫藥產物與獸醫及/或人類醫學用途的方法。
可以根據本發明的某些實施例使用鹽,例如調節調配物的離子強度及/或等滲性及/或增進蛋白質或本發明組成物中之其他成分的溶解性及/或物理穩定性。如眾所周知的,離子可經由結合至蛋白質表面上的帶電荷殘基和經由屏蔽蛋白質的帶電荷與極性基團,並減少它們的靜電交互作用、吸引力及排斥交互作用的強度來穩定蛋白質的天然狀態。離子也可以透過結合至(特別是)蛋白質的變性肽鍵聯(--CONH)來穩定蛋白質的變性狀態。此外,離子與蛋白質之與帶電荷和極性基團的交互作用還可以減少分子間靜電交互作用,並因此防止或減少蛋白質聚集和不溶解性。
離子種類在其對蛋白質的影響顯著不同。已開發了一些分類排名的離子及其對蛋白質的作用,其可用於調配根據本發明的醫藥組成物。一個實例是霍夫邁斯特(Hofmeister)系列,其可以藉由對蛋白質在溶液中的構形穩定效果排列離子和極性非離子溶質。穩定溶質被稱為「親液(kosmotropic)」。不穩定溶質被稱為「離液(chaotropic)」。親液劑通常是在高濃度(例如,>1莫耳濃度硫酸銨)下用於從溶液中沉澱蛋白質(「鹽析」)。離液劑通常用於假牙及/或溶解蛋白質(「鹽溶」)。離子對「鹽溶」和「鹽析」的相對效力定義為它們在霍夫邁斯特系列的位置。
游離胺基酸可以在本發明調配物的抗體構築體中根據本發明的各種具體例作為增積劑、穩定劑,和抗氧化劑,以及其他標準的用途。離胺酸、脯胺酸,絲胺酸和丙胺酸可用於穩定調配物中的蛋白質。甘胺酸是在凍乾時用以確保凍乾餅結構和特性正確。精胺酸可用於在液體和凍乾調配物中抑制蛋白聚集。甲硫胺酸可作為一種抗氧化劑。
多元醇包括糖,如甘露醇、蔗糖和山梨醇及多元醇,例如甘油和丙二醇,以及出於此處討論之目的,聚乙二醇(PEG)和有關物質。多元醇是親液。它們是有用的穩定劑,在液體和凍乾調配物中保護蛋白質免於物理和化學降解過程。多元醇也可用來調整調配物的張力。在本發明的選擇性具體例中有用的多元醇是甘露醇,常用來確保凍乾調配物中的凍乾餅結構穩定性。它確保凍乾餅的結構穩定性。它通常用於與凍乾保護劑(例如蔗糖)一起使用。山梨醇和蔗糖是用於調節張力的較佳試劑,並作為穩定劑以在運輸或大量製備期間或製造過程期間保護對抗凍-融壓力。還原糖(含有游離醛或酮基),諸如葡萄糖和乳糖,可以附糖化表面離胺酸及精胺酸殘基。因此,它們通常不是在根據本發明中使用的較佳多元醇。此外,形成這種反應性物質的糖(諸如蔗糖)在酸性條件下被水解為果糖和葡萄糖,並且因此滋生附糖化,也並非是本發明在這方面的較佳多元醇。PEG可用於穩定蛋白質並作為冷凍保護劑,並且可以用在本發明此方面中。
本發明調配物的抗體構築體的具體例進一步包括界面活性劑。蛋白質分子可能容易吸附在表面上,並且會變性和隨後聚集在氣-液、固-液和液-液界面。這些影響通常與蛋白質濃度成反比。這些有害的交互作用一般與蛋白質濃度成反比,並且通常會因為物理攪拌而加劇,諸如一個產品的運輸和處理過程中產生的。界面活性劑通常用於防止、減少,或降低表面吸附。本發明在這方面有用的界面活性劑包括聚山梨醇酯20、聚山梨酸酯80、聚氧乙烯去水山梨醇酐的其他脂肪酸酯,和泊洛沙姆188。界面活性劑通常也用於控制蛋白質構形穩定性。在這方面,使用界面活性劑是蛋白特異性的,因為任何給定的界面活性劑通常將穩定某些蛋白質,但破壞其他蛋白質。
聚山梨醇酯易受氧化降解,且通常在供給時含有足夠量的過氧化物使得蛋白質殘基側鏈(特別是甲硫胺酸)氧化。因此,聚山梨醇酯應謹慎使用,並且在使用時,應以它們的最低有效濃度使用。在這方面,聚山梨醇酯舉例說明該賦形劑應以其最低有效濃度來使用的一般規則。
本發明調配物的抗體構築體的具體例進一步包含一或多種抗氧化劑。在一定程度上可以在醫藥調配物中透過維持環境氧和溫度的適當水平,並透過避免暴露於光線來防止蛋白質的有害氧化。抗氧化劑賦形劑也可以用來防止蛋白質氧化降解。在這方面有用的抗氧化劑是還原劑、氧/自由基清除劑,和螯合劑。對於在根據本發明的治療性蛋白調配物中使用的抗氧化劑較佳是水溶性的,並且在整個產品的保存期內維持它們的活性。EDTA是在根據本發明這方面的一個較佳抗氧化劑。抗氧化劑可能會破壞蛋白質。例如,還原劑(例如特別是穀胱甘肽)可以破壞分子內二硫鍵聯。因此,在本發明中使用的抗氧化劑尤其被挑選過以消除或充分減少本身在調配物中破壞蛋白質的可能性。
根據本發明的調配物可包括金屬離子,其為蛋白質輔因子和形成蛋白質配位錯合物所必需,諸如形成某些胰島素懸浮物必需的鋅。金屬離子也可以抑制一些降解蛋白質的過程。然而,金屬離子也催化降解蛋白質的物理和化學過程。鎂離子(10-120 mM)可用於抑制天冬胺酸異構化為異天冬胺酸。Ca
+2離子(至高100 mM)可以提高人類去氧核糖核酸酶的穩定性。但是,Mg
+2、錳
+2和Zn
+2可以使rhDNase不穩定。同樣地,Ca
+2和Sr
+2可以穩定因子VIII,它可以因為Mg
+2、Mn
+2和Zn
+2,Cu
+2和Fe
+2而不穩定,其聚集可因為Al
+3離子而提高。
本發明調配物的抗體構築體的具體例進一步包含一或多種防腐劑。當開發涉及從相同容器多次抽取多劑量非經腸調配物時,防腐劑是必要的。其主要功能是抑制微生物的生長,並確保在整個保存期內或使用藥物產品的產品無菌性。常用的防腐劑包括苯甲醇、苯酚和間甲酚。儘管防腐劑有使用小分子非經腸劑有很長的歷史,開發包括防腐劑的蛋白質調配物還是具有挑戰性的。防腐劑對蛋白質幾乎總是去穩定作用(聚集),而這已經成為限制它們使用在多劑量蛋白調配物的一個主要因素。迄今,大多數蛋白質藥物被調配用於僅單次使用。然而,當多劑量調配物可行時,它們具有使患者方便的附加優點,而且增加了市場性。一個很好的例子是,人類生長激素(hGH),其中防腐調配物的發展致使更方便,多次使用注射筆外觀的商業化。含有hGH的防腐調配物的至少四個這樣的筆設備目前可在市場上找到。Norditropin (液體,Novo Nordisk)、Nutropin AQ (液體,Genentech) & Genotropin (凍乾—雙室匣,Pharmacia & Upjohn)含有苯酚,而Somatrope (Eli Lilly)調配有間甲酚。在調配和開發防腐劑型的過程中需要考慮到數個方面。在藥物產品中的有效防腐劑濃度必須被最佳化。這需要在賦予抗微生物效力不損害蛋白質穩定性的濃度範圍下測試該劑型的給定防腐劑。
可預期,開發含防腐劑的液體調配物比凍乾調配物更具挑戰性。冷凍乾燥的產品可以在沒有防腐劑的情況下被凍乾並在使用時用含有防腐劑的稀釋劑還原。這縮短了防腐劑與蛋白質接觸的時間,將相關的穩定性風險顯著降至最低。用液體調配物,在整個產品保存期內(約18至24個月)維持防腐劑有效性和穩定性。要注意的一個重要處是,防腐效果應在含有活性藥物和所有賦形劑組分的最終調配物中證明。
本文揭示的抗體構築體也可以被調配為免疫脂質體。「脂質體」是一種小囊泡,具有各種類型的脂質、磷脂及/或界面活性劑,可用於將藥物遞送給哺乳動物。脂質體的組分通常排列成雙層形式,與生物膜的脂質排列相似。含有抗體構築體的脂質體是由如技藝中已知的方法製備,諸如Epstein
et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985);Hwang
et al. , Proc. Natl Acad. Sci. USA, 77: 4030 (1980);美國專利第4,485,045號與第4,544,545號;以及W0 97/38731中所述。在美國專利第5,013,556號中揭示具有循環時間升高的脂質體。可以藉由用包含磷脂醯膽鹼、膽固醇和PEG衍生的磷脂醯乙醇胺(PEG-PE)的脂質組成物,透過逆相蒸發法生成特別有用的脂質體。脂質體通過規定孔徑的過濾器擠出而產生具有期望直徑的脂質體。本發明抗體構築體的Fab'片段可如Martin
et al.J. Biol. Chem. 257: 286-288 (1982中所述經由雙硫交換反應接合至脂質體。化療劑視情況包含在脂質體內。參見Gabizon
et al. J. National Cancer Inst. 81 (19) 1484 (1989)。
在醫藥組成物已被調配好之後,它可以被存儲在無菌小瓶作為溶液、懸浮液、凝膠、乳液、固體、結晶體,或作為脫水或凍乾粉末。這樣的調配物可以即用形式或以一種在投與之前還原的形式(例如,凍乾)被儲存。
本文定義的醫藥組成物的生物活性可以例如透過細胞毒性分析來測定,如WO 99/54440或由Schlereth
et al. (Cancer Immunol. Immunother. 20 (2005), 1-12)在以下實例中所述。「功效」或「活體內功效」如本文所用意指使用例如標準化的NCI反應標準,對本發明醫藥組成物之療法的反應。使用本發明醫藥組成物之療法的成功或活體內功效意指,出於預期目的之組成物有效性,亦即組成物導致其期望的能力(即病理細胞的耗竭,病理細胞為諸如腫瘤細胞)。活體內功效可以透過已建立的標準方法對各疾病實體(包括但不限於白血球計數、差異、螢光活化細胞分選、骨髓穿刺)進行監測。此外,可以使用各種疾病特異性臨床化學參數和其它已建立的標準方法。此外,可使用電腦輔助斷層掃描、X射線、核磁共振斷層掃描(例如,美國國家癌症研究所-基於標準的反應評估[Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244])、正電子發射斷層掃描,白血球計數、差異、螢光活化細胞分選、骨髓穿刺、淋巴結生檢/組織學,以及各種淋巴瘤特異性臨床化學參數(例如乳酸去氫酶)以及其他已建立的標準方法。
在開發藥物(諸如本發明醫藥組成物)時,另一個主要挑戰是藥動學性質的可預測的調節。為此,可以建立藥物候選物的藥動學概況(即,影響特定藥物治療給定條件的能力的藥動學參數的概況)。藥物影響藥物治療某些疾病實體之能力的藥動學參數包括但不限於:半衰期、分佈容積、肝首度代謝和血清結合度。一個給定藥劑的功效可能受過上述各參數影響。
「半衰期」表示所投與的藥物有50%是經由生物過程(例如代謝、排泄等)排除的時間。「肝首度代謝」表示指藥物在與肝臟首度接觸(亦即在其首次通過肝臟期間)之後被代謝的傾向。「分佈容積」表示藥物滯留在身體各個隔室(例如像胞內和胞外間隙、組織和器官等),和藥物分佈在這些隔室內的程度。「血清結合度」表示藥物與血清蛋白質(諸如白蛋白)交互作用並結合,從而導致藥物的生物學活性降低或損失的傾向。
藥動學參數還包括投與給定量之藥物的生物利用度、滯緩時間(Tlag)、Tmax、吸收率、更多發作及/或Cmax。「生物利用度」表示在血液隔室中的藥物量。「滯緩時間」表示投與藥物和它在血液或血漿中之檢測與可測性間的時間延遲,「Tmax」是達到藥物的最大血液濃度後的時間,而「Cmax」是一個給定藥物獲得的最大血液濃度。要達到生物效應所需之血液或組織濃度的時間受到所有參數影響。展現跨物種特異性的雙特異性抗體構築體的藥動學參數(其可以在臨床前動物測試中如上述於非黑猩猩靈長動物體內來測定)也闡述在Schlereth
et al.的出版物中(Cancer Immunol. Immunother. 20 (2005), 1-12)。
在一個具體例中,本發明提供本發明抗體構築體或根據本發明方法製造之抗體構築體用於預防、治療或改善癌症。
本文所述調配物可用作為醫藥組成物用以在有需要的患者中治療、改善及/或預防如本文所述病理醫學病況。術語「治療」意指治療性治療和預防性或預防性措施。治療包括將調配物施用或投與至患有疾病/病症、疾病/病症之症狀,或有疾病/病症易感性之患者的身體、經分離組織或細胞,目的在於治療、治癒、減輕、緩解、改變、補救、改善、增進或影響疾病,疾病的症狀,或疾病易感性。
術語「改善」如本文所用意指在將本發明抗體構築體投與給有需要的個體之後,具有如本文指明之(轉移性)腫瘤或癌症類型之一的患者的疾病狀態的任何改善。這種增進也可以被看作是減慢或停止患者的(轉移性)腫瘤或癌症進展。術語「預防」如本文所用表示在將本發明抗體構築體投與給有需要的個體之後,防止具有如本文指明之(轉移性)腫瘤或癌症類型之一的患者發病或復發。
術語「疾病」意指將受益於用本文所述抗體構築體或醫藥組成物治療的任何病況。這包括慢性和急性病症或疾病,包括那些使哺乳動物傾向罹患所述疾病的病理病況。
「贅瘤」是是組織的異常生長,通常但不總是形成團塊。當還形成一個團塊時,它通常被稱為「腫瘤」。贅瘤或腫瘤可以是良性的,潛在惡性(癌前期),或惡性的。惡性贅瘤通常稱為癌症。他們通常侵入和破壞周圍的組織,並且可以形成轉移,也就是說它們擴散到身體的其他部分、組織或器官。因此,術語「轉移性癌症」包括轉移到其他組織或器官而非原始腫瘤。淋巴瘤和白血病是淋巴組織贅瘤。出於本發明之目的,它們也被術語「腫瘤」或「癌症」含括。
在一個較佳具體例中,本發明提供本發明抗體構築體或根據本發明方法製造的抗體構築體,用於預防、治療或改善癌症,其中癌症選自由下列組成之群:肺癌、頭頸癌,原發性或繼發性CNS腫瘤、原發性或繼發性腦腫瘤、原發性CNS淋巴瘤、脊軸腫瘤、腦幹神經膠質瘤、神經膠質母細胞瘤、腦下垂體腺瘤、腎上腺皮質癌、食道癌、結腸癌、乳癌、卵巢癌、NSCLC (非小細胞肺癌)、SCLC (小細胞肺癌)、子宮內膜癌(endometrial cancer)、子宮頸癌、子宮癌、移行細胞癌、骨癌、胰臟癌、皮膚癌、皮膚或眼內黑色素瘤、肝癌、膽管癌、膽囊癌、腎癌、直腸癌、肛區癌、胃癌,胃腸(胃,結腸直腸和十二指腸)癌、小腸癌、膽道癌、尿道癌、腎細胞癌、子宮內膜癌(carcinoma of the endometrium)、甲狀腺癌、睪丸癌、皮膚鱗狀細胞癌、黑色素瘤、胃癌、前列腺癌、膀胱癌、骨肉瘤、間皮瘤、霍奇金病、非霍奇金淋巴瘤、慢性或急性白血病、慢性骨髓性白血病、淋巴細胞性淋巴瘤、多發性骨髓瘤、纖維肉瘤、神經母細胞瘤、視網膜母細胞瘤,與軟組織肉瘤,以及衍生自前述任何癌症的轉移性癌病。(轉移性)癌病較佳為P黏附蛋白陽性或表現P黏附蛋白的癌症。
在又一個較佳具體例中,本發明提供本發明抗體構築體或根據本發明方法製造的抗體構築體,用於預防,治療或改善癌症,其中癌症是(轉移性)鱗狀細胞癌。
本發明還提供一種治療或改善(轉移性)腫瘤或癌症的方法,包含向有需要的個體投與本發明抗體構築體或根據本發明方法製造的抗體構築體的步驟。
在一個較佳具體例中,本發明提供一種治療或改善腫瘤或癌症的方法,其中癌症選自由下列組成之群:肺癌、頭頸癌,原發性或繼發性CNS腫瘤、原發性或繼發性腦腫瘤、原發性CNS淋巴瘤、脊軸腫瘤、腦幹神經膠質瘤、腦下垂體腺瘤、腎上腺皮質癌、食道癌、結腸癌、乳癌、卵巢癌、NSCLC (非小細胞肺癌)、SCLC (小細胞肺癌)、子宮內膜癌、子宮頸癌、子宮癌、移行細胞癌、骨癌、胰臟癌、皮膚癌、皮膚或眼內黑色素瘤、肝癌、膽管癌、膽囊癌、腎癌、直腸癌、肛區癌、胃癌,胃腸(胃,結腸直腸和十二指腸)癌、小腸癌、膽道癌、尿道癌、腎細胞癌、子宮內膜癌、甲狀腺癌、睪丸癌、皮膚鱗狀細胞癌、黑色素瘤、胃癌、前列腺癌、膀胱癌、骨肉瘤、間皮瘤、霍奇金病、非霍奇金淋巴瘤、慢性或急性白血病、慢性骨髓性白血病、淋巴細胞性淋巴瘤、多發性骨髓瘤、纖維肉瘤、神經母細胞瘤、視網膜母細胞瘤,與軟組織肉瘤,以及衍生自前述任何癌症的轉移性癌病。該方法包含向有需要的個體投與本發明抗體構築體或根據本發明方法製造的抗體構築體的步驟。
在又一個較佳具體例中,本發明提供一種治療或改善腫瘤或癌症或轉移性腫瘤或癌症的方法,其中癌症是(轉移性)鱗狀細胞癌。
術語「有需要的受試者」或那些「有治療需要」包括那些已患有病症者,以及那些病症被預防者。有需要的個體或「患者」包括人類和其他哺乳動物個體,他們接受預防性或治療性治療。
本發明抗體構築體將通常會針對投與的特定路徑和方法、針對特定劑量和投與頻率、針特定疾病的特定治療,在生物可用性和持久性的範圍內進行設計。組成物的材料較佳調配成投藥部位可接受的濃度。
調配物和組成物因此可根據本發明設計成藉由任何適當投與途徑遞送。在本發明的上下文中,投與途徑包括,但不限於
• 部途徑(諸如表皮、吸入、經鼻、眼用、耳/耳、陰道、黏膜);
• 腸途徑(諸如口服、胃腸道、舌下、脣下、頰、直腸);以及
• 非經腸途徑(諸如靜脈內、動脈內、骨內、肌肉內、腦內、腦室內、硬膜外、鞘內、皮下、腹膜內、羊膜外、關節內、心內、皮內、病灶內、子宮內、膀胱內、玻璃體內、經皮、鼻內、經黏膜、滑膜內、腔內)。
本發明的醫藥組成物和抗體構築體特別是用於非經腸投藥,例如皮下或靜脈內遞送,例如透過注射(諸如推注)或透過輸注(諸如連續輸注)。醫藥組成物可以使用醫學裝置來投藥。施用醫藥組成物的醫學裝置的實例描述於美國專利案第4,475,196號;第4,439,196號;第4,447,224號;第4,447,233號;第4,486,194號;第4,487,603號;第4,596,556號;第4,790,824號;第4,941,880號;第5,064,413號;第5,312,335號;第5,312,335號;第5,383,851號;和第5,399,163號中。
特別是,本發明提供適當組成物的不間斷投藥。作為一個非限制性實例,不間斷或實質上不間斷(亦即連續投藥)可透過患者佩戴小泵系統用以將計量治療劑流入患者體內來實現。包含本發明抗體構築體的醫藥組成物可透過使用該泵系統來投藥。此等泵系統在本技藝中通常為已知的,並且通常仰賴定期交換含有待輸注治療劑的藥匣。當交換在這種泵系統中的藥匣時,治療劑的不間斷流可能暫時中斷流入患者體內。在這樣的情況下,投藥前階段以及藥匣替換後的投藥階段仍應被認為是落在本發明醫藥裝置與方法的涵義內,一起組成此治療劑的「不間斷投藥」。
本發明抗體構築體的連續或不間斷投藥可以是借助流體遞送設備或小泵系統而呈靜脈內或皮下的方式,流體遞送設備或小泵系統包括一個用於驅動流體從貯器流出的流體驅動機構以及用於致動該驅動機構的致動機構。用於皮下投與的泵系統可包括針頭或插管,用於穿透患者的皮膚病將合適組成物地送到患者體內。該泵系統可被直接固定或連接於患者的皮膚上而與靜脈、動脈或血管無涉,由此允許泵系統和患者皮膚之間直接接觸。泵系統可附接到患者的皮膚歷時24小時至高到數天。泵系統可為小尺寸的且具有小體積貯器。作為一個非限制性實例,用於待投與之合適醫藥組成物的貯器體積可以是0.1和50 ml之間。
連續投藥也可以是借助配戴在皮膚上並每隔一段時間替換的貼片而呈穿皮的方式。習於技藝者知道適合此目的之藥物遞送貼片系統。要注意,穿皮投藥尤其適合於不間斷投藥,因為第一個用完的貼片可以有利地同時與新的第二個貼片交換,例如在皮膚表面上緊鄰第一個用完的貼片並且就在撕除第一個域完的貼片之前。不會出現流動中斷或電源單元不良的問題。
若醫藥組成物已被凍乾,則在投藥之間於適當液體中先將凍乾材料還原。可以在例如抑菌性注射用水(BWFI)、生理鹽水、磷酸鹽緩衝鹽水(PBS),或蛋白質被凍乾之前在同一調配物中被還原。
本發明組成物可以在其可被確定的適當劑量被投藥,例如依據劑量漸增研究,透過投與劑量漸增之對非黑猩猩靈長動物(例如獼猴)展現本文所述跨物種特異性之本發明抗體構築體。如上所述,展現本文所述跨物種特異性之本發明抗體構築體可以有利地以相同形式在臨床前測試中於非黑猩猩靈長動物體內使用並且在人類體內用作藥物。劑量方案將由主治醫生和臨床因素來確定。如在醫學領域所熟知的,任一患者的劑量取決於許多因素,包括病人的身材、體表面積、年齡、待投與的特定化合物、性別、投藥時間和途徑、一般健康狀況,和其他同時投與的藥物。
術語「有效劑量」或「有效劑量」被定義為,足以達到或至少部分達到預期效果的數量。術語「治療有效劑量」被定義為,足以治癒或至少部分阻止受疾病所苦之患者的疾病和併發症的數量。就這個用途而言有效的數量或劑量將取決於待治療病況(適應症)、所述遞送抗體構築體、治療背景和目的、疾病的嚴重程度、先前的治療、患者的臨床病史和對治療劑的反應、投要途徑、患者的身材(體重、體表面積或器官大小)及/或條件(年齡和一般健康狀況),和患者自身免疫系統的大體狀態。適當的劑量可以根據主治醫生的判斷,使得它可以被一次性投藥或一系列投藥給患者,並且為了獲得最佳治療效果來進行調整。
典型的劑量可為約0.1 μg/kg至高達約30 mg/kg或更多,取決於上面提及的因素。在特定具體例中,劑量範圍可以是1.0 μg/kg到高達約20 mg/kg,視情況從10 μg/kg到高達約10 mg/kg,或從100 μg/kg到高達約5 mg/kg。
本發明抗體構築體的治療有效量較佳會使得疾病症狀的嚴重程度降低、無疾病症狀頻率或持續期間提高或預防因為罹病所導致的障礙或失能。用於治療表現CDH3的腫瘤,治療有效量的本發明抗體構築體(例如,抗CDH3/抗CD3抗體構築體)較佳地相對於未經治療的患者抑制細胞生長或腫瘤生長達至少約20%、至少約40%、至少約50%、至少約60%、至少約70%、至少約80%,或至少約90%。化合物抑制腫瘤生長的能力可能在預測於人類腫瘤中之功效的動物模型內進行評估。
醫藥組成物可以視需要做為單一治療劑投藥或與其他療法(諸如抗癌療法)(例如其他蛋白質和非蛋白質藥物)或組合給藥。這些藥物可以與包含如本文所定義之抗體構築體的組成物同時投與,或在該抗體構築體投藥之前或之後以有時間限制的間隔與劑量被分開投與。
術語「有效且無毒的劑量」如本文所用意指本發明抗體構築體的可耐受劑量,其是高到足以引起病理性細胞、腫瘤消除、腫瘤收縮或疾病的穩定,但不會或基本上不會有明顯毒性效用。這等有效且無毒的劑量可例如透過如技藝中所述的劑量遞增研究來決定,並應在會誘發嚴重不利副作用事件的劑量以下(劑量限制性毒性,DLT)。
術語「毒性」如本文所用意指在不良事件或嚴重不良事件中表現出來的藥物毒性效用。這些不良事件可能大體上是缺乏藥物耐受性及/或在給藥後缺少局部耐受性。毒性也可能包括由藥物導致的致畸胎或致癌作用。
術語「安全性」、「活體內安全性」或「耐受性」如本文所用定義為就在藥物給藥後未引起嚴重不良事件(局部耐受性)以及在施用藥物的長時間期間未引起嚴重不良事件。「安全性」、「活體內安全性」或「耐受性」可以在治療和隨訪期間例如定期地進行評估。測量包括臨床評估,如器官徵象和實驗室異常篩檢。可以實施臨床評估並相對於根據NCI-CTC及/或MedDRA標準紀錄/編碼的正規實驗結果有所偏離。器官徵象可包括例如過敏/免疫學、血液/骨髓、心律不整、凝血及類似者的標準,如在不良事件通用術語標準3.0 (CTCAE)中所述。可測試的實驗室參數包括,例如血液學、臨床化學、凝血概況和尿分析並檢驗其他體液(諸如血清、血漿,淋巴或脊髓液)、液體與類似物。因此,安全性可例如透過體檢、成像技術(如超音波、X射線、CT掃描、磁共振成像(MRI)、其他測量方法),利用技術設備(如心電圖)、生命徵象,藉由測量實驗室參數和記錄不良的事件來評估。例如,在根據本發明的用途和方法中,於非黑猩猩靈長動物的不良事件可以透過組織病理學及/或組織化學方法檢驗。
例如在生物技術衍生之藥物的臨床前安全性評估;在1997年7月16日召開的I ICH Steering Committee中也提到以上術語。
在另一個具體例中,本發明提供包含本發明抗體構築物、依據本發明方法製造的抗體構築體、本發明載體,及/或本發明宿主細胞的套組。
在本發明的上下文中,術語「套組」是指兩種或更多種組分-其中一者對應於本發明抗體構築體、醫藥組成物、載體或宿主細胞-一起包裝於容器(container)、容器(recipient)中或以其他方式包裝。因此,套組可以被描述為足以達到某個目標的一組產品及/或用具,其可做為單一組件(unit)銷售。
套組可包含具有任何適當的形狀、大小和材料(較佳為防水的,例如塑膠或玻璃)的一或多個容器(如小瓶、安瓿、容器、注射器、瓶、袋),其含有呈投藥用適當劑量的本發明抗體構築體或醫藥組成物(見上文)。套組可另外含有使用說明(例如呈單張或說明書的形式)、用於投與本發明抗體構築體的用具(諸如注射器、泵、輸注器或類似用具)、用於還原本發明抗體構築體的用具及/或用於稀釋本發明抗體構築體的用具。
本發明亦提供了單劑量投藥單位用的套組。本發明套組還可以含有一個第一容器,其包含經乾燥/凍乾抗體構築;以及第二容器,其包含水性調配物。在本發明的某些具體例,提供含有單室和多室預填充式注射器的套組(例如液體注射器與凍乾注射器)。
| 原有 | 例示置換 | 較佳置換 |
| Ala (A) | val、leu、ile | val |
| Arg (R) | lys、gln、asn | lys |
| Asn (N) | gln、his、asp、lys、arg | gln |
| Asp (D) | glu、asn | glu |
| Cys (C) | ser、ala | ser |
| Gln (Q) | asn、glu | asn |
| Glu (E) | asp、gln | asp |
| Gly (G) | Ala | ala |
| His (H) | asn、gln、lys、arg | arg |
| Ile (I) | leu、val、met、ala、phe | leu |
| Leu (L) | norleucine、ile、val、met、ala | ile |
| Lys (K) | arg、gln、asn | arg |
| Met (M) | leu、phe、ile | leu |
| Phe (F) | leu、val、ile、ala、tyr | tyr |
| Pro (P) | Ala | ala |
| Ser (S) | Thr | thr |
| Thr (T) | Ser | ser |
| Trp (W) | tyr、phe | tyr |
| Tyr (Y) | trp、phe、thr、ser | phe |
| Val (V) | ile、leu、met、phe、ala | leu |
實例:下面實例說明本發明。這些實施例不應被解釋為限制本發明的範疇。本發明僅受申請專利範圍所囿限。
實例 1 產生表現野生型和嵌合 CDH3 的 CHO 細胞關於構築表位定位所使用的嵌合分子,人類CDH3的各別五個胞外域Dom1至Dom5 (或D1至D5)及其子域(A、B和C)的序列被替換成對應鼠類序列。產生下面20個分子;也可參見圖1和圖2:
• Hu CDH3 / DOM1 mu (AA 108-215) SEQ ID NO: 13
• Hu CDH3 / Dom1A mu (AA 108-143) SEQ ID NO: 14
• Hu CDH3 / Dom1B mu (AA 144-179) SEQ ID NO: 15
• Hu CDH3 / Dom1C mu (AA 180-215) SEQ ID NO: 16
• Hu CDH3 / DOM2 mu (AA 216-327) SEQ ID NO: 17
• Hu CDH3 / Dom2A mu (AA 216-252) SEQ ID NO: 18
• Hu CDH3 / Dom2B mu (AA 253-290) SEQ ID NO: 19
• Hu CDH3 / mu Dom2C(AA 291-327) SEQ ID NO: 20
• Hu CDH3 / DOM3 mu (AA 328-440) SEQ ID NO: 21
• Hu CDH3 / Dom3A mu (AA 328-363) SEQ ID NO: 22
• Hu CDH3 / Dom3B mu (AA 364-403) SEQ ID NO: 23
• Hu CDH3 / Dom3C mu (AA 404-440) SEQ ID NO: 24
• Hu CDH3 / Dom4 mu (AA 441-546) SEQ ID NO: 25
• Hu CDH3 / Dom4A mu (AA 441-474) SEQ ID NO: 26
• Hu CDH3 / Dom4B mu (AA 475-511) SEQ ID NO: 27
• Hu CDH3 / Dom4C mu (AA 512-546) SEQ ID NO: 28
• Hu CDH3 / Dom5 mu (AA 547-650) SEQ ID NO: 29
• Hu CDH3 / Dom5A mu (AA 547-581) SEQ ID NO: 30
• Hu CDH3 / Dom5B mu (AA 582-616) SEQ ID NO: 31
• Hu CDH3 / Dom5C mu (AA 617-650) SEQID NO:32
以上清單顯示了在人類CDH3胺基酸序列中,不同結構域(Dom1-Dom5)還有各個子域A-C的位置,如SEQ ID NO: 1中所示。例如,子域D1A是位於SEQ ID NO: 1的胺基酸位置108-143。同樣適用於上面列出的所有其他結構域。
關於在CHO細胞中表現,上述嵌合胞外域的編碼序列之後呈框架內的形式是一個人工Ser/Gly-連接子,然後是一個衍生自人類EpCAM跨膜/胞內域的結構域(序列的胺基酸266-314,如GenBank登錄號NM_002354中所公開)。所有嵌合構築體包含N-端信號序列(信號肽)和前肽。
關於產生表現人類、食蟹獼猴(「獼猴」),小鼠和人類/小鼠嵌合CDH3的CHO細胞,人類CDH3 (SEQ ID NO: 2,也參見GenBank登錄號NM_001793)、獼猴CDH3( SEQ ID NO: 6)、小鼠CDH3(SEQ ID NO: 10,也參見GenBank登錄號NM_001037809)和20個人類-小鼠CDH3嵌合體(參見上文)的各別編碼序列被選殖到命名為pEF-DHFR的質體中(pEF-DHFR描述於Raum
et al.Cancer Immunol Immunother 50 (2001) 141-150中)。藉由標準選殖,使用獼猴脾臟cDNA庫(BioChain)以及人類序列特異性寡核苷酸(5’ GGCCCGCCGTCGCGGCAGC 3’;5’ CTCCTTCTCCAGGTTTGCTGGC 3’;5’ AACTGAGACCCCTTGGAGATGC 3’;5’ TAGTCGTCCTCCCCGCCACC 3’;5’ GGAGGGTGGGACAAACACAGG 3’;5’ ACGTTGAAGTGACCAACGAGGC 3’)在人類CDH3 mRNA轉譯本(NM_001793)的未轉譯區或保守序列區中雜交而獲得獼猴CDH3的編碼序列。序列分析揭示,相較於恒河猴CDH3 GenBank序列(JU473826、JU473827),核心胞外域的胺基酸序列相似性。所有選殖程序是根據標準程序(Sambrook, Molecular Cloning; A Laboratory Manual, 3rd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York (2001))進行。關於每個構築體,將一個對應質體轉染到DHFR缺陷型CHO細胞中用於真核表現,如Kaufman R.J. (1990) Methods Enzymol. 185, 537-566所述。
CDH3(人類,鼠類和嵌合構築體)在CHO細胞上的表現是使用單株小鼠IgG1抗人類CDH3抗體在FACS分析中進行檢核,單株小鼠IgG1抗人類CDH3抗體具有鼠類交叉反應性。用抗小鼠IgG Fcγ-PE偵測結合的單株抗體。作為陰性對照,將細胞與PBS/2% FCS一起培育,而不是第一抗體。透過流式細胞儀測量樣品。結果顯示於圖3中。用接合PE的R&D 861-P偵測人類與食蟹獼猴CDH3在CHO細胞上的表現(參見實例5)。
實例 2 鼠類 scFv- 片段的表位集簇經人類或鼠類CDH3,或嵌合人類/小鼠CDH3分子(參見實例1)轉染的細胞用含有結合至人類/獼猴CDH3之scFv的粗製、未稀釋周質萃取物染色。用小鼠單株抗FLAG-M2抗體(1 µg/ml;50 µl於PBS/2%FCS中;Sigma F1804),隨後抗小鼠IgG Fcγ-PE (1:100,50 µl;Jackson Immunoresearch # 115-116-071)偵測結合的scFv分子。所有抗體稀釋於具有2% FCS的PBS中。作為陰性對照,將細胞與PBS / 2%FCS一起培育,而不是周質萃取物。透過流式細胞儀測量樣品。結果顯示於圖4中。
具體而言,圖4A顯示辨識人類CDH3之胞外域D1(且更確切來說是子域D1B)的結合子(在各別嵌合CDH3構築體中失去FACS信號)。注意到被稱為CDH3-6的結合子是CDH3-4的親本結合子。被稱為CDH3-10的結合子是CDH3-1、CDH3-2和CDH3-3的親本結合子。圖4B顯示辨識人類CDH3的胞外域D2(且更確切來說是子域D2C)的結合子。注意到被稱為CDH3-21的結合子是CDH3-11、CDH3-12和CDH3-14的親本結合子。被稱為CDH3-23的結合子是CDH3-13的親本結合子。最後,圖4C顯示辨識人類CDH3的胞外域D3(更確切來說是子域D3A)的結合子。注意到結合子CDH3-32更結合至子域D3C。被稱為CDH3-32的結合子是CDH3-25、CDH3-26和CDH3-27的親本結合子。被稱為CDH3-33的結合子是CDH3-24的親本結合子。術語「親本結合子」在上下文中表示開發這些結合物以產生或獲得最佳化結合子。
結合子CDH3-11、CDH3-12、CDH3-13和CDH3-14全都進行表位簇集分析,並且以顯示它們會辨識人類CDH3的胞外域D2,並且更確切來說柿子域D2C(數據未顯示)。進一步使用結合子CDH3-24、CDH3-25、CDH3-26和CDH3-27進行相同分析。這些結合子辨識人類CDH3的胞外域D3,並且更確切來說是子域D3A(數據未顯示)。
實例 3 基於 Biacore 測定對人類和食蟹獼侯 CDH3 的抗體親和力使用重組CDH3(分別為人類和食蟹獼猴CDH3)融合蛋白與人類白蛋白(HALB)進行Biacore分析實驗,以確定CDH3目標結合至本發明抗體。
詳言之,根據製造商手冊,將CM5感應晶片(GE Healthcare)以約600-800 RU的個別重組抗原使用乙酸鹽緩衝液pH 4.5予以固定。以五個濃度加載CDH3xCD3雙特異性抗體樣品:50 nM、25 nM、12.5 nM、6.25 nM與3.13 nM,稀釋於HBS-EP運行緩衝液(GE Healthcare)中。流速為30 μl/min歷時3分鐘,然後再次以30 μl/min的流速施加HBS-EP運行緩衝液歷時8分鐘至20分鐘。用10mM甘胺酸、10 mM NaCl的pH 1.5溶液進行晶片再生。使用BiaEval軟體分析數據集。大體上進行兩個獨立實驗。
根據本發明的CDH3xCD3雙特異性抗體顯示對人類CDH3有高親和力,在1位奈莫耳範圍內。結合至獼猴CDH3是平衡的,也顯示出類似範圍的親和力。親和力值以及所計算的親和力差距顯示於表2中。CDH3-25 x F12q-HALB和CDH3-13- xI2C-HLE(Fc)分別在個別分析測量,並顯示出分別具有
• 31.8 ± 1.9 nM的KD (hu),40.9 ± 3.89 nM的KD (食蟹獼猴)與1.29的親和力差距,
• 12.95 ± 0.5 nM的KD (hu),12.35 ± 0.35 nM的KD (石蟹獼猴)與0.95的親和力差距。
表 2:如透過Biacore分析,以及計算出的物種間親和力差距來測定CDH3xCD3雙特異性抗體對人和獼猴CDH3的親和力。
實例 4 CDH3xCD3 雙特異性抗體 親和力對目標抗原陽性細胞上之人類和獼猴 CDH3 的基於 斯卡查德 (Scatchard) 分析以及物種間親和力差距也藉由斯卡查德分析測定CDH3xCD3雙特異性抗體對經人類或獼猴CDH3轉染的CHO細胞的親和力,作為用於測定人類與獼猴CDH3之間潛在親和力差距最可靠方法。就斯卡查德分析來說,使用單價偵測系統來進行飽和結合實驗,以準確測定CDH3xCD3雙特異性抗體對個別細胞株的單價結合。
個別細胞株(表現重組人類CDH3的CHO細胞株,表現重組獼猴CDH3的CHO細胞株)的2×104個細胞分別與50 µl三重稀釋系列(以1:2進行12次稀釋)的個別CDH3xCD3雙特異性抗體(達到飽和為止)從10-20 nM開始一起培育,然後在4℃下攪拌並培育16小時,和一個殘餘物洗滌步驟。然後,將細胞與30 µl的CD3xALEXA488接合物溶液培育又一小時。在一個洗滌步驟後,將細胞再懸浮在150 µl含3.5%甲醛的FACS緩衝液中、再培養15分鐘、離心,再懸浮於FACS緩衝液並使用FACS CantoII機器和FACS Diva軟體進行分析。從兩個獨立的兩組實驗中(每個三重複)產生數據。計算各自斯卡查德分析來推論最大結合(Bmax)。確定CDH3xCD3雙特異性抗體在半最大結合時的濃度反映了各自的KD。三重複測量值描繪為雙曲線和S形曲線,以顯示從最小至最佳結合的適當濃度範圍。
表3中所述之值是依據CDH3xCD3雙特異性抗體由兩個獨立實驗衍生而來。基於細胞的斯卡查德分析證實,本發明CDH3xCD3雙特異性抗體對人類CDH3的親和力在奈莫耳至次奈莫耳,且存在的低微石蟹獼猴/人類物種間CD`H3親和力差距大約為1。在個別分析中分別測定的CDH3-25 x F12q-HALB和CDH3-13 x I2C-HLE(Fc)顯示為分別具有:
• 0.37 ± 0.11 nM的基於細胞親和力(人類hu),0.35 ± 0.08 nM的基於細胞親和力(食蟹獼猴)且親和力差距為0.95,以及
• 0.32 ± 0.003 nM的基於細胞親和力(人類),0.5 ± 0.09 nM的基於細胞親和力(食蟹獼猴)且親和力差距為1.56。
表 3 :CDH3xCD3雙特異性抗體如在基於細胞的斯卡查德分析中測定的親和力(KD)以及計算出的親和力差距KD獼猴CHD3/KD人類CDH3。在兩個獨立實驗中測定抗體,各自使用三重複。
實例 5 雙特異性結合和物種間交叉反應 性為確認對人類CDH3和CD3和結合至食蟹獼猴CDH3和CD34的結合,使用下列藉由流式細胞儀來測試雙特異性抗體
• 分別經人類和食蟹獼猴CDH3轉染的CHO細胞,
• 人類CDH3陽性表皮樣癌細胞株A431,
• 表現CD3的人T細胞白血病細胞株HPB-all (DSMZ, Braunschweig, ACC483),以及
• 表現食蟹獼猴CD3的T細胞株HSC-F。
此外,使用經鼠類CDH3轉染的CHO細胞作為陰性對照。
關於流式細胞儀,各細胞株的200,000個細胞用50 μl經純化雙特異性抗體在5 μg/ml的濃度下於冰上培育30分鐘。在PBS/2% FCS中洗滌細胞兩次並用對CD3結合部分具有特異性的內部小鼠抗體偵測構築體的結合。洗滌後,用山羊抗小鼠的Fcγ-PE偵測結合的小鼠抗體。藉由流式細胞儀測定樣品。
結果顯示於圖5A和5B中。本發明CDH3xCD3雙特異性抗體染上經人類CDH3和食蟹獼猴CDH3轉染的CHO細胞,它們也染上人類CDH3陽性表皮樣癌細胞株A431(天然表現者),以及表現CD3的人類和食蟹獼猴T細胞。此外,陰性對照細胞沒有染色(經鼠類CDH3轉染的CHO)。
實例 6 不結合至人類和獼猴旁系同源物的確認人類和獼猴CDH3旁系同源物(CDH1 = E-黏附蛋白、CDH2 = N-黏附蛋白、CDH4 = R-黏附蛋白和CDH5 = VE黏附蛋白)被穩定轉染至dhfr
-/-CHO細胞中。在FACS分析中使用對個別旁系同源物具有特異性的抗體進行確認。抗體是R&D MAB18381 (用於CDH1)、eBioscience 12-3259-41 (用於CDH2)、R&D Systems多株AF2217 (用於CDH4)以及BD Bioscience # 555661 (用於CDH5)。
在序列表中確認如在本實例中使用的旁系同源物的序列(SEQ ID NO: 41-44)。它們也可以下列GenBank登錄號而被找到:
NM_004360 [人類CDH1]
NM_001792 [人類CDH2]
NM_001794 [人類CDH4]
NM_001795 [人類CDH5]
如實例5中所述進行流式細胞儀分析。結果顯示於圖5C和5D中。分析證實,本發明CDH3xCD3雙特異性抗體中沒有一個會與任何測試的人類CDH3旁系同源物交叉反應。
本發明抗體也經證實不會與獼猴CDH3旁系同源物CDH1、CDH2、CDH4和CDH5交叉反應(數據未顯示)。如上對於人類旁系同源物的描述,對CHO細胞上的獼猴旁系同源物表現進行驗證。在序列表中確認如在本實例中使用的獼猴旁系同源物的序列(SEQ ID NO: 45-48)。它們也可以下列GenBank登錄號而被找到:
XM_002802516 [獼猴CDH1]
JU321883 [獼猴CDH2]
XM_002802511 [獼猴CDH5]
此外,從Ensembl Genome Browser (ENSMMUT00000017252)中獲得獼猴CDH4序列和在框架內與人類CDH4信號肽(胺基酸1-19)N端融合。
實施例 7 : 與人類生殖系的一致性為了分析抗體與人類抗體生殖系基因的序列一致性/相似性,本發明的CDH3結合子如下進行排比:排比全VL,包括所有的CDR;相對於人類抗體生殖系基因(Vbase)排比全VH,包括CDR1和2,除了CDR3以外。更多細節可以在本申請案的說明書中找到。結果顯示於下面表4中:
表 4 :VH和VL與人類生殖系的一致性
實例 8 細胞毒性活性在五個活體外細胞毒性分析中分析本發明CDH3xCD3雙特異性抗體在重新定向效應T細胞對抗表現CDH3之目標細胞方面的效力:
• 在18小時51-鉻釋放分析中,測定CDH3xCD3雙特異性抗體在重新定向受刺激人類CD8+效應T細胞對抗經人類CDH3轉染之CHO細胞方面的效力。結果參見圖6。
• 在18小時51-鉻釋放分析中,測定CDH3xCD3雙特異性抗體在重新定向受刺激人類CD8+效應T細胞對抗CDH3陽性人類癌細胞株A431方面的效力。結果參見圖7。
• 在48小時基於FACS的細胞毒性分析中,測定CDH3xCD3雙特異性抗體在重新定向未受刺激人類PBMC之T細胞對抗經人類CDH3轉染的CHO細胞方面的效力。結果參見圖8。
• 在48小時基於FACS的細胞毒性分析中,測定CDH3xCD3雙特異性抗體在重新定向未受刺激人類PBMC之T細胞對抗CDH3陽性人類癌細胞株A431方面的效力。結果參見圖9。
• 為確認交叉反應性,CDH3xCD3雙特異性抗體能夠重新定向獼猴T細胞對抗經獼猴CDH3轉染的CHO細胞,使用獼猴T細胞作為效應T細胞進行48小時基於FACS的細胞毒性分析。結果參見圖10。
實例 8.1 使用受刺激的人類 T 細胞的鉻釋放分析如下文所述獲得富含CD8
+T細胞的受刺激T細胞。培養皿(直徑145 mm,Greiner bio-one GmbH, Kremsmünster)在37℃下塗佈最終濃度為1 µg/ml的商用抗-CD3特異性抗體(OKT3,Orthoclone)歷時1小時。透過用PBS洗滌一次步驟除去未結合的蛋白。3 - 5×10
7個人類PBMC被加入至預先塗佈的培養皿中,培養皿還有120 ml的RPMI 1640加上穩定的麩胺醯胺酸/ 10%FCS / IL-2 20 U/ml (Proleukin®,Chiron),並刺激歷時2天。在第三天,收集細胞,並用RPMI 1640洗滌一次。添加IL-2達20 U/ml的最終濃度,並如上述在相同細胞培養基中再培養一天。根據製造商的方案,CD8
+細胞毒性T淋巴細胞(CTL)是使用Dynal-珠粒藉著耗盡CD4
+T細胞和CD56
+NK細胞而被富集。
用PBS洗滌經食蟹獼猴CDH3或人類CDH3轉染的CHO目標細胞兩次,並在37℃下用11.1 MBq
51Cr以100 µl RPMI加上50% FCS的最終體積標記歷時60分鐘。隨後,將標記的目標細胞用5 ml RPMI洗滌3次,然後在細胞毒性分析中使用。於補充E:T比率為10:1之200 µl RPMI中,在96孔盤內進行分析。使用起始濃度為0.01 – 1 µg/ml的經純化雙特異性抗體及其三倍稀釋液。分析培育時間為18小時。細胞毒性測定為相對於溶解(添加Triton-X)和自發性溶解裂解(沒有效應細胞)的最大差異,上清液中釋放的相對鉻值。所有測量均以四重複進行。在一個Wizard 3’’ γ計數器(Perkin Elmer Life Sciences GmbH, Köln, Germany)中進行上清液中的鉻活性測定。結果是使用Windows用的Prism 5 (version 5.0, GraphPad Software Inc., San Diego, California, USA)進行分析。透過從S形劑量反應曲線的分析程式計算的EC 50值被用於比較細胞毒性活性。
實例 8.2 使受刺激的人類效應 T 細胞重新定向對抗經人類 CDH3 轉染的 CHO 細胞 的效力在51-鉻(
51Cr)釋放細胞毒性分析中,使用經人類CDH3轉染的CHO細胞作為目標細胞以及受刺激人類CD8+ T細胞作為效應細胞,分析本發明CDH3xCD3雙特異性抗體的細胞毒性活性。如實例8.1中所述進行實驗。
結果顯示於圖6和表5中。CDH3xCD3雙特異性抗體顯示強效的細胞毒性活性對抗經人類CDH3轉染的CHO細胞,即使低至1位數皮莫耳範圍。所請求保護的抗體 – 對相應於人類CDH3的位置291-363的表位簇具有特異性 – 呈現出有利的表位-活性相關性,支持強有力的雙特異性抗體媒介的細胞毒性活性。在個別的分析中測定CDH3-25 x F12q-HALB與CDH3-13 xI2C-HLE (Fc),並顯示分別具有3.6 pM以及8.9 pM的EC50。
表 5 :在51鉻(
51Cr)釋放細胞毒性分析中,使用經人類CDH3轉染的CHO細胞作為目標細胞以及受刺激人類CD8 T細胞作為效應細胞,分析CDH3xCD3雙特異性抗體的EC50值[pg/ml]。
實例 8.3 使受刺激的人類效應 T 細胞重新定向對抗 CDH3 陽性人類癌細胞株 A431 的效力在51-鉻(
51Cr)釋放細胞毒性分析中,使用CDH3陽性人類表皮樣癌細胞株A431作為目標細胞來源以及受刺激人類CD8+ T細胞作為效應細胞,分析本發明CDH3xCD3雙特異性抗體的細胞毒性活性。如實例8.1中所述進行實驗。
與使用經人類CDH3轉染的CHO細胞作為目標細胞以及受刺激人類CD8 T細胞作為效應細胞的51-鉻釋放分析結果一致,本發明CDH3xCD3雙特異性抗體的細胞毒性活性強力對抗天然表現者目標細胞(圖7和表6)。在個別的分析中測定CDH3-25 x F12q-HALB與CDH3-13 xI2C-HLE (Fc),並顯示分別具有1.2 pM以及16 pM的EC50。
表 6 :在18小時的51-鉻(
51Cr)釋放細胞毒性分析中,使用CDH3陽性人類癌細胞株A431作為目標細胞來源以及受刺激的經富集人類CD8 T細胞作為效應細胞,分析CDH3xCD3雙特異性抗體的EC50值[pg/ml]。
實例 8.4 使用未受刺激人類 PBMC 之基於 FACS 的細胞毒性分析 效應細胞的分離人類周邊血液單核細胞(PBMC)是由經富集淋巴細胞製品(膚色血球層)(輸血用血庫採血管的副產物)透過Ficoll密度梯度離心來製備。膚色血球層是由當地血庫提供而PBMC是在採血同一天製備。Ficoll密度離心並用杜貝可氏PBS (Gibco)充分洗滌之後,透過與紅血球溶解緩衝液(155 mM NH
4Cl、10 mM KHCO
3、100 µM EDTA)一起培育而將剩餘紅血球自PBMC移除。血小板是經由以100×g離心PBMC後的上清液而被移除。其餘淋巴細胞主要包括B淋巴細胞和T淋巴細胞,NK細胞和單核細胞。於37℃/ 5% CO
2下,將PBMC保持在有10% FCS(Gibco)的RPMI培養基(Gibco)中培養。
CD14
+ 和 CD56
+ 細胞的耗竭關於CD14
+細胞的耗竭,人類CD14 MicroBeads (Milteny Biotec, MACS, #130-050-201)用於NK細胞人類CD56 MicroBeads (MACS, #130-050-401)的耗竭。計數PBMC並在室溫下以300 × g離心歷時10分鐘。丟棄上清液,並將細胞粒再懸浮於MACS分離緩衝液[80 µL/ 10
7細胞;PBS (Invitrogen, #20012-043)、0.5% (v/v) FBS (Gibco, #10270-106)、2 mM EDTA (Sigma-Aldrich, #E-6511)]。添加CD14 MicroBeads和CD56 MicroBeads (20 µL/10
7個細胞)並在4-8℃下培育歷時15分鐘。用MACS分離緩衝液洗滌細胞(1 – 2 ml/10
7個細胞)。離心(參見上文)後,丟棄上清液並將細胞再懸浮於MACS分離緩衝液(500 µL/10
8個細胞)中。然後使用LS管柱(Miltenyi Biotec, #130-042-401)分離CD14/CD56陰性細胞。PBMC w/o CD14+/CD56+細胞培養於37℃的恆溫箱中培養在RPMI完全培養基中,即RPMI1640 (Biochrom AG, #FG1215)補充有10% FBS (Biochrom AG, #S0115)、1×非必需胺基酸(Biochrom AG, #K0293)、10 mM Hepes緩衝液(Biochrom AG, #L1613),1 mM丙酮酸鈉(Biochrom AG, #L0473)和100 U/mL青黴素/鏈黴素(Biochrom AG, #A2213),直到需要為止。
目標細胞標記關於在流式細胞儀中的細胞溶解分析,螢光膜染料DiOC
18(DiO) (Molecular Probes, #V22886)被用來標記經人類CDH3-或獼猴CDH3轉染的CHO細胞作為目標細胞,並與效應細胞區分開來。簡言之,收取細胞,用PBS洗滌一次,並在含有2% (v/v) FBS與膜染料DiO (5 µL/10
6個細胞)的PBS中調整至10
6個細胞/ml。在37℃下培育歷時3分鐘後,在完全RPMI培養基洗滌細胞兩次,並且將細胞數目調節至1.25×10
5細胞/ mL。用0.5%(v/v)的等滲EosinG溶液(Roth, #45380)測定細胞活力。
以流式細胞儀為基礎的分析本分析被設計成,在CDH3雙特異性抗體的連續稀釋液存在下,量化經食蟹獼猴或人類CDH3轉染的CHO細胞的溶解。將等體積的經DiO-標記的目標細胞和效應細胞(即,PBMC w/o CD14
+細胞)混合,得到10:1的E:T細胞比率。將160 µl的此懸浮液轉移到96孔盤的各孔。添加40 µl的CDH3xCD3雙特異性抗體連續稀釋液,而添加陰性對照雙特異性(基於CD3雙特異性抗體,辨識不相關的目標抗原)或RPMI完全培養基作為額外的陰性對照。雙特異性抗體媒介的細胞毒性反應在7% CO
2濕化培養箱進行48小時。然後將細胞轉移到新的96孔盤,並透過添加1 µg/mL最終濃度的碘化丙啶(PI)監測目標細胞膜完整性的喪失。PI是通常被排除在活細胞之外,而死亡的細胞將它攝入並變得能被螢光發射辨識的膜不滲透性染料。
借助流式細胞儀在FACSCanto II儀器上測量樣品,並透過FACSDiva軟體予以分析(均來自Becton Dickinson)。目標細胞被鑑定為DiO陽性細胞。PI陰性目標細胞被列為活目標細胞。細胞毒性的百分比是根據下列公式計算:
n =事件數
使用GraphPad Prism 5軟體(Graph Pad Software, San Diego),繪製細胞毒性百分率相對於對應雙特異性抗體濃度的圖。用四參數邏輯回歸模型分析劑量反應曲線,以供評估具有固定坡斜率的S形劑量反應曲線並計算EC50值。
實例 8.5 使未受刺激的人類 PBMC 重新定向對抗經人類 CDH3 轉染的 CHO 細胞的效力在以FACS為主的細胞毒性分析中,使用經人類CDH3轉染的CHO細胞作為目標細胞以及未受刺激人類PBMC作為效應細胞,分析CDH3xCD3雙特異性抗體的細胞毒性活性。如上面實例8.4中所述進行分析。
使用未受刺激人類PBMC作為效應細胞以及經人類CDH3轉染的CHO細胞作為目標細胞,以FACS為主的細胞毒性分析結果顯示於圖8和表7中。在個別的分析中分別測定CDH3-25 x F12q-HALB與CDH3-13 xI2C-HLE (Fc),並顯示分別具有4.6 pM以及5.6 pM的EC50。
表 7 :如在48小時以FACS為主的細胞毒性分析中,使用未受刺激人類PBMC作為效應細胞以及經人類CDH3轉染的CHO細胞作為目標細胞,測量的CDH3xCD3雙特異性抗體的EC50值[pg/ml]。
實例 8.6 使未受刺激的人類 PBMC 重新定向對抗 CDH3 陽性人類癌細胞株 A431 的效力在以FACS為主的細胞毒性分析中,使用CDH3陽性人類表皮樣癌細胞株A431做為目標細胞來源以及未受刺激人類PBMC作為效應細胞,進一步分析CDH3xCD3雙特異性抗體的細胞毒性活性。如上面實例8.4中所述進行分析。結果顯示於圖9和表8中。在個別的分析中分別測定CDH3-25 x F12q-HALB與CDH3-13 xI2C-HLE (Fc),並顯示分別具有2.3 pM以及32 pM的EC50。
表 8 :如在48小時以FACS為主的細胞毒性分析中,使用未受刺激人類PBMC作為效應細胞以及人類A431細胞株作為目標細胞來源,測量的CDH3xCD3雙特異性抗體的EC50值[pg/ml]。
一如預期,EC50值在使用未受刺激PBMC作為效應細胞的細胞毒性分析中比使用受刺激人類CD8+ T細胞的細胞毒性分析還高。
實例 8.7 使獼猴 T 細胞重新定向對抗表現獼猴 CDH3 的 CHO 細胞的效力最後,在以FACS為主的細胞毒性分析中,使用經獼猴(食蟹獼猴) CDH3轉染的CHO細胞作為目標細胞,以及獼猴T細胞株作為效應細胞來源,分析CDH3xCD3雙特異性抗體的細胞毒性活性。獼猴T細胞株4119LnPx (Knappe et al. Blood 95:3256-61 (2000))用作為效應細胞來源。經獼猴CDH3轉染的CHO細胞的目標細胞標記和以流式細胞儀為主的細胞毒性活性分析如上文所述進行。
結果顯示輿圖10和表9中。細胞株4119LnPx的獼猴T細胞受到本發明CDH3xCD3雙特異性抗體誘導而有效率地殺滅經獼猴CDH3轉染的CHO細胞
,CDH3xCD3雙特異性抗體亦即結合至對應於人類CDH3的位置291-363的人類CDH表位簇,並含括相鄰子域D2C(位置291-327)和D3A(位置328-363)的抗體。抗體在本發明中以2位數至極低4位數pg/ml的EC50值有力地呈現,確認這些抗體在獼猴系統中非常活躍。
在表位簇集期間已鑑定出另一群抗-CDH3抗體(參見實例2),其結合至人類CDH3的胞外域D1,更具體而言,結合至子域D1B。出乎意料的是,這群CDH3xCD3雙特異性抗體 - 雖然在細胞毒性活性方面強效對抗經人類CDH3轉染的CHO細胞 - 證明表現出非常弱的細胞毒性活性對抗經獼猴CDH3轉染的CHO細胞(參見圖10C和表9)。這群抗體顯示明顯較弱效力,EC50值在非常高的4位數以及甚至5位數pg/ml範圍內。在個別的分析中分別測定CDH3-25 x F12q-HALB與CDH3-13 xI2C-HLE (Fc),並分別顯示具有1.4 pM以及4.0 pM的EC50。
本發明CDH3xCD3抗體結合至對應於位置291-363的CDH3表位簇,因此在獼猴系統中比結合至胞外域D1的抗體更為強效大約5至幾乎1000倍,且更特異性地結合至CDH3子域D1B。
表 9 :如在48小時以FACS為主的細胞毒性分析中,使用獼猴T細胞株4119LnPx作為效應細胞以及經獼猴CDH3轉染的CHO細胞作為目標細胞,測量結合至對應於位置291-363 (第1至8列)之CDH3表位簇的CDH3xCD3雙特異性抗體,以及結合至CDH3表位簇/子域D1B(第9至12列)的CDH3xCD3雙特異性抗體的EC50值[pg/ml]。
實例 9 在 (i) 三個冷凍 / 解凍循環及 (ii) 以 250 µg/ml 培育 7 天之後,單體至二聚體的轉換雙特異性CDH3xCD3抗體單體受到不同的壓力條件,隨後藉由高效SEC確定已被轉換成抗體二聚體的初始單體樣抗體百分率。
(i)使用通用調配緩衝液將15 μg單體樣抗體調整成250 μg/m的濃度,然後於-80℃下冷凍30分鐘,隨後在室溫下解凍30分鐘。經過三次冷凍/解凍循環後,透過HP-SEC測定二聚體含量。
(ii)使用通用調配緩衝液將15 μg單體樣抗體調整成250 μg/m的濃度,然後於37℃下培育歷時7天。透過HP-SEC測定二聚體含量。
高解析度SEC管柱TSK凝膠G3000 SWXL(Tosoh, Tokyo-Japan)被連接到配備有A905自動取樣器的Äkta淨化器10 FPLC (GE Lifesciences)。管柱平衡和運行緩衝液是由100 mM KH2PO4 – 200 mM Na2SO4組成,調整至pH 6.6。抗體溶液(15 μg蛋白質)被施加到平衡管柱並以0.75 ml/min的流速,在最大壓力7 MPa下進行溶離。在280、254和210 nm光學吸光度下監測整個運行。分析是透過將記錄在Äkta Unicorn軟體運行評估表單中的210 nm訊號進行峰積分來完成。二聚體含量是藉由將二聚體峰面積除以單體加二聚體的總峰總面積來計算。
結果顯示於下面表10中。結合至表位簇/胞外子域D2C的CDH3xCD3雙特異性抗體在三次凍/解凍循環還有在37℃下培育7天之後呈現≤1%的二聚體百分率,並且更確切來說為0.0%的二聚體百分率,這被認為是非常好的。表位簇/胞外子域D3A之CDH3xCD3雙特異性抗體的二聚體轉換率達到≤2%的值,並且更確切來說介於0.2和1.8之間,這被認為是良好的。在個別的分析中分別測定CDH3-25 x F12q-HALB與CDH3-13 x I2C-HLE (Fc),且顯示在三次冷凍/解凍循環之後分別具有1.1與0.84的二聚體百分率,而在培育7天之後具有0.0的二聚體百分率(均為HLE構築體)。
表 10 :如透過高效尺寸排阻層析(HP-SEC)測定,單體CDH3xCD3雙特異性抗體相對於二聚體CDH3xCD3雙特異性抗體的百分率
例 10 熱穩定性如下測定抗體聚集溫度:250 µg/ml的40 µl抗體溶液被轉移到一個單次用比色管中,並置於Wyatt動態光散射裝置DynaPro Nanostar (Wyatt)中。將樣品從40℃以0.5℃/min的加熱速率加熱至70℃,同時恆定採集所測量的半徑。半徑增加表示蛋白熔融和聚集,被用DLS裝置遞送的軟體套件用來計算抗體的聚集溫度。
本發明的所有測試CDH3xCD3雙特異性抗體顯示了非常良好的熱穩定性,聚集溫度高於54℃,如下表11中所示。在一個單獨的分析中測定CDH3-25 x F12q-HALB,並顯示具有56.3℃的熱穩定性。
表 11 :如透過DLS(動態光散射)所測定的雙特異性抗體的熱穩定性
實例 11 在人類血漿中培育 24 小時後的穩定性以1:5的比率在37℃下於人類血漿庫中培育最終濃度為2-20 µg/ml的經純化雙特異性抗體歷時24小時至96小時。在血漿培育之後,於使用受刺激人類T細胞以及經CDH3轉染之CHO細胞(起始濃度為0.01-0.1 µg/ml且效應細胞對目標細胞的比率(E:T)為10:1)的51鉻釋放分析中比較抗體(如實例8.1中所述的分析,使用受刺激人類T細胞的鉻釋放分析)。納入未經培育、剛解凍的雙特異性抗體作為對照。結果顯示於表12中。所有測試抗體有一個≤ 4的有利血漿穩定性(EC
50血漿/EC
50對照),結合至D3A的該群抗體甚至具有≤3的血漿穩定性。在一個單獨的分析中各別測定CDH3-25 x F12q-HALB與CDH3-13 x I2C-HLE (Fc),並且顯示分別具有
• 4.4 pM的EC50 w/血漿,3.6 pM的EC50 w/o血漿,與血漿與對照比率為1.2,
• 3.4 pM的EC50 w/血漿,8.9 pM的EC50 w/o血漿,與血漿與對照比率為0.4。
表 12 :在有或沒有血漿培育的情況下,抗體的EC50值以及計算之血漿/對照值
實例 12 在 2500 µg/ml 抗體濃度 下的濁度將250 µg/ml的1ml經純化單體抗體溶液藉由自旋濃縮單元濃縮至2500 µg/ml。儲存在5℃下歷時16小時後,依據OD340 nm光學吸收測量相對於通用調配緩衝液來測定抗體溶液的濁度。結果顯示於下表13中。所有測試抗體有一個≤0.05的非常有利濁度。在一個單獨的分析中各別測定CDH3-25 x F12q-HALB與CDH3-13 x I2C-HLE (Fc),並顯示分別具有0.066和0.026的濁度。
表 13 :抗體在濃縮至2.5 mg/ml隔夜之後的濁度
實例 14 CDH3xCD3 雙特異性抗體在人類腫瘤異種移植模型中的 治療功效在研究的第1天,將人類表皮樣癌細胞株A-431的細胞以及新鮮分離之人類PBMC皮下共注射至雌性NOD/SCID小鼠的右背側(E:T細胞比率為1:2)。載劑對照組1的小鼠(n = 5)未接受效應細胞並作為未移植對照,用於與載劑對照2相比較(n = 10,接受效應細胞),以監控抗體不存在時PBMC對腫瘤生長的影響。
在第一天腫瘤細胞注射之後約2小時起,藉由每日靜脈內推祝歷時連續10天,小鼠用0.5 mg/kg/天(第3組,n = 10)、0.05 mg/kg/天(第4組,n = 10),或0.005 mg/kg/天(第5組,n = 10) CDH3xCD3雙特異性抗體處理,CDH3xCD3雙特異性抗體特異地結合至胞外CDH3子域D2C。
在研究和進展期間是經由卡尺測量腫瘤,透過組間比較腫瘤體積(TV)來進行比較。腫瘤生長抑制T/C [%]是藉由計算TV為T/C(%)= 100×(分析組的中位數TV)/(對照組2的平均TV)決定。
結果顯示於圖11中。以0.5 mg/kg/天的劑量水準使用CDH3xCD3雙特異性抗體處理小鼠會導致腫瘤形成受到完全抑制,且沒有動物長成腫瘤直至研究結束(字40天)。
實例 15 CDH3xCD3 雙特異性 HLE 抗體在 HCT-116 腫瘤模型中的抗腫瘤活性在皮下注射有人類HCT-116結腸癌細胞的雌性NOD/SCID小鼠體內進行分析。效應細胞在活體外擴展並活化人類CD3
+T細胞(第12天)。當腫瘤已經達到〜200 mm
3的體積時開始治療(第17天)。對照組為經q5d載劑處理組加上T細胞。具有SEQ ID NO: 425的抗體以5 mg/kg/投藥(第2組)和0.5 mg/kg/投藥(第3組)的濃度,每五天(q5d)經由靜脈內推注而被投與。結果顯示於圖12A和12B。具體而言,圖12B區分有反應動物(7/10)和無反應動物(3/10)的結果。而無反應佔30%動物的原因不明,圖12B顯示了以5 mg/kg的濃度向有反應動物投與半衰期延長雙特異性構築體會在抗體投藥那時開始導致腫瘤生長中斷。
實例 16 T 細胞活化活化分析由健康人類供體分離的PBMC分別與濃度增加的CDH3-13xI2C或CDH3-13xI2C-HALB雙特異性抗體構築體(0.001 PM-20 μM的連續稀釋液)培養歷時48小時。藉由免疫染色以及流式細胞儀與抗原特異性接合物mAb對CD4+和CD8+ T細胞上的活化標記CD69表現進行測定。結果顯示於圖13並在本文上面所討論。
實例 17 半衰期擴展之 CDH3xCD3 構築體的食蟹獼猴藥動學研究雌性食蟹獼猴接受靜脈內輸注0.015 mg/kg於緩衝液中的半衰期擴展CDH3xCD3雙特異性抗體構築體(投與體積為1 ml/kg)歷時60分鐘。測試的三個HLE形式為P156、HALB及HALB變異體1 (參見SEQ ID NO: 437、443和444),每一個融合至各自構築體的C端。這些HLE構築體在食蟹獼猴模型中的半衰期是基於投藥後96小時與研究中止之間的四個(P156)與六個(HALB、HALB變異體1)時間點之時所分析的血漿濃度為基礎來計算。結果分別是,具有P156的HLE構築體顯示半衰期為57小時,具有HALB的HLE構築體半衰期為63-85小時而具有HALB變異體1的半衰期為68小時。這些PK性質表明在人類中每週一次靜脈內給藥。
拜耳 II 序列
| CDH3xCD3雙特異性抗體 | KD人類 DH3 [nM] | KD食蟹獼猴CDH3 [nM] | 親和力差距 食蟹獼猴/人類 |
| CDH3-11 | 7.5 | 6.2 | 0.83 |
| CDH3-12 | 8.8 | 7.5 | 0.85 |
| CDH3-13 | 7.4 | 6 | 0.81 |
| CDH3-14 | 9.5 | 8.1 | 0.85 |
| CDH3-24 | 6.1 | 5.2 | 0.85 |
| CDH3-25 | 7.9 | 6.7 | 0.85 |
| CDH3-26 | 8.8 | 7.5 | 0.85 |
| CDH3-27 | 8.7 | 7.6 | 0.87 |
| CDH3xCD3雙特異性抗體 | 基於細胞的親和力 人類CDH-3 [nM] | 基於細胞的親和力 獼猴 CDH-3 [nM] | 親和力差距 KD獼猴/KD人類CDH-3 |
| CDH3-11 | 1.74 ±0.37 | 1.98 ±0.67 | 1.14 |
| CDH3-12 | 0.40 ±0.27 | 0.52 ±0.21 | 1.30 |
| CDH3-13 | 0.42 ±0.35 | 0.41 ±0.28 | 0.98 |
| CDH3-14 | 0.49 ±0.14 | 0.41 ±0.03 | 0.84 |
| CDH3-24 | 0.09 ±0.03 | 0.15 ±0.07 | 1.67 |
| CDH3-25 | 0.12 ±0.01 | 0.11 ±0.03 | 0.96 |
| CDH3-26 | 0.17 ±0.01 | 0.16 ±0.04 | 0.94 |
| CDH3-27 | 0.20 ±0.10 | 0.23 ±0.03 | 1.15 |
| CDH3xCD3雙特異性抗體 | VH和VL與人類生殖系的一致性[%] |
| CDH3-11 | 92.7 |
| CDH3-12 | 93.6 |
| CDH3-13 | 87.8 |
| CDH3-14 | 94.1 |
| CDH3-24 | 89.4 |
| CDH3-25 | 89.8 |
| CDH3-26 | 89.8 |
| CDH3-27 | 90.7 |
| CDH3xCD3雙特異性抗體 | EC 50 [pg/ml] |
| CDH3-11 | 76 |
| CDH3-12 | 370 |
| CDH3-13 | 7.2 |
| CDH3-14 | 138 |
| CDH3-24 | 14 |
| CDH3-25 | 4.9 |
| CDH3-26 | 21 |
| CDH3-27 | 61 |
| CDH3xCD3雙特異性抗體 | EC 50 [pg/ml] |
| CDH3-11 | 47 |
| CDH3-12 | 362 |
| CDH3-13 | 62 |
| CDH3-14 | 385 |
| CDH3-24 | 5.8 |
| CDH3-25 | 4.6 |
| CDH3-26 | 19 |
| CDH3-27 | 31 |
| CDH3xCD3雙特異性抗體 | EC 50 [pg/ml] |
| CDH3-11 | 462 |
| CDH3-12 | 1021 |
| CDH3-13 | 129 |
| CDH3-14 | 1885 |
| CDH3-24 | 19 |
| CDH3-25 | 10 |
| CDH3-26 | 47 |
| CDH3-27 | 61 |
| CDH3xCD3雙特異性抗體 | EC 50 [pg/ml] |
| CDH3-11 | 389 |
| CDH3-12 | 3141 |
| CDH3-13 | 83 |
| CDH3-14 | 4842 |
| CDH3-24 | 15 |
| CDH3-25 | 9.2 |
| CDH3-26 | 35 |
| CDH3-27 | 41 |
| CDH3xCD3雙特異性抗體 | EC 50 [pg/ml] | |
| 1 | CDH3-11 | 1183 |
| 2 | CDH3-12 | 1325 |
| 3 | CDH3-13 | 257 |
| 4 | CDH3-14 | 1015 |
| 5 | CDH3-24 | 32 |
| 6 | CDH3-25 | 14 |
| 7 | CDH3-26 | 37 |
| 8 | CDH3-27 | 98 |
| 9 | CDH3-1 | 13055 |
| 10 | CDH3-2 | 12862 |
| 11 | CDH3-3 | 8390 |
| 12 | CDH3-4 | 8795 |
| CDH3xCD3抗體 | 三次冷凍/解凍循環後的二聚體百分率 | 培育7天之後的二聚體百分率 |
| CDH3-11 | 0.00 | 0.00 |
| CDH3-12 | 0.00 | 0.00 |
| CDH3-13 | 0.00 | 0.00 |
| CDH3-14 | 0.00 | 0.00 |
| CDH3-24 | 1.01 | 0.20 |
| CDH3-25 | 1.31 | 0.60 |
| CDH3-26 | 0.82 | 1.80 |
| CDH3-27 | 1.69 | 1.50 |
| CDH3xCD3雙特異性抗體 | 熱穩定性(DLS ℃聚集) |
| CDH3-11 | 59.8 |
| CDH3-12 | 55.9 |
| CDH3-13 | 59.6 |
| CDH3-14 | 59.6 |
| CDH3-24 | 55.1 |
| CDH3-25 | 55.4 |
| CDH3-26 | 54.9 |
| CDH3-27 | 54.1 |
| CDH3xCD3雙特異性抗體 | EC 50[pg/mL] W /血漿 W / O血漿 | 血漿相對對照比率 (EC 50血漿/EC 50對照) | |
| CDH3-11 | 47 | 76 | 0.6 |
| CDH3-12 | 296 | 370 | 0.8 |
| CDH3-13 | 25 | 7.2 | 3.5 |
| CDH3-14 | 291 | 138 | 2.1 |
| CDH3-24 | 19 | 14 | 1.4 |
| CDH3-25 | 9.9 | 4.9 | 2.0 |
| CDH3-26 | 24 | 21 | 1.1 |
| CDH3-27 | 129 | 61 | 2.1 |
| CDH3xCD3雙特異性抗體 | 在2500 µg/ml下的濁度 |
| CDH3-11 | 0.035 |
| CDH3-12 | 0.025 |
| CDH3-13 | 0.030 |
| CDH3-14 | 0.025 |
| CDH3-24 | 0.019 |
| CDH3-25 | 0.026 |
| CDH3-26 | 0.028 |
| CDH3-27 | 0.022 |
| SEQ ID NO | 表位 | 命名 | 形式/來源 | 類型 | 序列 |
| 1 | 人類CDH3 | 人類 | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaiytyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggfilpvlgavlallflllvllllvrkkrkikeplllpeddtrdnvfyygeegggeedqdyditqlhrglearpevvlrndvaptiiptpmyrprpanpdeignfiienlkaantdptappydtllvfdyegsgsdaaslssltssasdqdqdydylnewgsrfkkladmygggedd | |
| 2 | 人類CDH3 | 人類 | na | atggggctccctcgtggacctctcgcgtctctcctccttctccaggtttgctggctgcagtgcgcggcctccgagccgtgccgggcggtcttcagggaggctgaagtgaccttggaggcgggaggcgcggagcaggagcccggccaggcgctggggaaagtattcatgggctgccctgggcaagagccagctctgtttagcactgataatgatgacttcactgtgcggaatggcgagacagtccaggaaagaaggtcactgaaggaaaggaatccattgaagatcttcccatccaaacgtatcttacgaagacacaagagagattgggtggttgctccaatatctgtccctgaaaatggcaagggtcccttcccccagagactgaatcagctcaagtctaataaagatagagacaccaagattttctacagcatcacggggccgggggcagacagcccccctgagggtgtcttcgctgtagagaaggagacaggctggttgttgttgaataagccactggaccgggaggagattgccaagtatgagctctttggccacgctgtgtcagagaatggtgcctcagtggaggaccccatgaacatctccatcatcgtgaccgaccagaatgaccacaagcccaagtttacccaggacaccttccgagggagtgtcttagagggagtcctaccaggtacttctgtgatgcaggtgacagccacggatgaggatgatgccatctacacctacaatggggtggttgcttactccatccatagccaagaaccaaaggacccacacgacctcatgttcaccattcaccggagcacaggcaccatcagcgtcatctccagtggcctggaccgggaaaaagtccctgagtacacactgaccatccaggccacagacatggatggggacggctccaccaccacggcagtggcagtagtggagatccttgatgccaatgacaatgctcccatgtttgacccccagaagtacgaggcccatgtgcctgagaatgcagtgggccatgaggtgcagaggctgacggtcactgatctggacgcccccaactcaccagcgtggcgtgccacctaccttatcatgggcggtgacgacggggaccattttaccatcaccacccaccctgagagcaaccagggcatcctgacaaccaggaagggtttggattttgaggccaaaaaccagcacaccctgtacgttgaagtgaccaacgaggccccttttgtgctgaagctcccaacctccacagccaccatagtggtccacgtggaggatgtgaatgaggcacctgtgtttgtcccaccctccaaagtcgttgaggtccaggagggcatccccactggggagcctgtgtgtgtctacactgcagaagaccctgacaaggagaatcaaaagatcagctaccgcatcctgagagacccagcagggtggctagccatggacccagacagtgggcaggtcacagctgtgggcaccctcgaccgtgaggatgagcagtttgtgaggaacaacatctatgaagtcatggtcttggccatggacaatggaagccctcccaccactggcacgggaacccttctgctaacactgattgatgtcaatgaccatggcccagtccctgagccccgtcagatcaccatctgcaaccaaagccctgtgcgccaggtgctgaacatcacggacaaggacctgtctccccacacctcccctttccaggcccagctcacagatgactcagacatctactggacggcagaggtcaacgaggaaggtgacacagtggtcttgtccctgaagaagttcctgaagcaggatacatatgacgtgcacctttctctgtctgaccatggcaacaaagagcagctgacggtgatcagggccactgtgtgcgactgccatggccatgtcgaaacctgccctggaccctggaagggaggtttcatcctccctgtgctgggggctgtcctggctctgctgttcctcctgctggtgctgcttttgttggtgagaaagaagcggaagatcaaggagcccctcctactcccagaagatgacacccgtgacaacgtcttctactatggcgaagaggggggtggcgaagaggaccaggactatgacatcacccagctccaccgaggtctggaggccaggccggaggtggttctccgcaatgacgtggcaccaaccatcatcccgacacccatgtaccgtcctcggccagccaacccagatgaaatcggcaactttataattgagaacctgaaggcggctaacacagaccccacagccccgccctacgacaccctcttggtgttcgactatgagggcagcggctccgacgccgcgtccctgagctccctcacctcctccgcctccgaccaagaccaagattacgattatctgaacgagtggggcagccgcttcaagaagctggcagacatgtacggtggcggggaggacgac | |
| 3 | 人類CDH3 ECD | 人類 | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaiytyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkgg | |
| 4 | 人類CDH3 ECD | 人類 | na | atggggctccctcgtggacctctcgcgtctctcctccttctccaggtttgctggctgcagtgcgcggcctccgagccgtgccgggcggtcttcagggaggctgaagtgaccttggaggcgggaggcgcggagcaggagcccggccaggcgctggggaaagtattcatgggctgccctgggcaagagccagctctgtttagcactgataatgatgacttcactgtgcggaatggcgagacagtccaggaaagaaggtcactgaaggaaaggaatccattgaagatcttcccatccaaacgtatcttacgaagacacaagagagattgggtggttgctccaatatctgtccctgaaaatggcaagggtcccttcccccagagactgaatcagctcaagtctaataaagatagagacaccaagattttctacagcatcacggggccgggggcagacagcccccctgagggtgtcttcgctgtagagaaggagacaggctggttgttgttgaataagccactggaccgggaggagattgccaagtatgagctctttggccacgctgtgtcagagaatggtgcctcagtggaggaccccatgaacatctccatcatcgtgaccgaccagaatgaccacaagcccaagtttacccaggacaccttccgagggagtgtcttagagggagtcctaccaggtacttctgtgatgcaggtgacagccacggatgaggatgatgccatctacacctacaatggggtggttgcttactccatccatagccaagaaccaaaggacccacacgacctcatgttcaccattcaccggagcacaggcaccatcagcgtcatctccagtggcctggaccgggaaaaagtccctgagtacacactgaccatccaggccacagacatggatggggacggctccaccaccacggcagtggcagtagtggagatccttgatgccaatgacaatgctcccatgtttgacccccagaagtacgaggcccatgtgcctgagaatgcagtgggccatgaggtgcagaggctgacggtcactgatctggacgcccccaactcaccagcgtggcgtgccacctaccttatcatgggcggtgacgacggggaccattttaccatcaccacccaccctgagagcaaccagggcatcctgacaaccaggaagggtttggattttgaggccaaaaaccagcacaccctgtacgttgaagtgaccaacgaggccccttttgtgctgaagctcccaacctccacagccaccatagtggtccacgtggaggatgtgaatgaggcacctgtgtttgtcccaccctccaaagtcgttgaggtccaggagggcatccccactggggagcctgtgtgtgtctacactgcagaagaccctgacaaggagaatcaaaagatcagctaccgcatcctgagagacccagcagggtggctagccatggacccagacagtgggcaggtcacagctgtgggcaccctcgaccgtgaggatgagcagtttgtgaggaacaacatctatgaagtcatggtcttggccatggacaatggaagccctcccaccactggcacgggaacccttctgctaacactgattgatgtcaatgaccatggcccagtccctgagccccgtcagatcaccatctgcaaccaaagccctgtgcgccaggtgctgaacatcacggacaaggacctgtctccccacacctcccctttccaggcccagctcacagatgactcagacatctactggacggcagaggtcaacgaggaaggtgacacagtggtcttgtccctgaagaagttcctgaagcaggatacatatgacgtgcacctttctctgtctgaccatggcaacaaagagcagctgacggtgatcagggccactgtgtgcgactgccatggccatgtcgaaacctgccctggaccctggaagggaggt | |
| 5 | 獼猴CDH3 | 食蟹獼猴 | aa | mglprgplaclllvqvcwlqcaasepcraifgeaevtleaggaeqepsqalgkvfmgcpgqkpalfstvnddftvqngetvqdrkslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaihtyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapvfdpqkyeshvpenavghevqrltvtdldapnspawratylivggddgdhftiathpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgeavcvytakdpdkenqkisyrilrdpagwlamdpdsgqvtvagtldrederfvrnniyevmvlavdngsppttgtgtllltlidvndhgpvpepreiticnqspesqvlnitdkdlsphtspfqaqltddsdiywmaevnekddtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvekcpdpwkggfilpvlgavlallllllvllllvrkkrkvkeplllpeddtrdnvfyygeegggeedqdyditqlhrglearpevvlrndvaptfiptpmyrprpanpdeignfiienlkaantdptappydsllvfdyegsgsdaaslsslttstsdqdqdydylnewgsrfkkladmygggddd | |
| 6 | 獼猴CDH3 | 食蟹獼猴 | na | atggggctccctcgtggacctctcgcgtgtctcctcctcgtccaggtttgctggctgcaatgcgcggcctccgagccgtgccgggcgatcttcggggaggctgaagtgaccttggaggcgggaggcgcggagcaggagcccagccaggccctggggaaagtattcatgggctgccctgggcaaaagccagctctgtttagcactgttaatgacgacttcactgtgcagaatggcgagacagtccaggacagaaagtcactgaaagaaaggaatccattgaagatcttcccatccaaacgtatcttacgaagacacaagagagattgggtggttgctccaatatctgtccctgaaaatggcaagggtcccttcccgcagaggctgaatcagctcaagtctaataaagacagagacacgaagattttctacagcatcacggggccgggggcagacagcccccctgagggcgtctttgctgtagagaaagagacaggctggttgttgttgaacaagccactggaccgggaggagattgccaagtatgagctctttggccacgctgtgtcagagaatggtgcctcagtggaggatcccatgaacatctccatcatcgtgaccgaccagaatgaccacaagcccaagtttacccaggacaccttccgagggagtgtcttagagggagtcctaccaggtacttctgtgatgcaggtgacggccacagatgaggatgatgccatccacacctacaatggggtggttgcgtactccatccatagccaagaaccaaaggatccacacgacctgatgtttaccattcaccggagcacaggcaccatcagcgtcatctccagcggcctggaccgggaaaaagtccctgagtacacactgaccatccaggccacagacatggatggggacggctccaccaccacggcagtggcagtagtggagatcctcgatgccaatgacaatgctcccgtgtttgacccccagaagtatgagtcccatgtgcctgagaatgcagtgggccatgaggtgcagaggctgacggtcactgatctggacgcccccaactcaccagcgtggcgtgccacctacctcatcgtgggcggtgacgacggggaccattttaccatcgccacccaccctgagagcaaccagggcatcctgacaaccaggaagggtttggattttgaggccaaaaaccagcacaccctgtacgttgaagtgaccaacgaggccccttttgtgctgaagctcccaacctcaacagccaccatagtggtccacgtggaggatgtgaatgaggcacccgtgtttgtcccgccctccaaagtcgttgaggtccaggagggcatccccactggggaggctgtgtgtgtctacactgcaaaagaccctgacaaggagaatcaaaagatcagctaccgcatcctgagagacccagcagggtggctagccatggacccagacagtgggcaggtcactgttgcgggcaccctagaccgtgaggatgagcggtttgtgagaaacaacatctacgaagtcatggtcttggctgtggacaatggaagccctcccaccactggcacgggaaccctcctgctaacactgattgatgtcaacgaccatggcccagtccctgagccccgtgagatcaccatctgcaaccaaagccctgagtcccaggtgctgaacatcacggacaaggacctgtccccccacacctcccctttccaggcccagctcacagacgactcagacatctactggatggcagaggtcaacgagaaagatgacacggtggtcttgtccctgaagaagttcctgaagcaggacacatatgatgtgcacctttctctgtctgaccatggcaacaaggagcagctgacagtgatcagggccaccgtgtgtgactgccacggccatgtcgagaaatgccctgatccctggaaggggggtttcatcctccctgtgctgggggctgtcctggctctgctgctcctcctgctggtgctgctcttgttggtgagaaagaagcggaaggtcaaggagcccctcctactcccagaagatgacacccgtgacaacgtcttctactacggcgaagaggggggtggcgaagaggaccaggactatgacatcacccagctccaccgaggtctggaggccaggccggaggtggttctccgcaatgacgtggcaccaaccttcatccccacacccatgtaccgtcctcggccagccaacccagatgaaatcggcaactttataatcgagaacctgaaggcagctaacacggaccccacagccccgccctacgactcccttttggtgttcgactatgagggcagcggctccgacgccgcgtccctgagctccctcaccacctccacctctgaccaggaccaagattacgactatctgaacgagtggggcagccgcttcaagaagctggcagacatgtacggtggcggggacgacgac | |
| 7 | 獼猴CDH3 ECD | 食蟹獼猴 | aa | mglprgplaclllvqvcwlqcaasepcraifgeaevtleaggaeqepsqalgkvfmgcpgqkpalfstvnddftvqngetvqdrkslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaihtyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapvfdpqkyeshvpenavghevqrltvtdldapnspawratylivggddgdhftiathpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgeavcvytakdpdkenqkisyrilrdpagwlamdpdsgqvtvagtldrederfvrnniyevmvlavdngsppttgtgtllltlidvndhgpvpepreiticnqspesqvlnitdkdlsphtspfqaqltddsdiywmaevnekddtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvekcpdpwkgg | |
| 8 | 獼猴CDH3 ECD | 食蟹獼猴 | na | atggggctccctcgtggacctctcgcgtgtctcctcctcgtccaggtttgctggctgcaatgcgcggcctccgagccgtgccgggcgatcttcggggaggctgaagtgaccttggaggcgggaggcgcggagcaggagcccagccaggccctggggaaagtattcatgggctgccctgggcaaaagccagctctgtttagcactgttaatgacgacttcactgtgcagaatggcgagacagtccaggacagaaagtcactgaaagaaaggaatccattgaagatcttcccatccaaacgtatcttacgaagacacaagagagattgggtggttgctccaatatctgtccctgaaaatggcaagggtcccttcccgcagaggctgaatcagctcaagtctaataaagacagagacacgaagattttctacagcatcacggggccgggggcagacagcccccctgagggcgtctttgctgtagagaaagagacaggctggttgttgttgaacaagccactggaccgggaggagattgccaagtatgagctctttggccacgctgtgtcagagaatggtgcctcagtggaggatcccatgaacatctccatcatcgtgaccgaccagaatgaccacaagcccaagtttacccaggacaccttccgagggagtgtcttagagggagtcctaccaggtacttctgtgatgcaggtgacggccacagatgaggatgatgccatccacacctacaatggggtggttgcgtactccatccatagccaagaaccaaaggatccacacgacctgatgtttaccattcaccggagcacaggcaccatcagcgtcatctccagcggcctggaccgggaaaaagtccctgagtacacactgaccatccaggccacagacatggatggggacggctccaccaccacggcagtggcagtagtggagatcctcgatgccaatgacaatgctcccgtgtttgacccccagaagtatgagtcccatgtgcctgagaatgcagtgggccatgaggtgcagaggctgacggtcactgatctggacgcccccaactcaccagcgtggcgtgccacctacctcatcgtgggcggtgacgacggggaccattttaccatcgccacccaccctgagagcaaccagggcatcctgacaaccaggaagggtttggattttgaggccaaaaaccagcacaccctgtacgttgaagtgaccaatgaggccccttttgtgctgaagctcccaacctcaacagccaccatagtggtccacgtggaggatgtgaatgaggcacccgtgtttgtcccgccctccaaagtcgttgaggtccaggagggcatccccactggggaggctgtgtgtgtctacactgcaaaagaccctgacaaggagaatcaaaagatcagctaccgcatcctgagagacccagcagggtggctagccatggacccagacagtgggcaggtcactgttgcgggcaccctagaccgtgaggatgagcggtttgtgagaaacaacatctacgaagtcatggtcttggctgtggacaatggaagccctcccaccactggcacgggaaccctcctgctaacactgattgatgtcaacgaccatggcccagtccctgagccccgtgagatcaccatctgcaaccaaagccctgagtcccaggtgctgaacatcacggacaaggacctgtccccccacacctcccctttccaggcccagctcacagacgactcagacatctactggatggcagaggtcaacgagaaagatgacacggtggtcttgtccctgaagaagttcctgaagcaggacacatatgatgtgcacctttctctgtctgaccatggcaacaaggagcagctgacagtgatcagggccaccgtgtgtgactgccacggccatgtcgagaaatgccctgatccctggaaggggggt | |
| 9 | 鼠類 CDH3 | 鼠類 | aa | mellsgphaflllllqvcwlrsvvsepyragfigeagvtlevegtdlepsqvlgkvalagqgmhhadngdiimltrgtvqggkdamhspptrilrrrkrewvmppifvpengkgpfpqrlnqlksnkdrgtkifysitgpgadsppegvftiekesgwlllhmpldrekivkyelyghavsengasveepmnisiivtdqndnkpkftqdtfrgsvlegvmpgtsvmqvtatdeddavntyngvvaysihsqepkephdlmftihkstgtisvissgldrekvpeyrltvqatdmdgegstttaeavvqildandnapefepqkyeawvpenevghevqrltvtdldvpnspawratyhivggddgdhftitthpetnqgvlttkkgldfeaqdqhtlyvevtneapfavklptatatvvvhvkdvneapvfvppskvieaqegisigelvciytaqdpdkedqkisytisrdpanwlavdpdsgqitaagildredeqfvknnvyevmvlatdsgnppttgtgtllltltdindhgpipeprqiiicnqspvpqvlnitdkdlspnsspfqaqlthdsdiywmaevsekgdtvalslkkflkqdtydlhlslsdhgnreqltmiratvcdchgqvfndcprpwkggfilpilgavlalltlllallllvrkkrkvkeplllpeddtrdnvfyygeegggeedqdyditqlhrglearpevvlrndvvptfiptpmyrprpanpdeignfiienlkaantdptappydsllvfdyegsgsdaaslsslttsasdqdqdynylnewgsrfkkladmygggedd | |
| 10 | 鼠類 CDH3 | 鼠類 | na | atggagcttcttagtgggcctcacgccttcctgctcctcctgctccaggtttgctggctacgcagcgtggtctccgagccctaccgagcgggcttcatcggggaggctggagtgaccttggaggtggaaggaactgacctggagccgagccaagttctggggaaagtagccttggctggacagggcatgcaccatgcagacaatggagacatcattatgctgactagggggacagttcagggagggaaggatgcgatgcactccccacccacccgcatcttaaggagacgaaagagagagtgggtgatgccaccaatattcgtccccgagaatggcaagggtcccttccctcagaggctgaatcagctcaaatctaataaggacagaggcaccaagattttctacagcatcacagggcctggcgcagacagtccccccgaaggagtcttcaccatagagaaggagtcgggctggctgttgttgcatatgccactggacagggagaagattgtcaagtacgagctttatggccacgctgtatctgagaatggtgcctctgtagaggagcccatgaacatatccatcattgtgacagaccagaatgacaacaagcccaagttcactcaagacaccttcagagggagtgttctggagggagtaatgcctggcacttctgtgatgcaggtgacagccacagatgaggacgatgctgtcaacacttacaatggggtggtggcttactccatccatagccaagagccgaaggagccacacgacctcatgttcaccatccataaaagcacgggaaccattagcgtcatatccagtggcctggaccgagagaaagtccctgagtacagactgaccgtccaggccacagacatggatggagagggctctaccacgacggcagaggccgttgtgcaaatccttgatgccaacgataacgctcccgagtttgagccgcagaagtatgaggcttgggtgcctgagaacgaagtgggccatgaggtacagaggctgacagtgactgatctcgatgtccccaactcgccagcgtggcgtgccacctaccacatcgtgggaggtgatgatggggaccatttcaccatcaccactcacccagagaccaaccaaggcgtcctgacaaccaagaagggtttggattttgaggctcaggaccaacacaccctgtatgtagaagtgaccaacgaggctccctttgcagtgaagctcccgacagccactgccaccgtggtggtccatgtgaaagatgtcaacgaagcccctgtgtttgttccaccttccaaggtcattgaggcccaggaaggcatctctattggggaactggtctgcatctataccgcacaggacccagacaaggaggaccagaagatcagctacaccatctcgagagatccagccaactggcttgctgtggacccagacagtggtcagataactgccgcaggcatcttggatcgtgaggacgagcagtttgtgaaaaacaatgtctacgaagtcatggttttggccacagacagtggaaaccctcccaccaccggcactgggaccctcctgcttacacttactgacatcaacgaccatggcccgatccctgaacccaggcagatcatcatctgtaaccaaagccctgtgcctcaagtgctgaacatcactgacaaggacctgtcccccaactcctcccctttccaggcccagctaacacatgactcagatatctactggatggcagaagtcagcgagaaaggagacaccgtggccttgtccctgaagaagttcctgaaacaagacacgtatgacttgcatctttctttgtctgaccatggcaacagggaacagctaaccatgatcagggccactgtgtgtgactgccatggccaagtgttcaatgactgccccagaccctggaagggtggtttcatcctccccatcctgggtgctgtcctggcactgctgacccttctactggcactcctcctgttggtgaggaagaagaggaaggtcaaagagccccttctgctcccagaagatgacacgcgagacaatgtcttctattatggagaagagggtggtggtgaagaggaccaggactatgacatcacccaactccaccggggactggaggccaggcctgaggtggttctccgaaacgatgtagtgccaaccttcatccccacccccatgtaccgaccccggcccgccaacccagatgaaatcgggaacttcatcatcgagaacctgaaggctgccaacactgaccctactgccccgccctacgactccctgctggtttttgactacgagggcagcggctctgatgccgcctccctgagctccctcaccacctccgcctccgaccaggatcaggactacaactaccttaacgagtggggaagtcgattcaagaaactggcggacatgtatggtggcggtgaggatgactag | |
| 11 | 鼠類 CDH3 ECD | 鼠類 | aa | ewvmppifvpengkgpfpqrlnqlksnkdrgtkifysitgpgadsppegvftiekesgwlllhmpldrekivkyelyghavsengasveepmnisiivtdqndnkpkftqdtfrgsvlegvmpgtsvmqvtatdeddavntyngvvaysihsqepkephdlmftihkstgtisvissgldrekvpeyrltvqatdmdgegstttaeavvqildandnapefepqkyeawvpenevghevqrltvtdldvpnspawratyhivggddgdhftitthpetnqgvlttkkgldfeaqdqhtlyvevtneapfavklptatatvvvhvkdvneapvfvppskvieaqegisigelvciytaqdpdkedqkisytisrdpanwlavdpdsgqitaagildredeqfvknnvyevmvlatdsgnppttgtgtllltltdindhgpipeprqiiicnqspvpqvlnitdkdlspnsspfqaqlthdsdiywmaevsekgdtvalslkkflkqdtydlhlslsdhgnreqltmiratvcdchgqvfndcprpwkgg | |
| 12 | 鼠類 CDH3 ECD | 鼠類 | na | gagtgggtgatgccaccaatattcgtccccgagaatggcaagggtcccttccctcagaggctgaatcagctcaaatctaataaggacagaggcaccaagattttctacagcatcacagggcctggcgcagacagtccccccgaaggagtcttcaccatagagaaggagtcgggctggctgttgttgcatatgccactggacagggagaagattgtcaagtacgagctttatggccacgctgtatctgagaatggtgcctctgtagaggagcccatgaacatatccatcattgtgacagaccagaatgacaacaagcccaagttcactcaagacaccttcagagggagtgttctggagggagtaatgcctggcacttctgtgatgcaggtgacagccacagatgaggacgatgctgtcaacacttacaatggggtggtggcttactccatccatagccaagagccgaaggagccacacgacctcatgttcaccatccataaaagcacgggaaccattagcgtcatatccagtggcctggaccgagagaaagtccctgagtacagactgaccgtccaggccacagacatggatggagagggctctaccacgacggcagaggccgttgtgcaaatccttgatgccaacgataacgctcccgagtttgagccgcagaagtatgaggcttgggtgcctgagaacgaagtgggccatgaggtacagaggctgacagtgactgatctcgatgtccccaactcgccagcgtggcgtgccacctaccacatcgtgggaggtgatgatggggaccatttcaccatcaccactcacccagagaccaaccaaggcgtcctgacaaccaagaagggtttggattttgaggctcaggaccaacacaccctgtatgtagaagtgaccaacgaggctccctttgcagtgaagctcccgacagccactgccaccgtggtggtccatgtgaaagatgtcaacgaagcccctgtgtttgttccaccttccaaggtcattgaggcccaggaaggcatctctattggggaactggtctgcatctataccgcacaggacccagacaaggaggaccagaagatcagctacaccatctcgagagatccagccaactggcttgctgtggacccagacagtggtcagataactgccgcaggcatcttggatcgtgaggacgagcagtttgtgaaaaacaatgtctacgaagtcatggttttggccacagacagtggaaaccctcccaccaccggcactgggaccctcctgcttacacttactgacatcaacgaccatggcccgatccctgaacccaggcagatcatcatctgtaaccaaagccctgtgcctcaagtgctgaacatcactgacaaggacctgtcccccaactcctcccctttccaggcccagctaacacatgactcagatatctactggatggcagaagtcagcgagaaaggagacaccgtggccttgtccctgaagaagttcctgaaacaagacacgtatgacttgcatctttctttgtctgaccatggcaacagggaacagctaaccatgatcagggccactgtgtgtgactgccatggccaagtgttcaatgactgccccagaccctggaagggtggt | |
| 13 | Hu CDH3 Dom1mu (aa 108-215) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKREWVMPPIFVPENGKGPFPQRLNQLKSNKDRGTKIFYSITGPGADSPPEGVFTIEKESGWLLLHMPLDREKIVKYELYGHAVSENGASVEEPMNISIIVTDQNDNKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 14 | Hu CDH3 Dom1A mu (aa 108-143) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKREWVMPPIFVPENGKGPFPQRLNQLKSNKDRGTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 15 | Hu CDH3 Dom1B mu (aa 144-179) | 嵌合hu/mu | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvftiekesgwlllhmpldrekivkyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaiytyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna | |
| 16 | Hu CDH3 Dom1C mu (aa 180-215) | 嵌合hu/mu | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelyghavsengasveepmnisiivtdqndnkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaiytyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna | |
| 17 | Hu CDH3 Dom2 mu (aa 216-327) | 嵌合hu/mu | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvmpgtsvmqvtatdeddavntyngvvaysihsqepkephdlmftihkstgtisvissgldrekvpeyrltvqatdmdgegstttaeavvqildandnapefdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna | |
| 18 | Hu CDH3 Dom2A mu (aa 216-252) | 嵌合hu/mu | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvmpgtsvmqvtatdeddavntyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpvpeprqiticnqspvrqvlnitdkdlsphtspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna | |
| 19 | Hu CDH3 Dom2B mu (aa 253-290) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKEPHDLMFTIHKSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 20 | Hu CDH3 Dom2C mu (aa 291-327) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYRLTVQATDMDGEGSTTTAEAVVQILDANDNAPEFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 21 | Hu CDH3 Dom3 mu (aa 328-440) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFEPQKYEAWVPENEVGHEVQRLTVTDLDVPNSPAWRATYHIVGGDDGDHFTITTHPETNQGVLTTKKGLDFEAQDQHTLYVEVTNEAPFAVKLPTATATVVVHVKDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 22 | Hu CDH3 Dom3A mu (aa 328-363) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFEPQKYEAWVPENEVGHEVQRLTVTDLDVPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 23 | Hu CDH3 Dom3B mu (aa 364-403) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYHIVGGDDGDHFTITTHPETNQGVLTTKKGLDFEAQDQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 24 | Hu CDH3 Dom3C mu (aa 404-440) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFAVKLPTATATVVVHVKDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 25 | Hu CDH3 Dom4 mu (aa 441-546) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVIEAQEGISIGELVCIYTAQDPDKEDQKISYTISRDPANWLAVDPDSGQITAAGILDREDEQFVKNNVYEVMVLATDSGNPPTTGTGTLLLTLTDINDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 26 | Hu CDH3 Dom4A mu (aa 441-474) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVIEAQEGISIGELVCIYTAQDPDKEDQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 27 | Hu CDH3 Dom4B mu (aa 475-511) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYTISRDPANWLAVDPDSGQITAAGILDREDEQFVKNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 28 | Hu CDH3 Dom4C mu (aa 512-546) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNVYEVMVLATDSGNPPTTGTGTLLLTLTDINDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 29 | Hu CDH3 Dom5 mu (aa 547-650) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPIPEPRQIIICNQSPVPQVLNITDKDLSPNSSPFQAQLTHDSDIYWMAEVSEKGDTVALSLKKFLKQDTYDLHLSLSDHGNREQLTMIRATVCDCHGQVFNDCPRPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 30 | Hu CDH3 Dom5A mu (aa 547-581) | 嵌合hu/mu | aa | mglprgplasllllqvcwlqcaasepcravfreaevtleaggaeqepgqalgkvfmgcpgqepalfstdnddftvrngetvqerrslkernplkifpskrilrrhkrdwvvapisvpengkgpfpqrlnqlksnkdrdtkifysitgpgadsppegvfaveketgwlllnkpldreeiakyelfghavsengasvedpmnisiivtdqndhkpkftqdtfrgsvlegvlpgtsvmqvtatdeddaiytyngvvaysihsqepkdphdlmftihrstgtisvissgldrekvpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawratylimggddgdhftitthpesnqgilttrkgldfeaknqhtlyvevtneapfvlklptstativvhvedvneapvfvppskvvevqegiptgepvcvytaedpdkenqkisyrilrdpagwlamdpdsgqvtavgtldredeqfvrnniyevmvlamdngsppttgtgtllltlidvndhgpipeprqiiicnqspvpqvlnitdkdlspnsspfqaqltddsdiywtaevneegdtvvlslkkflkqdtydvhlslsdhgnkeqltviratvcdchghvetcpgpwkggsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna | |
| 31 | Hu CDH3 Dom5B mu (aa 582-616) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTHDSDIYWMAEVSEKGDTVALSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 32 | Hu CDH3 Dom5C mu (aa 617-650) | 嵌合hu/mu | aa | MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDLHLSLSDHGNREQLTMIRATVCDCHGQVFNDCPRPWKGGSGGGGSGAGVIAVIVVVVIAIVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA | |
| 33 | 人類表位簇D1B | 人類 | aa | sitgpgadsppegvfaveketgwlllnkpldreeia | |
| 34 | 人類表位簇D2C | 人類 | aa | vpeytltiqatdmdgdgstttavavveildandnapm | |
| 35 | 人類表位簇D3A | 人類 | aa | fdpqkyeahvpenavghevqrltvtdldapnspawr | |
| 36 | 人類表位簇 D2C+D3A | 人類 | aa | vpeytltiqatdmdgdgstttavavveildandnapmfdpqkyeahvpenavghevqrltvtdldapnspawr | |
| 37 | 獼猴表位簇D1B | 食蟹獼猴 | aa | sitgpgadsppegvfaveketgwlllnkpldreeia | |
| 38 | 獼猴表位簇D2C | 食蟹獼猴 | aa | vpeytltiqatdmdgdgstttavavveildandnapv | |
| 39 | 獼猴表位簇D3A | 食蟹獼猴 | aa | Fdpqkyeshvpenavghevqrltvtdldapnspawr | |
| 40 | 獼猴表位簇 D2C+D3A | 食蟹獼猴 | aa | vpeytltiqatdmdgdgstttavavveildandnapvfdpqkyeshvpenavghevqrltvtdldapnspawr | |
| 41 | 人類CDH1 (E-cad.) | 人類 | aa | mgpwsrslsalllllqvsswlcqepepchpgfdaesytftvprrhlergrvlgrvnfedctgrqrtayfsldtrfkvgtdgvitvkrplrfhnpqihflvyawdstyrkfstkvtlntvghhhrppphqasvsgiqaelltfpnsspglrrqkrdwvippiscpenekgpfpknlvqiksnkdkegkvfysitgqgadtppvgvfiieretgwlkvtepldreriatytlfshavssngnavedpmeilitvtdqndnkpeftqevfkgsvmegalpgtsvmevtatdadddvntynaaiaytilsqdpelpdknmftinrntgvisvvttgldresfptytlvvqaadlqgeglsttatavitvtdtndnppifnpttykgqvpeneanvvittlkvtdadapntpaweavytilnddggqfvvttnpvnndgilktakgldfeakqqyilhvavtnvvpfevslttstatvtvdvldvneapifvppekrvevsedfgvgqeitsytaqepdtfmeqkityriwrdtanwleinpdtgaistraeldredfehvknstytaliiatdngspvatgtgtlllilsdvndnapipeprtiffcernpkpqviniidadlppntspftaelthgasanwtiqyndptqesiilkpkmalevgdykinlklmdnqnkdqvttlevsvcdcegaagvcrkaqpveaglqipailgilggilallililllllflrrravvkepllppeddtrdnvyyydeegggeedqdfdlsqlhrgldarpevtrndvaptlmsvprylprpanpdeignfidenlkaadtdptappydsllvfdyegsgseaaslsslnssesdkdqdydylnewgnrfkkladmygggedd | |
| 42 | 人類CDH2 (N-cad.) | 人類 | aa | mcriagalrtllpllaallqasveasgeialcktgfpedvysavlskdvhegqpllnvkfsncngkrkvqyessepadfkvdedgmvyavrsfplssehakfliyaqdketqekwqvavklslkptlteesvkesaeveeivfprqfskhsghlqrqkrdwvippinlpensrgpfpqelvrirsdrdknlslrysvtgpgadqpptgifiinpisgqlsvtkpldreqiarfhlrahavdingnqvenpidivinvidmndnrpeflhqvwngtvpegskpgtyvmtvtaidaddpnalngmlryrivsqapstpspnmftinnetgdiitvaagldrekvqqytliiqatdmegnptyglsntatavitvtdvndnppeftamtfygevpenrvdiivanltvtdkdqphtpawnavyrisggdptgrfaiqtdpnsndglvtvvkpidfetnrmfvltvaaenqvplakgiqhppqstatvsvtvidvnenpyfapnpkiirqeeglhagtmlttftaqdpdrymqqnirytklsdpanwlkidpvngqittiavldrespnvknniynatflasdngippmsgtgtlqiylldindnapqvlpqeaetcetpdpnsinitaldydidpnagpfafdlplspvtikrnwtitrlngdfaqlnlkikfleagiyevpiiitdsgnppksnisilrvkvcqcdsngdctdvdrivgaglgtgaiiaillciiillilvlmfvvwmkrrdkerqakqllidpeddvrdnilkydeegggeedqdydlsqlqqpdtvepdaikpvgirrmderpihaepqypvrsaaphpgdigdfineglkaadndptappydsllvfdyegsgstagslsslnssssggeqdydylndwgprfkkladmygggdd | |
| 43 | 人類CDH4 (R-cad.) | 人類 | aa | mtagagvlllllslsgalrahnedlttretckagfseddytalisqnilegekllqvkfsscvgtkgtqyetnsmdfkvgadgtvfatrelqvpseqvaftvtawdsqtaekwdavvrllvaqtssphsghkpqkgkkvvaldpspppkdtllpwpqhqnanglrrrkrdwvippinvpensrgpfpqqlvrirsdkdndipirysitgvgadqppmevfsidsmsgrmyvtrpmdreehasyhlrahavdmngnkvenpidlyiyvidmndnrpefinqvyngsvdegskpgtyvmtvtandaddsttangmvryrivtqtpqspsqnmftinsetgdivtvaagldrekvqqytvivqatdmegnlnyglsntataiitvtdvndnppeftastfagevpenrvetvvanltvmdrdqphspnwnavyriisgdpsghfsvrtdpvtnegmvtvvkavdyelnrafmltvmvsnqaplasgiqmsfqstagvtisimdineapyfpsnhklirleegvppgtvlttfsavdpdrfmqqavrysklsdpaswlhinatngqittaavldreslytknnvyeatflaadngippasgtgtlqiylidindnapellpkeaqicekpnlnainitaadadvdpnigpyvfelpfvpaavrknwtitrlngdyaqlslrilyleagmydvpiivtdsgnpplsntsiikvkvcpcddngdcttigavaaaglgtgaivailicililltmvllfvmwmkrrekerhtkqllidpeddvrdnilkydeegggeedqdydlsqlqqpeamghvpskapgvrrvderpvgaepqypirpmvphpgdigdfineglraadndptappydsllvfdyegsgstagsvsslnssssgdqdydylndwgprfkkladmygggeed | |
| 44 | 人類CDH5 (VE-cad) | 人類 | aa | mqrlmmllatsgaclgllavaavaaaganpaqrdthsllpthrrqkrdwiwnqmhideekntslphhvgkikssvsrknakyllkgeyvgkvfrvdaetgdvfaierldreniseyhltavivdkdtgenletpssftikvhdvndnwpvfthrlfnasvpessavgtsvisvtavdaddptvgdhasvmyqilkgkeyfaidnsgriititksldrekqaryeivveardaqglrgdsgtatvlvtlqdindnfpfftqtkytfvvpedtrvgtsvgslfvedpdepqnrmtkysilrgdyqdaftietnpahnegiikpmkpldyeyiqqysfiveatdptidlrymsppagnraqviinitdvdeppifqqpfyhfqlkenqkkpligtvlamdpdaarhsigysirrtsdkgqffrvtkkgdiynekeldrevypwynltveakeldstgtptgkesivqvhievldendnapefakpyqpkvcenavhgqlvlqisaidkditprnvkfkfilntennftltdnhdntanitvkygqfdrehtkvhflpvvisdngmpsrtgtstltvavckcneqgeftfcedmaaqvgvsiqavvaillciltitvitlliflrrrlrkqarahgksvpeiheqlvtydeegggemdttsydvsvlnsvrrggakpprpaldarpslyaqvqkpprhapgahggpgemaamievkkdeadhdgdgppydtlhiygyegsesiaeslsslgtdssdsdvdydflndwgprfkmlaelygsdpreelly | |
| 45 | 獼猴CDH1 | 食蟹獼猴 | aa | mgpwsrslsalllllqvsswlcqepepchpgfdaesytftvprrhlergrvlgrvsfedctgrqrtayfsldtrfkvgpdgvitvkrplqfhnpqihflvyawdstyrkfstkvtlntvghhsrtpplhasvsgvqaelltfpnsspglrrwkrdwvippiscpenekgpfpknlvqiksnkdkegkvfysitgqgadtppvgvfiieretgwlkvtepldreniatytlfshavssngnavedpmeilitvtdqndnkpvftqevfkgsvmegalpgtsvmevtatdadddvntynaaiaysilsqdpelpdknmftinkntgvisvvttgldresfpmytlvvqaadlqgeglsttatavitvtdtndnppvfnpttykgqvpenqanfvittlkvtdadapntpaweavytilndndgqfvvttnpvtndgilktakgldfeakqqyilhvavtnvapfevslttstatvtvdvldvneapifvppekrvevsedfgvgqeitsytarepdtfmeqkityriwrdaanwleinpdtgaistraeldredvehvknstytaliiatdndhhlcdfleshfldeevklikkiaqesiilkpkialevgdykinlklmdnqkkdqvttlevsvcdcegaagickkaplveagmqipailgilggilallililllllflrrravvkepllppeddtrdnvyyydeegggeedqdfdlsqlhrgldarpevtrndvaptllsvprylprpanpdeignfidenlkaadsdptappydsllvfdyegsgseaaslsslnssesdkdqdydylnewgnrfkkladmygggedd | |
| 46 | 獼猴CDH2 | 食蟹獼猴 | aa | mcriagalrtllpllaallqasveasgeialcktgfpedvysavlskdvhegqpllnvkfsncngkrkvqyessepadfkvdedgmvyavrsfplssehakfliyaqdketqekwqvavklslkpalteesvkeppeveeivfprqlskhsghlqrqkrdwvippinlpensrgpfpqelvrirsdrdknlslrysvtgpgadqpptgifiinpisgqlsvtkpldreqiarfhlrahavdingnqvenpidivinvidmndnrpeflhqvwngtvpegskpgtyvmtvtaidaddpnalngmlryrilsqapstpspnmftinnetgdiitvaagldrekvqqytliiqatdmegnptyglsntataiitvtdvndnppeftamtfygevpenrvdvivanltvtdkdqphtpawnavyrisggdptgrfaiqtdpnsndglvtvvkpidfetnrmfvltvaaenqvplakgiqhppqstatvsvtvidvnenpyfapnpkiirqeeglhagtmlttftaqdpdrymqqnirytklsdpanwlkidpvngqittiavldrespnvknniynatflasdngippmsgtgtlqiylldindnapqvlpqeaetcetpdpnsinitaldydidpnagpfafdlplspvtikrnwtitrlngdfaqlnlkikfleagiyevpiiitdsgnppksnisilrvkvcqcdsngdctdvdrivgaglgtgaiiaillciiillilvlmfvvwmkrrdkerqakqllidpeddvrdnilkydeegggeedqdydlsqlqqpdtvepdaikpvgirrmderpihaepqypvrsaaphpgdigdfineglkaadndptappydsllvfdyegsgstagslsslnssssggeqdydylndwgprfkkladmygggdd | |
| 47 | 獼猴CDH4 | 食蟹獼猴 | aa | mtagagvlllllslsgalrahnedlttretckagfseddytalisqnilegekllqvkfsscvgtkgtqyetnsvdfkvgsdgtvfatrelqvpseqvaftvtawdsqtaerwdavvrllvaqtsslhsghkpqkgkkivaldpspppkdtllpwprhqnadglrrrkrdwvippinvpensrgpfpqqlvrirsdkdndipirysitgvgadqppmevfsidsmsgrmyvtrpmdreehasyhlrahavdmngnkvenpidlyiyvidmndnrpefinqvyngsvdegskpgeafsfstrlsspntttapgngdshhvvtrrprggqglgtqtcaagdivslsrgmsreakvqqytvivqatdmegnlnyglsntataiitvtdvndnppeftastfagevpenrvetvvanltvmdrdqphspnwnavyriisgdpsghfsvrtdpvtnegmvtvvkavdyelnrafmltvmvsnqaplasgiqmsfqstagvtisvmdineapyfpsnhklirleegvppgtvlttfsavdpdrfmqqavrysklsdpanwlhinttngqittaavldreslytknnvyeatflaadngippasgtgtlqiylidindnapellpkeaqicekpnlnainitaadadvdpnigpyvfelpfvpaavrknwtitrlngdyaqlslrilyleagmydvpiivtdsgnpplsntsiikvkvcpcddngdcttigavaaaglgtgaivailicililltmvllfvmwmkrrekerhtkqllidpeddvrdnilkydeegggeedqdydlsqlqqpeamghvpskapgvrrvderpvgaepqypvrpmvphpgdigdfineglraadndptappydsllvfdyegsgstagsvsslnssssgdqdydylndwgprfkkladmygggeed | |
| 48 | 獼猴CDH5 | 食蟹獼猴 | aa | mqrlmmlvatsgaclgllaaaaaaaaaganpaqrdtpsllpthrrqkrdwiwnqmhideekntslphhvgkikssvsrknakyllkgefvdkvfrvdaetgdvfaierldreniseyhltavivdkdtgenletpssftikvhdvndnwpvfthrlfnasvpessavgtsvisvtavdaddptvgdhasvmyqilkgkeyfaidnsgrivtitksldrekqaryeivveardaqglrgdsgtatvlvtlqdindnfpfftqtkytfvvpedtrvgtsvgslfvedpdepqnrmtkysilrgdyqdaftietnpthnegiikpmkpldyeyiqqysfiveatdptidlrylsppagnraqviinitdvdeppifqqpfyhfqlkenqkkpligtvlamdpdaarhsigysirrtsdkgqffrvtkkgdiynekeldrevypwynltveakeldstgtptgkesivqvhievldendnapefaqpyqpkvcenaahgqlvlqisaidkditprnvkfkftlntennftltdnhdntanitvkygqfdrehtkvhflpvvisdngmpsrtgtstltvavckcneqgeftfcedmaaqvgvsiqavvaillsiltitvialliflrrrlrkqarahgksvpeiheqlvtydeegggemdttsydvsvlnsvrrggakpprpaldarpslyaqvqkpprhapgahggpgemaamievkkdeadhdgdgppydtlhiygyegsesiaeslsslgtdssdsdvdydflndwgprfkmlaelygsdpreelly | |
| 49 | D1B | CDH3-1 | VH CDR1 | aa | syams |
| 50 | VH CDR2 | aa | tissgghytyypdsvkg | ||
| 51 | VH CDR3 | aa | yyygipfgy | ||
| 52 | VL CDR1 | aa | rasqdiginli | ||
| 53 | VL CDR2 | aa | dtsslds | ||
| 54 | VL CDR3 | aa | lqygssplt | ||
| 55 | VH | aa | evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstissgghytyypdsvkgrftisrdnakntlylqmnslraedtavyycasyyygipfgywgqgtlvtvss | ||
| 56 | VL | aa | diqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 57 | scFv | aa | evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstissgghytyypdsvkgrftisrdnakntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 58 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstissgghytyypdsvkgrftisrdnakntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 59 | D1B | CDH3-2 | VH CDR1 | aa | syams |
| 60 | VH CDR2 | aa | tissgghytyypdsvkg | ||
| 61 | VH CDR3 | aa | yyygipfgy | ||
| 62 | VL CDR1 | aa | rasqdiginli | ||
| 63 | VL CDR2 | aa | dtsslds | ||
| 64 | VL CDR3 | aa | lqygssplt | ||
| 65 | VH | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvss | ||
| 66 | VL | aa | diqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 67 | scFv | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 68 | 雙特異性分子 | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 69 | D1B | CDH3-3 | VH CDR1 | aa | syams |
| 70 | VH CDR2 | aa | tissgghytyypdsvkg | ||
| 71 | VH CDR3 | aa | yyygipfgy | ||
| 72 | VL CDR1 | aa | rasqdiginli | ||
| 73 | VL CDR2 | aa | dtsslds | ||
| 74 | VL CDR3 | aa | lqygssplt | ||
| 75 | VH | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvss | ||
| 76 | VL | aa | diqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 77 | scFv | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveik | ||
| 78 | 雙特異性分子 | aa | evqllesggglvkpggslrlscaasgftfssyamswvrqapgkglewvatissgghytyypdsvkgrftisrdnskntlylqmnslraedtavyycasyyygipfgywgqgtlvtvssggggsggggsggggsdiqmtqspstlsaslgdrvtitcrasqdiginliwlqqkpgkapkrliydtssldsgvpsrfsgsgsgteftltisslqpddfatyyclqygsspltfgggtkveiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 79 | D1B | CDH3-4 | VH CDR1 | aa | sswmn |
| 80 | VH CDR2 | aa | riypgdgetkyadsvkg | ||
| 81 | VH CDR3 | aa | qrdygalyamdy | ||
| 82 | VL CDR1 | aa | rvsddiysyla | ||
| 83 | VL CDR2 | aa | naktlae | ||
| 84 | VL CDR3 | aa | qnhyvtpft | ||
| 85 | VH | aa | evqllesggglvqpggslrlscaasgftfssswmnwvrqapgkglewvsriypgdgetkyadsvkgrftisrdnskntlylqmnslraedtavyycakqrdygalyamdywgqgtlvtvss | ||
| 86 | VL | aa | diqltqspsflsasvgdrvtitcrvsddiysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqnhyvtpftfgqgtkleik | ||
| 87 | scFv | aa | evqllesggglvqpggslrlscaasgftfssswmnwvrqapgkglewvsriypgdgetkyadsvkgrftisrdnskntlylqmnslraedtavyycakqrdygalyamdywgqgtlvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrvsddiysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqnhyvtpftfgqgtkleik | ||
| 88 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgftfssswmnwvrqapgkglewvsriypgdgetkyadsvkgrftisrdnskntlylqmnslraedtavyycakqrdygalyamdywgqgtlvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrvsddiysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqnhyvtpftfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 89 | D1B | CDH3-5 | VH CDR1 | aa | tswmn |
| 90 | VH CDR2 | aa | riypgdgetkyngkfkg | ||
| 91 | VH CDR3 | aa | qrdygalyaldy | ||
| 92 | VL CDR1 | aa | raseniysyla | ||
| 93 | VL CDR2 | aa | naktlae | ||
| 94 | VL CDR3 | aa | qhhyvppyt | ||
| 95 | VH | aa | evqlveqsgaelvkpgasvkisckasgyafstswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlssltsedsavyfcarqrdygalyaldywgqgtrvtvss | ||
| 96 | VL | aa | elmmtqtpaslsasvgetvtftcraseniysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgsyycqhhyvppytfgggtkleik | ||
| 97 | scFv | aa | EVQLVEQSGAELVKPGASVKISCKASGYAFSTSWMNWVKQRPGKGLEWIGRIYPGDGETKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARQRDYGALYALDYWGQGTRVTVSSGGGGSGGGGSGGGGSELMMTQTPASLSASVGETVTFTCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYVPPYTFGGGTKLEIK | ||
| 98 | 雙特異性分子 | aa | evqlveqsgaelvkpgasvkisckasgyafstswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlssltsedsavyfcarqrdygalyaldywgqgtrvtvssggggsggggsggggselmmtqtpaslsasvgetvtftcraseniysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgsyycqhhyvppytfgggtkleikrtggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 99 | D1B | CDH3-6 | VH CDR1 | aa | sswmn |
| 100 | VH CDR2 | aa | riypgdgetkyngkfkg | ||
| 101 | VH CDR3 | aa | qrdygalyamdy | ||
| 102 | VL CDR1 | aa | rasddiysyla | ||
| 103 | VL CDR2 | aa | naktlae | ||
| 104 | VL CDR3 | aa | qnhyvtpft | ||
| 105 | VH | aa | evqlveesgpelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlssltsedsavyfcarqrdygalyamdywgqgtsvtvss | ||
| 106 | VL | aa | elvmtqspaslsasvgetvtitcrasddiysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgtyycqnhyvtpftfgagtkleik | ||
| 107 | scFv | aa | evqlveesgpelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlssltsedsavyfcarqrdygalyamdywgqgtsvtvssggggsggggsggggselvmtqspaslsasvgetvtitcrasddiysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgtyycqnhyvtpftfgagtkleik | ||
| 108 | 雙特異性分子 | aa | evqlveesgpelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlssltsedsavyfcarqrdygalyamdywgqgtsvtvssggggsggggsggggselvmtqspaslsasvgetvtitcrasddiysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgtyycqnhyvtpftfgagtkleikrtggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 109 | D1B | CDH3-7 | VH CDR1 | aa | sswmn |
| 110 | VH CDR2 | aa | riypgdgetkyngkfkg | ||
| 111 | VH CDR3 | aa | qrdygalyamdy | ||
| 112 | VL CDR1 | aa | rlseniysyla | ||
| 113 | VL CDR2 | aa | nsktlae | ||
| 114 | VL CDR3 | aa | qnhygfpft | ||
| 115 | VH | aa | evqlveqsgaelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlstltsedsavyfcarqrdygalyamdywgqgtsvtvss | ||
| 116 | VL | aa | elqmtqspaslsasvgetvtitcrlseniysylawyrqkegespqllvynsktlaegvpsrfsgsgsgtqfslkinslqpedfgnyycqnhygfpftfgagtkleik | ||
| 117 | scFv | aa | evqlveqsgaelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlstltsedsavyfcarqrdygalyamdywgqgtsvtvssggggsggggsggggselqmtqspaslsasvgetvtitcrlseniysylawyrqkegespqllvynsktlaegvpsrfsgsgsgtqfslkinslqpedfgnyycqnhygfpftfgagtkleik | ||
| 118 | 雙特異性分子 | aa | evqlveqsgaelvkpgasvkisckasgyafssswmnwvkqrpgkglewigriypgdgetkyngkfkgkatltadkssstaymqlstltsedsavyfcarqrdygalyamdywgqgtsvtvssggggsggggsggggselqmtqspaslsasvgetvtitcrlseniysylawyrqkegespqllvynsktlaegvpsrfsgsgsgtqfslkinslqpedfgnyycqnhygfpftfgagtkleikrtggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 119 | D1B | CDH3-8 | VH CDR1 | aa | sywmn |
| 120 | VH CDR2 | aa | hiypgdgdtnyngkfkg | ||
| 121 | VH CDR3 | aa | drgsfgawfay | ||
| 122 | VL CDR1 | aa | rasqdisnyln | ||
| 123 | VL CDR2 | aa | ytsrlhs | ||
| 124 | VL CDR3 | aa | qqgnrnppt | ||
| 125 | VH | aa | evqlveqsgaevvkpgasvkitckasgyafssywmnwvrqrpgkglewighiypgdgdtnyngkfkgkvtltadkssntaymqlsdltpedsavyfcardrgsfgawfaywgqgttvtvss | ||
| 126 | VL | aa | elvmtqtpsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgnrnpptfgggtkleik | ||
| 127 | scFv | aa | evqlveqsgaevvkpgasvkitckasgyafssywmnwvrqrpgkglewighiypgdgdtnyngkfkgkvtltadkssntaymqlsdltpedsavyfcardrgsfgawfaywgqgttvtvssggggsggggsggggselvmtqtpsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgnrnpptfgggtkleik | ||
| 128 | 雙特異性分子 | aa | evqlveqsgaevvkpgasvkitckasgyafssywmnwvrqrpgkglewighiypgdgdtnyngkfkgkvtltadkssntaymqlsdltpedsavyfcardrgsfgawfaywgqgttvtvssggggsggggsggggselvmtqtpsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgnrnpptfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 129 | D1B | CDH3-9 | VH CDR1 | aa | tygms |
| 130 | VH CDR2 | aa | tissgghysyypdsvkg | ||
| 131 | VH CDR3 | aa | yyygspfay | ||
| 132 | VL CDR1 | aa | rasqdigssln | ||
| 133 | VL CDR2 | aa | dtsslds | ||
| 134 | VL CDR3 | aa | vqygssplt | ||
| 135 | VH | aa | evqlveesggdlvkpggslklscaasgftfstygmswvrqtpdkrlewvatissgghysyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygspfaywgqgttvtvss | ||
| 136 | VL | aa | elqmtqspsslsaslgervsltcrasqdigsslnwlqqkpdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfgdyycvqygsspltfgagtkleik | ||
| 137 | scFv | aa | evqlveesggdlvkpggslklscaasgftfstygmswvrqtpdkrlewvatissgghysyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygspfaywgqgttvtvssggggsggggsggggselqmtqspsslsaslgervsltcrasqdigsslnwlqqkpdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfgdyycvqygsspltfgagtkleik | ||
| 138 | 雙特異性分子 | aa | evqlveesggdlvkpggslklscaasgftfstygmswvrqtpdkrlewvatissgghysyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygspfaywgqgttvtvssggggsggggsggggselqmtqspsslsaslgervsltcrasqdigsslnwlqqkpdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfgdyycvqygsspltfgagtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 139 | D1B | CDH3-10 | VH CDR1 | aa | syams |
| 140 | VH CDR2 | aa | tissgghytyypdsvkg | ||
| 141 | VH CDR3 | aa | yyygipfgy | ||
| 142 | VL CDR1 | aa | rasqdiginli | ||
| 143 | VL CDR2 | aa | dtsslds | ||
| 144 | VL CDR3 | aa | lqygssplt | ||
| 145 | VH | aa | evqlveesggglvkpggslklscaasgftfssyamswvrqtpdkrlewvatissgghytyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygipfgywgqgttvtvss | ||
| 146 | VL | aa | elvmtqspsslsaslgegvsltcrasqdiginliwlrqepdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfvhyyclqygsspltfgagtkleik | ||
| 147 | scFv | aa | evqlveesggglvkpggslklscaasgftfssyamswvrqtpdkrlewvatissgghytyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygipfgywgqgttvtvssggggsggggsggggselvmtqspsslsaslgegvsltcrasqdiginliwlrqepdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfvhyyclqygsspltfgagtkleik | ||
| 148 | 雙特異性分子 | aa | evqlveesggglvkpggslklscaasgftfssyamswvrqtpdkrlewvatissgghytyypdsvkgrftisrdnakntlylqmsslksedtamyycasyyygipfgywgqgttvtvssggggsggggsggggselvmtqspsslsaslgegvsltcrasqdiginliwlrqepdgtikrliydtssldsgvpkrfsgsrsgsdysltisslesedfvhyyclqygsspltfgagtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 149 | D2C | CDH3-11 | VH CDR1 | aa | sypin |
| 150 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 151 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 152 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 153 | VL CDR2 | aa | wastres | ||
| 154 | VL CDR3 | aa | qqyysypyt | ||
| 155 | VH | aa | evqllesggglvqpggslrlscavsgftlssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvss | ||
| 156 | VL | aa | divmtqspdslavsvgervtinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 157 | scFv | aa | evqllesggglvqpggslrlscavsgftlssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavsvgervtinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 158 | 雙特異性分子 | aa | evqllesggglvqpggslrlscavsgftlssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavsvgervtinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 159 | D2C | CDH3-12 | VH CDR1 | aa | sypin |
| 160 | VH CDR2 | aa | viwtgggtnynpslks | ||
| 161 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 162 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 163 | VL CDR2 | aa | wastres | ||
| 164 | VL CDR3 | aa | qqyysypyt | ||
| 165 | VH | aa | qvqlqesgpglvkpsetlsltctvsgvsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvss | ||
| 166 | VL | aa | divmtqspaslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 167 | scFv | aa | qvqlqesgpglvkpsetlsltctvsgvsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspaslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 168 | 雙特異性分子 | aa | qvqlqesgpglvkpsetlsltctvsgvsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspaslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 169 | D2C | CDH3-13 | VH CDR1 | aa | sypin |
| 170 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 171 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 172 | VL CDR1 | aa | kssqsllyssnqknyfa | ||
| 173 | VL CDR2 | aa | wastres | ||
| 174 | VL CDR3 | aa | qqyysypyt | ||
| 175 | VH | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvss | ||
| 176 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 177 | scFv | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 178 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 179 | D2C | CDH3-14 | VH CDR1 | aa | sypin |
| 180 | VH CDR2 | aa | viwtgggtnynpslks | ||
| 181 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 182 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 183 | VL CDR2 | aa | wastres | ||
| 184 | VL CDR3 | aa | qqyysypyt | ||
| 185 | VH | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvss | ||
| 186 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 187 | scFv | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 188 | 雙特異性分子 | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 189 | D2C | CDH3-15 | VH CDR1 | aa | sypin |
| 190 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 191 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 192 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 193 | VL CDR2 | aa | wastres | ||
| 194 | VL CDR3 | aa | qqyysypyt | ||
| 195 | VH | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvss | ||
| 196 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleik | ||
| 197 | scFv | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleik | ||
| 198 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 199 | D2C | CDH3-16 | VH CDR1 | aa | sypin |
| 200 | VH CDR2 | aa | viwtgggtnynpslks | ||
| 201 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 202 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 203 | VL CDR2 | aa | wastres | ||
| 204 | VL CDR3 | aa | qqyysypyt | ||
| 205 | VH | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqvslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvss | ||
| 206 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 207 | scFv | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqvslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 208 | 雙特異性分子 | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqvslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 209 | D2C | CDH3-17 | VH CDR1 | aa | sypin |
| 210 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 211 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 212 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 213 | VL CDR2 | aa | wastres | ||
| 214 | VL CDR3 | aa | qqyysypyt | ||
| 215 | VH | aa | evqllesggglvppggslrlscavsgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlflqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvss | ||
| 216 | VL | aa | divmtqspdslavsvgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 217 | scFv | aa | evqllesggglvppggslrlscavsgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlflqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavsvgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 218 | 雙特異性分子 | aa | evqllesggglvppggslrlscavsgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlflqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavsvgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 219 | D2C | CDH3-18 | VH CDR1 | aa | sypin |
| 220 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 221 | VH CDR3 | aa | srgaydfdgrgamdy | ||
| 222 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 223 | VL CDR2 | aa | wastres | ||
| 224 | VL CDR3 | aa | qqyysypyt | ||
| 225 | VH | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgaydfdgrgamdywgqgtlvtvss | ||
| 226 | VL | aa | divmtqspdslavslgekatinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 227 | scFv | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgaydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgekatinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 228 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgaydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgekatinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 229 | D2C | CDH3-19 | VH CDR1 | aa | sypin |
| 230 | VH CDR2 | aa | viwtgggtnyassvkg | ||
| 231 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 232 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 233 | VL CDR2 | aa | wastres | ||
| 234 | VL CDR3 | aa | qqyysypyt | ||
| 235 | VH | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewlsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvss | ||
| 236 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleik | ||
| 237 | scFv | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewlsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleik | ||
| 238 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewlsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltissvqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 239 | D2C | CDH3-20 | VH CDR1 | aa | sypin |
| 240 | VH CDR2 | aa | viwtgggtnyadsvkg | ||
| 241 | VH CDR3 | aa | rgvydfdgrgamdy | ||
| 242 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 243 | VL CDR2 | aa | wastres | ||
| 244 | VL CDR3 | aa | qqyysypyt | ||
| 245 | VH | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyadsvkgrftisrdnskntlylqmnslraedtavyycakrgvydfdgrgamdywgqgtlvtvss | ||
| 246 | VL | aa | divmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 247 | scFv | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyadsvkgrftisrdnskntlylqmnslraedtavyycakrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleik | ||
| 248 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgftfssypinwvrqapgkglewvsviwtgggtnyadsvkgrftisrdnskntlylqmnslraedtavyycakrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 249 | D2C | CDH3-21 | VH CDR1 | aa | sypin |
| 250 | VH CDR2 | aa | viwtgggtnynsalks | ||
| 251 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 252 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 253 | VL CDR2 | aa | WASTRES | ||
| 254 | VL CDR3 | aa | qqyysypyt | ||
| 255 | VH | aa | evqlleesgpglvtpsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvss | ||
| 256 | VL | aa | elvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 257 | scFv | aa | evqlleesgpglvtpsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 258 | 雙特異性分子 | aa | evqlleesgpglvtpsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 259 | D2C | CDH3-22 | VH CDR1 | aa | sypin |
| 260 | VH CDR2 | aa | viwtgggtnynsalks | ||
| 261 | VH CDR3 | aa | srgvydfdgrgamdy | ||
| 262 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 263 | VL CDR2 | aa | WASTRES | ||
| 264 | VL CDR3 | aa | qqyysypyt | ||
| 265 | VH | aa | evqlleesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvss | ||
| 266 | VL | aa | elvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 267 | scFv | aa | evqlleesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 268 | 雙特異性分子 | aa | evqlleesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnynsalksrlsitkdnsksqvflkmtslqtddtaryycaksrgvydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 269 | D2C | CDH3-23 | VH CDR1 | aa | sypin |
| 270 | VH CDR2 | aa | viwtgggtnydsalks | ||
| 271 | VH CDR3 | aa | srgaydfdgrgamdy | ||
| 272 | VL CDR1 | aa | kssqsllyssnqknyla | ||
| 273 | VL CDR2 | aa | wastres | ||
| 274 | VL CDR3 | aa | qqyysypyt | ||
| 275 | VH | aa | evqlveesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnydsalksrltiskdnsksqvflkmnslqtddtaryycarsrgaydfdgrgamdywgqgttvtvss | ||
| 276 | VL | aa | elvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 277 | scFv | aa | evqlveesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnydsalksrltiskdnsksqvflkmnslqtddtaryycarsrgaydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleik | ||
| 278 | 雙特異性分子 | aa | evqlveesgpglvapsqslsitctvsgfsltsypinwvrqppgkglewlgviwtgggtnydsalksrltiskdnsksqvflkmnslqtddtaryycarsrgaydfdgrgamdywgqgttvtvssggggsggggsggggselvmtqspsslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypytfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 279 | D3A | CDH3-24 | VH CDR1 | aa | sywmh |
| 280 | VH CDR2 | aa | vidtsdsytiynqkfqg | ||
| 281 | VH CDR3 | aa | sgpgyfdv | ||
| 282 | VL CDR1 | aa | rasgnihnyla | ||
| 283 | VL CDR2 | aa | naktlad | ||
| 284 | VL CDR3 | aa | qhfwstpyt | ||
| 285 | VH | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststaymelsslrsedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 286 | VL | aa | diqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftlkisslqpedfatyycqhfwstpytfgqgtkleik | ||
| 287 | scFv | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststaymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftlkisslqpedfatyycqhfwstpytfgqgtkleik | ||
| 288 | 雙特異性分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststaymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftlkisslqpedfatyycqhfwstpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 289 | D3A | CDH3-25 | VH CDR1 | aa | sywmh |
| 290 | VH CDR2 | aa | vidtsdsytiynqkfkg | ||
| 291 | VH CDR3 | aa | sgpgyfdv | ||
| 292 | VL CDR1 | aa | raseniysyla | ||
| 293 | VL CDR2 | aa | naktlae | ||
| 294 | VL CDR3 | aa | qhhygtpyt | ||
| 295 | VH | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfkgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 296 | VL | aa | diqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 297 | scFv | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfkgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 298 | 雙特異性分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfkgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 299 | D3A | CDH3-26 | VH CDR1 | aa | sywmh |
| 300 | VH CDR2 | aa | vidtsdsytiynqkfqg | ||
| 301 | VH CDR3 | aa | sgpgyfdv | ||
| 302 | VL CDR1 | aa | raseniysyla | ||
| 303 | VL CDR2 | aa | naktlae | ||
| 304 | VL CDR3 | aa | qhhygtpyt | ||
| 305 | VH | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 306 | VL | aa | diqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapkllvynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 307 | scFv | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapkllvynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 308 | 雙特異性分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapkllvynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 309 | D3A | CDH3-27 | VH CDR1 | aa | sywmh |
| 310 | VH CDR2 | aa | vidtsdsytiyaqkfqg | ||
| 311 | VH CDR3 | aa | sgpgyfdv | ||
| 312 | VL CDR1 | aa | raseniysyla | ||
| 313 | VL CDR2 | aa | naktlae | ||
| 314 | VL CDR3 | aa | qhhygtpyt | ||
| 315 | VH | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiyaqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 316 | VL | aa | diqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 317 | scFv | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiyaqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleik | ||
| 318 | 雙特異性分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiyaqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 319 | D3A | CDH3-28 | VH CDR1 | aa | sywmh |
| 320 | VH CDR2 | aa | vidtsdsytiynqkvkg | ||
| 321 | VH CDR3 | aa | sgpgyfdv | ||
| 322 | VL CDR1 | aa | rasgnihnyla | ||
| 323 | VL CDR2 | aa | naktlad | ||
| 324 | VL CDR3 | aa | qhswstpyt | ||
| 325 | VH | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 326 | VL | aa | diqltqspsflsasvgdrvtitcrasgnihnylawyqqkqgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleik | ||
| 327 | scFv | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkqgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleik | ||
| 328 | 雙特異性分子 | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkqgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 329 | D3A | CDH3-29 | VH CDR1 | aa | sywmh |
| 330 | VH CDR2 | aa | vidtsdsytiynqkvkg | ||
| 331 | VH CDR3 | aa | sgpgyfdv | ||
| 332 | VL CDR1 | aa | rasgnihnyla | ||
| 333 | VL CDR2 | aa | naktlad | ||
| 334 | VL CDR3 | aa | qhswstpyt | ||
| 335 | VH | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvss | ||
| 336 | VL | aa | diqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleik | ||
| 337 | scFv | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleik | ||
| 338 | 雙特異性分子 | aa | evqllesggglvrpggslrlscaasgytfssywmhwvrqapgkglewigvidtsdsytiynqkvkgrftisrdnskntvylqmnslraedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftltisslqpedfatyycqhswstpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 339 | D3A | CDH3-30 | VH CDR1 | aa | sywmh |
| 340 | VH CDR2 | aa | vidtsdsytiynqkvkg | ||
| 341 | VH CDR3 | aa | sgpgyfdv | ||
| 342 | VL CDR1 | aa | raseniysyla | ||
| 343 | VL CDR2 | aa | naktlae | ||
| 344 | VL CDR3 | aa | qhhygtpyt | ||
| 345 | VH | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewmgvidtsdsytiynqkvkgrftisrdnskntvylqmnslragdtavyycarsgpgyfdvwgqgtmvtvss | ||
| 346 | VL | aa | diqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfgtyycqhhygtpytfgqgtkleik | ||
| 347 | scFv | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewmgvidtsdsytiynqkvkgrftisrdnskntvylqmnslragdtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfgtyycqhhygtpytfgqgtkleik | ||
| 348 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewmgvidtsdsytiynqkvkgrftisrdnskntvylqmnslragdtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfgtyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 349 | D3A | CDH3-31 | VH CDR1 | aa | sywmh |
| 350 | VH CDR2 | aa | vidtsdsytiynqkvkg | ||
| 351 | VH CDR3 | aa | sgpgyfdv | ||
| 352 | VL CDR1 | aa | raseniysyla | ||
| 353 | VL CDR2 | aa | naktlae | ||
| 354 | VL CDR3 | aa | qhhygtpyt | ||
| 355 | VH | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewvgvidtsdsytiynqkvkgrftisrdtskntvylqlnslraedtavyycaksgpgyfdvwgqgtmvtvss | ||
| 356 | VL | aa | diqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfasyycqhhygtpytfgqgtkleik | ||
| 357 | scFv | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewvgvidtsdsytiynqkvkgrftisrdtskntvylqlnslraedtavyycaksgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfasyycqhhygtpytfgqgtkleik | ||
| 358 | 雙特異性分子 | aa | evqllesggglvqpggslrlscaasgytfssywmhwvrqapgkglewvgvidtsdsytiynqkvkgrftisrdtskntvylqlnslraedtavyycaksgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfasyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | ||
| 359 | D3A | CDH3-32 | VH CDR1 | aa | sywmh |
| 360 | VH CDR2 | aa | vidtsdsytiynqkfkg | ||
| 361 | VH CDR3 | aa | sgpgyfdv | ||
| 362 | VL CDR1 | aa | raseniysyla | ||
| 363 | VL CDR2 | aa | naktlae | ||
| 364 | VL CDR3 | aa | qhhygtpyt | ||
| 365 | VH | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsedssvyfcarsgpgyfdvwgqgttvtvss | ||
| 366 | VL | aa | elqmtqspaslsasvgetvtitcraseniysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgsyycqhhygtpytfgggtkleik | ||
| 367 | scFv | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsedssvyfcarsgpgyfdvwgqgttvtvssggggsggggsggggselqmtqspaslsasvgetvtitcraseniysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgsyycqhhygtpytfgggtkleik | ||
| 368 | 雙特異性分子 | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsedssvyfcarsgpgyfdvwgqgttvtvssggggsggggsggggselqmtqspaslsasvgetvtitcraseniysylawyqqkqgkspqllvynaktlaegvpsrfsgsgsgtqfslkinslqpedfgsyycqhhygtpytfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 369 | D3A | CDH3-33 | VH CDR1 | aa | sywmh |
| 370 | VH CDR2 | aa | vidtsdsytiynqkfkg | ||
| 371 | VH CDR3 | aa | sgpgyfdv | ||
| 372 | VL CDR1 | aa | rasgnihnyla | ||
| 373 | VL CDR2 | aa | naktlad | ||
| 374 | VL CDR3 | aa | qhfwstpyt | ||
| 375 | VH | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsgdssvyfcarsgpgyfdvwgqgttvtvss | ||
| 376 | VL | aa | elvmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgtyycqhfwstpytfgggtkleik | ||
| 377 | scFv | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsgdssvyfcarsgpgyfdvwgqgttvtvssggggsggggsggggselvmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgtyycqhfwstpytfgggtkleik | ||
| 378 | 雙特異性分子 | aa | evqlveqpgaelvrpgtsvklsckasgytftsywmhwvkqrpgqglewigvidtsdsytiynqkfkgkatltvdtssstaymqlssltsgdssvyfcarsgpgyfdvwgqgttvtvssggggsggggsggggselvmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgtyycqhfwstpytfgggtkleikrtsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlhhhhhh | ||
| 379 | D2C | CDH3-13 xI2C -HALB | aa | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQAPGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLPGGGGSDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL | |
| 380 | D2C | CDH3-13 xI2C -HALB-變異體-1 | aa | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQAPGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLPGGGGSDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL | |
| 381 | D2C | CDH3-13 xI2C -LY-FcB-CH | aa | QRFVTGHFGGLYPANGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFCTGHFGGLHPCNGP | |
| 382 | D2C | CDH3-13 xI2C -LH-FcB-CH | aa | QRFVTGHFGGLHPANGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFCTGHFGGLHPCNGP | |
| 383 | D2C | CDH3-13 xI2C -LH-FcB-LH | aa | QRFVTGHFGGLHPANGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFVTGHFGGLHPANGp | |
| 384 | D2C | CDH3-13 xI2C -LY-FcB-LH | aa | QRFVTGHFGGLYPANGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFVTGHFGGLHPANGp | |
| 385 | D2C | CDH3-13 xI2C -CH-FcB-LH | aa | QRFCTGHFGGLHPCNGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFVTGHFGGLHPANGp | |
| 386 | D2C | CDH3-13 xI2C -CH-FcB-LY | aa | QRFCTGHFGGLHPCNGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFVTGHFGGLYPANGp | |
| 387 | D2C | CDH3-13 xI2C -156 | aa | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQAPGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGSRDWDFDVFGGGTPVGGP | |
| 388 | D2C | CDH3-13 xI2C -LY-FcB-CH-156 | aa | QRFVTGHFGGLYPANGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFCTGHFGGLHPCNGGGGGSGGGSRDWDFDVFGGGTPVGGP | |
| 389 | D2C | CDH3-13 xI2C -CH-FcB-LY-156 | aa | QRFCTGHFGGLHPCNGGGGGSevqllesggglvqpggslrlscaasgfsfssypinwvrqapgkglewvgviwtgggtnyassvkgrftisrdnskntvylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknyfawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGSQRFVTGHFGGLYPANGGGGGSGGGSRDWDFDVFGGGTPVGGP | |
| 390 | 人類表位簇D3C | 人類 | aa | htlyvevtneapfvlklptstativvhvedvneapvf | |
| 391 | 獼猴表位簇D3C | 食蟹獼猴 | aa | htlyvevtneapfvlklptstativvhvedvneapvf | |
| 392 | 連接子1 | 人工 | aa | GGGG | |
| 393 | 連接子2 | 人工 | aa | GGGGS | |
| 394 | 連接子3 | 人工 | aa | GGGGQ | |
| 395 | 連接子4 | 人工 | aa | SGGGGS | |
| 396 | 連接子5 | 人工 | aa | PGGGGS | |
| 397 | 連接子6 | 人工 | aa | PGGDGS | |
| 398 | 連接子7 | 人工 | aa | GGGGSGGGS | |
| 399 | 連接子8 | 人工 | aa | GGGGSGGGGS | |
| 400 | 連接子9 | 人工 | aa | GGGGSGGGGSGGGGS | |
| 401 | 連接子10 (G 4S) 4 | 人工 | aa | GGGGSGGGGSGGGGSGGGGS | |
| 402 | 連接子11 (G 4S) 5 | 人工 | aa | GGGGSGGGGSGGGGSGGGGSGGGGS | |
| 403 | 連接子12 (G 4S) 6 | 人工 | aa | GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS | |
| 404 | 連接子13 (G 4S) 7 | 人工 | aa | GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS | |
| 405 | 連接子14 (G 4S) 8 | 人工 | aa | GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS | |
| 406 | Fc單體-1 +c/-g | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 407 | Fc單體-2 +c/-g/ delGK | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 408 | Fc單體-3 -c/+g | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 409 | Fc單體-4 -c/+g/ delGK | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 410 | Fc單體-5 -c/-g | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 411 | Fc單體-6 -c/-g/ delGK | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 412 | Fc單體-7 +c/+g | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 413 | Fc單體-8 +c/+g/ delGK | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 414 | scFc-1 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 415 | scFc-2 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 416 | scFc-3 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 417 | scFc-4 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 418 | scFc-5 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 419 | scFc-6 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 420 | scFc-7 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk | |
| 421 | scFc-8 | 人工 | aa | dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp | |
| 422 | D2C | CDH3-11 xI2C -scFc | 雙特異性HLE 分子 | aa | evqllesggglvqpggslrlscavsgftlssypinwvrqapgkglewvsviwtgggtnyassvkgrftisrdnskntlylqmnslraedtavyycaksrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavsvgervtinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 423 | D2C | CDH3-12 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlqesgpglvkpsetlsltctvsgvsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspaslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 424 | D2C | CDH3-12 xI2C -scFc | 雙特異性HLE 分子 | aa | qvqlqesgpglvkpsetlsltctvsgvsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspaslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 425 | D2C | CDH3-13 xI2C -scFc | 雙特異性HLE 分子 | aa | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQAPGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 426 | D2C | CDH3-14 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 427 | D2C | CDH3-14 xI2C -scFc | 雙特異性 HLE 分子 | aa | qvqlqesgpglvkpsetlsltctvsggsitsypinwirqppgkglewigviwtgggtnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgvydfdgrgamdywgqgtlvtvssggggsggggsggggsdivmtqspdslavslgeratinckssqsllyssnqknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysypytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 428 | D3A | CDH3-24 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststaymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftlkisslqpedfatyycqhfwstpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 429 | D3A | CDH3-24 xI2C -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststaymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcrasgnihnylawyqqkpgkapklliynaktladgvpsrfsgsgsgteftlkisslqpedfatyycqhfwstpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 430 | D3A | CDH3-25 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfkgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 431 | D3A | CDH3-25 xI2C -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfkgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 432 | D3A | CDH3-26 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiynqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapkllvynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 433 | D3A | CDH3-26 xI2C -scFc | 雙特異性HLE 分子 | aa | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGVIDTSDSYTIYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSGPGYFDVWGQGTMVTVSSGGGGSGGGGSGGGGSDIQLTQSPSFLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLVYNAKTLAEGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHHYGTPYTFGQGTKLEIKsggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 434 | D3A | CDH3-27 xF12q -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiyaqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 435 | D3A | CDH3-27 xI2C -scFc | 雙特異性HLE 分子 | aa | qvqlvqsgaevkkpgasvkvsckasgytftsywmhwvrqapgqglewmgvidtsdsytiyaqkfqgrvtmtrdtststvymelsslrsedtavyycarsgpgyfdvwgqgtmvtvssggggsggggsggggsdiqltqspsflsasvgdrvtitcraseniysylawyqqkpgkapklliynaktlaegvpsrfsgsgsgteftltisslqpedfatyycqhhygtpytfgqgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 436 | 六-his | 人工 | aa | HHHHHH | |
| 437 | P156 | 人工 | aa | RDWDFDVFGGGTPVGG | |
| 438 | 線性FcRn BP | 人工 | aa | QRFVTGHFGGLXPANG | |
| 439 | 線性FcRn BP-Y | 人工 | aa | QRFVTGHFGGLYPANG | |
| 440 | 線性FcRn BP-H | 人工 | aa | QRFVTGHFGGLHPANG | |
| 441 | 核心FcRn BP-H | 人工 | aa | TGHFGGLHP | |
| 442 | 環狀FcRn BP-H | 人工 | aa | QRFCTGHFGGLHPCNG | |
| 443 | HALB | 人類 | aa | DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL | |
| 444 | HALB變異體1 | 人類 | aa | DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL | |
| 445 | F6A的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 446 | F6A的CDR-L2 | 人工 | aa | GTKFLAP | |
| 447 | F6A 的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 448 | F6A的CDR-H1 | 人工 | aa | IYAMN | |
| 449 | F6A的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKS | |
| 450 | F6A的CDR-H3 | 人工 | aa | HGNFGNSYVSFFAY | |
| 451 | F6A的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfniyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvsffaywgqgtlvtvss | |
| 452 | F6A的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 453 | F6A的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfniyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvsffaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 454 | H2C的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 455 | H2C的CDR-L2 | 人工 | aa | GTKFLAP | |
| 456 | H2C的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 457 | H2C的CDR-H1 | 人工 | aa | KYAMN | |
| 458 | H2C的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKD | |
| 459 | H2C的CDR-H3 | 人工 | aa | HGNFGNSYISYWAY | |
| 460 | H2C的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvss | |
| 461 | H2C的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 462 | H2C的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 463 | H1E的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 464 | H1E的CDR-L2 | 人工 | aa | GTKFLAP | |
| 465 | H1E的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 466 | H1E的CDR-H1 | 人工 | aa | SYAMN | |
| 467 | H1E的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKG | |
| 468 | H1E的CDR-H3 | 人工 | aa | HGNFGNSYLSFWAY | |
| 469 | H1E的VH | 人工 | aa | EVQLVESgggleqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsfwaywgqgtlvtvss | |
| 470 | H1E的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 471 | H1E的VH-VL | 人工 | aa | EVQLVESgggleqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsfwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 472 | G4H的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 473 | G4H的CDR-L2 | 人工 | aa | GTKFLAP | |
| 474 | G4H的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 475 | G4H的CDR-H1 | 人工 | aa | RYAMN | |
| 476 | G4H的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKG | |
| 477 | G4H的CDR-H3 | 人工 | aa | HGNFGNSYLSYFAY | |
| 478 | G4H的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnryamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsyfaywgqgtlvtvss | |
| 479 | G4H的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 480 | G4H的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnryamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsyfaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 481 | A2J的CDR-L1 | 人工 | aa | RSSTGAVTSGYYPN | |
| 482 | A2J的CDR-L2 | 人工 | aa | ATDMRPS | |
| 483 | A2J的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 484 | A2J的CDR-H1 | 人工 | aa | VYAMN | |
| 485 | A2J的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKK | |
| 486 | A2J的CDR-H3 | 人工 | aa | HGNFGNSYLSWWAY | |
| 487 | A2J的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylswwaywgqgtlvtvss | |
| 488 | A2J的VL | 人工 | aa | QTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 489 | A2J的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 490 | E1L的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 491 | E1L的CDR-L2 | 人工 | aa | GTKFLAP | |
| 492 | E1L的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 493 | E1L的CDR-H1 | 人工 | aa | KYAMN | |
| 494 | E1L的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKS | |
| 495 | E1L的CDR-H3 | 人工 | aa | HGNFGNSYTSYYAY | |
| 496 | E1L的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsytsyyaywgqgtlvtvss | |
| 497 | E1L的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 498 | E1L的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsytsyyaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 499 | E2M的CDR-L1 | 人工 | aa | RSSTGAVTSGYYPN | |
| 500 | E2M的CDR-L2 | 人工 | aa | ATDMRPS | |
| 501 | E2M的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 502 | E2M的CDR-H1 | 人工 | aa | GYAMN | |
| 503 | E2M的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKE | |
| 504 | E2M的CDR-H3 | 人工 | aa | HRNFGNSYLSWFAY | |
| 505 | E2M的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfngyamnwvrqapgkglewvarirskynnyatyyadsvkerftisrddskntaylqmnnlktedtavyycvrhrnfgnsylswfaywgqgtlvtvss | |
| 506 | E2M的VL | 人工 | aa | QTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 507 | E2M的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfngyamnwvrqapgkglewvarirskynnyatyyadsvkerftisrddskntaylqmnnlktedtavyycvrhrnfgnsylswfaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 508 | F7O的CDR-L1 | 人工 | aa | GSSTGAVTSGYYPN | |
| 509 | F7O的CDR-L2 | 人工 | aa | GTKFLAP | |
| 510 | F7O的CDR-L3 | 人工 | aa | ALWYSNRWV | |
| 511 | F7O的CDR-H1 | 人工 | aa | VYAMN | |
| 512 | F7O的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKK | |
| 513 | F7O的CDR-H3 | 人工 | aa | HGNFGNSYISWWAY | |
| 514 | F7O的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyiswwaywgqgtlvtvss | |
| 515 | F7O的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 516 | F7O的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyiswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl | |
| 517 | F12Q的CDR-L1 | 人工 | aa | gsstgavtsgnypn | |
| 518 | F12Q的CDR-L2 | 人工 | aa | gtkflap | |
| 519 | F12Q的CDR-L3 | 人工 | aa | vlwysnrwv | |
| 520 | F12Q的CDR-H1 | 人工 | aa | syamn | |
| 521 | F12Q的CDR-H2 | 人工 | aa | rirskynnyatyyadsvkg | |
| 522 | F12Q的CDR-H3 | 人工 | aa | hgnfgnsyvswway | |
| 523 | F12Q的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvswwaywgqgtlvtvss | |
| 524 | F12Q的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
| 525 | F12Q的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
| 526 | I2C的CDR-L1 | 人工 | aa | GSSTGAVTSGNYPN | |
| 527 | I2C的CDR-L2 | 人工 | aa | GTKFLAP | |
| 528 | I2C的CDR-L3 | 人工 | aa | VLWYSNRWV | |
| 529 | I2C的CDR-H1 | 人工 | aa | KYAMN | |
| 530 | I2C的CDR-H2 | 人工 | aa | RIRSKYNNYATYYADSVKD | |
| 531 | I2C的CDR-H3 | 人工 | aa | HGNFGNSYISYWAY | |
| 532 | I2C的VH | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvss | |
| 533 | I2C的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
| 534 | I2C的VH-VL | 人工 | aa | EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
| 535 | F12q的VH | 人工 | aa | evqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvss | |
| 536 | F12q的VL | 人工 | aa | QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
| 537 | F12q的VH-VL | 人工 | aa | evqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl | |
圖示顯示:
圖 1 :人類CDH3、鼠類CDH3以及一個例示性嵌合CDH3(在本文為:「D1B鼠」)的五個胞外域D1-D5的示意圖。下面又顯示了五個結構域且它們進一步分成三個子域。例示性FACS信號(見實例2的「表位集簇」)的說明顯示在右下。
圖 2 :人類CDH3和鼠類CDH3的序列排比以及不同結構域的例示性表示:信號肽、前肽、胞外域D1-D5、跨膜域和細胞質域。將五個胞外域的鼠類序列互換引入至人體CDH3骨架,參見實例1,而嵌合構築體之後用於進行表位集簇(表位定位),參見實例2。
圖 3 :如透過流式細胞儀所示,表現在CHO細胞表面上的人類和鼠類CDH3以及20個嵌合人類-鼠類CDH3構築體(五個胞外域(ECD)),還有每個ECD的三個子域。人類野生型CDH3、鼠類野生型CDH3與嵌合CDH3構築體在CHO細胞上的表現是用單株小鼠IgG1抗人類CDH3抗體來檢核,單株小鼠IgG1抗人類CDH3抗體是鼠類交叉反應性。用抗小鼠IgG Fcγ-PE檢測結合的單株抗體(1:100,50 µl;Jackson Immunoresearch # 115-116-071). D1*):Hu CDH3 D1 mu-CHO。
圖 4 :CDH3構築體的表位定位。對不同表位簇/胞外子域具有特異性的結合分子實例,由藉由嵌合CDH3構築體的表位定位所檢測,參見實例2。圖4A:D1B結合子。圖4B:D2C結合子。圖4C:D3A結合子。
圖 5 :5 µg/mL經純化雙特異性抗體單體在指定細胞株上的FACS結合分析。也使用對雙特異性抗體的CD3結合部分具有特異性的內部小鼠抗體,接著是山羊抗小鼠Fcγ-PE進行CDH3xCD3雙特異性抗體結合的檢測。陰性對照是只有緩衝液,隨後檢測抗體。
圖 5A 和 5B :就結合至經人類CDH3轉染的CHO細胞、人類T細胞系HPB-all上的人類CD3、經獼猴CDH3轉染的CHO細胞、表現獼猴CD3之T細胞株上的獼猴CD3、人CDH3陽性細胞株A431,和經鼠類CDH3轉染的CHO細胞(陰性對照)來分析CDH3xCD3雙特異性結合子(圖5A:表位簇/胞外子域D2C;圖5B:表位簇/胞外子域D3A)。除了陰性對照外,在所有情況下都偵測到結合。
圖 5C 和 5D :就結合至人類CDH3旁系同源物CDH1、CDH2、CDH4和CDH5來分析CDH3xCD3雙特異性結合子(圖5C:表位簇/胞外子域D2C;圖5D:表位簇/胞外子域D3A)。偵測到不結合至旁系同源物。偵測到不結合至dhfr
-/CHO細胞(陰性對照)。
圖 6 :如在18小時的
51鉻釋放分析中所測定,在CDH3xCD3雙特異性抗體存在時,經刺激之人類CD8+ T細胞對抗經人類CDH3轉染的CHO細胞的細胞毒性活性。效應細胞:經刺激的富集人類CD8+ T細胞。目標細胞:經人類CDH3轉染的CHO細胞。效應細胞對目標細胞(E:T)的比率:10:1。對表位簇/胞外子域D2C (圖6A)和D3A (圖6B)具有特異性的抗體。
圖 7 :如在18小時的
51鉻釋放分析中所測定,在CDH3xCD3雙特異性抗體存在時,經刺激之人類CD8+ T細胞對抗人類CDH3陽性表皮樣癌細胞株A431的細胞毒性活性。效應細胞:富集的人類CD8+ T細胞。目標細胞:人類A431細胞。效應細胞對目標細胞(E:T)的比率:10:1。對表位簇/胞外子域D2C (圖7A)和D3A (圖7B)具有特異性的抗體。
圖 8 :如在48小時的基於FACS之細胞毒性分析中所測定,在CDH3xCD3雙特異性抗體存在時,未受刺激的人類PBMC對抗經人類CDH3轉染的CHO細胞的細胞毒性活性。效應細胞:未受刺激的人PBMC (CD14-/CD56-)。目標細胞:經人類CDH3轉染的CHO細胞。效應細胞對目標細胞(E:T)的比率:10:1。對表位簇/胞外子域D2C (圖8A)和D3A (圖8B)具有特異性的抗體。
圖 9 :如在48小時的基於FACS之細胞毒性分析中所測定,在CDH3xCD3雙特異性抗體存在時,未受刺激的人類PBMC對抗人類CDH3陽性表皮樣癌細胞株A431的細胞毒性活性。效應細胞:未受刺激的人類PBMC (CD14-/CD56-)。目標細胞:人類A431細胞。效應細胞對目標細胞(E:T)的比率:10:1。對表位簇/胞外子域D2C (圖9A)和D3A (圖9B)具有特異性的抗體。
圖 10 :如在48小時的基於FACS之細胞毒性分析中所測定,在CDH3xCD3雙特異性抗體存在時,獼猴T細胞株對抗經獼猴CDH3轉染的CHO細胞株的細胞毒性活性。效應細胞:獼猴CD3陽性T細胞株LnPx4119。目標細胞:經獼猴CDH3轉染的CHO細胞。效應細胞對目標細胞(E:T)的比率:10:1。對表位簇/胞外子域D2C (圖10A)、D3A (圖10B)和D1B (圖10C)具有特異性的抗體。
圖 11 :在人腫瘤異種移植模型中,表位簇/胞外子域D2C(CDH3-13)的CDH3xCD3雙特異性抗體的抗腫瘤活性(參見實例14)。抗體劑量在人類PBMC存在時依賴性地防止A-431腫瘤形成。在測定開始時(第5天)有高腫瘤體積,因為在第1天注射大體積的細胞混合物。** P <0.01;*** P <0.0001。
圖 12 :在人類腫瘤異種移植模型中,表位簇/胞外子域D2C(CDH3-13)之CDH3xCD3雙特異性抗體和半衰期延長(HLE)抗體的抗腫瘤活性(參見實例15)。在人類PBMC存在時,HLE抗體劑量依賴性地防止人類HCT-116腫瘤形成。雖然圖12A顯示整體結果,但圖12B將較高抗體濃度(第2組)所得結果分成反應動物(7/10)和無反應動物(3/10)。
圖 13 :在構築體C端處有(上圖)或沒有(下圖)白蛋白融合存在時,使用雙特異性抗體構築體於目標細胞不存在下的T細胞活化。
<![CDATA[<110> 德商安美基研究(慕尼黑)公司 (AMGEN RESEARCH (MUNICH) GMBH) ]]>
<![CDATA[<120> CDH3與CD3之雙特異性抗體構築體]]>
<![CDATA[<130> TW105112022]]>
<![CDATA[<150> EP15164154.5]]>
<![CDATA[<151> 2015-04-17]]>
<![CDATA[<160> 537 ]]>
<![CDATA[<170> PatentIn version 3.5]]>
<![CDATA[<210> 1]]>
<![CDATA[<211> 836]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH3]]>
<![CDATA[<400> 1]]>
Arg Ala Asn Gly Ile Asn Ala Met Gly Leu Pro Arg Gly Pro Leu Ala
1 5 10 15
Ser Leu Leu Leu Leu Gln Val Cys Trp Leu Gln Cys Ala Ala Ser Glu
20 25 30
Pro Cys Arg Ala Val Phe Arg Glu Ala Glu Val Thr Leu Glu Ala Gly
35 40 45
Gly Ala Glu Gln Glu Pro Gly Gln Ala Leu Gly Lys Val Phe Met Gly
50 55 60
Cys Pro Gly Gln Glu Pro Ala Leu Phe Ser Thr Asp Asn Asp Asp Phe
65 70 75 80
Thr Val Arg Asn Gly Glu Thr Val Gln Glu Arg Arg Ser Leu Lys Glu
85 90 95
Arg Asn Pro Leu Lys Ile Phe Pro Ser Lys Arg Ile Leu Arg Arg His
100 105 110
Lys Arg Asp Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly Lys
115 120 125
Gly Pro Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg
130 135 140
Asp Thr Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro
145 150 155 160
Pro Glu Gly Val Phe Ala Val Glu Lys Glu Thr Gly Trp Leu Leu Leu
165 170 175
Asn Lys Pro Leu Asp Arg Glu Glu Ile Ala Lys Tyr Glu Leu Phe Gly
180 185 190
His Ala Val Ser Glu Asn Gly Ala Ser Val Glu Asp Pro Met Asn Ile
195 200 205
Ser Ile Ile Val Thr Asp Gln Asn Asp His Lys Pro Lys Phe Thr Gln
210 215 220
Asp Thr Phe Arg Gly Ser Val Leu Glu Gly Val Leu Pro Gly Thr Ser
225 230 235 240
Val Met Gln Val Thr Ala Thr Asp Glu Asp Asp Ala Ile Tyr Thr Tyr
245 250 255
Asn Gly Val Val Ala Tyr Ser Ile His Ser Gln Glu Pro Lys Asp Pro
260 265 270
His Asp Leu Met Phe Thr Ile His Arg Ser Thr Gly Thr Ile Ser Val
275 280 285
Ile Ser Ser Gly Leu Asp Arg Glu Lys Val Pro Glu Tyr Thr Leu Thr
290 295 300
Ile Gln Ala Thr Asp Met Asp Gly Asp Gly Ser Thr Thr Thr Ala Val
305 310 315 320
Ala Val Val Glu Ile Leu Asp Ala Asn Asp Asn Ala Pro Met Phe Asp
325 330 335
Pro Gln Lys Tyr Glu Ala His Val Pro Glu Asn Ala Val Gly His Glu
340 345 350
Val Gln Arg Leu Thr Val Thr Asp Leu Asp Ala Pro Asn Ser Pro Ala
355 360 365
Trp Arg Ala Thr Tyr Leu Ile Met Gly Gly Asp Asp Gly Asp His Phe
370 375 380
Thr Ile Thr Thr His Pro Glu Ser Asn Gln Gly Ile Leu Thr Thr Arg
385 390 395 400
Lys Gly Leu Asp Phe Glu Ala Lys Asn Gln His Thr Leu Tyr Val Glu
405 410 415
Val Thr Asn Glu Ala Pro Phe Val Leu Lys Leu Pro Thr Ser Thr Ala
420 425 430
Thr Ile Val Val His Val Glu Asp Val Asn Glu Ala Pro Val Phe Val
435 440 445
Pro Pro Ser Lys Val Val Glu Val Gln Glu Gly Ile Pro Thr Gly Glu
450 455 460
Pro Val Cys Val Tyr Thr Ala Glu Asp Pro Asp Lys Glu Asn Gln Lys
465 470 475 480
Ile Ser Tyr Arg Ile Leu Arg Asp Pro Ala Gly Trp Leu Ala Met Asp
485 490 495
Pro Asp Ser Gly Gln Val Thr Ala Val Gly Thr Leu Asp Arg Glu Asp
500 505 510
Glu Gln Phe Val Arg Asn Asn Ile Tyr Glu Val Met Val Leu Ala Met
515 520 525
Asp Asn Gly Ser Pro Pro Thr Thr Gly Thr Gly Thr Leu Leu Leu Thr
530 535 540
Leu Ile Asp Val Asn Asp His Gly Pro Val Pro Glu Pro Arg Gln Ile
545 550 555 560
Thr Ile Cys Asn Gln Ser Pro Val Arg Gln Val Leu Asn Ile Thr Asp
565 570 575
Lys Asp Leu Ser Pro His Thr Ser Pro Phe Gln Ala Gln Leu Thr Asp
580 585 590
Asp Ser Asp Ile Tyr Trp Thr Ala Glu Val Asn Glu Glu Gly Asp Thr
595 600 605
Val Val Leu Ser Leu Lys Lys Phe Leu Lys Gln Asp Thr Tyr Asp Val
610 615 620
His Leu Ser Leu Ser Asp His Gly Asn Lys Glu Gln Leu Thr Val Ile
625 630 635 640
Arg Ala Thr Val Cys Asp Cys His Gly His Val Glu Thr Cys Pro Gly
645 650 655
Pro Trp Lys Gly Gly Phe Ile Leu Pro Val Leu Gly Ala Val Leu Ala
660 665 670
Leu Leu Phe Leu Leu Leu Val Leu Leu Leu Leu Val Arg Lys Lys Arg
675 680 685
Lys Ile Lys Glu Pro Leu Leu Leu Pro Glu Asp Asp Thr Arg Asp Asn
690 695 700
Val Phe Tyr Tyr Gly Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Tyr
705 710 715 720
Asp Ile Thr Gln Leu His Arg Gly Leu Glu Ala Arg Pro Glu Val Val
725 730 735
Leu Arg Asn Asp Val Ala Pro Thr Ile Ile Pro Thr Pro Met Tyr Arg
740 745 750
Pro Arg Pro Ala Asn Pro Asp Glu Ile Gly Asn Phe Ile Ile Glu Asn
755 760 765
Leu Lys Ala Ala Asn Thr Asp Pro Thr Ala Pro Pro Tyr Asp Thr Leu
770 775 780
Leu Val Phe Asp Tyr Glu Gly Ser Gly Ser Asp Ala Ala Ser Leu Ser
785 790 795 800
Ser Leu Thr Ser Ser Ala Ser Asp Gln Asp Gln Asp Tyr Asp Tyr Leu
805 810 815
Asn Glu Trp Gly Ser Arg Phe Lys Lys Leu Ala Asp Met Tyr Gly Gly
820 825 830
Gly Glu Asp Asp
835
<![CDATA[<210> 2]]>
<![CDATA[<211> 2487]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 人類CDH3]]>
<![CDATA[<400> 2]]>
atggggctcc ctcgtggacc tctcgcgtct ctcctccttc tccaggtttg ctggctgcag 60
tgcgcggcct ccgagccgtg ccgggcggtc ttcagggagg ctgaagtgac cttggaggcg 120
ggaggcgcgg agcaggagcc cggccaggcg ctggggaaag tattcatggg ctgccctggg 180
caagagccag ctctgtttag cactgataat gatgacttca ctgtgcggaa tggcgagaca 240
gtccaggaaa gaaggtcact gaaggaaagg aatccattga agatcttccc atccaaacgt 300
atcttacgaa gacacaagag agattgggtg gttgctccaa tatctgtccc tgaaaatggc 360
aagggtccct tcccccagag actgaatcag ctcaagtcta ataaagatag agacaccaag 420
attttctaca gcatcacggg gccgggggca gacagccccc ctgagggtgt cttcgctgta 480
gagaaggaga caggctggtt gttgttgaat aagccactgg accgggagga gattgccaag 540
tatgagctct ttggccacgc tgtgtcagag aatggtgcct cagtggagga ccccatgaac 600
atctccatca tcgtgaccga ccagaatgac cacaagccca agtttaccca ggacaccttc 660
cgagggagtg tcttagaggg agtcctacca ggtacttctg tgatgcaggt gacagccacg 720
gatgaggatg atgccatcta cacctacaat ggggtggttg cttactccat ccatagccaa 780
gaaccaaagg acccacacga cctcatgttc accattcacc ggagcacagg caccatcagc 840
gtcatctcca gtggcctgga ccgggaaaaa gtccctgagt acacactgac catccaggcc 900
acagacatgg atggggacgg ctccaccacc acggcagtgg cagtagtgga gatccttgat 960
gccaatgaca atgctcccat gtttgacccc cagaagtacg aggcccatgt gcctgagaat 1020
gcagtgggcc atgaggtgca gaggctgacg gtcactgatc tggacgcccc caactcacca 1080
gcgtggcgtg ccacctacct tatcatgggc ggtgacgacg gggaccattt taccatcacc 1140
acccaccctg agagcaacca gggcatcctg acaaccagga agggtttgga ttttgaggcc 1200
aaaaaccagc acaccctgta cgttgaagtg accaacgagg ccccttttgt gctgaagctc 1260
ccaacctcca cagccaccat agtggtccac gtggaggatg tgaatgaggc acctgtgttt 1320
gtcccaccct ccaaagtcgt tgaggtccag gagggcatcc ccactgggga gcctgtgtgt 1380
gtctacactg cagaagaccc tgacaaggag aatcaaaaga tcagctaccg catcctgaga 1440
gacccagcag ggtggctagc catggaccca gacagtgggc aggtcacagc tgtgggcacc 1500
ctcgaccgtg aggatgagca gtttgtgagg aacaacatct atgaagtcat ggtcttggcc 1560
atggacaatg gaagccctcc caccactggc acgggaaccc ttctgctaac actgattgat 1620
gtcaatgacc atggcccagt ccctgagccc cgtcagatca ccatctgcaa ccaaagccct 1680
gtgcgccagg tgctgaacat cacggacaag gacctgtctc cccacacctc ccctttccag 1740
gcccagctca cagatgactc agacatctac tggacggcag aggtcaacga ggaaggtgac 1800
acagtggtct tgtccctgaa gaagttcctg aagcaggata catatgacgt gcacctttct 1860
ctgtctgacc atggcaacaa agagcagctg acggtgatca gggccactgt gtgcgactgc 1920
catggccatg tcgaaacctg ccctggaccc tggaagggag gtttcatcct ccctgtgctg 1980
ggggctgtcc tggctctgct gttcctcctg ctggtgctgc ttttgttggt gagaaagaag 2040
cggaagatca aggagcccct cctactccca gaagatgaca cccgtgacaa cgtcttctac 2100
tatggcgaag aggggggtgg cgaagaggac caggactatg acatcaccca gctccaccga 2160
ggtctggagg ccaggccgga ggtggttctc cgcaatgacg tggcaccaac catcatcccg 2220
acacccatgt accgtcctcg gccagccaac ccagatgaaa tcggcaactt tataattgag 2280
aacctgaagg cggctaacac agaccccaca gccccgccct acgacaccct cttggtgttc 2340
gactatgagg gcagcggctc cgacgccgcg tccctgagct ccctcacctc ctccgcctcc 2400
gaccaagacc aagattacga ttatctgaac gagtggggca gccgcttcaa gaagctggca 2460
gacatgtacg gtggcgggga ggacgac 2487
<![CDATA[<210> 3]]>
<![CDATA[<211> 654]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH3 ECD]]>
<![CDATA[<400> 3]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly
645 650
<![CDATA[<210> 4]]>
<![CDATA[<211> 1962]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 人類CDH3 ECD]]>
<![CDATA[<400> 4]]>
atggggctcc ctcgtggacc tctcgcgtct ctcctccttc tccaggtttg ctggctgcag 60
tgcgcggcct ccgagccgtg ccgggcggtc ttcagggagg ctgaagtgac cttggaggcg 120
ggaggcgcgg agcaggagcc cggccaggcg ctggggaaag tattcatggg ctgccctggg 180
caagagccag ctctgtttag cactgataat gatgacttca ctgtgcggaa tggcgagaca 240
gtccaggaaa gaaggtcact gaaggaaagg aatccattga agatcttccc atccaaacgt 300
atcttacgaa gacacaagag agattgggtg gttgctccaa tatctgtccc tgaaaatggc 360
aagggtccct tcccccagag actgaatcag ctcaagtcta ataaagatag agacaccaag 420
attttctaca gcatcacggg gccgggggca gacagccccc ctgagggtgt cttcgctgta 480
gagaaggaga caggctggtt gttgttgaat aagccactgg accgggagga gattgccaag 540
tatgagctct ttggccacgc tgtgtcagag aatggtgcct cagtggagga ccccatgaac 600
atctccatca tcgtgaccga ccagaatgac cacaagccca agtttaccca ggacaccttc 660
cgagggagtg tcttagaggg agtcctacca ggtacttctg tgatgcaggt gacagccacg 720
gatgaggatg atgccatcta cacctacaat ggggtggttg cttactccat ccatagccaa 780
gaaccaaagg acccacacga cctcatgttc accattcacc ggagcacagg caccatcagc 840
gtcatctcca gtggcctgga ccgggaaaaa gtccctgagt acacactgac catccaggcc 900
acagacatgg atggggacgg ctccaccacc acggcagtgg cagtagtgga gatccttgat 960
gccaatgaca atgctcccat gtttgacccc cagaagtacg aggcccatgt gcctgagaat 1020
gcagtgggcc atgaggtgca gaggctgacg gtcactgatc tggacgcccc caactcacca 1080
gcgtggcgtg ccacctacct tatcatgggc ggtgacgacg gggaccattt taccatcacc 1140
acccaccctg agagcaacca gggcatcctg acaaccagga agggtttgga ttttgaggcc 1200
aaaaaccagc acaccctgta cgttgaagtg accaacgagg ccccttttgt gctgaagctc 1260
ccaacctcca cagccaccat agtggtccac gtggaggatg tgaatgaggc acctgtgttt 1320
gtcccaccct ccaaagtcgt tgaggtccag gagggcatcc ccactgggga gcctgtgtgt 1380
gtctacactg cagaagaccc tgacaaggag aatcaaaaga tcagctaccg catcctgaga 1440
gacccagcag ggtggctagc catggaccca gacagtgggc aggtcacagc tgtgggcacc 1500
ctcgaccgtg aggatgagca gtttgtgagg aacaacatct atgaagtcat ggtcttggcc 1560
atggacaatg gaagccctcc caccactggc acgggaaccc ttctgctaac actgattgat 1620
gtcaatgacc atggcccagt ccctgagccc cgtcagatca ccatctgcaa ccaaagccct 1680
gtgcgccagg tgctgaacat cacggacaag gacctgtctc cccacacctc ccctttccag 1740
gcccagctca cagatgactc agacatctac tggacggcag aggtcaacga ggaaggtgac 1800
acagtggtct tgtccctgaa gaagttcctg aagcaggata catatgacgt gcacctttct 1860
ctgtctgacc atggcaacaa agagcagctg acggtgatca gggccactgt gtgcgactgc 1920
catggccatg tcgaaacctg ccctggaccc tggaagggag gt 1962
<![CDATA[<210> 5]]>
<![CDATA[<211> 829]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH3]]>
<![CDATA[<400> 5]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Cys Leu Leu Leu Val Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Ile Phe Gly
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Ser
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Lys Pro Ala
50 55 60
Leu Phe Ser Thr Val Asn Asp Asp Phe Thr Val Gln Asn Gly Glu Thr
65 70 75 80
Val Gln Asp Arg Lys Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile His Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Val Phe Asp Pro Gln Lys Tyr Glu Ser His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Val Gly Gly Asp Asp Gly Asp His Phe Thr Ile Ala Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Ala Val Cys Val Tyr Thr Ala
450 455 460
Lys Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Val Ala Gly Thr Leu Asp Arg Glu Asp Glu Arg Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Val Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Glu Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Glu Ser Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Met
580 585 590
Ala Glu Val Asn Glu Lys Asp Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Lys Cys Pro Asp Pro Trp Lys Gly Gly Phe Ile
645 650 655
Leu Pro Val Leu Gly Ala Val Leu Ala Leu Leu Leu Leu Leu Leu Val
660 665 670
Leu Leu Leu Leu Val Arg Lys Lys Arg Lys Val Lys Glu Pro Leu Leu
675 680 685
Leu Pro Glu Asp Asp Thr Arg Asp Asn Val Phe Tyr Tyr Gly Glu Glu
690 695 700
Gly Gly Gly Glu Glu Asp Gln Asp Tyr Asp Ile Thr Gln Leu His Arg
705 710 715 720
Gly Leu Glu Ala Arg Pro Glu Val Val Leu Arg Asn Asp Val Ala Pro
725 730 735
Thr Phe Ile Pro Thr Pro Met Tyr Arg Pro Arg Pro Ala Asn Pro Asp
740 745 750
Glu Ile Gly Asn Phe Ile Ile Glu Asn Leu Lys Ala Ala Asn Thr Asp
755 760 765
Pro Thr Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu Gly
770 775 780
Ser Gly Ser Asp Ala Ala Ser Leu Ser Ser Leu Thr Thr Ser Thr Ser
785 790 795 800
Asp Gln Asp Gln Asp Tyr Asp Tyr Leu Asn Glu Trp Gly Ser Arg Phe
805 810 815
Lys Lys Leu Ala Asp Met Tyr Gly Gly Gly Asp Asp Asp
820 825
<![CDATA[<210> 6]]>
<![CDATA[<211> 2487]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 獼猴CDH3]]>
<![CDATA[<400> 6]]>
atggggctcc ctcgtggacc tctcgcgtgt ctcctcctcg tccaggtttg ctggctgcaa 60
tgcgcggcct ccgagccgtg ccgggcgatc ttcggggagg ctgaagtgac cttggaggcg 120
ggaggcgcgg agcaggagcc cagccaggcc ctggggaaag tattcatggg ctgccctggg 180
caaaagccag ctctgtttag cactgttaat gacgacttca ctgtgcagaa tggcgagaca 240
gtccaggaca gaaagtcact gaaagaaagg aatccattga agatcttccc atccaaacgt 300
atcttacgaa gacacaagag agattgggtg gttgctccaa tatctgtccc tgaaaatggc 360
aagggtccct tcccgcagag gctgaatcag ctcaagtcta ataaagacag agacacgaag 420
attttctaca gcatcacggg gccgggggca gacagccccc ctgagggcgt ctttgctgta 480
gagaaagaga caggctggtt gttgttgaac aagccactgg accgggagga gattgccaag 540
tatgagctct ttggccacgc tgtgtcagag aatggtgcct cagtggagga tcccatgaac 600
atctccatca tcgtgaccga ccagaatgac cacaagccca agtttaccca ggacaccttc 660
cgagggagtg tcttagaggg agtcctacca ggtacttctg tgatgcaggt gacggccaca 720
gatgaggatg atgccatcca cacctacaat ggggtggttg cgtactccat ccatagccaa 780
gaaccaaagg atccacacga cctgatgttt accattcacc ggagcacagg caccatcagc 840
gtcatctcca gcggcctgga ccgggaaaaa gtccctgagt acacactgac catccaggcc 900
acagacatgg atggggacgg ctccaccacc acggcagtgg cagtagtgga gatcctcgat 960
gccaatgaca atgctcccgt gtttgacccc cagaagtatg agtcccatgt gcctgagaat 1020
gcagtgggcc atgaggtgca gaggctgacg gtcactgatc tggacgcccc caactcacca 1080
gcgtggcgtg ccacctacct catcgtgggc ggtgacgacg gggaccattt taccatcgcc 1140
acccaccctg agagcaacca gggcatcctg acaaccagga agggtttgga ttttgaggcc 1200
aaaaaccagc acaccctgta cgttgaagtg accaacgagg ccccttttgt gctgaagctc 1260
ccaacctcaa cagccaccat agtggtccac gtggaggatg tgaatgaggc acccgtgttt 1320
gtcccgccct ccaaagtcgt tgaggtccag gagggcatcc ccactgggga ggctgtgtgt 1380
gtctacactg caaaagaccc tgacaaggag aatcaaaaga tcagctaccg catcctgaga 1440
gacccagcag ggtggctagc catggaccca gacagtgggc aggtcactgt tgcgggcacc 1500
ctagaccgtg aggatgagcg gtttgtgaga aacaacatct acgaagtcat ggtcttggct 1560
gtggacaatg gaagccctcc caccactggc acgggaaccc tcctgctaac actgattgat 1620
gtcaacgacc atggcccagt ccctgagccc cgtgagatca ccatctgcaa ccaaagccct 1680
gagtcccagg tgctgaacat cacggacaag gacctgtccc cccacacctc ccctttccag 1740
gcccagctca cagacgactc agacatctac tggatggcag aggtcaacga gaaagatgac 1800
acggtggtct tgtccctgaa gaagttcctg aagcaggaca catatgatgt gcacctttct 1860
ctgtctgacc atggcaacaa ggagcagctg acagtgatca gggccaccgt gtgtgactgc 1920
cacggccatg tcgagaaatg ccctgatccc tggaaggggg gtttcatcct ccctgtgctg 1980
ggggctgtcc tggctctgct gctcctcctg ctggtgctgc tcttgttggt gagaaagaag 2040
cggaaggtca aggagcccct cctactccca gaagatgaca cccgtgacaa cgtcttctac 2100
tacggcgaag aggggggtgg cgaagaggac caggactatg acatcaccca gctccaccga 2160
ggtctggagg ccaggccgga ggtggttctc cgcaatgacg tggcaccaac cttcatcccc 2220
acacccatgt accgtcctcg gccagccaac ccagatgaaa tcggcaactt tataatcgag 2280
aacctgaagg cagctaacac ggaccccaca gccccgccct acgactccct tttggtgttc 2340
gactatgagg gcagcggctc cgacgccgcg tccctgagct ccctcaccac ctccacctct 2400
gaccaggacc aagattacga ctatctgaac gagtggggca gccgcttcaa gaagctggca 2460
gacatgtacg gtggcgggga cgacgac 2487
<![CDATA[<210> 7]]>
<![CDATA[<211> 654]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH3 ECD]]>
<![CDATA[<400> 7]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Cys Leu Leu Leu Val Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Ile Phe Gly
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Ser
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Lys Pro Ala
50 55 60
Leu Phe Ser Thr Val Asn Asp Asp Phe Thr Val Gln Asn Gly Glu Thr
65 70 75 80
Val Gln Asp Arg Lys Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile His Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Val Phe Asp Pro Gln Lys Tyr Glu Ser His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Val Gly Gly Asp Asp Gly Asp His Phe Thr Ile Ala Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Ala Val Cys Val Tyr Thr Ala
450 455 460
Lys Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Val Ala Gly Thr Leu Asp Arg Glu Asp Glu Arg Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Val Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Glu Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Glu Ser Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Met
580 585 590
Ala Glu Val Asn Glu Lys Asp Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Lys Cys Pro Asp Pro Trp Lys Gly Gly
645 650
<![CDATA[<210> 8]]>
<![CDATA[<211> 1962]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 獼猴CDH3 ECD]]>
<![CDATA[<400> 8]]>
atggggctcc ctcgtggacc tctcgcgtgt ctcctcctcg tccaggtttg ctggctgcaa 60
tgcgcggcct ccgagccgtg ccgggcgatc ttcggggagg ctgaagtgac cttggaggcg 120
ggaggcgcgg agcaggagcc cagccaggcc ctggggaaag tattcatggg ctgccctggg 180
caaaagccag ctctgtttag cactgttaat gacgacttca ctgtgcagaa tggcgagaca 240
gtccaggaca gaaagtcact gaaagaaagg aatccattga agatcttccc atccaaacgt 300
atcttacgaa gacacaagag agattgggtg gttgctccaa tatctgtccc tgaaaatggc 360
aagggtccct tcccgcagag gctgaatcag ctcaagtcta ataaagacag agacacgaag 420
attttctaca gcatcacggg gccgggggca gacagccccc ctgagggcgt ctttgctgta 480
gagaaagaga caggctggtt gttgttgaac aagccactgg accgggagga gattgccaag 540
tatgagctct ttggccacgc tgtgtcagag aatggtgcct cagtggagga tcccatgaac 600
atctccatca tcgtgaccga ccagaatgac cacaagccca agtttaccca ggacaccttc 660
cgagggagtg tcttagaggg agtcctacca ggtacttctg tgatgcaggt gacggccaca 720
gatgaggatg atgccatcca cacctacaat ggggtggttg cgtactccat ccatagccaa 780
gaaccaaagg atccacacga cctgatgttt accattcacc ggagcacagg caccatcagc 840
gtcatctcca gcggcctgga ccgggaaaaa gtccctgagt acacactgac catccaggcc 900
acagacatgg atggggacgg ctccaccacc acggcagtgg cagtagtgga gatcctcgat 960
gccaatgaca atgctcccgt gtttgacccc cagaagtatg agtcccatgt gcctgagaat 1020
gcagtgggcc atgaggtgca gaggctgacg gtcactgatc tggacgcccc caactcacca 1080
gcgtggcgtg ccacctacct catcgtgggc ggtgacgacg gggaccattt taccatcgcc 1140
acccaccctg agagcaacca gggcatcctg acaaccagga agggtttgga ttttgaggcc 1200
aaaaaccagc acaccctgta cgttgaagtg accaatgagg ccccttttgt gctgaagctc 1260
ccaacctcaa cagccaccat agtggtccac gtggaggatg tgaatgaggc acccgtgttt 1320
gtcccgccct ccaaagtcgt tgaggtccag gagggcatcc ccactgggga ggctgtgtgt 1380
gtctacactg caaaagaccc tgacaaggag aatcaaaaga tcagctaccg catcctgaga 1440
gacccagcag ggtggctagc catggaccca gacagtgggc aggtcactgt tgcgggcacc 1500
ctagaccgtg aggatgagcg gtttgtgaga aacaacatct acgaagtcat ggtcttggct 1560
gtggacaatg gaagccctcc caccactggc acgggaaccc tcctgctaac actgattgat 1620
gtcaacgacc atggcccagt ccctgagccc cgtgagatca ccatctgcaa ccaaagccct 1680
gagtcccagg tgctgaacat cacggacaag gacctgtccc cccacacctc ccctttccag 1740
gcccagctca cagacgactc agacatctac tggatggcag aggtcaacga gaaagatgac 1800
acggtggtct tgtccctgaa gaagttcctg aagcaggaca catatgatgt gcacctttct 1860
ctgtctgacc atggcaacaa ggagcagctg acagtgatca gggccaccgt gtgtgactgc 1920
cacggccatg tcgagaaatg ccctgatccc tggaaggggg gt 1962
<![CDATA[<210> 9]]>
<![CDATA[<211> 822]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 鼠類CDH3]]>
<![CDATA[<400> 9]]>
Met Glu Leu Leu Ser Gly Pro His Ala Phe Leu Leu Leu Leu Leu Gln
1 5 10 15
Val Cys Trp Leu Arg Ser Val Val Ser Glu Pro Tyr Arg Ala Gly Phe
20 25 30
Ile Gly Glu Ala Gly Val Thr Leu Glu Val Glu Gly Thr Asp Leu Glu
35 40 45
Pro Ser Gln Val Leu Gly Lys Val Ala Leu Ala Gly Gln Gly Met His
50 55 60
His Ala Asp Asn Gly Asp Ile Ile Met Leu Thr Arg Gly Thr Val Gln
65 70 75 80
Gly Gly Lys Asp Ala Met His Ser Pro Pro Thr Arg Ile Leu Arg Arg
85 90 95
Arg Lys Arg Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly
100 105 110
Lys Gly Pro Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp
115 120 125
Arg Gly Thr Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser
130 135 140
Pro Pro Glu Gly Val Phe Thr Ile Glu Lys Glu Ser Gly Trp Leu Leu
145 150 155 160
Leu His Met Pro Leu Asp Arg Glu Lys Ile Val Lys Tyr Glu Leu Tyr
165 170 175
Gly His Ala Val Ser Glu Asn Gly Ala Ser Val Glu Glu Pro Met Asn
180 185 190
Ile Ser Ile Ile Val Thr Asp Gln Asn Asp Asn Lys Pro Lys Phe Thr
195 200 205
Gln Asp Thr Phe Arg Gly Ser Val Leu Glu Gly Val Met Pro Gly Thr
210 215 220
Ser Val Met Gln Val Thr Ala Thr Asp Glu Asp Asp Ala Val Asn Thr
225 230 235 240
Tyr Asn Gly Val Val Ala Tyr Ser Ile His Ser Gln Glu Pro Lys Glu
245 250 255
Pro His Asp Leu Met Phe Thr Ile His Lys Ser Thr Gly Thr Ile Ser
260 265 270
Val Ile Ser Ser Gly Leu Asp Arg Glu Lys Val Pro Glu Tyr Arg Leu
275 280 285
Thr Val Gln Ala Thr Asp Met Asp Gly Glu Gly Ser Thr Thr Thr Ala
290 295 300
Glu Ala Val Val Gln Ile Leu Asp Ala Asn Asp Asn Ala Pro Glu Phe
305 310 315 320
Glu Pro Gln Lys Tyr Glu Ala Trp Val Pro Glu Asn Glu Val Gly His
325 330 335
Glu Val Gln Arg Leu Thr Val Thr Asp Leu Asp Val Pro Asn Ser Pro
340 345 350
Ala Trp Arg Ala Thr Tyr His Ile Val Gly Gly Asp Asp Gly Asp His
355 360 365
Phe Thr Ile Thr Thr His Pro Glu Thr Asn Gln Gly Val Leu Thr Thr
370 375 380
Lys Lys Gly Leu Asp Phe Glu Ala Gln Asp Gln His Thr Leu Tyr Val
385 390 395 400
Glu Val Thr Asn Glu Ala Pro Phe Ala Val Lys Leu Pro Thr Ala Thr
405 410 415
Ala Thr Val Val Val His Val Lys Asp Val Asn Glu Ala Pro Val Phe
420 425 430
Val Pro Pro Ser Lys Val Ile Glu Ala Gln Glu Gly Ile Ser Ile Gly
435 440 445
Glu Leu Val Cys Ile Tyr Thr Ala Gln Asp Pro Asp Lys Glu Asp Gln
450 455 460
Lys Ile Ser Tyr Thr Ile Ser Arg Asp Pro Ala Asn Trp Leu Ala Val
465 470 475 480
Asp Pro Asp Ser Gly Gln Ile Thr Ala Ala Gly Ile Leu Asp Arg Glu
485 490 495
Asp Glu Gln Phe Val Lys Asn Asn Val Tyr Glu Val Met Val Leu Ala
500 505 510
Thr Asp Ser Gly Asn Pro Pro Thr Thr Gly Thr Gly Thr Leu Leu Leu
515 520 525
Thr Leu Thr Asp Ile Asn Asp His Gly Pro Ile Pro Glu Pro Arg Gln
530 535 540
Ile Ile Ile Cys Asn Gln Ser Pro Val Pro Gln Val Leu Asn Ile Thr
545 550 555 560
Asp Lys Asp Leu Ser Pro Asn Ser Ser Pro Phe Gln Ala Gln Leu Thr
565 570 575
His Asp Ser Asp Ile Tyr Trp Met Ala Glu Val Ser Glu Lys Gly Asp
580 585 590
Thr Val Ala Leu Ser Leu Lys Lys Phe Leu Lys Gln Asp Thr Tyr Asp
595 600 605
Leu His Leu Ser Leu Ser Asp His Gly Asn Arg Glu Gln Leu Thr Met
610 615 620
Ile Arg Ala Thr Val Cys Asp Cys His Gly Gln Val Phe Asn Asp Cys
625 630 635 640
Pro Arg Pro Trp Lys Gly Gly Phe Ile Leu Pro Ile Leu Gly Ala Val
645 650 655
Leu Ala Leu Leu Thr Leu Leu Leu Ala Leu Leu Leu Leu Val Arg Lys
660 665 670
Lys Arg Lys Val Lys Glu Pro Leu Leu Leu Pro Glu Asp Asp Thr Arg
675 680 685
Asp Asn Val Phe Tyr Tyr Gly Glu Glu Gly Gly Gly Glu Glu Asp Gln
690 695 700
Asp Tyr Asp Ile Thr Gln Leu His Arg Gly Leu Glu Ala Arg Pro Glu
705 710 715 720
Val Val Leu Arg Asn Asp Val Val Pro Thr Phe Ile Pro Thr Pro Met
725 730 735
Tyr Arg Pro Arg Pro Ala Asn Pro Asp Glu Ile Gly Asn Phe Ile Ile
740 745 750
Glu Asn Leu Lys Ala Ala Asn Thr Asp Pro Thr Ala Pro Pro Tyr Asp
755 760 765
Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly Ser Asp Ala Ala Ser
770 775 780
Leu Ser Ser Leu Thr Thr Ser Ala Ser Asp Gln Asp Gln Asp Tyr Asn
785 790 795 800
Tyr Leu Asn Glu Trp Gly Ser Arg Phe Lys Lys Leu Ala Asp Met Tyr
805 810 815
Gly Gly Gly Glu Asp Asp
820
<![CDATA[<210> 10]]>
<![CDATA[<211> 2469]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 鼠類CDH3]]>
<![CDATA[<400> 10]]>
atggagcttc ttagtgggcc tcacgccttc ctgctcctcc tgctccaggt ttgctggcta 60
cgcagcgtgg tctccgagcc ctaccgagcg ggcttcatcg gggaggctgg agtgaccttg 120
gaggtggaag gaactgacct ggagccgagc caagttctgg ggaaagtagc cttggctgga 180
cagggcatgc accatgcaga caatggagac atcattatgc tgactagggg gacagttcag 240
ggagggaagg atgcgatgca ctccccaccc acccgcatct taaggagacg aaagagagag 300
tgggtgatgc caccaatatt cgtccccgag aatggcaagg gtcccttccc tcagaggctg 360
aatcagctca aatctaataa ggacagaggc accaagattt tctacagcat cacagggcct 420
ggcgcagaca gtccccccga aggagtcttc accatagaga aggagtcggg ctggctgttg 480
ttgcatatgc cactggacag ggagaagatt gtcaagtacg agctttatgg ccacgctgta 540
tctgagaatg gtgcctctgt agaggagccc atgaacatat ccatcattgt gacagaccag 600
aatgacaaca agcccaagtt cactcaagac accttcagag ggagtgttct ggagggagta 660
atgcctggca cttctgtgat gcaggtgaca gccacagatg aggacgatgc tgtcaacact 720
tacaatgggg tggtggctta ctccatccat agccaagagc cgaaggagcc acacgacctc 780
atgttcacca tccataaaag cacgggaacc attagcgtca tatccagtgg cctggaccga 840
gagaaagtcc ctgagtacag actgaccgtc caggccacag acatggatgg agagggctct 900
accacgacgg cagaggccgt tgtgcaaatc cttgatgcca acgataacgc tcccgagttt 960
gagccgcaga agtatgaggc ttgggtgcct gagaacgaag tgggccatga ggtacagagg 1020
ctgacagtga ctgatctcga tgtccccaac tcgccagcgt ggcgtgccac ctaccacatc 1080
gtgggaggtg atgatgggga ccatttcacc atcaccactc acccagagac caaccaaggc 1140
gtcctgacaa ccaagaaggg tttggatttt gaggctcagg accaacacac cctgtatgta 1200
gaagtgacca acgaggctcc ctttgcagtg aagctcccga cagccactgc caccgtggtg 1260
gtccatgtga aagatgtcaa cgaagcccct gtgtttgttc caccttccaa ggtcattgag 1320
gcccaggaag gcatctctat tggggaactg gtctgcatct ataccgcaca ggacccagac 1380
aaggaggacc agaagatcag ctacaccatc tcgagagatc cagccaactg gcttgctgtg 1440
gacccagaca gtggtcagat aactgccgca ggcatcttgg atcgtgagga cgagcagttt 1500
gtgaaaaaca atgtctacga agtcatggtt ttggccacag acagtggaaa ccctcccacc 1560
accggcactg ggaccctcct gcttacactt actgacatca acgaccatgg cccgatccct 1620
gaacccaggc agatcatcat ctgtaaccaa agccctgtgc ctcaagtgct gaacatcact 1680
gacaaggacc tgtcccccaa ctcctcccct ttccaggccc agctaacaca tgactcagat 1740
atctactgga tggcagaagt cagcgagaaa ggagacaccg tggccttgtc cctgaagaag 1800
ttcctgaaac aagacacgta tgacttgcat ctttctttgt ctgaccatgg caacagggaa 1860
cagctaacca tgatcagggc cactgtgtgt gactgccatg gccaagtgtt caatgactgc 1920
cccagaccct ggaagggtgg tttcatcctc cccatcctgg gtgctgtcct ggcactgctg 1980
acccttctac tggcactcct cctgttggtg aggaagaaga ggaaggtcaa agagcccctt 2040
ctgctcccag aagatgacac gcgagacaat gtcttctatt atggagaaga gggtggtggt 2100
gaagaggacc aggactatga catcacccaa ctccaccggg gactggaggc caggcctgag 2160
gtggttctcc gaaacgatgt agtgccaacc ttcatcccca cccccatgta ccgaccccgg 2220
cccgccaacc cagatgaaat cgggaacttc atcatcgaga acctgaaggc tgccaacact 2280
gaccctactg ccccgcccta cgactccctg ctggtttttg actacgaggg cagcggctct 2340
gatgccgcct ccctgagctc cctcaccacc tccgcctccg accaggatca ggactacaac 2400
taccttaacg agtggggaag tcgattcaag aaactggcgg acatgtatgg tggcggtgag 2460
gatgactag 2469
<![CDATA[<210> 11]]>
<![CDATA[<211> 548]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 鼠類CDH3 ECD]]>
<![CDATA[<400> 11]]>
Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro
1 5 10 15
Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr
20 25 30
Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
35 40 45
Gly Val Phe Thr Ile Glu Lys Glu Ser Gly Trp Leu Leu Leu His Met
50 55 60
Pro Leu Asp Arg Glu Lys Ile Val Lys Tyr Glu Leu Tyr Gly His Ala
65 70 75 80
Val Ser Glu Asn Gly Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile
85 90 95
Ile Val Thr Asp Gln Asn Asp Asn Lys Pro Lys Phe Thr Gln Asp Thr
100 105 110
Phe Arg Gly Ser Val Leu Glu Gly Val Met Pro Gly Thr Ser Val Met
115 120 125
Gln Val Thr Ala Thr Asp Glu Asp Asp Ala Val Asn Thr Tyr Asn Gly
130 135 140
Val Val Ala Tyr Ser Ile His Ser Gln Glu Pro Lys Glu Pro His Asp
145 150 155 160
Leu Met Phe Thr Ile His Lys Ser Thr Gly Thr Ile Ser Val Ile Ser
165 170 175
Ser Gly Leu Asp Arg Glu Lys Val Pro Glu Tyr Arg Leu Thr Val Gln
180 185 190
Ala Thr Asp Met Asp Gly Glu Gly Ser Thr Thr Thr Ala Glu Ala Val
195 200 205
Val Gln Ile Leu Asp Ala Asn Asp Asn Ala Pro Glu Phe Glu Pro Gln
210 215 220
Lys Tyr Glu Ala Trp Val Pro Glu Asn Glu Val Gly His Glu Val Gln
225 230 235 240
Arg Leu Thr Val Thr Asp Leu Asp Val Pro Asn Ser Pro Ala Trp Arg
245 250 255
Ala Thr Tyr His Ile Val Gly Gly Asp Asp Gly Asp His Phe Thr Ile
260 265 270
Thr Thr His Pro Glu Thr Asn Gln Gly Val Leu Thr Thr Lys Lys Gly
275 280 285
Leu Asp Phe Glu Ala Gln Asp Gln His Thr Leu Tyr Val Glu Val Thr
290 295 300
Asn Glu Ala Pro Phe Ala Val Lys Leu Pro Thr Ala Thr Ala Thr Val
305 310 315 320
Val Val His Val Lys Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro
325 330 335
Ser Lys Val Ile Glu Ala Gln Glu Gly Ile Ser Ile Gly Glu Leu Val
340 345 350
Cys Ile Tyr Thr Ala Gln Asp Pro Asp Lys Glu Asp Gln Lys Ile Ser
355 360 365
Tyr Thr Ile Ser Arg Asp Pro Ala Asn Trp Leu Ala Val Asp Pro Asp
370 375 380
Ser Gly Gln Ile Thr Ala Ala Gly Ile Leu Asp Arg Glu Asp Glu Gln
385 390 395 400
Phe Val Lys Asn Asn Val Tyr Glu Val Met Val Leu Ala Thr Asp Ser
405 410 415
Gly Asn Pro Pro Thr Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Thr
420 425 430
Asp Ile Asn Asp His Gly Pro Ile Pro Glu Pro Arg Gln Ile Ile Ile
435 440 445
Cys Asn Gln Ser Pro Val Pro Gln Val Leu Asn Ile Thr Asp Lys Asp
450 455 460
Leu Ser Pro Asn Ser Ser Pro Phe Gln Ala Gln Leu Thr His Asp Ser
465 470 475 480
Asp Ile Tyr Trp Met Ala Glu Val Ser Glu Lys Gly Asp Thr Val Ala
485 490 495
Leu Ser Leu Lys Lys Phe Leu Lys Gln Asp Thr Tyr Asp Leu His Leu
500 505 510
Ser Leu Ser Asp His Gly Asn Arg Glu Gln Leu Thr Met Ile Arg Ala
515 520 525
Thr Val Cys Asp Cys His Gly Gln Val Phe Asn Asp Cys Pro Arg Pro
530 535 540
Trp Lys Gly Gly
545
<![CDATA[<210> 12]]>
<![CDATA[<211> 1644]]>
<![CDATA[<212> DNA]]>
<![CDATA[<213> 鼠類CDH3 ECD]]>
<![CDATA[<400> 12]]>
gagtgggtga tgccaccaat attcgtcccc gagaatggca agggtccctt ccctcagagg 60
ctgaatcagc tcaaatctaa taaggacaga ggcaccaaga ttttctacag catcacaggg 120
cctggcgcag acagtccccc cgaaggagtc ttcaccatag agaaggagtc gggctggctg 180
ttgttgcata tgccactgga cagggagaag attgtcaagt acgagcttta tggccacgct 240
gtatctgaga atggtgcctc tgtagaggag cccatgaaca tatccatcat tgtgacagac 300
cagaatgaca acaagcccaa gttcactcaa gacaccttca gagggagtgt tctggaggga 360
gtaatgcctg gcacttctgt gatgcaggtg acagccacag atgaggacga tgctgtcaac 420
acttacaatg gggtggtggc ttactccatc catagccaag agccgaagga gccacacgac 480
ctcatgttca ccatccataa aagcacggga accattagcg tcatatccag tggcctggac 540
cgagagaaag tccctgagta cagactgacc gtccaggcca cagacatgga tggagagggc 600
tctaccacga cggcagaggc cgttgtgcaa atccttgatg ccaacgataa cgctcccgag 660
tttgagccgc agaagtatga ggcttgggtg cctgagaacg aagtgggcca tgaggtacag 720
aggctgacag tgactgatct cgatgtcccc aactcgccag cgtggcgtgc cacctaccac 780
atcgtgggag gtgatgatgg ggaccatttc accatcacca ctcacccaga gaccaaccaa 840
ggcgtcctga caaccaagaa gggtttggat tttgaggctc aggaccaaca caccctgtat 900
gtagaagtga ccaacgaggc tccctttgca gtgaagctcc cgacagccac tgccaccgtg 960
gtggtccatg tgaaagatgt caacgaagcc cctgtgtttg ttccaccttc caaggtcatt 1020
gaggcccagg aaggcatctc tattggggaa ctggtctgca tctataccgc acaggaccca 1080
gacaaggagg accagaagat cagctacacc atctcgagag atccagccaa ctggcttgct 1140
gtggacccag acagtggtca gataactgcc gcaggcatct tggatcgtga ggacgagcag 1200
tttgtgaaaa acaatgtcta cgaagtcatg gttttggcca cagacagtgg aaaccctccc 1260
accaccggca ctgggaccct cctgcttaca cttactgaca tcaacgacca tggcccgatc 1320
cctgaaccca ggcagatcat catctgtaac caaagccctg tgcctcaagt gctgaacatc 1380
actgacaagg acctgtcccc caactcctcc cctttccagg cccagctaac acatgactca 1440
gatatctact ggatggcaga agtcagcgag aaaggagaca ccgtggcctt gtccctgaag 1500
aagttcctga aacaagacac gtatgacttg catctttctt tgtctgacca tggcaacagg 1560
gaacagctaa ccatgatcag ggccactgtg tgtgactgcc atggccaagt gttcaatgac 1620
tgccccagac cctggaaggg tggt 1644
<![CDATA[<210> 13]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom1 mu]]>
<![CDATA[<400> 13]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Glu Trp Val Met Pro
100 105 110
Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Thr Ile
145 150 155 160
Glu Lys Glu Ser Gly Trp Leu Leu Leu His Met Pro Leu Asp Arg Glu
165 170 175
Lys Ile Val Lys Tyr Glu Leu Tyr Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp Asn Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 14]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom1A mu]]>
<![CDATA[<400> 14]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Glu Trp Val Met Pro
100 105 110
Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 15]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom1B mu]]>
<![CDATA[<400> 15]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Thr Ile
145 150 155 160
Glu Lys Glu Ser Gly Trp Leu Leu Leu His Met Pro Leu Asp Arg Glu
165 170 175
Lys Ile Val Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 16]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom1C mu]]>
<![CDATA[<400> 16]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Tyr Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp Asn Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 17]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom2 mu]]>
<![CDATA[<400> 17]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Met Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Val Asn Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Glu Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Lys Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Arg Leu Thr Val Gln Ala Thr Asp Met Asp
290 295 300
Gly Glu Gly Ser Thr Thr Thr Ala Glu Ala Val Val Gln Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Glu Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 18]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom2A mu]]>
<![CDATA[<400> 18]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Met Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Val Asn Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 19]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom2B mu]]>
<![CDATA[<400> 19]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Glu Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Lys Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 20]]>
<![CDATA[<211> ]]> 710
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom2C mu]]>
<![CDATA[<400> 20]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Arg Leu Thr Val Gln Ala Thr Asp Met Asp
290 295 300
Gly Glu Gly Ser Thr Thr Thr Ala Glu Ala Val Val Gln Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Glu Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 21]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom3 mu]]>
<![CDATA[<400> 21]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Glu Pro Gln Lys Tyr Glu Ala Trp
325 330 335
Val Pro Glu Asn Glu Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Val Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr His Ile
355 360 365
Val Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Thr Asn Gln Gly Val Leu Thr Thr Lys Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Gln Asp Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Ala Val Lys Leu Pro Thr Ala Thr Ala Thr Val Val Val His Val Lys
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 22]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom3A mu]]>
<![CDATA[<400> 22]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Glu Pro Gln Lys Tyr Glu Ala Trp
325 330 335
Val Pro Glu Asn Glu Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Val Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> ]]>23
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom3B mu]]>
<![CDATA[<400> 23]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr His Ile
355 360 365
Val Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Thr Asn Gln Gly Val Leu Thr Thr Lys Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Gln Asp Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 24]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom3C mu]]>
<![CDATA[<400> 24]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Ala Val Lys Leu Pro Thr Ala Thr Ala Thr Val Val Val His Val Lys
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 25]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom4 mu]]>
<![CDATA[<400> 25]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Ile Glu
435 440 445
Ala Gln Glu Gly Ile Ser Ile Gly Glu Leu Val Cys Ile Tyr Thr Ala
450 455 460
Gln Asp Pro Asp Lys Glu Asp Gln Lys Ile Ser Tyr Thr Ile Ser Arg
465 470 475 480
Asp Pro Ala Asn Trp Leu Ala Val Asp Pro Asp Ser Gly Gln Ile Thr
485 490 495
Ala Ala Gly Ile Leu Asp Arg Glu Asp Glu Gln Phe Val Lys Asn Asn
500 505 510
Val Tyr Glu Val Met Val Leu Ala Thr Asp Ser Gly Asn Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Thr Asp Ile Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 26]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom4A mu]]>
<![CDATA[<400> 26]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Ile Glu
435 440 445
Ala Gln Glu Gly Ile Ser Ile Gly Glu Leu Val Cys Ile Tyr Thr Ala
450 455 460
Gln Asp Pro Asp Lys Glu Asp Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 27]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom4B mu]]>
<![CDATA[<400> 27]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Thr Ile Ser Arg
465 470 475 480
Asp Pro Ala Asn Trp Leu Ala Val Asp Pro Asp Ser Gly Gln Ile Thr
485 490 495
Ala Ala Gly Ile Leu Asp Arg Glu Asp Glu Gln Phe Val Lys Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 28]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom4C mu]]>
<![CDATA[<400> 28]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Val Tyr Glu Val Met Val Leu Ala Thr Asp Ser Gly Asn Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Thr Asp Ile Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 29]]>
<![CDATA[<211> 711]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom5 mu]]>
<![CDATA[<400> 29]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Ile Pro Glu Pro Arg Gln Ile Ile Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Pro Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro Asn Ser
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr His Asp Ser Asp Ile Tyr Trp Met
580 585 590
Ala Glu Val Ser Glu Lys Gly Asp Thr Val Ala Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Leu His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Arg Glu Gln Leu Thr Met Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly Gln Val Phe Asn Asp Cys Pro Arg Pro Trp Lys Gly Gly Ser
645 650 655
Gly Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val
660 665 670
Val Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys
675 680 685
Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu
690 695 700
Met His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 30]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom5A mu]]>
<![CDATA[<400> 30]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Ile Pro Glu Pro Arg Gln Ile Ile Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Pro Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro Asn Ser
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 31]]>
<![CDATA[<211> 710]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom5B mu]]>
<![CDATA[<400> 31]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr His Asp Ser Asp Ile Tyr Trp Met
580 585 590
Ala Glu Val Ser Glu Lys Gly Asp Thr Val Ala Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Val His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Lys Glu Gln Leu Thr Val Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly His Val Glu Thr Cys Pro Gly Pro Trp Lys Gly Gly Ser Gly
645 650 655
Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val
660 665 670
Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
675 680 685
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
690 695 700
His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 32]]>
<![CDATA[<211> 711]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Hu CDH3 Dom5C mu]]>
<![CDATA[<400> 32]]>
Met Gly Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu Leu Leu Gln Val
1 5 10 15
Cys Trp Leu Gln Cys Ala Ala Ser Glu Pro Cys Arg Ala Val Phe Arg
20 25 30
Glu Ala Glu Val Thr Leu Glu Ala Gly Gly Ala Glu Gln Glu Pro Gly
35 40 45
Gln Ala Leu Gly Lys Val Phe Met Gly Cys Pro Gly Gln Glu Pro Ala
50 55 60
Leu Phe Ser Thr Asp Asn Asp Asp Phe Thr Val Arg Asn Gly Glu Thr
65 70 75 80
Val Gln Glu Arg Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
85 90 95
Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
100 105 110
Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
115 120 125
Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
130 135 140
Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
145 150 155 160
Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg Glu
165 170 175
Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala Val Ser Glu Asn Gly
180 185 190
Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile Ile Val Thr Asp Gln
195 200 205
Asn Asp His Lys Pro Lys Phe Thr Gln Asp Thr Phe Arg Gly Ser Val
210 215 220
Leu Glu Gly Val Leu Pro Gly Thr Ser Val Met Gln Val Thr Ala Thr
225 230 235 240
Asp Glu Asp Asp Ala Ile Tyr Thr Tyr Asn Gly Val Val Ala Tyr Ser
245 250 255
Ile His Ser Gln Glu Pro Lys Asp Pro His Asp Leu Met Phe Thr Ile
260 265 270
His Arg Ser Thr Gly Thr Ile Ser Val Ile Ser Ser Gly Leu Asp Arg
275 280 285
Glu Lys Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp
290 295 300
Gly Asp Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp
305 310 315 320
Ala Asn Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His
325 330 335
Val Pro Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr
340 345 350
Asp Leu Asp Ala Pro Asn Ser Pro Ala Trp Arg Ala Thr Tyr Leu Ile
355 360 365
Met Gly Gly Asp Asp Gly Asp His Phe Thr Ile Thr Thr His Pro Glu
370 375 380
Ser Asn Gln Gly Ile Leu Thr Thr Arg Lys Gly Leu Asp Phe Glu Ala
385 390 395 400
Lys Asn Gln His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe
405 410 415
Val Leu Lys Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu
420 425 430
Asp Val Asn Glu Ala Pro Val Phe Val Pro Pro Ser Lys Val Val Glu
435 440 445
Val Gln Glu Gly Ile Pro Thr Gly Glu Pro Val Cys Val Tyr Thr Ala
450 455 460
Glu Asp Pro Asp Lys Glu Asn Gln Lys Ile Ser Tyr Arg Ile Leu Arg
465 470 475 480
Asp Pro Ala Gly Trp Leu Ala Met Asp Pro Asp Ser Gly Gln Val Thr
485 490 495
Ala Val Gly Thr Leu Asp Arg Glu Asp Glu Gln Phe Val Arg Asn Asn
500 505 510
Ile Tyr Glu Val Met Val Leu Ala Met Asp Asn Gly Ser Pro Pro Thr
515 520 525
Thr Gly Thr Gly Thr Leu Leu Leu Thr Leu Ile Asp Val Asn Asp His
530 535 540
Gly Pro Val Pro Glu Pro Arg Gln Ile Thr Ile Cys Asn Gln Ser Pro
545 550 555 560
Val Arg Gln Val Leu Asn Ile Thr Asp Lys Asp Leu Ser Pro His Thr
565 570 575
Ser Pro Phe Gln Ala Gln Leu Thr Asp Asp Ser Asp Ile Tyr Trp Thr
580 585 590
Ala Glu Val Asn Glu Glu Gly Asp Thr Val Val Leu Ser Leu Lys Lys
595 600 605
Phe Leu Lys Gln Asp Thr Tyr Asp Leu His Leu Ser Leu Ser Asp His
610 615 620
Gly Asn Arg Glu Gln Leu Thr Met Ile Arg Ala Thr Val Cys Asp Cys
625 630 635 640
His Gly Gln Val Phe Asn Asp Cys Pro Arg Pro Trp Lys Gly Gly Ser
645 650 655
Gly Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val
660 665 670
Val Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys
675 680 685
Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu
690 695 700
Met His Arg Glu Leu Asn Ala
705 710
<![CDATA[<210> 33]]>
<![CDATA[<211> 36]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類表位簇D1B]]>
<![CDATA[<400> 33]]>
Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala
1 5 10 15
Val Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg
20 25 30
Glu Glu Ile Ala
35
<![CDATA[<210> 34]]>
<![CDATA[<211> 37]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類表位簇D2C]]>
<![CDATA[<400> 34]]>
Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp Gly Asp
1 5 10 15
Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp Ala Asn
20 25 30
Asp Asn Ala Pro Met
35
<![CDATA[<210> 35]]>
<![CDATA[<211> 36]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類表位簇D3A]]>
<![CDATA[<400> 35]]>
Phe Asp Pro Gln Lys Tyr Glu Ala His Val Pro Glu Asn Ala Val Gly
1 5 10 15
His Glu Val Gln Arg Leu Thr Val Thr Asp Leu Asp Ala Pro Asn Ser
20 25 30
Pro Ala Trp Arg
35
<![CDATA[<210> 36]]>
<![CDATA[<211> 73]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類表位簇D2C+D3A]]>
<![CDATA[<400> 36]]>
Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp Gly Asp
1 5 10 15
Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp Ala Asn
20 25 30
Asp Asn Ala Pro Met Phe Asp Pro Gln Lys Tyr Glu Ala His Val Pro
35 40 45
Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr Asp Leu
50 55 60
Asp Ala Pro Asn Ser Pro Ala Trp Arg
65 70
<![CDATA[<210> 37]]>
<![CDATA[<211> 36]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴表位簇D1B]]>
<![CDATA[<400> 37]]>
Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala
1 5 10 15
Val Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys Pro Leu Asp Arg
20 25 30
Glu Glu Ile Ala
35
<![CDATA[<210> 38]]>
<![CDATA[<211> 37]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴表位簇D2C]]>
<![CDATA[<400> 38]]>
Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp Gly Asp
1 5 10 15
Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp Ala Asn
20 25 30
Asp Asn Ala Pro Val
35
<![CDATA[<210> 39]]>
<![CDATA[<211> 36]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴表位簇D3A]]>
<![CDATA[<400> 39]]>
Phe Asp Pro Gln Lys Tyr Glu Ser His Val Pro Glu Asn Ala Val Gly
1 5 10 15
His Glu Val Gln Arg Leu Thr Val Thr Asp Leu Asp Ala Pro Asn Ser
20 25 30
Pro Ala Trp Arg
35
<![CDATA[<210> 40]]>
<![CDATA[<211> 73]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴表位簇D2C+D3A]]>
<![CDATA[<400> 40]]>
Val Pro Glu Tyr Thr Leu Thr Ile Gln Ala Thr Asp Met Asp Gly Asp
1 5 10 15
Gly Ser Thr Thr Thr Ala Val Ala Val Val Glu Ile Leu Asp Ala Asn
20 25 30
Asp Asn Ala Pro Val Phe Asp Pro Gln Lys Tyr Glu Ser His Val Pro
35 40 45
Glu Asn Ala Val Gly His Glu Val Gln Arg Leu Thr Val Thr Asp Leu
50 55 60
Asp Ala Pro Asn Ser Pro Ala Trp Arg
65 70
<![CDATA[<210> 41]]>
<![CDATA[<211> 882]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH1]]>
<![CDATA[<400> 41]]>
Met Gly Pro Trp Ser Arg Ser Leu Ser Ala Leu Leu Leu Leu Leu Gln
1 5 10 15
Val Ser Ser Trp Leu Cys Gln Glu Pro Glu Pro Cys His Pro Gly Phe
20 25 30
Asp Ala Glu Ser Tyr Thr Phe Thr Val Pro Arg Arg His Leu Glu Arg
35 40 45
Gly Arg Val Leu Gly Arg Val Asn Phe Glu Asp Cys Thr Gly Arg Gln
50 55 60
Arg Thr Ala Tyr Phe Ser Leu Asp Thr Arg Phe Lys Val Gly Thr Asp
65 70 75 80
Gly Val Ile Thr Val Lys Arg Pro Leu Arg Phe His Asn Pro Gln Ile
85 90 95
His Phe Leu Val Tyr Ala Trp Asp Ser Thr Tyr Arg Lys Phe Ser Thr
100 105 110
Lys Val Thr Leu Asn Thr Val Gly His His His Arg Pro Pro Pro His
115 120 125
Gln Ala Ser Val Ser Gly Ile Gln Ala Glu Leu Leu Thr Phe Pro Asn
130 135 140
Ser Ser Pro Gly Leu Arg Arg Gln Lys Arg Asp Trp Val Ile Pro Pro
145 150 155 160
Ile Ser Cys Pro Glu Asn Glu Lys Gly Pro Phe Pro Lys Asn Leu Val
165 170 175
Gln Ile Lys Ser Asn Lys Asp Lys Glu Gly Lys Val Phe Tyr Ser Ile
180 185 190
Thr Gly Gln Gly Ala Asp Thr Pro Pro Val Gly Val Phe Ile Ile Glu
195 200 205
Arg Glu Thr Gly Trp Leu Lys Val Thr Glu Pro Leu Asp Arg Glu Arg
210 215 220
Ile Ala Thr Tyr Thr Leu Phe Ser His Ala Val Ser Ser Asn Gly Asn
225 230 235 240
Ala Val Glu Asp Pro Met Glu Ile Leu Ile Thr Val Thr Asp Gln Asn
245 250 255
Asp Asn Lys Pro Glu Phe Thr Gln Glu Val Phe Lys Gly Ser Val Met
260 265 270
Glu Gly Ala Leu Pro Gly Thr Ser Val Met Glu Val Thr Ala Thr Asp
275 280 285
Ala Asp Asp Asp Val Asn Thr Tyr Asn Ala Ala Ile Ala Tyr Thr Ile
290 295 300
Leu Ser Gln Asp Pro Glu Leu Pro Asp Lys Asn Met Phe Thr Ile Asn
305 310 315 320
Arg Asn Thr Gly Val Ile Ser Val Val Thr Thr Gly Leu Asp Arg Glu
325 330 335
Ser Phe Pro Thr Tyr Thr Leu Val Val Gln Ala Ala Asp Leu Gln Gly
340 345 350
Glu Gly Leu Ser Thr Thr Ala Thr Ala Val Ile Thr Val Thr Asp Thr
355 360 365
Asn Asp Asn Pro Pro Ile Phe Asn Pro Thr Thr Tyr Lys Gly Gln Val
370 375 380
Pro Glu Asn Glu Ala Asn Val Val Ile Thr Thr Leu Lys Val Thr Asp
385 390 395 400
Ala Asp Ala Pro Asn Thr Pro Ala Trp Glu Ala Val Tyr Thr Ile Leu
405 410 415
Asn Asp Asp Gly Gly Gln Phe Val Val Thr Thr Asn Pro Val Asn Asn
420 425 430
Asp Gly Ile Leu Lys Thr Ala Lys Gly Leu Asp Phe Glu Ala Lys Gln
435 440 445
Gln Tyr Ile Leu His Val Ala Val Thr Asn Val Val Pro Phe Glu Val
450 455 460
Ser Leu Thr Thr Ser Thr Ala Thr Val Thr Val Asp Val Leu Asp Val
465 470 475 480
Asn Glu Ala Pro Ile Phe Val Pro Pro Glu Lys Arg Val Glu Val Ser
485 490 495
Glu Asp Phe Gly Val Gly Gln Glu Ile Thr Ser Tyr Thr Ala Gln Glu
500 505 510
Pro Asp Thr Phe Met Glu Gln Lys Ile Thr Tyr Arg Ile Trp Arg Asp
515 520 525
Thr Ala Asn Trp Leu Glu Ile Asn Pro Asp Thr Gly Ala Ile Ser Thr
530 535 540
Arg Ala Glu Leu Asp Arg Glu Asp Phe Glu His Val Lys Asn Ser Thr
545 550 555 560
Tyr Thr Ala Leu Ile Ile Ala Thr Asp Asn Gly Ser Pro Val Ala Thr
565 570 575
Gly Thr Gly Thr Leu Leu Leu Ile Leu Ser Asp Val Asn Asp Asn Ala
580 585 590
Pro Ile Pro Glu Pro Arg Thr Ile Phe Phe Cys Glu Arg Asn Pro Lys
595 600 605
Pro Gln Val Ile Asn Ile Ile Asp Ala Asp Leu Pro Pro Asn Thr Ser
610 615 620
Pro Phe Thr Ala Glu Leu Thr His Gly Ala Ser Ala Asn Trp Thr Ile
625 630 635 640
Gln Tyr Asn Asp Pro Thr Gln Glu Ser Ile Ile Leu Lys Pro Lys Met
645 650 655
Ala Leu Glu Val Gly Asp Tyr Lys Ile Asn Leu Lys Leu Met Asp Asn
660 665 670
Gln Asn Lys Asp Gln Val Thr Thr Leu Glu Val Ser Val Cys Asp Cys
675 680 685
Glu Gly Ala Ala Gly Val Cys Arg Lys Ala Gln Pro Val Glu Ala Gly
690 695 700
Leu Gln Ile Pro Ala Ile Leu Gly Ile Leu Gly Gly Ile Leu Ala Leu
705 710 715 720
Leu Ile Leu Ile Leu Leu Leu Leu Leu Phe Leu Arg Arg Arg Ala Val
725 730 735
Val Lys Glu Pro Leu Leu Pro Pro Glu Asp Asp Thr Arg Asp Asn Val
740 745 750
Tyr Tyr Tyr Asp Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Phe Asp
755 760 765
Leu Ser Gln Leu His Arg Gly Leu Asp Ala Arg Pro Glu Val Thr Arg
770 775 780
Asn Asp Val Ala Pro Thr Leu Met Ser Val Pro Arg Tyr Leu Pro Arg
785 790 795 800
Pro Ala Asn Pro Asp Glu Ile Gly Asn Phe Ile Asp Glu Asn Leu Lys
805 810 815
Ala Ala Asp Thr Asp Pro Thr Ala Pro Pro Tyr Asp Ser Leu Leu Val
820 825 830
Phe Asp Tyr Glu Gly Ser Gly Ser Glu Ala Ala Ser Leu Ser Ser Leu
835 840 845
Asn Ser Ser Glu Ser Asp Lys Asp Gln Asp Tyr Asp Tyr Leu Asn Glu
850 855 860
Trp Gly Asn Arg Phe Lys Lys Leu Ala Asp Met Tyr Gly Gly Gly Glu
865 870 875 880
Asp Asp
<![CDATA[<210> 42]]>
<![CDATA[<211> 906]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH2]]>
<![CDATA[<400> 42]]>
Met Cys Arg Ile Ala Gly Ala Leu Arg Thr Leu Leu Pro Leu Leu Ala
1 5 10 15
Ala Leu Leu Gln Ala Ser Val Glu Ala Ser Gly Glu Ile Ala Leu Cys
20 25 30
Lys Thr Gly Phe Pro Glu Asp Val Tyr Ser Ala Val Leu Ser Lys Asp
35 40 45
Val His Glu Gly Gln Pro Leu Leu Asn Val Lys Phe Ser Asn Cys Asn
50 55 60
Gly Lys Arg Lys Val Gln Tyr Glu Ser Ser Glu Pro Ala Asp Phe Lys
65 70 75 80
Val Asp Glu Asp Gly Met Val Tyr Ala Val Arg Ser Phe Pro Leu Ser
85 90 95
Ser Glu His Ala Lys Phe Leu Ile Tyr Ala Gln Asp Lys Glu Thr Gln
100 105 110
Glu Lys Trp Gln Val Ala Val Lys Leu Ser Leu Lys Pro Thr Leu Thr
115 120 125
Glu Glu Ser Val Lys Glu Ser Ala Glu Val Glu Glu Ile Val Phe Pro
130 135 140
Arg Gln Phe Ser Lys His Ser Gly His Leu Gln Arg Gln Lys Arg Asp
145 150 155 160
Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro Phe
165 170 175
Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu Ser
180 185 190
Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr Gly
195 200 205
Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys Pro
210 215 220
Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala Val
225 230 235 240
Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile Asn
245 250 255
Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe Leu His Gln Val Trp
260 265 270
Asn Gly Thr Val Pro Glu Gly Ser Lys Pro Gly Thr Tyr Val Met Thr
275 280 285
Val Thr Ala Ile Asp Ala Asp Asp Pro Asn Ala Leu Asn Gly Met Leu
290 295 300
Arg Tyr Arg Ile Val Ser Gln Ala Pro Ser Thr Pro Ser Pro Asn Met
305 310 315 320
Phe Thr Ile Asn Asn Glu Thr Gly Asp Ile Ile Thr Val Ala Ala Gly
325 330 335
Leu Asp Arg Glu Lys Val Gln Gln Tyr Thr Leu Ile Ile Gln Ala Thr
340 345 350
Asp Met Glu Gly Asn Pro Thr Tyr Gly Leu Ser Asn Thr Ala Thr Ala
355 360 365
Val Ile Thr Val Thr Asp Val Asn Asp Asn Pro Pro Glu Phe Thr Ala
370 375 380
Met Thr Phe Tyr Gly Glu Val Pro Glu Asn Arg Val Asp Ile Ile Val
385 390 395 400
Ala Asn Leu Thr Val Thr Asp Lys Asp Gln Pro His Thr Pro Ala Trp
405 410 415
Asn Ala Val Tyr Arg Ile Ser Gly Gly Asp Pro Thr Gly Arg Phe Ala
420 425 430
Ile Gln Thr Asp Pro Asn Ser Asn Asp Gly Leu Val Thr Val Val Lys
435 440 445
Pro Ile Asp Phe Glu Thr Asn Arg Met Phe Val Leu Thr Val Ala Ala
450 455 460
Glu Asn Gln Val Pro Leu Ala Lys Gly Ile Gln His Pro Pro Gln Ser
465 470 475 480
Thr Ala Thr Val Ser Val Thr Val Ile Asp Val Asn Glu Asn Pro Tyr
485 490 495
Phe Ala Pro Asn Pro Lys Ile Ile Arg Gln Glu Glu Gly Leu His Ala
500 505 510
Gly Thr Met Leu Thr Thr Phe Thr Ala Gln Asp Pro Asp Arg Tyr Met
515 520 525
Gln Gln Asn Ile Arg Tyr Thr Lys Leu Ser Asp Pro Ala Asn Trp Leu
530 535 540
Lys Ile Asp Pro Val Asn Gly Gln Ile Thr Thr Ile Ala Val Leu Asp
545 550 555 560
Arg Glu Ser Pro Asn Val Lys Asn Asn Ile Tyr Asn Ala Thr Phe Leu
565 570 575
Ala Ser Asp Asn Gly Ile Pro Pro Met Ser Gly Thr Gly Thr Leu Gln
580 585 590
Ile Tyr Leu Leu Asp Ile Asn Asp Asn Ala Pro Gln Val Leu Pro Gln
595 600 605
Glu Ala Glu Thr Cys Glu Thr Pro Asp Pro Asn Ser Ile Asn Ile Thr
610 615 620
Ala Leu Asp Tyr Asp Ile Asp Pro Asn Ala Gly Pro Phe Ala Phe Asp
625 630 635 640
Leu Pro Leu Ser Pro Val Thr Ile Lys Arg Asn Trp Thr Ile Thr Arg
645 650 655
Leu Asn Gly Asp Phe Ala Gln Leu Asn Leu Lys Ile Lys Phe Leu Glu
660 665 670
Ala Gly Ile Tyr Glu Val Pro Ile Ile Ile Thr Asp Ser Gly Asn Pro
675 680 685
Pro Lys Ser Asn Ile Ser Ile Leu Arg Val Lys Val Cys Gln Cys Asp
690 695 700
Ser Asn Gly Asp Cys Thr Asp Val Asp Arg Ile Val Gly Ala Gly Leu
705 710 715 720
Gly Thr Gly Ala Ile Ile Ala Ile Leu Leu Cys Ile Ile Ile Leu Leu
725 730 735
Ile Leu Val Leu Met Phe Val Val Trp Met Lys Arg Arg Asp Lys Glu
740 745 750
Arg Gln Ala Lys Gln Leu Leu Ile Asp Pro Glu Asp Asp Val Arg Asp
755 760 765
Asn Ile Leu Lys Tyr Asp Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp
770 775 780
Tyr Asp Leu Ser Gln Leu Gln Gln Pro Asp Thr Val Glu Pro Asp Ala
785 790 795 800
Ile Lys Pro Val Gly Ile Arg Arg Met Asp Glu Arg Pro Ile His Ala
805 810 815
Glu Pro Gln Tyr Pro Val Arg Ser Ala Ala Pro His Pro Gly Asp Ile
820 825 830
Gly Asp Phe Ile Asn Glu Gly Leu Lys Ala Ala Asp Asn Asp Pro Thr
835 840 845
Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly
850 855 860
Ser Thr Ala Gly Ser Leu Ser Ser Leu Asn Ser Ser Ser Ser Gly Gly
865 870 875 880
Glu Gln Asp Tyr Asp Tyr Leu Asn Asp Trp Gly Pro Arg Phe Lys Lys
885 890 895
Leu Ala Asp Met Tyr Gly Gly Gly Asp Asp
900 905
<![CDATA[<210> 43]]>
<![CDATA[<211> 916]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH4]]>
<![CDATA[<400> 43]]>
Met Thr Ala Gly Ala Gly Val Leu Leu Leu Leu Leu Ser Leu Ser Gly
1 5 10 15
Ala Leu Arg Ala His Asn Glu Asp Leu Thr Thr Arg Glu Thr Cys Lys
20 25 30
Ala Gly Phe Ser Glu Asp Asp Tyr Thr Ala Leu Ile Ser Gln Asn Ile
35 40 45
Leu Glu Gly Glu Lys Leu Leu Gln Val Lys Phe Ser Ser Cys Val Gly
50 55 60
Thr Lys Gly Thr Gln Tyr Glu Thr Asn Ser Met Asp Phe Lys Val Gly
65 70 75 80
Ala Asp Gly Thr Val Phe Ala Thr Arg Glu Leu Gln Val Pro Ser Glu
85 90 95
Gln Val Ala Phe Thr Val Thr Ala Trp Asp Ser Gln Thr Ala Glu Lys
100 105 110
Trp Asp Ala Val Val Arg Leu Leu Val Ala Gln Thr Ser Ser Pro His
115 120 125
Ser Gly His Lys Pro Gln Lys Gly Lys Lys Val Val Ala Leu Asp Pro
130 135 140
Ser Pro Pro Pro Lys Asp Thr Leu Leu Pro Trp Pro Gln His Gln Asn
145 150 155 160
Ala Asn Gly Leu Arg Arg Arg Lys Arg Asp Trp Val Ile Pro Pro Ile
165 170 175
Asn Val Pro Glu Asn Ser Arg Gly Pro Phe Pro Gln Gln Leu Val Arg
180 185 190
Ile Arg Ser Asp Lys Asp Asn Asp Ile Pro Ile Arg Tyr Ser Ile Thr
195 200 205
Gly Val Gly Ala Asp Gln Pro Pro Met Glu Val Phe Ser Ile Asp Ser
210 215 220
Met Ser Gly Arg Met Tyr Val Thr Arg Pro Met Asp Arg Glu Glu His
225 230 235 240
Ala Ser Tyr His Leu Arg Ala His Ala Val Asp Met Asn Gly Asn Lys
245 250 255
Val Glu Asn Pro Ile Asp Leu Tyr Ile Tyr Val Ile Asp Met Asn Asp
260 265 270
Asn Arg Pro Glu Phe Ile Asn Gln Val Tyr Asn Gly Ser Val Asp Glu
275 280 285
Gly Ser Lys Pro Gly Thr Tyr Val Met Thr Val Thr Ala Asn Asp Ala
290 295 300
Asp Asp Ser Thr Thr Ala Asn Gly Met Val Arg Tyr Arg Ile Val Thr
305 310 315 320
Gln Thr Pro Gln Ser Pro Ser Gln Asn Met Phe Thr Ile Asn Ser Glu
325 330 335
Thr Gly Asp Ile Val Thr Val Ala Ala Gly Leu Asp Arg Glu Lys Val
340 345 350
Gln Gln Tyr Thr Val Ile Val Gln Ala Thr Asp Met Glu Gly Asn Leu
355 360 365
Asn Tyr Gly Leu Ser Asn Thr Ala Thr Ala Ile Ile Thr Val Thr Asp
370 375 380
Val Asn Asp Asn Pro Pro Glu Phe Thr Ala Ser Thr Phe Ala Gly Glu
385 390 395 400
Val Pro Glu Asn Arg Val Glu Thr Val Val Ala Asn Leu Thr Val Met
405 410 415
Asp Arg Asp Gln Pro His Ser Pro Asn Trp Asn Ala Val Tyr Arg Ile
420 425 430
Ile Ser Gly Asp Pro Ser Gly His Phe Ser Val Arg Thr Asp Pro Val
435 440 445
Thr Asn Glu Gly Met Val Thr Val Val Lys Ala Val Asp Tyr Glu Leu
450 455 460
Asn Arg Ala Phe Met Leu Thr Val Met Val Ser Asn Gln Ala Pro Leu
465 470 475 480
Ala Ser Gly Ile Gln Met Ser Phe Gln Ser Thr Ala Gly Val Thr Ile
485 490 495
Ser Ile Met Asp Ile Asn Glu Ala Pro Tyr Phe Pro Ser Asn His Lys
500 505 510
Leu Ile Arg Leu Glu Glu Gly Val Pro Pro Gly Thr Val Leu Thr Thr
515 520 525
Phe Ser Ala Val Asp Pro Asp Arg Phe Met Gln Gln Ala Val Arg Tyr
530 535 540
Ser Lys Leu Ser Asp Pro Ala Ser Trp Leu His Ile Asn Ala Thr Asn
545 550 555 560
Gly Gln Ile Thr Thr Ala Ala Val Leu Asp Arg Glu Ser Leu Tyr Thr
565 570 575
Lys Asn Asn Val Tyr Glu Ala Thr Phe Leu Ala Ala Asp Asn Gly Ile
580 585 590
Pro Pro Ala Ser Gly Thr Gly Thr Leu Gln Ile Tyr Leu Ile Asp Ile
595 600 605
Asn Asp Asn Ala Pro Glu Leu Leu Pro Lys Glu Ala Gln Ile Cys Glu
610 615 620
Lys Pro Asn Leu Asn Ala Ile Asn Ile Thr Ala Ala Asp Ala Asp Val
625 630 635 640
Asp Pro Asn Ile Gly Pro Tyr Val Phe Glu Leu Pro Phe Val Pro Ala
645 650 655
Ala Val Arg Lys Asn Trp Thr Ile Thr Arg Leu Asn Gly Asp Tyr Ala
660 665 670
Gln Leu Ser Leu Arg Ile Leu Tyr Leu Glu Ala Gly Met Tyr Asp Val
675 680 685
Pro Ile Ile Val Thr Asp Ser Gly Asn Pro Pro Leu Ser Asn Thr Ser
690 695 700
Ile Ile Lys Val Lys Val Cys Pro Cys Asp Asp Asn Gly Asp Cys Thr
705 710 715 720
Thr Ile Gly Ala Val Ala Ala Ala Gly Leu Gly Thr Gly Ala Ile Val
725 730 735
Ala Ile Leu Ile Cys Ile Leu Ile Leu Leu Thr Met Val Leu Leu Phe
740 745 750
Val Met Trp Met Lys Arg Arg Glu Lys Glu Arg His Thr Lys Gln Leu
755 760 765
Leu Ile Asp Pro Glu Asp Asp Val Arg Asp Asn Ile Leu Lys Tyr Asp
770 775 780
Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Tyr Asp Leu Ser Gln Leu
785 790 795 800
Gln Gln Pro Glu Ala Met Gly His Val Pro Ser Lys Ala Pro Gly Val
805 810 815
Arg Arg Val Asp Glu Arg Pro Val Gly Ala Glu Pro Gln Tyr Pro Ile
820 825 830
Arg Pro Met Val Pro His Pro Gly Asp Ile Gly Asp Phe Ile Asn Glu
835 840 845
Gly Leu Arg Ala Ala Asp Asn Asp Pro Thr Ala Pro Pro Tyr Asp Ser
850 855 860
Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly Ser Thr Ala Gly Ser Val
865 870 875 880
Ser Ser Leu Asn Ser Ser Ser Ser Gly Asp Gln Asp Tyr Asp Tyr Leu
885 890 895
Asn Asp Trp Gly Pro Arg Phe Lys Lys Leu Ala Asp Met Tyr Gly Gly
900 905 910
Gly Glu Glu Asp
915
<![CDATA[<210> 44]]>
<![CDATA[<211> 784]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類CDH5]]>
<![CDATA[<400> 44]]>
Met Gln Arg Leu Met Met Leu Leu Ala Thr Ser Gly Ala Cys Leu Gly
1 5 10 15
Leu Leu Ala Val Ala Ala Val Ala Ala Ala Gly Ala Asn Pro Ala Gln
20 25 30
Arg Asp Thr His Ser Leu Leu Pro Thr His Arg Arg Gln Lys Arg Asp
35 40 45
Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Thr Ser Leu
50 55 60
Pro His His Val Gly Lys Ile Lys Ser Ser Val Ser Arg Lys Asn Ala
65 70 75 80
Lys Tyr Leu Leu Lys Gly Glu Tyr Val Gly Lys Val Phe Arg Val Asp
85 90 95
Ala Glu Thr Gly Asp Val Phe Ala Ile Glu Arg Leu Asp Arg Glu Asn
100 105 110
Ile Ser Glu Tyr His Leu Thr Ala Val Ile Val Asp Lys Asp Thr Gly
115 120 125
Glu Asn Leu Glu Thr Pro Ser Ser Phe Thr Ile Lys Val His Asp Val
130 135 140
Asn Asp Asn Trp Pro Val Phe Thr His Arg Leu Phe Asn Ala Ser Val
145 150 155 160
Pro Glu Ser Ser Ala Val Gly Thr Ser Val Ile Ser Val Thr Ala Val
165 170 175
Asp Ala Asp Asp Pro Thr Val Gly Asp His Ala Ser Val Met Tyr Gln
180 185 190
Ile Leu Lys Gly Lys Glu Tyr Phe Ala Ile Asp Asn Ser Gly Arg Ile
195 200 205
Ile Thr Ile Thr Lys Ser Leu Asp Arg Glu Lys Gln Ala Arg Tyr Glu
210 215 220
Ile Val Val Glu Ala Arg Asp Ala Gln Gly Leu Arg Gly Asp Ser Gly
225 230 235 240
Thr Ala Thr Val Leu Val Thr Leu Gln Asp Ile Asn Asp Asn Phe Pro
245 250 255
Phe Phe Thr Gln Thr Lys Tyr Thr Phe Val Val Pro Glu Asp Thr Arg
260 265 270
Val Gly Thr Ser Val Gly Ser Leu Phe Val Glu Asp Pro Asp Glu Pro
275 280 285
Gln Asn Arg Met Thr Lys Tyr Ser Ile Leu Arg Gly Asp Tyr Gln Asp
290 295 300
Ala Phe Thr Ile Glu Thr Asn Pro Ala His Asn Glu Gly Ile Ile Lys
305 310 315 320
Pro Met Lys Pro Leu Asp Tyr Glu Tyr Ile Gln Gln Tyr Ser Phe Ile
325 330 335
Val Glu Ala Thr Asp Pro Thr Ile Asp Leu Arg Tyr Met Ser Pro Pro
340 345 350
Ala Gly Asn Arg Ala Gln Val Ile Ile Asn Ile Thr Asp Val Asp Glu
355 360 365
Pro Pro Ile Phe Gln Gln Pro Phe Tyr His Phe Gln Leu Lys Glu Asn
370 375 380
Gln Lys Lys Pro Leu Ile Gly Thr Val Leu Ala Met Asp Pro Asp Ala
385 390 395 400
Ala Arg His Ser Ile Gly Tyr Ser Ile Arg Arg Thr Ser Asp Lys Gly
405 410 415
Gln Phe Phe Arg Val Thr Lys Lys Gly Asp Ile Tyr Asn Glu Lys Glu
420 425 430
Leu Asp Arg Glu Val Tyr Pro Trp Tyr Asn Leu Thr Val Glu Ala Lys
435 440 445
Glu Leu Asp Ser Thr Gly Thr Pro Thr Gly Lys Glu Ser Ile Val Gln
450 455 460
Val His Ile Glu Val Leu Asp Glu Asn Asp Asn Ala Pro Glu Phe Ala
465 470 475 480
Lys Pro Tyr Gln Pro Lys Val Cys Glu Asn Ala Val His Gly Gln Leu
485 490 495
Val Leu Gln Ile Ser Ala Ile Asp Lys Asp Ile Thr Pro Arg Asn Val
500 505 510
Lys Phe Lys Phe Ile Leu Asn Thr Glu Asn Asn Phe Thr Leu Thr Asp
515 520 525
Asn His Asp Asn Thr Ala Asn Ile Thr Val Lys Tyr Gly Gln Phe Asp
530 535 540
Arg Glu His Thr Lys Val His Phe Leu Pro Val Val Ile Ser Asp Asn
545 550 555 560
Gly Met Pro Ser Arg Thr Gly Thr Ser Thr Leu Thr Val Ala Val Cys
565 570 575
Lys Cys Asn Glu Gln Gly Glu Phe Thr Phe Cys Glu Asp Met Ala Ala
580 585 590
Gln Val Gly Val Ser Ile Gln Ala Val Val Ala Ile Leu Leu Cys Ile
595 600 605
Leu Thr Ile Thr Val Ile Thr Leu Leu Ile Phe Leu Arg Arg Arg Leu
610 615 620
Arg Lys Gln Ala Arg Ala His Gly Lys Ser Val Pro Glu Ile His Glu
625 630 635 640
Gln Leu Val Thr Tyr Asp Glu Glu Gly Gly Gly Glu Met Asp Thr Thr
645 650 655
Ser Tyr Asp Val Ser Val Leu Asn Ser Val Arg Arg Gly Gly Ala Lys
660 665 670
Pro Pro Arg Pro Ala Leu Asp Ala Arg Pro Ser Leu Tyr Ala Gln Val
675 680 685
Gln Lys Pro Pro Arg His Ala Pro Gly Ala His Gly Gly Pro Gly Glu
690 695 700
Met Ala Ala Met Ile Glu Val Lys Lys Asp Glu Ala Asp His Asp Gly
705 710 715 720
Asp Gly Pro Pro Tyr Asp Thr Leu His Ile Tyr Gly Tyr Glu Gly Ser
725 730 735
Glu Ser Ile Ala Glu Ser Leu Ser Ser Leu Gly Thr Asp Ser Ser Asp
740 745 750
Ser Asp Val Asp Tyr Asp Phe Leu Asn Asp Trp Gly Pro Arg Phe Lys
755 760 765
Met Leu Ala Glu Leu Tyr Gly Ser Asp Pro Arg Glu Glu Leu Leu Tyr
770 775 780
<![CDATA[<210> 45]]>
<![CDATA[<211> 830]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH1]]>
<![CDATA[<400> 45]]>
Met Gly Pro Trp Ser Arg Ser Leu Ser Ala Leu Leu Leu Leu Leu Gln
1 5 10 15
Val Ser Ser Trp Leu Cys Gln Glu Pro Glu Pro Cys His Pro Gly Phe
20 25 30
Asp Ala Glu Ser Tyr Thr Phe Thr Val Pro Arg Arg His Leu Glu Arg
35 40 45
Gly Arg Val Leu Gly Arg Val Ser Phe Glu Asp Cys Thr Gly Arg Gln
50 55 60
Arg Thr Ala Tyr Phe Ser Leu Asp Thr Arg Phe Lys Val Gly Pro Asp
65 70 75 80
Gly Val Ile Thr Val Lys Arg Pro Leu Gln Phe His Asn Pro Gln Ile
85 90 95
His Phe Leu Val Tyr Ala Trp Asp Ser Thr Tyr Arg Lys Phe Ser Thr
100 105 110
Lys Val Thr Leu Asn Thr Val Gly His His Ser Arg Thr Pro Pro Leu
115 120 125
His Ala Ser Val Ser Gly Val Gln Ala Glu Leu Leu Thr Phe Pro Asn
130 135 140
Ser Ser Pro Gly Leu Arg Arg Trp Lys Arg Asp Trp Val Ile Pro Pro
145 150 155 160
Ile Ser Cys Pro Glu Asn Glu Lys Gly Pro Phe Pro Lys Asn Leu Val
165 170 175
Gln Ile Lys Ser Asn Lys Asp Lys Glu Gly Lys Val Phe Tyr Ser Ile
180 185 190
Thr Gly Gln Gly Ala Asp Thr Pro Pro Val Gly Val Phe Ile Ile Glu
195 200 205
Arg Glu Thr Gly Trp Leu Lys Val Thr Glu Pro Leu Asp Arg Glu Asn
210 215 220
Ile Ala Thr Tyr Thr Leu Phe Ser His Ala Val Ser Ser Asn Gly Asn
225 230 235 240
Ala Val Glu Asp Pro Met Glu Ile Leu Ile Thr Val Thr Asp Gln Asn
245 250 255
Asp Asn Lys Pro Val Phe Thr Gln Glu Val Phe Lys Gly Ser Val Met
260 265 270
Glu Gly Ala Leu Pro Gly Thr Ser Val Met Glu Val Thr Ala Thr Asp
275 280 285
Ala Asp Asp Asp Val Asn Thr Tyr Asn Ala Ala Ile Ala Tyr Ser Ile
290 295 300
Leu Ser Gln Asp Pro Glu Leu Pro Asp Lys Asn Met Phe Thr Ile Asn
305 310 315 320
Lys Asn Thr Gly Val Ile Ser Val Val Thr Thr Gly Leu Asp Arg Glu
325 330 335
Ser Phe Pro Met Tyr Thr Leu Val Val Gln Ala Ala Asp Leu Gln Gly
340 345 350
Glu Gly Leu Ser Thr Thr Ala Thr Ala Val Ile Thr Val Thr Asp Thr
355 360 365
Asn Asp Asn Pro Pro Val Phe Asn Pro Thr Thr Tyr Lys Gly Gln Val
370 375 380
Pro Glu Asn Gln Ala Asn Phe Val Ile Thr Thr Leu Lys Val Thr Asp
385 390 395 400
Ala Asp Ala Pro Asn Thr Pro Ala Trp Glu Ala Val Tyr Thr Ile Leu
405 410 415
Asn Asp Asn Asp Gly Gln Phe Val Val Thr Thr Asn Pro Val Thr Asn
420 425 430
Asp Gly Ile Leu Lys Thr Ala Lys Gly Leu Asp Phe Glu Ala Lys Gln
435 440 445
Gln Tyr Ile Leu His Val Ala Val Thr Asn Val Ala Pro Phe Glu Val
450 455 460
Ser Leu Thr Thr Ser Thr Ala Thr Val Thr Val Asp Val Leu Asp Val
465 470 475 480
Asn Glu Ala Pro Ile Phe Val Pro Pro Glu Lys Arg Val Glu Val Ser
485 490 495
Glu Asp Phe Gly Val Gly Gln Glu Ile Thr Ser Tyr Thr Ala Arg Glu
500 505 510
Pro Asp Thr Phe Met Glu Gln Lys Ile Thr Tyr Arg Ile Trp Arg Asp
515 520 525
Ala Ala Asn Trp Leu Glu Ile Asn Pro Asp Thr Gly Ala Ile Ser Thr
530 535 540
Arg Ala Glu Leu Asp Arg Glu Asp Val Glu His Val Lys Asn Ser Thr
545 550 555 560
Tyr Thr Ala Leu Ile Ile Ala Thr Asp Asn Asp His His Leu Cys Asp
565 570 575
Phe Leu Glu Ser His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys
580 585 590
Ile Ala Gln Glu Ser Ile Ile Leu Lys Pro Lys Ile Ala Leu Glu Val
595 600 605
Gly Asp Tyr Lys Ile Asn Leu Lys Leu Met Asp Asn Gln Lys Lys Asp
610 615 620
Gln Val Thr Thr Leu Glu Val Ser Val Cys Asp Cys Glu Gly Ala Ala
625 630 635 640
Gly Ile Cys Lys Lys Ala Pro Leu Val Glu Ala Gly Met Gln Ile Pro
645 650 655
Ala Ile Leu Gly Ile Leu Gly Gly Ile Leu Ala Leu Leu Ile Leu Ile
660 665 670
Leu Leu Leu Leu Leu Phe Leu Arg Arg Arg Ala Val Val Lys Glu Pro
675 680 685
Leu Leu Pro Pro Glu Asp Asp Thr Arg Asp Asn Val Tyr Tyr Tyr Asp
690 695 700
Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Phe Asp Leu Ser Gln Leu
705 710 715 720
His Arg Gly Leu Asp Ala Arg Pro Glu Val Thr Arg Asn Asp Val Ala
725 730 735
Pro Thr Leu Leu Ser Val Pro Arg Tyr Leu Pro Arg Pro Ala Asn Pro
740 745 750
Asp Glu Ile Gly Asn Phe Ile Asp Glu Asn Leu Lys Ala Ala Asp Ser
755 760 765
Asp Pro Thr Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu
770 775 780
Gly Ser Gly Ser Glu Ala Ala Ser Leu Ser Ser Leu Asn Ser Ser Glu
785 790 795 800
Ser Asp Lys Asp Gln Asp Tyr Asp Tyr Leu Asn Glu Trp Gly Asn Arg
805 810 815
Phe Lys Lys Leu Ala Asp Met Tyr Gly Gly Gly Glu Asp Asp
820 825 830
<![CDATA[<210> 46]]>
<![CDATA[<211> 906]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH2]]>
<![CDATA[<400> 46]]>
Met Cys Arg Ile Ala Gly Ala Leu Arg Thr Leu Leu Pro Leu Leu Ala
1 5 10 15
Ala Leu Leu Gln Ala Ser Val Glu Ala Ser Gly Glu Ile Ala Leu Cys
20 25 30
Lys Thr Gly Phe Pro Glu Asp Val Tyr Ser Ala Val Leu Ser Lys Asp
35 40 45
Val His Glu Gly Gln Pro Leu Leu Asn Val Lys Phe Ser Asn Cys Asn
50 55 60
Gly Lys Arg Lys Val Gln Tyr Glu Ser Ser Glu Pro Ala Asp Phe Lys
65 70 75 80
Val Asp Glu Asp Gly Met Val Tyr Ala Val Arg Ser Phe Pro Leu Ser
85 90 95
Ser Glu His Ala Lys Phe Leu Ile Tyr Ala Gln Asp Lys Glu Thr Gln
100 105 110
Glu Lys Trp Gln Val Ala Val Lys Leu Ser Leu Lys Pro Ala Leu Thr
115 120 125
Glu Glu Ser Val Lys Glu Pro Pro Glu Val Glu Glu Ile Val Phe Pro
130 135 140
Arg Gln Leu Ser Lys His Ser Gly His Leu Gln Arg Gln Lys Arg Asp
145 150 155 160
Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro Phe
165 170 175
Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu Ser
180 185 190
Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr Gly
195 200 205
Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys Pro
210 215 220
Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala Val
225 230 235 240
Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile Asn
245 250 255
Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe Leu His Gln Val Trp
260 265 270
Asn Gly Thr Val Pro Glu Gly Ser Lys Pro Gly Thr Tyr Val Met Thr
275 280 285
Val Thr Ala Ile Asp Ala Asp Asp Pro Asn Ala Leu Asn Gly Met Leu
290 295 300
Arg Tyr Arg Ile Leu Ser Gln Ala Pro Ser Thr Pro Ser Pro Asn Met
305 310 315 320
Phe Thr Ile Asn Asn Glu Thr Gly Asp Ile Ile Thr Val Ala Ala Gly
325 330 335
Leu Asp Arg Glu Lys Val Gln Gln Tyr Thr Leu Ile Ile Gln Ala Thr
340 345 350
Asp Met Glu Gly Asn Pro Thr Tyr Gly Leu Ser Asn Thr Ala Thr Ala
355 360 365
Ile Ile Thr Val Thr Asp Val Asn Asp Asn Pro Pro Glu Phe Thr Ala
370 375 380
Met Thr Phe Tyr Gly Glu Val Pro Glu Asn Arg Val Asp Val Ile Val
385 390 395 400
Ala Asn Leu Thr Val Thr Asp Lys Asp Gln Pro His Thr Pro Ala Trp
405 410 415
Asn Ala Val Tyr Arg Ile Ser Gly Gly Asp Pro Thr Gly Arg Phe Ala
420 425 430
Ile Gln Thr Asp Pro Asn Ser Asn Asp Gly Leu Val Thr Val Val Lys
435 440 445
Pro Ile Asp Phe Glu Thr Asn Arg Met Phe Val Leu Thr Val Ala Ala
450 455 460
Glu Asn Gln Val Pro Leu Ala Lys Gly Ile Gln His Pro Pro Gln Ser
465 470 475 480
Thr Ala Thr Val Ser Val Thr Val Ile Asp Val Asn Glu Asn Pro Tyr
485 490 495
Phe Ala Pro Asn Pro Lys Ile Ile Arg Gln Glu Glu Gly Leu His Ala
500 505 510
Gly Thr Met Leu Thr Thr Phe Thr Ala Gln Asp Pro Asp Arg Tyr Met
515 520 525
Gln Gln Asn Ile Arg Tyr Thr Lys Leu Ser Asp Pro Ala Asn Trp Leu
530 535 540
Lys Ile Asp Pro Val Asn Gly Gln Ile Thr Thr Ile Ala Val Leu Asp
545 550 555 560
Arg Glu Ser Pro Asn Val Lys Asn Asn Ile Tyr Asn Ala Thr Phe Leu
565 570 575
Ala Ser Asp Asn Gly Ile Pro Pro Met Ser Gly Thr Gly Thr Leu Gln
580 585 590
Ile Tyr Leu Leu Asp Ile Asn Asp Asn Ala Pro Gln Val Leu Pro Gln
595 600 605
Glu Ala Glu Thr Cys Glu Thr Pro Asp Pro Asn Ser Ile Asn Ile Thr
610 615 620
Ala Leu Asp Tyr Asp Ile Asp Pro Asn Ala Gly Pro Phe Ala Phe Asp
625 630 635 640
Leu Pro Leu Ser Pro Val Thr Ile Lys Arg Asn Trp Thr Ile Thr Arg
645 650 655
Leu Asn Gly Asp Phe Ala Gln Leu Asn Leu Lys Ile Lys Phe Leu Glu
660 665 670
Ala Gly Ile Tyr Glu Val Pro Ile Ile Ile Thr Asp Ser Gly Asn Pro
675 680 685
Pro Lys Ser Asn Ile Ser Ile Leu Arg Val Lys Val Cys Gln Cys Asp
690 695 700
Ser Asn Gly Asp Cys Thr Asp Val Asp Arg Ile Val Gly Ala Gly Leu
705 710 715 720
Gly Thr Gly Ala Ile Ile Ala Ile Leu Leu Cys Ile Ile Ile Leu Leu
725 730 735
Ile Leu Val Leu Met Phe Val Val Trp Met Lys Arg Arg Asp Lys Glu
740 745 750
Arg Gln Ala Lys Gln Leu Leu Ile Asp Pro Glu Asp Asp Val Arg Asp
755 760 765
Asn Ile Leu Lys Tyr Asp Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp
770 775 780
Tyr Asp Leu Ser Gln Leu Gln Gln Pro Asp Thr Val Glu Pro Asp Ala
785 790 795 800
Ile Lys Pro Val Gly Ile Arg Arg Met Asp Glu Arg Pro Ile His Ala
805 810 815
Glu Pro Gln Tyr Pro Val Arg Ser Ala Ala Pro His Pro Gly Asp Ile
820 825 830
Gly Asp Phe Ile Asn Glu Gly Leu Lys Ala Ala Asp Asn Asp Pro Thr
835 840 845
Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly
850 855 860
Ser Thr Ala Gly Ser Leu Ser Ser Leu Asn Ser Ser Ser Ser Gly Gly
865 870 875 880
Glu Gln Asp Tyr Asp Tyr Leu Asn Asp Trp Gly Pro Arg Phe Lys Lys
885 890 895
Leu Ala Asp Met Tyr Gly Gly Gly Asp Asp
900 905
<![CDATA[<210> 47]]>
<![CDATA[<211> 917]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH4]]>
<![CDATA[<400> 47]]>
Met Thr Ala Gly Ala Gly Val Leu Leu Leu Leu Leu Ser Leu Ser Gly
1 5 10 15
Ala Leu Arg Ala His Asn Glu Asp Leu Thr Thr Arg Glu Thr Cys Lys
20 25 30
Ala Gly Phe Ser Glu Asp Asp Tyr Thr Ala Leu Ile Ser Gln Asn Ile
35 40 45
Leu Glu Gly Glu Lys Leu Leu Gln Val Lys Phe Ser Ser Cys Val Gly
50 55 60
Thr Lys Gly Thr Gln Tyr Glu Thr Asn Ser Val Asp Phe Lys Val Gly
65 70 75 80
Ser Asp Gly Thr Val Phe Ala Thr Arg Glu Leu Gln Val Pro Ser Glu
85 90 95
Gln Val Ala Phe Thr Val Thr Ala Trp Asp Ser Gln Thr Ala Glu Arg
100 105 110
Trp Asp Ala Val Val Arg Leu Leu Val Ala Gln Thr Ser Ser Leu His
115 120 125
Ser Gly His Lys Pro Gln Lys Gly Lys Lys Ile Val Ala Leu Asp Pro
130 135 140
Ser Pro Pro Pro Lys Asp Thr Leu Leu Pro Trp Pro Arg His Gln Asn
145 150 155 160
Ala Asp Gly Leu Arg Arg Arg Lys Arg Asp Trp Val Ile Pro Pro Ile
165 170 175
Asn Val Pro Glu Asn Ser Arg Gly Pro Phe Pro Gln Gln Leu Val Arg
180 185 190
Ile Arg Ser Asp Lys Asp Asn Asp Ile Pro Ile Arg Tyr Ser Ile Thr
195 200 205
Gly Val Gly Ala Asp Gln Pro Pro Met Glu Val Phe Ser Ile Asp Ser
210 215 220
Met Ser Gly Arg Met Tyr Val Thr Arg Pro Met Asp Arg Glu Glu His
225 230 235 240
Ala Ser Tyr His Leu Arg Ala His Ala Val Asp Met Asn Gly Asn Lys
245 250 255
Val Glu Asn Pro Ile Asp Leu Tyr Ile Tyr Val Ile Asp Met Asn Asp
260 265 270
Asn Arg Pro Glu Phe Ile Asn Gln Val Tyr Asn Gly Ser Val Asp Glu
275 280 285
Gly Ser Lys Pro Gly Glu Ala Phe Ser Phe Ser Thr Arg Leu Ser Ser
290 295 300
Pro Asn Thr Thr Thr Ala Pro Gly Asn Gly Asp Ser His His Val Val
305 310 315 320
Thr Arg Arg Pro Arg Gly Gly Gln Gly Leu Gly Thr Gln Thr Cys Ala
325 330 335
Ala Gly Asp Ile Val Ser Leu Ser Arg Gly Met Ser Arg Glu Ala Lys
340 345 350
Val Gln Gln Tyr Thr Val Ile Val Gln Ala Thr Asp Met Glu Gly Asn
355 360 365
Leu Asn Tyr Gly Leu Ser Asn Thr Ala Thr Ala Ile Ile Thr Val Thr
370 375 380
Asp Val Asn Asp Asn Pro Pro Glu Phe Thr Ala Ser Thr Phe Ala Gly
385 390 395 400
Glu Val Pro Glu Asn Arg Val Glu Thr Val Val Ala Asn Leu Thr Val
405 410 415
Met Asp Arg Asp Gln Pro His Ser Pro Asn Trp Asn Ala Val Tyr Arg
420 425 430
Ile Ile Ser Gly Asp Pro Ser Gly His Phe Ser Val Arg Thr Asp Pro
435 440 445
Val Thr Asn Glu Gly Met Val Thr Val Val Lys Ala Val Asp Tyr Glu
450 455 460
Leu Asn Arg Ala Phe Met Leu Thr Val Met Val Ser Asn Gln Ala Pro
465 470 475 480
Leu Ala Ser Gly Ile Gln Met Ser Phe Gln Ser Thr Ala Gly Val Thr
485 490 495
Ile Ser Val Met Asp Ile Asn Glu Ala Pro Tyr Phe Pro Ser Asn His
500 505 510
Lys Leu Ile Arg Leu Glu Glu Gly Val Pro Pro Gly Thr Val Leu Thr
515 520 525
Thr Phe Ser Ala Val Asp Pro Asp Arg Phe Met Gln Gln Ala Val Arg
530 535 540
Tyr Ser Lys Leu Ser Asp Pro Ala Asn Trp Leu His Ile Asn Thr Thr
545 550 555 560
Asn Gly Gln Ile Thr Thr Ala Ala Val Leu Asp Arg Glu Ser Leu Tyr
565 570 575
Thr Lys Asn Asn Val Tyr Glu Ala Thr Phe Leu Ala Ala Asp Asn Gly
580 585 590
Ile Pro Pro Ala Ser Gly Thr Gly Thr Leu Gln Ile Tyr Leu Ile Asp
595 600 605
Ile Asn Asp Asn Ala Pro Glu Leu Leu Pro Lys Glu Ala Gln Ile Cys
610 615 620
Glu Lys Pro Asn Leu Asn Ala Ile Asn Ile Thr Ala Ala Asp Ala Asp
625 630 635 640
Val Asp Pro Asn Ile Gly Pro Tyr Val Phe Glu Leu Pro Phe Val Pro
645 650 655
Ala Ala Val Arg Lys Asn Trp Thr Ile Thr Arg Leu Asn Gly Asp Tyr
660 665 670
Ala Gln Leu Ser Leu Arg Ile Leu Tyr Leu Glu Ala Gly Met Tyr Asp
675 680 685
Val Pro Ile Ile Val Thr Asp Ser Gly Asn Pro Pro Leu Ser Asn Thr
690 695 700
Ser Ile Ile Lys Val Lys Val Cys Pro Cys Asp Asp Asn Gly Asp Cys
705 710 715 720
Thr Thr Ile Gly Ala Val Ala Ala Ala Gly Leu Gly Thr Gly Ala Ile
725 730 735
Val Ala Ile Leu Ile Cys Ile Leu Ile Leu Leu Thr Met Val Leu Leu
740 745 750
Phe Val Met Trp Met Lys Arg Arg Glu Lys Glu Arg His Thr Lys Gln
755 760 765
Leu Leu Ile Asp Pro Glu Asp Asp Val Arg Asp Asn Ile Leu Lys Tyr
770 775 780
Asp Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Tyr Asp Leu Ser Gln
785 790 795 800
Leu Gln Gln Pro Glu Ala Met Gly His Val Pro Ser Lys Ala Pro Gly
805 810 815
Val Arg Arg Val Asp Glu Arg Pro Val Gly Ala Glu Pro Gln Tyr Pro
820 825 830
Val Arg Pro Met Val Pro His Pro Gly Asp Ile Gly Asp Phe Ile Asn
835 840 845
Glu Gly Leu Arg Ala Ala Asp Asn Asp Pro Thr Ala Pro Pro Tyr Asp
850 855 860
Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly Ser Thr Ala Gly Ser
865 870 875 880
Val Ser Ser Leu Asn Ser Ser Ser Ser Gly Asp Gln Asp Tyr Asp Tyr
885 890 895
Leu Asn Asp Trp Gly Pro Arg Phe Lys Lys Leu Ala Asp Met Tyr Gly
900 905 910
Gly Gly Glu Glu Asp
915
<![CDATA[<210> 48]]>
<![CDATA[<211> 785]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴CDH5]]>
<![CDATA[<400> 48]]>
Met Gln Arg Leu Met Met Leu Val Ala Thr Ser Gly Ala Cys Leu Gly
1 5 10 15
Leu Leu Ala Ala Ala Ala Ala Ala Ala Ala Ala Gly Ala Asn Pro Ala
20 25 30
Gln Arg Asp Thr Pro Ser Leu Leu Pro Thr His Arg Arg Gln Lys Arg
35 40 45
Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Thr Ser
50 55 60
Leu Pro His His Val Gly Lys Ile Lys Ser Ser Val Ser Arg Lys Asn
65 70 75 80
Ala Lys Tyr Leu Leu Lys Gly Glu Phe Val Asp Lys Val Phe Arg Val
85 90 95
Asp Ala Glu Thr Gly Asp Val Phe Ala Ile Glu Arg Leu Asp Arg Glu
100 105 110
Asn Ile Ser Glu Tyr His Leu Thr Ala Val Ile Val Asp Lys Asp Thr
115 120 125
Gly Glu Asn Leu Glu Thr Pro Ser Ser Phe Thr Ile Lys Val His Asp
130 135 140
Val Asn Asp Asn Trp Pro Val Phe Thr His Arg Leu Phe Asn Ala Ser
145 150 155 160
Val Pro Glu Ser Ser Ala Val Gly Thr Ser Val Ile Ser Val Thr Ala
165 170 175
Val Asp Ala Asp Asp Pro Thr Val Gly Asp His Ala Ser Val Met Tyr
180 185 190
Gln Ile Leu Lys Gly Lys Glu Tyr Phe Ala Ile Asp Asn Ser Gly Arg
195 200 205
Ile Val Thr Ile Thr Lys Ser Leu Asp Arg Glu Lys Gln Ala Arg Tyr
210 215 220
Glu Ile Val Val Glu Ala Arg Asp Ala Gln Gly Leu Arg Gly Asp Ser
225 230 235 240
Gly Thr Ala Thr Val Leu Val Thr Leu Gln Asp Ile Asn Asp Asn Phe
245 250 255
Pro Phe Phe Thr Gln Thr Lys Tyr Thr Phe Val Val Pro Glu Asp Thr
260 265 270
Arg Val Gly Thr Ser Val Gly Ser Leu Phe Val Glu Asp Pro Asp Glu
275 280 285
Pro Gln Asn Arg Met Thr Lys Tyr Ser Ile Leu Arg Gly Asp Tyr Gln
290 295 300
Asp Ala Phe Thr Ile Glu Thr Asn Pro Thr His Asn Glu Gly Ile Ile
305 310 315 320
Lys Pro Met Lys Pro Leu Asp Tyr Glu Tyr Ile Gln Gln Tyr Ser Phe
325 330 335
Ile Val Glu Ala Thr Asp Pro Thr Ile Asp Leu Arg Tyr Leu Ser Pro
340 345 350
Pro Ala Gly Asn Arg Ala Gln Val Ile Ile Asn Ile Thr Asp Val Asp
355 360 365
Glu Pro Pro Ile Phe Gln Gln Pro Phe Tyr His Phe Gln Leu Lys Glu
370 375 380
Asn Gln Lys Lys Pro Leu Ile Gly Thr Val Leu Ala Met Asp Pro Asp
385 390 395 400
Ala Ala Arg His Ser Ile Gly Tyr Ser Ile Arg Arg Thr Ser Asp Lys
405 410 415
Gly Gln Phe Phe Arg Val Thr Lys Lys Gly Asp Ile Tyr Asn Glu Lys
420 425 430
Glu Leu Asp Arg Glu Val Tyr Pro Trp Tyr Asn Leu Thr Val Glu Ala
435 440 445
Lys Glu Leu Asp Ser Thr Gly Thr Pro Thr Gly Lys Glu Ser Ile Val
450 455 460
Gln Val His Ile Glu Val Leu Asp Glu Asn Asp Asn Ala Pro Glu Phe
465 470 475 480
Ala Gln Pro Tyr Gln Pro Lys Val Cys Glu Asn Ala Ala His Gly Gln
485 490 495
Leu Val Leu Gln Ile Ser Ala Ile Asp Lys Asp Ile Thr Pro Arg Asn
500 505 510
Val Lys Phe Lys Phe Thr Leu Asn Thr Glu Asn Asn Phe Thr Leu Thr
515 520 525
Asp Asn His Asp Asn Thr Ala Asn Ile Thr Val Lys Tyr Gly Gln Phe
530 535 540
Asp Arg Glu His Thr Lys Val His Phe Leu Pro Val Val Ile Ser Asp
545 550 555 560
Asn Gly Met Pro Ser Arg Thr Gly Thr Ser Thr Leu Thr Val Ala Val
565 570 575
Cys Lys Cys Asn Glu Gln Gly Glu Phe Thr Phe Cys Glu Asp Met Ala
580 585 590
Ala Gln Val Gly Val Ser Ile Gln Ala Val Val Ala Ile Leu Leu Ser
595 600 605
Ile Leu Thr Ile Thr Val Ile Ala Leu Leu Ile Phe Leu Arg Arg Arg
610 615 620
Leu Arg Lys Gln Ala Arg Ala His Gly Lys Ser Val Pro Glu Ile His
625 630 635 640
Glu Gln Leu Val Thr Tyr Asp Glu Glu Gly Gly Gly Glu Met Asp Thr
645 650 655
Thr Ser Tyr Asp Val Ser Val Leu Asn Ser Val Arg Arg Gly Gly Ala
660 665 670
Lys Pro Pro Arg Pro Ala Leu Asp Ala Arg Pro Ser Leu Tyr Ala Gln
675 680 685
Val Gln Lys Pro Pro Arg His Ala Pro Gly Ala His Gly Gly Pro Gly
690 695 700
Glu Met Ala Ala Met Ile Glu Val Lys Lys Asp Glu Ala Asp His Asp
705 710 715 720
Gly Asp Gly Pro Pro Tyr Asp Thr Leu His Ile Tyr Gly Tyr Glu Gly
725 730 735
Ser Glu Ser Ile Ala Glu Ser Leu Ser Ser Leu Gly Thr Asp Ser Ser
740 745 750
Asp Ser Asp Val Asp Tyr Asp Phe Leu Asn Asp Trp Gly Pro Arg Phe
755 760 765
Lys Met Leu Ala Glu Leu Tyr Gly Ser Asp Pro Arg Glu Glu Leu Leu
770 775 780
Tyr
785
<![CDATA[<210> 49]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VH CDR1]]>
<![CDATA[<400> 49]]>
Ser Tyr Ala Met Ser
1 5
<![CDATA[<210> 50]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VH CDR2]]>
<![CDATA[<400> 50]]>
Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 51]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VH CDR3]]>
<![CDATA[<400> 51]]>
Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr
1 5
<![CDATA[<210> 52]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VL CDR1]]>
<![CDATA[<400> 52]]>
Arg Ala Ser Gln Asp Ile Gly Ile Asn Leu Ile
1 5 10
<![CDATA[<210> 53]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VL CDR2]]>
<![CDATA[<400> 53]]>
Asp Thr Ser Ser Leu Asp Ser
1 5
<![CDATA[<210> 54]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VL CDR3]]>
<![CDATA[<400> 54]]>
Leu Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<![CDATA[<210> 55]]>
<![CDATA[<211> 118]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VH]]>
<![CDATA[<400> 55]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<![CDATA[<210> 56]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 VL]]>
<![CDATA[<400> 56]]>
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Gly Ile Asn
20 25 30
Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35 40 45
Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<![CDATA[<210> 57]]>
<![CDATA[<211> 240]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1 scFv]]>
<![CDATA[<400> 57]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
<![CDATA[<210> 58]]>
<![CDATA[<211> 495]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-1雙特異性分子]]>
<![CDATA[<400> 58]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
245 250 255
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
260 265 270
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
275 280 285
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
290 295 300
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
305 310 315 320
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
325 330 335
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
340 345 350
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
355 360 365
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
385 390 395 400
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
405 410 415
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
420 425 430
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
435 440 445
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
450 455 460
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
465 470 475 480
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490 495
<![CDATA[<210> 59]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VH CDR1]]>
<![CDATA[<400> 59]]>
Ser Tyr Ala Met Ser
1 5
<![CDATA[<210> 60]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VH CDR2]]>
<![CDATA[<400> 60]]>
Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 61]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VH CDR3]]>
<![CDATA[<400> 61]]>
Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr
1 5
<![CDATA[<210> 62]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VL CDR1]]>
<![CDATA[<400> 62]]>
Arg Ala Ser Gln Asp Ile Gly Ile Asn Leu Ile
1 5 10
<![CDATA[<210> 63]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VL CDR2]]>
<![CDATA[<400> 63]]>
Asp Thr Ser Ser Leu Asp Ser
1 5
<![CDATA[<210> 64]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VL CDR3]]>
<![CDATA[<400> 64]]>
Leu Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<![CDATA[<210> 65]]>
<![CDATA[<211> 118]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VH]]>
<![CDATA[<400> 65]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<![CDATA[<210> 66]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 VL]]>
<![CDATA[<400> 66]]>
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Gly Ile Asn
20 25 30
Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35 40 45
Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<![CDATA[<210> 67]]>
<![CDATA[<211> 240]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2 scFv]]>
<![CDATA[<400> 67]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
<![CDATA[<210> 68]]>
<![CDATA[<211> 495]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-2雙特異性分子]]>
<![CDATA[<400> 68]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
245 250 255
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
260 265 270
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
275 280 285
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
290 295 300
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
305 310 315 320
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
325 330 335
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
340 345 350
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
355 360 365
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
385 390 395 400
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
405 410 415
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
420 425 430
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
435 440 445
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
450 455 460
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
465 470 475 480
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490 495
<![CDATA[<210> 69]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VH CDR1]]>
<![CDATA[<400> 69]]>
Ser Tyr Ala Met Ser
1 5
<![CDATA[<210> 70]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VH CDR2]]>
<![CDATA[<400> 70]]>
Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 71]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VH CDR3]]>
<![CDATA[<400> 71]]>
Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr
1 5
<![CDATA[<210> 72]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VL CDR1]]>
<![CDATA[<400> 72]]>
Arg Ala Ser Gln Asp Ile Gly Ile Asn Leu Ile
1 5 10
<![CDATA[<210> 73]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VL CDR2]]>
<![CDATA[<400> 73]]>
Asp Thr Ser Ser Leu Asp Ser
1 5
<![CDATA[<210> 74]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VL CDR3]]>
<![CDATA[<400> 74]]>
Leu Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<![CDATA[<210> 75]]>
<![CDATA[<211> 118]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VH]]>
<![CDATA[<400> 75]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<![CDATA[<210> 76]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 VL]]>
<![CDATA[<400>]]> 76
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Gly Ile Asn
20 25 30
Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35 40 45
Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<![CDATA[<210> 77]]>
<![CDATA[<211> 240]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3 scFv]]>
<![CDATA[<400> 77]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
<![CDATA[<210> 78]]>
<![CDATA[<211> 495]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3雙特異性分子]]>
<![CDATA[<400> 78]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu
130 135 140
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
145 150 155 160
Asp Ile Gly Ile Asn Leu Ile Trp Leu Gln Gln Lys Pro Gly Lys Ala
165 170 175
Pro Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
195 200 205
Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr
210 215 220
Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
225 230 235 240
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
245 250 255
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
260 265 270
Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
275 280 285
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
290 295 300
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
305 310 315 320
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr
325 330 335
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
340 345 350
Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
355 360 365
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
385 390 395 400
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
405 410 415
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
420 425 430
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
435 440 445
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
450 455 460
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
465 470 475 480
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490 495
<![CDATA[<210> 79]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VH CDR1]]>
<![CDATA[<400> 79]]>
Ser Ser Trp Met Asn
1 5
<![CDATA[<210> 80]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VH CDR2]]>
<![CDATA[<400> 80]]>
Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 81]]>
<![CDATA[<211> 12]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VH CDR3]]>
<![CDATA[<400> 81]]>
Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr
1 5 10
<![CDATA[<210> 82]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VL CDR1]]>
<![CDATA[<400> 82]]>
Arg Val Ser Asp Asp Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 83]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VL CDR2]]>
<![CDATA[<400> 83]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 84]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VL CDR3]]>
<![CDATA[<400> 84]]>
Gln Asn His Tyr Val Thr Pro Phe Thr
1 5
<![CDATA[<210> 85]]>
<![CDATA[<211> 121]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VH]]>
<![CDATA[<400> 85]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 86]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 VL]]>
<![CDATA[<400> 86]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Val Ser Asp Asp Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn His Tyr Val Thr Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 87]]>
<![CDATA[<211> 243]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4 scFv]]>
<![CDATA[<400> 87]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro
130 135 140
Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Val Ser Asp Asp Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Asn His Tyr Val Thr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
225 230 235 240
Glu Ile Lys
<![CDATA[<210> 88]]>
<![CDATA[<211> 498]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-4雙特異性分子]]>
<![CDATA[<400> ]]> 88
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro
130 135 140
Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Val Ser Asp Asp Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Asn His Tyr Val Thr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
225 230 235 240
Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser
245 250 255
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala
260 265 270
Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln
275 280 285
Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr
290 295 300
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr
305 310 315 320
Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn
325 330 335
Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn
340 345 350
Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr
355 360 365
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
370 375 380
Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr
385 390 395 400
Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly
405 410 415
Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly
420 425 430
Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly
435 440 445
Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu
450 455 460
Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val
465 470 475 480
Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr
485 490 495
Val Leu
<![CDATA[<210> 89]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VH CDR1]]>
<![CDATA[<400> 89]]>
Thr Ser Trp Met Asn
1 5
<![CDATA[<210> 90]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VH CDR2]]>
<![CDATA[<400> 90]]>
Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 91]]>
<![CDATA[<211> 12]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VH CDR3]]>
<![CDATA[<400> 91]]>
Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Leu Asp Tyr
1 5 10
<![CDATA[<210> 92]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VL CDR1]]>
<![CDATA[<400> 92]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 93]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VL CDR2]]>
<![CDATA[<400> 93]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 94]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VL CDR3]]>
<![CDATA[<400> 94]]>
Gln His His Tyr Val Pro Pro Tyr Thr
1 5
<![CDATA[<210> 95]]>
<![CDATA[<211> 122]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VH]]>
<![CDATA[<400> 95]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Thr
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Arg Val Thr Val Ser Ser
115 120
<![CDATA[<210> 96]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 VL]]>
<![CDATA[<400> 96]]>
Glu Leu Met Met Thr Gln Thr Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Phe Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Val Pro Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 97]]>
<![CDATA[<211> 244]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5 scFv]]>
<![CDATA[<400> 97]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Thr
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Arg Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Met Met Thr Gln Thr
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Phe Thr Cys
145 150 155 160
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys
165 170 175
Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr
210 215 220
Cys Gln His His Tyr Val Pro Pro Tyr Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys
<![CDATA[<210> 98]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-5雙特異性分子]]>
<![CDATA[<400> 98]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Thr
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Arg Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Met Met Thr Gln Thr
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Phe Thr Cys
145 150 155 160
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys
165 170 175
Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr
210 215 220
Cys Gln His His Tyr Val Pro Pro Tyr Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys Arg Thr Gly Gly Gly Gly Ser Glu Val Gln Leu Val
245 250 255
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser
260 265 270
Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser
290 295 300
Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg
305 310 315 320
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met
325 330 335
Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His
340 345 350
Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln
355 360 365
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser
385 390 395 400
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser
405 410 415
Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys
420 425 430
Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala
435 440 445
Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala
450 455 460
Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr
465 470 475 480
Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys
485 490 495
Leu Thr Val Leu His His His His His His
500 505
<![CDATA[<210> 99]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VH CDR1]]>
<![CDATA[<400> 99]]>
Ser Ser Trp Met Asn
1 5
<![CDATA[<210> 100]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VH CDR2]]>
<![CDATA[<400> 100]]>
Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 101]]>
<![CDATA[<211> 12]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VH CDR3]]>
<![CDATA[<400> 101]]>
Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr
1 5 10
<![CDATA[<210> 102]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213>]]> CDH3-6 VL CDR1
<![CDATA[<400> 102]]>
Arg Ala Ser Asp Asp Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 103]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VL CDR2]]>
<![CDATA[<400> 103]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 104]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VL CDR3]]>
<![CDATA[<400> 104]]>
Gln Asn His Tyr Val Thr Pro Phe Thr
1 5
<![CDATA[<210> 105]]>
<![CDATA[<211> 122]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VH]]>
<![CDATA[<400> 105]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<![CDATA[<210> 106]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 VL]]>
<![CDATA[<400> 106]]>
Glu Leu Val Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Asp Asp Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Thr Tyr Tyr Cys Gln Asn His Tyr Val Thr Pro Phe
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 107]]>
<![CDATA[<211> 244]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6 scFv]]>
<![CDATA[<400> 107]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys
145 150 155 160
Arg Ala Ser Asp Asp Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys
165 170 175
Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr
210 215 220
Cys Gln Asn His Tyr Val Thr Pro Phe Thr Phe Gly Ala Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys
<![CDATA[<210> 108]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-6雙特異性分子]]>
<![CDATA[<400> 108]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys
145 150 155 160
Arg Ala Ser Asp Asp Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys
165 170 175
Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr
210 215 220
Cys Gln Asn His Tyr Val Thr Pro Phe Thr Phe Gly Ala Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys Arg Thr Gly Gly Gly Gly Ser Glu Val Gln Leu Val
245 250 255
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser
260 265 270
Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser
290 295 300
Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg
305 310 315 320
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met
325 330 335
Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His
340 345 350
Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln
355 360 365
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser
385 390 395 400
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser
405 410 415
Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys
420 425 430
Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala
435 440 445
Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala
450 455 460
Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr
465 470 475 480
Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys
485 490 495
Leu Thr Val Leu His His His His His His
500 505
<![CDATA[<210> 109]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VH CDR1]]>
<![CDATA[<400> 109]]>
Ser Ser Trp Met Asn
1 5
<![CDATA[<210> 110]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VH CDR2]]>
<![CDATA[<400> 110]]>
Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> ]]>111
<![CDATA[<211> 12]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VH CDR3]]>
<![CDATA[<400> 111]]>
Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr
1 5 10
<![CDATA[<210> 112]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VL CDR1]]>
<![CDATA[<400> 112]]>
Arg Leu Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 113]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VL CDR2]]>
<![CDATA[<400> 113]]>
Asn Ser Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 114]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VL CDR3]]>
<![CDATA[<400> 114]]>
Gln Asn His Tyr Gly Phe Pro Phe Thr
1 5
<![CDATA[<210> 115]]>
<![CDATA[<211> 122]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VH]]>
<![CDATA[<400> 115]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Thr Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<![CDATA[<210> 116]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 VL]]>
<![CDATA[<400> 116]]>
Glu Leu Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Arg Leu Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Arg Gln Lys Glu Gly Glu Ser Pro Gln Leu Leu Val
35 40 45
Tyr Asn Ser Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Asn Tyr Tyr Cys Gln Asn His Tyr Gly Phe Pro Phe
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 117]]>
<![CDATA[<211> 244]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7 scFv]]>
<![CDATA[<400> 117]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Thr Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys
145 150 155 160
Arg Leu Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Arg Gln Lys
165 170 175
Glu Gly Glu Ser Pro Gln Leu Leu Val Tyr Asn Ser Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Asn Tyr Tyr
210 215 220
Cys Gln Asn His Tyr Gly Phe Pro Phe Thr Phe Gly Ala Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys
<![CDATA[<210> 118]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-7雙特異性分子]]>
<![CDATA[<400> 118]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Lys Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Thr Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Arg Asp Tyr Gly Ala Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser
130 135 140
Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys
145 150 155 160
Arg Leu Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Arg Gln Lys
165 170 175
Glu Gly Glu Ser Pro Gln Leu Leu Val Tyr Asn Ser Lys Thr Leu Ala
180 185 190
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe
195 200 205
Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Asn Tyr Tyr
210 215 220
Cys Gln Asn His Tyr Gly Phe Pro Phe Thr Phe Gly Ala Gly Thr Lys
225 230 235 240
Leu Glu Ile Lys Arg Thr Gly Gly Gly Gly Ser Glu Val Gln Leu Val
245 250 255
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser
260 265 270
Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser
290 295 300
Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg
305 310 315 320
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met
325 330 335
Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His
340 345 350
Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln
355 360 365
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser
385 390 395 400
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser
405 410 415
Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys
420 425 430
Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala
435 440 445
Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala
450 455 460
Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr
465 470 475 480
Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys
485 490 495
Leu Thr Val Leu His His His His His His
500 505
<![CDATA[<210> 119]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VH CDR1]]>
<![CDATA[<400> 119]]>
Ser Tyr Trp Met Asn
1 5
<![CDATA[<210> 120]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3]]>-8 VH CDR2
<![CDATA[<400> 120]]>
His Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 121]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VH CDR3]]>
<![CDATA[<400> 121]]>
Asp Arg Gly Ser Phe Gly Ala Trp Phe Ala Tyr
1 5 10
<![CDATA[<210> 122]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VL CDR1]]>
<![CDATA[<400> 122]]>
Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10
<![CDATA[<210> 123]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VL CDR2]]>
<![CDATA[<400> 123]]>
Tyr Thr Ser Arg Leu His Ser
1 5
<![CDATA[<210> 124]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VL CDR3]]>
<![CDATA[<400> 1]]>24
Gln Gln Gly Asn Arg Asn Pro Pro Thr
1 5
<![CDATA[<210> 125]]>
<![CDATA[<211> 121]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VH]]>
<![CDATA[<400> 125]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Val Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Thr Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Tyr Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly His Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Asp Leu Thr Pro Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Asp Arg Gly Ser Phe Gly Ala Trp Phe Ala Tyr Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<![CDATA[<210> 126]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 VL]]>
<![CDATA[<400> 126]]>
Glu Leu Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65 70 75 80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Arg Asn Pro Pro
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 127]]>
<![CDATA[<211> 243]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8 scFv]]>
<![CDATA[<400> 127]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Val Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Thr Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Tyr Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly His Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Asp Leu Thr Pro Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Asp Arg Gly Ser Phe Gly Ala Trp Phe Ala Tyr Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Thr Pro
130 135 140
Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
145 150 155 160
Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser
195 200 205
Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys
210 215 220
Gln Gln Gly Asn Arg Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu
225 230 235 240
Glu Ile Lys
<![CDATA[<210> 128]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-8雙特異性分子]]>
<![CDATA[<400> 128]]>
Glu Val Gln Leu Val Glu Gln Ser Gly Ala Glu Val Val Lys Pro Gly
1 5 10 15
Ala Ser Val Lys Ile Thr Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser
20 25 30
Tyr Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly His Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys
50 55 60
Phe Lys Gly Lys Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Asp Leu Thr Pro Glu Asp Ser Ala Val Tyr Phe
85 90 95
Cys Ala Arg Asp Arg Gly Ser Phe Gly Ala Trp Phe Ala Tyr Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Thr Pro
130 135 140
Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
145 150 155 160
Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser
195 200 205
Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys
210 215 220
Gln Gln Gly Asn Arg Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu
225 230 235 240
Glu Ile Lys Arg Thr Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val
245 250 255
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser
260 265 270
Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser
290 295 300
Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg
305 310 315 320
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met
325 330 335
Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His
340 345 350
Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln
355 360 365
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
370 375 380
Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser
385 390 395 400
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser
405 410 415
Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys
420 425 430
Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala
435 440 445
Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala
450 455 460
Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr
465 470 475 480
Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys
485 490 495
Leu Thr Val Leu His His His His His His
500 505
<![CDATA[<210> 129]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VH CDR1]]>
<![CDATA[<400> 129]]>
Thr Tyr Gly Met Ser
1 5
<![CDATA[<210> 130]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VH CDR2]]>
<![CDATA[<400> 130]]>
Thr Ile Ser Ser Gly Gly His Tyr Ser Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 131]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VH CDR3]]>
<![CDATA[<400> 131]]>
Tyr Tyr Tyr Gly Ser Pro Phe Ala Tyr
1 5
<![CDATA[<210> 132]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VL CDR1]]>
<![CDATA[<400> 132]]>
Arg Ala Ser Gln Asp Ile Gly Ser Ser Leu Asn
1 5 10
<![CDATA[<210> 133]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VL CDR2]]>
<![CDATA[<400> 133]]>
Asp Thr Ser Ser Leu Asp Ser
1 5
<![CDATA[<210> 134]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VL CDR3]]>
<![CDATA[<400> 134]]>
Val Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<![CDATA[<210> 135]]>
<![CDATA[<211> 119]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VH]]>
<![CDATA[<400> 135]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr
20 25 30
Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Ser Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ser Pro Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser
115
<![CDATA[<210> 136]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 VL]]>
<![CDATA[<400> 136]]>
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Asp Ile Gly Ser Ser
20 25 30
Leu Asn Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile
35 40 45
Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
50 55 60
Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
65 70 75 80
Glu Asp Phe Gly Asp Tyr Tyr Cys Val Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 137]]>
<![CDATA[<211> 241]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9 scFv]]>
<![CDATA[<400> 137]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr
20 25 30
Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Ser Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ser Pro Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser Pro Ser Ser
130 135 140
Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser
145 150 155 160
Gln Asp Ile Gly Ser Ser Leu Asn Trp Leu Gln Gln Lys Pro Asp Gly
165 170 175
Thr Ile Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val
180 185 190
Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr
195 200 205
Ile Ser Ser Leu Glu Ser Glu Asp Phe Gly Asp Tyr Tyr Cys Val Gln
210 215 220
Tyr Gly Ser Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
225 230 235 240
Lys
<![CDATA[<210> 138]]>
<![CDATA[<211> 504]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-9雙特異性分子]]>
<![CDATA[<400> ]]> 138
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr
20 25 30
Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Ser Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ser Pro Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser Pro Ser Ser
130 135 140
Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser
145 150 155 160
Gln Asp Ile Gly Ser Ser Leu Asn Trp Leu Gln Gln Lys Pro Asp Gly
165 170 175
Thr Ile Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val
180 185 190
Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr
195 200 205
Ile Ser Ser Leu Glu Ser Glu Asp Phe Gly Asp Tyr Tyr Cys Val Gln
210 215 220
Tyr Gly Ser Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
225 230 235 240
Lys Arg Thr Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser
245 250 255
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala
260 265 270
Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln
275 280 285
Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr
290 295 300
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr
305 310 315 320
Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn
325 330 335
Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn
340 345 350
Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr
355 360 365
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
370 375 380
Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr
385 390 395 400
Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly
405 410 415
Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly
420 425 430
Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly
435 440 445
Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu
450 455 460
Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val
465 470 475 480
Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr
485 490 495
Val Leu His His His His His His
500
<![CDATA[<210> 139]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VH CDR1]]>
<![CDATA[<400> 139]]>
Ser Tyr Ala Met Ser
1 5
<![CDATA[<210> 140]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VH CDR2]]>
<![CDATA[<400> 140]]>
Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Gly
<![CDATA[<210> 141]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VH CDR3]]>
<![CDATA[<400> 141]]>
Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr
1 5
<![CDATA[<210> 142]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VL CDR1]]>
<![CDATA[<400> 142]]>
Arg Ala Ser Gln Asp Ile Gly Ile Asn Leu Ile
1 5 10
<![CDATA[<210> 143]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VL CDR2]]>
<![CDATA[<40]]>0> 143]]>
<br/>
<br/><![CDATA[Asp Thr Ser Ser Leu Asp Ser
1 5
<![CDATA[<210> 144]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VL CDR3]]>
<![CDATA[<400> 144]]>
Leu Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<![CDATA[<210> 145]]>
<![CDATA[<211> 119]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VH]]>
<![CDATA[<400> 145]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
20 25 30
Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser
115
<![CDATA[<210> 146]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 VL]]>
<![CDATA[<400> 146]]>
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Glu Gly Val Ser Leu Thr Cys Arg Ala Ser Gln Asp Ile Gly Ile Asn
20 25 30
Leu Ile Trp Leu Arg Gln Glu Pro Asp Gly Thr Ile Lys Arg Leu Ile
35 40 45
Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
50 55 60
Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
65 70 75 80
Glu Asp Phe Val His Tyr Tyr Cys Leu Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 147]]>
<![CDATA[<211> 241]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 scFv]]>
<![CDATA[<400> 147]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
20 25 30
Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser Pro Ser Ser
130 135 140
Leu Ser Ala Ser Leu Gly Glu Gly Val Ser Leu Thr Cys Arg Ala Ser
145 150 155 160
Gln Asp Ile Gly Ile Asn Leu Ile Trp Leu Arg Gln Glu Pro Asp Gly
165 170 175
Thr Ile Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val
180 185 190
Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr
195 200 205
Ile Ser Ser Leu Glu Ser Glu Asp Phe Val His Tyr Tyr Cys Leu Gln
210 215 220
Tyr Gly Ser Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
225 230 235 240
Lys
<![CDATA[<210> 148]]>
<![CDATA[<211> 504]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-10 scFv]]>
<![CDATA[<400> 148]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly
1 5 10 15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
20 25 30
Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp
35 40 45
Val Ala Thr Ile Ser Ser Gly Gly His Tyr Thr Tyr Tyr Pro Asp Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Tyr Tyr Tyr Gly Ile Pro Phe Gly Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser Pro Ser Ser
130 135 140
Leu Ser Ala Ser Leu Gly Glu Gly Val Ser Leu Thr Cys Arg Ala Ser
145 150 155 160
Gln Asp Ile Gly Ile Asn Leu Ile Trp Leu Arg Gln Glu Pro Asp Gly
165 170 175
Thr Ile Lys Arg Leu Ile Tyr Asp Thr Ser Ser Leu Asp Ser Gly Val
180 185 190
Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr
195 200 205
Ile Ser Ser Leu Glu Ser Glu Asp Phe Val His Tyr Tyr Cys Leu Gln
210 215 220
Tyr Gly Ser Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
225 230 235 240
Lys Arg Thr Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser
245 250 255
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala
260 265 270
Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln
275 280 285
Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr
290 295 300
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr
305 310 315 320
Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn
325 330 335
Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn
340 345 350
Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr
355 360 365
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
370 375 380
Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr
385 390 395 400
Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly
405 410 415
Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly
420 425 430
Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly
435 440 445
Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu
450 455 460
Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val
465 470 475 480
Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr
485 490 495
Val Leu His His His His His His
500
<![CDATA[<210> 149]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VH CDR1]]>
<![CDATA[<400> 149]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 150]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VH CDR2]]>
<![CDATA[<400> 150]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 151]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VH CDR3]]>
<![CDATA[<400> 151]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 152]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VL CDR1]]>
<![CDATA[<400> 152]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 153]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VL CDR2]]>
<![CDATA[<400> 153]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 154]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VL CDR3]]>
<![CDATA[<400> 154]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 155]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VH]]>
<![CDATA[<400> 155]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 156]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 VL]]>
<![CDATA[<400> 156]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Arg Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 157]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 scFv]]>
<![CDATA[<400> 157]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Val Gly Glu Arg Val Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 158]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11雙特異性分子]]>
<![CDATA[<400> 158]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Val Gly Glu Arg Val Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 159]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VH CDR1]]>
<![CDATA[<400> 159]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 160]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VH CDR2]]>
<![CDATA[<400> 160]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<![CDATA[<210> 161]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VH CDR3]]>
<![CDATA[<400> 161]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 162]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VL CDR1]]>
<![CDATA[<400> 162]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 163]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VL CDR2]]>
<![CDATA[<400> 163]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 164]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VL CDR3]]>
<![CDATA[<400> 164]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 165]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VH]]>
<![CDATA[<400> 165]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 166]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 VL]]>
<![CDATA[<400> 166]]>
Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 167]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 scFv]]>
<![CDATA[<400> 167]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 168]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12雙特異性分子]]>
<![CDATA[<400> 168]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 169]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VH CDR1]]>
<![CDATA[<400> 169]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 170]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VH CDR2]]>
<![CDATA[<400> 170]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 171]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VH CDR3]]>
<![CDATA[<400> 171]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 172]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VL CDR1]]>
<![CDATA[<400> 172]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Phe
1 5 10 15
Ala
<![CDATA[<210> 173]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VL CDR2]]>
<![CDATA[<400> 173]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 174]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VL CDR3]]>
<![CDATA[<400> 174]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 175]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VH]]>
<![CDATA[<400> 175]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 176]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 VL]]>
<![CDATA[<400> 176]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 177]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 scFc]]>
<![CDATA[<400> 177]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 178]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13雙特異性分子]]>
<![CDATA[<400> 178]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 179]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VH CDR1]]>
<![CDATA[<400> 179]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 180]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VH CDR2]]>
<![CDATA[<400> 180]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<![CDATA[<210> 181]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VH CDR3]]>
<![CDATA[<400> 181]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 182]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VL CDR1]]>
<![CDATA[<400> 182]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 183]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VL CDR2]]>
<![CDATA[<400> 183]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 184]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VL CDR3]]>
<![CDATA[<400> 184]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 185]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VH]]>
<![CDATA[<400> 185]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 186]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 VL]]>
<![CDATA[<400> 186]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 187]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 scFv]]>
<![CDATA[<400> 187]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 188]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14雙特異性分子]]>
<![CDATA[<400> 188]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 189]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VH CDR1]]>
<![CDATA[<400> 189]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 190]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VH CDR2]]>
<![CDATA[<400> 190]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 191]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VH CDR3]]>
<![CDATA[<400> 191]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 192]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VL CDR1]]>
<![CDATA[<400> 192]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 193]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VL CDR2]]>
<![CDATA[<400> 193]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 194]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VL CDR3]]>
<![CDATA[<400> 194]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 195]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VH]]>
<![CDATA[<400> 195]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 196]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 VL]]>
<![CDATA[<400> 196]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 197]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15 scFv]]>
<![CDATA[<400> 197]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 198]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-15雙特異性分子]]>
<![CDATA[<400> 198]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 199]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VH CDR1]]>
<![CDATA[<400> 199]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 200]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VH CDR2]]>
<![CDATA[<400> 200]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<![CDATA[<210> 201]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VH CDR3]]>
<![CDATA[<400> 201]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 202]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VL CDR1]]>
<![CDATA[<400> 202]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 203]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VL CDR2]]>
<![CDATA[<400> 203]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 204]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VL CDR3]]>
<![CDATA[<400> 204]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 205]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VH]]>
<![CDATA[<400> 205]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 206]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 VL]]>
<![CDATA[<400> 206]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 207]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16 scFv]]>
<![CDATA[<400> 207]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 208]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-16雙特異性分子]]>
<![CDATA[<400> 208]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 209]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VH CDR1]]>
<![CDATA[<400> 209]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 210]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VH CDR2]]>
<![CDATA[<400> 210]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 211]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VH CDR3]]>
<![CDATA[<400> 211]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 212]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VL CDR1]]>
<![CDATA[<400> 212]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 213]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VL CDR2]]>
<![CDATA[<400> 213]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 214]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CD]]>H3-17 VL CDR3
<![CDATA[<400> 214]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 215]]>
<![CDATA[<21]]>1> 123]]>
<br/><![CDATA[<212> PRT]]>
<br/><![CDATA[<213> CDH3-17 VH]]>
<br/>
<br/><![CDATA[<400> 215]]>
<br/>
<br/><![CDATA[Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Pro Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 216]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 VL]]>
<![CDATA[<400> 216]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 217]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17 scFv]]>
<![CDATA[<400> 217]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Pro Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Val Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 218]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-17雙特異性分子]]>
<![CDATA[<400> 218]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Pro Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Val Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 219]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VH CDR1]]>
<![CDATA[<400> 219]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 220]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VH CDR2]]>
<![CDATA[<400> 220]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 221]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VH CDR3]]>
<![CDATA[<400> 221]]>
Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 222]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VL CDR1]]>
<![CDATA[<400> 222]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 223]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VL CDR2]]>
<![CDATA[<400> 223]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 224]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VL CDR3]]>
<![CDATA[<400> 224]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 225]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VH]]>
<![CDATA[<400> 225]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 226]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 VL]]>
<![CDATA[<400> 226]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Lys Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 227]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18 scFv]]>
<![CDATA[<400> 227]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Lys Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 228]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-18]]>雙特異性分子
<![CDATA[<40]]>0> 228]]>
<br/>
<br/><![CDATA[Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Lys Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 229]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VH CDR1]]>
<![CDATA[<400> 229]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 230]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VH CDR2]]>
<![CDATA[<400> 230]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 231]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VH CDR3]]>
<![CDATA[<400> 231]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 232]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VL CDR1]]>
<![CDATA[<400> 232]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 233]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VL CDR2]]>
<![CDATA[<400> 233]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 234]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VL CDR3]]>
<![CDATA[<400> 234]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 235]]>
<![CDATA[<211> 123]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VH]]>
<![CDATA[<400> 235]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 236]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 VL]]>
<![CDATA[<400> 236]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 237]]>
<![CDATA[<211> 251]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19 scFv]]>
<![CDATA[<400> 237]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 238]]>
<![CDATA[<211> 506]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-19雙特異性分子]]>
<![CDATA[<400> 238]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 239]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VH CDR1]]>
<![CDATA[<400> 239]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 240]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VH CDR2]]>
<![CDATA[<400> 240]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<![CDATA[<210> 241]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VH CDR3]]>
<![CDATA[<400> 241]]>
Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10
<![CDATA[<210> 242]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VL CDR1]]>
<![CDATA[<400> 242]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 243]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VL CDR2]]>
<![CDATA[<400> 243]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 244]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VL CDR3]]>
<![CDATA[<400> 244]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> ]]> 245
<![CDATA[<211> 122]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VH]]>
<![CDATA[<400> 245]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<![CDATA[<210> 246]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 VL]]>
<![CDATA[<400> 246]]>
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 247]]>
<![CDATA[<211> 250]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20 scFv]]>
<![CDATA[<400> 247]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser
130 135 140
Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys
145 150 155 160
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
165 170 175
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
180 185 190
Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
195 200 205
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu
210 215 220
Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
225 230 235 240
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 248]]>
<![CDATA[<211> 505]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-20雙特異性分子]]>
<![CDATA[<400> 248]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser
130 135 140
Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys
145 150 155 160
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
165 170 175
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
180 185 190
Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
195 200 205
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu
210 215 220
Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
225 230 235 240
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly Ser
245 250 255
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
260 265 270
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
275 280 285
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
290 295 300
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
305 310 315 320
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
325 330 335
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
340 345 350
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
355 360 365
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
370 375 380
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
385 390 395 400
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
405 410 415
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
420 425 430
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
435 440 445
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
450 455 460
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
465 470 475 480
Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe
485 490 495
Gly Gly Gly Thr Lys Leu Thr Val Leu
500 505
<![CDATA[<210> 249]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VH CDR1]]>
<![CDATA[<400> 249]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 250]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VH CDR2]]>
<![CDATA[<400> 250]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys Ser
1 5 10 15
<![CDATA[<210> 251]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VH CDR3]]>
<![CDATA[<400> 251]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 252]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VL CDR1]]>
<![CDATA[<400> 252]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 253]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VL CDR2]]>
<![CDATA[<400> 253]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 254]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VL CDR3]]>
<![CDATA[<400> 254]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 255]]>
<![CDATA[<211> 124]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VH]]>
<![CDATA[<400> 255]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Thr Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<![CDATA[<210> 256]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 VL]]>
<![CDATA[<400> 256]]>
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 257]]>
<![CDATA[<211> 252]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21 scFv]]>
<![CDATA[<400> 257]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Thr Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 258]]>
<![CDATA[<211> 515]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-21雙特異性分子]]>
<![CDATA[<400> 258]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Thr Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Ser Gly
245 250 255
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
260 265 270
Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
275 280 285
Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
290 295 300
Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr
305 310 315 320
Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp
325 330 335
Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp
340 345 350
Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr
355 360 365
Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
370 375 380
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
385 390 395 400
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
405 410 415
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
420 425 430
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
435 440 445
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
450 455 460
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
465 470 475 480
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
485 490 495
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu His His His
500 505 510
His His His
515
<![CDATA[<210> 259]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VH CDR1]]>
<![CDATA[<400> 259]]>
Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 260]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VH CDR2]]>
<![CDATA[<400> 260]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys Ser
1 5 10 15
<![CDATA[<210> 261]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VH CDR3]]>
<![CDATA[<400> 261]]>
Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 262]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VL CDR1]]>
<![CDATA[<400> 262]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 263]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VL CDR2]]>
<![CDATA[<400> 263]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 264]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VL CDR3]]>
<![CDATA[<400> 264]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 265]]>
<![CDATA[<211> 124]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VH]]>
<![CDATA[<400> 265]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<![CDATA[<210> 266]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 VL]]>
<![CDATA[<400> 266]]>
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 267]]>
<![CDATA[<211> 252]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22 scFv]]>
<![CDATA[<400> 267]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 268]]>
<![CDATA[<211> 515]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-22雙特異性分子]]>
<![CDATA[<400> 268]]>
Glu Val Gln Leu Leu Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu
50 55 60
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Ser Gly
245 250 255
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
260 265 270
Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
275 280 285
Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
290 295 300
Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr
305 310 315 320
Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp
325 330 335
Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp
340 345 350
Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr
355 360 365
Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
370 375 380
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
385 390 395 400
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
405 410 415
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
420 425 430
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
435 440 445
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
450 455 460
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
465 470 475 480
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
485 490 495
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu His His His
500 505 510
His His His
515
<![CDATA[<21]]>0> 269]]>
<br/><![CDATA[<211> 5]]>
<br/><![CDATA[<212> PRT]]>
<br/><![CDATA[<213> CDH3-23 VH CDR1]]>
<br/>
<br/><![CDATA[<400> 269]]>
<br/>
<br/><![CDATA[Ser Tyr Pro Ile Asn
1 5
<![CDATA[<210> 270]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VH CDR2]]>
<![CDATA[<400> 270]]>
Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asp Ser Ala Leu Lys Ser
1 5 10 15
<![CDATA[<210> 271]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VH CDR3]]>
<![CDATA[<400> 271]]>
Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
1 5 10 15
<![CDATA[<210> 272]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VL CDR1]]>
<![CDATA[<400> 272]]>
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<![CDATA[<210> 273]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VL CDR2]]>
<![CDATA[<400> 273]]>
Trp Ala Ser Thr Arg Glu Ser
1 5
<![CDATA[<210> 274]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VL CDR3]]>
<![CDATA[<400> 274]]>
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<![CDATA[<210> 275]]>
<![CDATA[<211> 124]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VH]]>
<![CDATA[<400> 275]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asp Ser Ala Leu
50 55 60
Lys Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<![CDATA[<210> 276]]>
<![CDATA[<211> 113]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 VL]]>
<![CDATA[<400> 276]]>
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<![CDATA[<210> 277]]>
<![CDATA[<211> 252]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23 scFv]]>
<![CDATA[<400> 277]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asp Ser Ala Leu
50 55 60
Lys Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
245 250
<![CDATA[<210> 278]]>
<![CDATA[<211> 515]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-23雙特異性分子]]>
<![CDATA[<400> 278]]>
Glu Val Gln Leu Val Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser
1 5 10 15
Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
20 25 30
Tyr Pro Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Leu Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asp Ser Ala Leu
50 55 60
Lys Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe
65 70 75 80
Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Ala Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Met Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met
145 150 155 160
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn
165 170 175
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
180 185 190
Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys
210 215 220
Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro
225 230 235 240
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Ser Gly
245 250 255
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
260 265 270
Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
275 280 285
Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
290 295 300
Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr
305 310 315 320
Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp
325 330 335
Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp
340 345 350
Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr
355 360 365
Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
370 375 380
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
385 390 395 400
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
405 410 415
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
420 425 430
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
435 440 445
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
450 455 460
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
465 470 475 480
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
485 490 495
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu His His His
500 505 510
His His His
515
<![CDATA[<210> 279]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VH CDR1]]>
<![CDATA[<400> 279]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 280]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VH CDR2]]>
<![CDATA[<400> 280]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe Gln
1 5 10 15
Gly
<![CDATA[<210> 281]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VH CDR3]]>
<![CDATA[<400> 281]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 282]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VL CDR1]]>
<![CDATA[<400> 282]]>
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<![CDATA[<210> 283]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 ]]>VL CDR2
<![CDATA[<400> 283]]>
Asn Ala Lys Thr Leu Ala Asp
1 5
<![CDATA[<210> 284]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VL CDR3]]>
<![CDATA[<400> 284]]>
Gln His Phe Trp Ser Thr Pro Tyr Thr
1 5
<![CDATA[<210> 285]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VH]]>
<![CDATA[<400> 285]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 286]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 VL]]>
<![CDATA[<400> 286]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 287]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 scFv]]>
<![CDATA[<400> 287]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 288]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24雙特異性分子]]>
<![CDATA[<400> 288]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 289]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VH CDR1]]>
<![CDATA[<400> 289]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 290]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VH CDR2]]>
<![CDATA[<400> 290]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 291]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VH CDR3]]>
<![CDATA[<400> 291]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 292]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VL CDR1]]>
<![CDATA[<400> 292]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 293]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VL CDR2]]>
<![CDATA[<400> 293]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 294]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VL CDR3]]>
<![CDATA[<400> 294]]>
Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 295]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VH]]>
<![CDATA[<400> 295]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 296]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 VL]]>
<![CDATA[<400> 296]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 297]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 scFv]]>
<![CDATA[<400> 297]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 298]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25雙特異性分子]]>
<![CDATA[<400> 298]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 299]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VH CDR1]]>
<![CDATA[<400> 299]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 300]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VH CDR2]]>
<![CDATA[<400> 300]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe Gln
1 5 10 15
Gly
<![CDATA[<210> 301]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VH CDR3]]>
<![CDATA[<400> 301]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 302]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VL CDR1]]>
<![CDATA[<400> 302]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 303]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VL CDR2]]>
<![CDATA[<400> 303]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 304]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VL CDR3]]>
<![CDATA[<400> 304]]>
Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 305]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VH]]>
<![CDATA[<400> 305]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 306]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 VL]]>
<![CDATA[<400> 306]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 307]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 scFv]]>
<![CDATA[<400> 307]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 308]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26雙特異性分子]]>
<![CDATA[<400> 308]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 309]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VH CDR1]]>
<![CDATA[<400> 309]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 310]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VH CDR2]]>
<![CDATA[<400> 310]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<![CDATA[<210> 311]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VH CDR3]]>
<![CDATA[<400> 311]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 312]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VL CDR1]]>
<![CDATA[<400> 312]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 313]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VL CDR2]]>
<![CDATA[<400> 313]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 314]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VL CDR3]]>
<![CDATA[<400> 314]]>
Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 315]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> ]]>CDH3-27 VH
<![CDATA[<400> 315]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 316]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 VL]]>
<![CDATA[<400> 316]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 317]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 scFv]]>
<![CDATA[<400> 317]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 318]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27雙特異性分子]]>
<![CDATA[<400> 318]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 319]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VH CDR1]]>
<![CDATA[<400> 319]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 320]]>
<![CDATA[<211> 17]]>
<![CDATA[<212]]>> PRT]]>
<br/><![CDATA[<213> CDH3-28 VH CDR2]]>
<br/>
<br/><![CDATA[<400> 320]]>
<br/>
<br/><![CDATA[Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val Lys
1 5 10 15
Gly
<![CDATA[<210> 321]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VH CDR3]]>
<![CDATA[<400> 321]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 322]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VL CDR1]]>
<![CDATA[<400> 322]]>
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<![CDATA[<210> 323]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VL CDR2]]>
<![CDATA[<400> 323]]>
Asn Ala Lys Thr Leu Ala Asp
1 5
<![CDATA[<210> 324]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VL CDR3]]>
<![CDATA[<400> 324]]>
Gln His Ser Trp Ser Thr Pro Tyr Thr
1 5
<![CDATA[<210> 32]]>5
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VH]]>
<![CDATA[<400> 325]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 326]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 VL]]>
<![CDATA[<400> 326]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 327]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28 scFv]]>
<![CDATA[<400> 327]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 328]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-28雙特異性分子]]>
<![CDATA[<400> 328]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 329]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VH CDR1]]>
<![CDATA[<400> 329]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 330]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VH CDR2]]>
<![CDATA[<400> 330]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val Lys
1 5 10 15
Gly
<![CDATA[<210> 331]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VH CDR3]]>
<![CDATA[<400> 331]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 332]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VL CDR1]]>
<![CDATA[<400> 332]]>
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<![CDATA[<210> 333]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VL CDR2]]>
<![CDATA[<400> 333]]>
Asn Ala Lys Thr Leu Ala Asp
1 5
<![CDATA[<210> 334]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VL CDR3]]>
<![CDATA[<400> 334]]>
Gln His Ser Trp Ser Thr Pro Tyr Thr
1 5
<![CDATA[<210> 335]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VH]]>
<![CDATA[<400> 335]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 336]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 VL]]>
<![CDATA[<400> 336]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 337]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29 scFv]]>
<![CDATA[<400> 337]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 338]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-29雙特異性分子]]>
<![CDATA[<400> 338]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 339]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VH CDR1]]>
<![CDATA[<400> 339]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 340]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VH CDR2]]>
<![CDATA[<400> 340]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val Lys
1 5 10 15
Gly
<![CDATA[<210> 341]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VH CDR3]]>
<![CDATA[<400> 341]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 342]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VL CDR1]]>
<![CDATA[<400> 342]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 343]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VL CDR2]]>
<![CDATA[<400> 343]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 344]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VL CDR3]]>
<![CDATA[<400> 344]]>
Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 345]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-3]]>0 VH
<![CDATA[<400> 345]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 346]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 VL]]>
<![CDATA[<400> 346]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 347]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30 scFv]]>
<![CDATA[<400> 347]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 348]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-30雙特異性分子]]>
<![CDATA[<400> 348]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 349]]>
<![CDATA[<211> 5]]>
<![CDATA[<212>]]> PRT
<![CDATA[<213> CDH3-31 VH CDR1]]>
<![CDATA[<400> 349]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 350]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VH CDR2]]>
<![CDATA[<400> 350]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val Lys
1 5 10 15
Gly
<![CDATA[<210> 351]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VH CDR3]]>
<![CDATA[<400> 351]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 352]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VL CDR1]]>
<![CDATA[<400> 352]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 353]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VL CDR2]]>
<![CDATA[<400> 353]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 354]]>
<![CDATA[<21]]>1> 9]]>
<br/><![CDATA[<212> PRT]]>
<br/><![CDATA[<213> CDH3-31 VL CDR3]]>
<br/>
<br/><![CDATA[<400> 354]]>
<br/>
<br/><![CDATA[Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 355]]>
<![CDATA[<211> 117]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VH]]>
<![CDATA[<400> 355]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser
115
<![CDATA[<210> 356]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 VL]]>
<![CDATA[<400> 356]]>
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 357]]>
<![CDATA[<211> 239]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31 scFv]]>
<![CDATA[<400> 357]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Ser Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
225 230 235
<![CDATA[<210> 358]]>
<![CDATA[<211> 494]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-31雙特異性分子]]>
<![CDATA[<400> 358]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Ser Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
485 490
<![CDATA[<210> 359]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VH CDR1]]>
<![CDATA[<400> 359]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 360]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VH CDR2]]>
<![CDATA[<400> 360]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 361]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3]]>-32 VH CDR3
<![CDATA[<400> 361]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 362]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VL CDR1]]>
<![CDATA[<400> 362]]>
Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala
1 5 10
<![CDATA[<210> 363]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VH CDR2]]>
<![CDATA[<400> 363]]>
Asn Ala Lys Thr Leu Ala Glu
1 5
<![CDATA[<210> 364]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VL CDR3]]>
<![CDATA[<400> 364]]>
Gln His His Tyr Gly Thr Pro Tyr Thr
1 5
<![CDATA[<210> 365]]>
<![CDATA[<211> 118]]>
<![CDATA[<212]]>> PRT]]>
<br/><![CDATA[<213> CDH3-32 VH]]>
<br/>
<br/><![CDATA[<400> 365]]>
<br/>
<br/><![CDATA[Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<![CDATA[<210> 366]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 VL]]>
<![CDATA[<400> 366]]>
Glu Leu Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 367]]>
<![CDATA[<211> 240]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32 scFv]]>
<![CDATA[<400> 367]]>
Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser Pro Ala Ser Leu
130 135 140
Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu
145 150 155 160
Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser
165 170 175
Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile
195 200 205
Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His
210 215 220
Tyr Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
225 230 235 240
<![CDATA[<210> 368]]>
<![CDATA[<211> 503]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-32雙特異性分子]]>
<![CDATA[<400> 368]]>
Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Glu Leu Gln Met Thr Gln Ser Pro Ala Ser Leu
130 135 140
Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu
145 150 155 160
Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser
165 170 175
Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile
195 200 205
Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His
210 215 220
Tyr Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
225 230 235 240
Arg Thr Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
245 250 255
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala
260 265 270
Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala
275 280 285
Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn
290 295 300
Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile
305 310 315 320
Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu
325 330 335
Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe
340 345 350
Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu
355 360 365
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
370 375 380
Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val
385 390 395 400
Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala
405 410 415
Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln
420 425 430
Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr
435 440 445
Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr
450 455 460
Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu
465 470 475 480
Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val
485 490 495
Leu His His His His His His
500
<![CDATA[<210> 369]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VH CDR1]]>
<![CDATA[<400> 369]]>
Ser Tyr Trp Met His
1 5
<![CDATA[<210> 370]]>
<![CDATA[<211> 17]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VH CDR2]]>
<![CDATA[<400> 370]]>
Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<![CDATA[<210> 371]]>
<![CDATA[<211> 8]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VH CDR3]]>
<![CDATA[<400> 371]]>
Ser Gly Pro Gly Tyr Phe Asp Val
1 5
<![CDATA[<210> 372]]>
<![CDATA[<211> 11]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VL CDR1]]>
<![CDATA[<400> 372]]>
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<![CDATA[<210> 373]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VL CDR2]]>
<![CDATA[<400> 373]]>
Asn Ala Lys Thr Leu Ala Asp
1 5
<![CDATA[<210> 374]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VL CDR3]]>
<![CDATA[<400> 374]]>
Gln His Phe Trp Ser Thr Pro Tyr Thr
1 5
<![CDATA[<210> 375]]>
<![CDATA[<211> 118]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VH]]>
<![CDATA[<400> 375]]>
Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<![CDATA[<210> 376]]>
<![CDATA[<211> 107]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 VL]]>
<![CDATA[<400> 376]]>
Glu Leu Val Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45
Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<![CDATA[<210> 377]]>
<![CDATA[<211> 240]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33 scFv]]>
<![CDATA[<400> 377]]>
Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser Pro Ala Ser Leu
130 135 140
Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly
145 150 155 160
Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser
165 170 175
Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile
195 200 205
Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe
210 215 220
Trp Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
225 230 235 240
<![CDATA[<210> 378]]>
<![CDATA[<211> 503]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-33雙特異性分子]]>
<![CDATA[<400> 378]]>
Glu Val Gln Leu Val Glu Gln Pro Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15
Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
20 25 30
Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Ser Ser Val Tyr Phe
85 90 95
Cys Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Glu Leu Val Met Thr Gln Ser Pro Ala Ser Leu
130 135 140
Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly
145 150 155 160
Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser
165 170 175
Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro
180 185 190
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile
195 200 205
Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe
210 215 220
Trp Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
225 230 235 240
Arg Thr Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
245 250 255
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala
260 265 270
Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala
275 280 285
Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn
290 295 300
Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile
305 310 315 320
Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu
325 330 335
Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe
340 345 350
Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu
355 360 365
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
370 375 380
Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val
385 390 395 400
Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala
405 410 415
Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln
420 425 430
Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr
435 440 445
Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr
450 455 460
Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu
465 470 475 480
Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val
485 490 495
Leu His His His His His His
500
<![CDATA[<210> 379]]>
<![CDATA[<211> 1097]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -HALB]]>
<![CDATA[<400> 379]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser
500 505 510
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
515 520 525
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
530 535 540
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
545 550 555 560
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
565 570 575
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
580 585 590
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
595 600 605
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
610 615 620
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
625 630 635 640
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
645 650 655
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
660 665 670
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
675 680 685
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
690 695 700
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
705 710 715 720
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
725 730 735
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
740 745 750
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
755 760 765
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
770 775 780
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
785 790 795 800
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
805 810 815
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
820 825 830
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
835 840 845
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
850 855 860
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
865 870 875 880
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
885 890 895
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
900 905 910
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
915 920 925
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
930 935 940
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
945 950 955 960
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
965 970 975
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
980 985 990
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
995 1000 1005
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala
1010 1015 1020
Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln
1025 1030 1035
Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys
1040 1045 1050
Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu
1055 1060 1065
Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu
1070 1075 1080
Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu
1085 1090 1095
<![CDATA[<210> 380]]>
<![CDATA[<211> 1097]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -HALB-變異體-1]]>
<![CDATA[<400> 380]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser
500 505 510
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
515 520 525
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
530 535 540
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
545 550 555 560
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
565 570 575
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
580 585 590
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
595 600 605
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
610 615 620
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
625 630 635 640
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
645 650 655
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
660 665 670
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
675 680 685
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
690 695 700
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
705 710 715 720
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
725 730 735
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
740 745 750
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
755 760 765
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
770 775 780
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
785 790 795 800
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
805 810 815
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
820 825 830
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
835 840 845
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
850 855 860
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
865 870 875 880
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
885 890 895
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
900 905 910
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
915 920 925
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
930 935 940
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
945 950 955 960
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
965 970 975
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
980 985 990
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
995 1000 1005
Tyr Val Pro Lys Glu Phe Asn Ala Gly Thr Phe Thr Phe His Ala
1010 1015 1020
Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln
1025 1030 1035
Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys
1040 1045 1050
Glu Gln Leu Lys Ala Ala Met Asp Asp Phe Ala Ala Phe Val Glu
1055 1060 1065
Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu
1070 1075 1080
Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu
1085 1090 1095
<![CDATA[<210> 381]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -LY-FcB-CH]]>
<![CDATA[<400> 381]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Cys Asn Gly Pro
545
<![CDATA[<210> 382]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -LH-FcB-CH]]>
<![CDATA[<400> 382]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His Pro Ala Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Cys Asn Gly Pro
545
<![CDATA[<210> 383]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -LH-FcB-LH]]>
<![CDATA[<400> 383]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His Pro Ala Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Ala Asn Gly Pro
545
<![CDATA[<210> 384]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -LY-FcB-LH]]>
<![CDATA[<400> 384]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Ala Asn Gly Pro
545
<![CDATA[<210> 385]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -CH-FcB-LH]]>
<![CDATA[<400> 385]]>
Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Ala Asn Gly Pro
545
<![CDATA[<210> 386]]>
<![CDATA[<211> 549]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -CH-FcB-LY]]>
<![CDATA[<400> 386]]>
Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr
530 535 540
Pro Ala Asn Gly Pro
545
<![CDATA[<210> 387]]>
<![CDATA[<211> 532]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -156]]>
<![CDATA[<400> 387]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
500 505 510
Gly Gly Ser Arg Asp Trp Asp Phe Asp Val Phe Gly Gly Gly Thr Pro
515 520 525
Val Gly Gly Pro
530
<![CDATA[<210> 388]]>
<![CDATA[<211> 574]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -LY-FcB-CH-156]]>
<![CDATA[<400> 388]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His
530 535 540
Pro Cys Asn Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Arg Asp Trp
545 550 555 560
Asp Phe Asp Val Phe Gly Gly Gly Thr Pro Val Gly Gly Pro
565 570
<![CDATA[<210> 389]]>
<![CDATA[<211> 574]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -CH-FcB-LY-156]]>
<![CDATA[<400> 389]]>
Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly
1 5 10 15
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Ser Phe Ser Ser Tyr Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr
65 70 75 80
Ala Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
85 90 95
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Ala Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg
115 120 125
Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
145 150 155 160
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu
165 170 175
Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser
180 185 190
Asn Gln Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro
195 200 205
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro
210 215 220
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
225 230 235 240
Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr
245 250 255
Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
260 265 270
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
275 280 285
Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
290 295 300
Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
305 310 315 320
Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr
325 330 335
Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
340 345 350
Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
355 360 365
Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn
370 375 380
Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
385 390 395 400
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
405 410 415
Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro
420 425 430
Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr
435 440 445
Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro
450 455 460
Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala
465 470 475 480
Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser
485 490 495
Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr
500 505 510
Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
515 520 525
Gly Gly Gly Ser Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr
530 535 540
Pro Ala Asn Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Arg Asp Trp
545 550 555 560
Asp Phe Asp Val Phe Gly Gly Gly Thr Pro Val Gly Gly Pro
565 570
<![CDATA[<210> 390]]>
<![CDATA[<211> 37]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 人類表位簇D3C]]>
<![CDATA[<400> 390]]>
His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe Val Leu Lys
1 5 10 15
Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu Asp Val Asn
20 25 30
Glu Ala Pro Val Phe
35
<![CDATA[<210> 391]]>
<![CDATA[<211> 37]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 獼猴表位簇D3C]]>
<![CDATA[<400> 391]]>
His Thr Leu Tyr Val Glu Val Thr Asn Glu Ala Pro Phe Val Leu Lys
1 5 10 15
Leu Pro Thr Ser Thr Ala Thr Ile Val Val His Val Glu Asp Val Asn
20 25 30
Glu Ala Pro Val Phe
35
<![CDATA[<210> 392]]>
<![CDATA[<211> 4]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子1]]>
<![CDATA[<400> 392]]>
Gly Gly Gly Gly
1
<![CDATA[<210> 393]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子2]]>
<![CDATA[<400> 393]]>
Gly Gly Gly Gly Ser
1 5
<![CDATA[<210> 394]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子3]]>
<![CDATA[<400> 394]]>
Gly Gly Gly Gly Gln
1 5
<![CDATA[<210> 395]]>
<![CDATA[<211> 6]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子4]]>
<![CDATA[<400> 395]]>
Ser Gly Gly Gly Gly Ser
1 5
<![CDATA[<210> 396]]>
<![CDATA[<211> 6]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子5]]>
<![CDATA[<400> 396]]>
Pro Gly Gly Gly Gly Ser
1 5
<![CDATA[<210> 397]]>
<![CDATA[<211> 6]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子6]]>
<![CDATA[<400> 397]]>
Pro Gly Gly Asp Gly Ser
1 5
<![CDATA[<210> 398]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子7]]>
<![CDATA[<400> 398]]>
Gly Gly Gly Gly Ser Gly Gly Gly Ser
1 5
<![CDATA[<210> 399]]>
<![CDATA[<211> 10]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子8]]>
<![CDATA[<400> 399]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
<![CDATA[<210> 400]]>
<![CDATA[<211> 15]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子9]]>
<![CDATA[<400> 400]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<![CDATA[<210> 401]]>
<![CDATA[<211> 20]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子10]]>
<![CDATA[<400> 401]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<![CDATA[<210> 402]]>
<![CDATA[<211> 25]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子11]]>
<![CDATA[<400> 402]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser
20 25
<![CDATA[<210> 403]]>
<![CDATA[<211> 30]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子12]]>
<![CDATA[<400> 403]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
20 25 30
<![CDATA[<210> 404]]>
<![CDATA[<211> 35]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子13]]>
<![CDATA[<400> 404]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
Gly Gly Ser
35
<![CDATA[<210> 405]]>
<![CDATA[<211> 40]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 連接子14]]>
<![CDATA[<400> 405]]>
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
Gly Gly Ser Gly Gly Gly Gly Ser
35 40
<![CDATA[<210> 406]]>
<![CDATA[<211> 227]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-1+c/-g]]>
<![CDATA[<400> 406]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys
225
<![CDATA[<210> 407]]>
<![CDATA[<211> 225]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-2 +c/-g/delGK]]>
<![CDATA[<400> 407]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro
225
<![CDATA[<210> 408]]>
<![CDATA[<211> 227]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-3 -c/+g]]>
<![CDATA[<400> 408]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys
225
<![CDATA[<210> 409]]>
<![CDATA[<211> 225]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-4 -c/+g/ delGK]]>
<![CDATA[<400> 409]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro
225
<![CDATA[<210> 410]]>
<![CDATA[<211> 227]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-5 -c/-g]]>
<![CDATA[<400> 410]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys
225
<![CDATA[<210> 411]]>
<![CDATA[<211> 225]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-6-c/-g/ delGK]]>
<![CDATA[<400> 411]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro
225
<![CDATA[<210> 412]]>
<![CDATA[<211> 227]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-7 +c/+g]]>
<![CDATA[<400> 412]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys
225
<![CDATA[<210> 413]]>
<![CDATA[<211> 225]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> Fc單體-8 +c/+g/ delGK]]>
<![CDATA[<400> 413]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro
225
<![CDATA[<210> 414]]>
<![CDATA[<211> 484]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-1]]>
<![CDATA[<400> 414]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225 230 235 240
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
245 250 255
Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
260 265 270
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
275 280 285
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
290 295 300
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
305 310 315 320
Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr
325 330 335
Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
340 345 350
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
355 360 365
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
370 375 380
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
385 390 395 400
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
405 410 415
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
420 425 430
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
435 440 445
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
450 455 460
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
465 470 475 480
Ser Pro Gly Lys
<![CDATA[<210> 415]]>
<![CDATA[<211> 480]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-2]]>
<![CDATA[<400> 415]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
225 230 235 240
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
245 250 255
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
260 265 270
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
275 280 285
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
290 295 300
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
305 310 315 320
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
325 330 335
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
340 345 350
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
355 360 365
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
370 375 380
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
385 390 395 400
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
405 410 415
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
420 425 430
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
435 440 445
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
450 455 460
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
465 470 475 480
<![CDATA[<210> 416]]>
<![CDATA[<211> 484]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-3]]>
<![CDATA[<400> 416]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225 230 235 240
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
245 250 255
Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
260 265 270
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
275 280 285
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
290 295 300
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
305 310 315 320
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
325 330 335
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
340 345 350
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
355 360 365
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
370 375 380
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
385 390 395 400
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
405 410 415
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
420 425 430
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
435 440 445
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
450 455 460
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
465 470 475 480
Ser Pro Gly Lys
<![CDATA[<210> 417]]>
<![CDATA[<211> 480]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-4]]>
<![CDATA[<400> 417]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
225 230 235 240
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
245 250 255
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
260 265 270
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
275 280 285
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
290 295 300
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
305 310 315 320
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
325 330 335
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
340 345 350
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
355 360 365
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
370 375 380
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
385 390 395 400
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
405 410 415
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
420 425 430
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
435 440 445
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
450 455 460
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
465 470 475 480
<![CDATA[<210> 418]]>
<![CDATA[<211> 484]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-5]]>
<![CDATA[<400> 418]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225 230 235 240
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
245 250 255
Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
260 265 270
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
275 280 285
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
290 295 300
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
305 310 315 320
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr
325 330 335
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
340 345 350
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
355 360 365
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
370 375 380
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
385 390 395 400
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
405 410 415
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
420 425 430
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
435 440 445
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
450 455 460
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
465 470 475 480
Ser Pro Gly Lys
<![CDATA[<210> 419]]>
<![CDATA[<211> 480]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-6]]>
<![CDATA[<400> 419]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
225 230 235 240
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
245 250 255
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
260 265 270
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
275 280 285
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
290 295 300
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
305 310 315 320
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
325 330 335
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
340 345 350
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
355 360 365
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
370 375 380
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
385 390 395 400
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
405 410 415
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
420 425 430
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
435 440 445
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
450 455 460
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
465 470 475 480
<![CDATA[<210> 420]]>
<![CDATA[<211> 484]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-7]]>
<![CDATA[<400> 420]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225 230 235 240
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
245 250 255
Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
260 265 270
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
275 280 285
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
290 295 300
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
305 310 315 320
Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr
325 330 335
Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
340 345 350
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
355 360 365
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
370 375 380
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
385 390 395 400
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
405 410 415
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
420 425 430
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
435 440 445
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
450 455 460
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
465 470 475 480
Ser Pro Gly Lys
<![CDATA[<210> 421]]>
<![CDATA[<211> 480]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> scFc-8]]>
<![CDATA[<400> 421]]>
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
225 230 235 240
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
245 250 255
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
260 265 270
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
275 280 285
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
290 295 300
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
305 310 315 320
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
325 330 335
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
340 345 350
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
355 360 365
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
370 375 380
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
385 390 395 400
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
405 410 415
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
420 425 430
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
435 440 445
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
450 455 460
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
465 470 475 480
<![CDATA[<210> 422]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-11 xI2C -scFc]]>
<![CDATA[<400> 422]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Val Gly Glu Arg Val Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 423]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 xF12q -scFc]]>
<![CDATA[<400> 423]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 424]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-12 xI2C -scFc]]>
<![CDATA[<400> 424]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 425]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-13 xI2C -scFc]]>
<![CDATA[<400> 425]]>
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Pro Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Ala Ser Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 426]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 xF12q -scFc]]>
<![CDATA[<400> 426]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 427]]>
<![CDATA[<211> 994]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-14 xI2C -scFc]]>
<![CDATA[<400> 427]]>
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr
20 25 30
Pro Ile Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Gly Val Tyr Asp Phe Asp Gly Arg Gly Ala Met Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln
130 135 140
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145 150 155 160
Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr
165 170 175
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
180 185 190
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
210 215 220
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr
225 230 235 240
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys
275 280 285
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
305 310 315 320
Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn
325 330 335
Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
340 345 350
Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr
355 360 365
Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
370 375 380
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val
385 390 395 400
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
405 410 415
Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro
420 425 430
Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly
435 440 445
Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
450 455 460
Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
465 470 475 480
Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val
485 490 495
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys
500 505 510
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
515 520 525
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
530 535 540
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
545 550 555 560
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
565 570 575
Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys
580 585 590
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
595 600 605
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
610 615 620
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
625 630 635 640
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
645 650 655
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
660 665 670
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
675 680 685
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
690 695 700
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
705 710 715 720
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
725 730 735
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
740 745 750
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
755 760 765
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
770 775 780
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
785 790 795 800
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
805 810 815
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
820 825 830
Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg
835 840 845
Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
850 855 860
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
865 870 875 880
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
885 890 895
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
900 905 910
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
915 920 925
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
930 935 940
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
945 950 955 960
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
965 970 975
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
980 985 990
Gly Lys
<![CDATA[<210> 428]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 xF12q -scFc]]>
<![CDATA[<400> 428]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 429]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-24 xI2C -scFc]]>
<![CDATA[<400> 429]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
145 150 155 160
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Lys Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp
210 215 220
Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 430]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 xF12q -scFc]]>
<![CDATA[<400> 430]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 431]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-25 xI2C -scFc]]>
<![CDATA[<400> 431]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 432]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 xF12q -scFc]]>
<![CDATA[<400> 432]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 433]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-26 xI2C -scFc]]>
<![CDATA[<400> 433]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 434]]>
<![CDATA[<211> ]]> 982
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 xF12q -scFc]]>
<![CDATA[<400> 434]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 435]]>
<![CDATA[<211> 982]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> CDH3-27 xI2C -scFc]]>
<![CDATA[<400> 435]]>
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Asp Thr Ser Asp Ser Tyr Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Pro Gly Tyr Phe Asp Val Trp Gly Gln Gly Thr Met
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser
130 135 140
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn
145 150 155 160
Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
165 170 175
Lys Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr
210 215 220
Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Ser
225 230 235 240
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
245 250 255
Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
260 265 270
Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys
275 280 285
Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
290 295 300
Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
305 310 315 320
Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu
325 330 335
Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser
340 345 350
Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
370 375 380
Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
385 390 395 400
Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser
405 410 415
Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
420 425 430
Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg
435 440 445
Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
450 455 460
Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser
465 470 475 480
Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly
485 490 495
Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
500 505 510
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
515 520 525
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
530 535 540
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
545 550 555 560
Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser
565 570 575
Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
580 585 590
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
610 615 620
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
625 630 635 640
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
645 650 655
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
660 665 670
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
675 680 685
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
690 695 700
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
705 710 715 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
725 730 735
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
740 745 750
Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
755 760 765
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
770 775 780
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
785 790 795 800
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
805 810 815
Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly
820 825 830
Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp
835 840 845
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
850 855 860
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
865 870 875 880
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
885 890 895
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
900 905 910
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
915 920 925
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
930 935 940
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
945 950 955 960
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
965 970 975
Ser Leu Ser Pro Gly Lys
980
<![CDATA[<210> 436]]>
<![CDATA[<211> 6]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 六-]]>his
<![CDATA[<400> 436]]>
His His His His His His
1 5
<![CDATA[<210> 437]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> P156]]>
<![CDATA[<400> 437]]>
Arg Asp Trp Asp Phe Asp Val Phe Gly Gly Gly Thr Pro Val Gly Gly
1 5 10 15
<![CDATA[<210> 438]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 線性FcRn BP]]>
<![CDATA[<220>]]>
<![CDATA[<221> 其他特徵]]>
<![CDATA[<222> (12)..(12)]]>
<![CDATA[<223> Xaa可為任何天然存在的胺基酸]]>
<![CDATA[<400> 438]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Xaa Pro Ala Asn Gly
1 5 10 15
<![CDATA[<210> 439]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 線性FcRn BP-Y]]>
<![CDATA[<400> 439]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly
1 5 10 15
<![CDATA[<210> 440]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 線性FcRn BP-H]]>
<![CDATA[<400> 440]]>
Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His Pro Ala Asn Gly
1 5 10 15
<![CDATA[<210> 441]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 核心FcRn BP-H]]>
<![CDATA[<400> 441]]>
Thr Gly His Phe Gly Gly Leu His Pro
1 5
<![CDATA[<210> 442]]>
<![CDATA[<211> 16]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> 環狀FcRn BP-H]]>
<![CDATA[<400> 442]]>
Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly
1 5 10 15
<![CDATA[<210> 443]]>
<![CDATA[<211> 585]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> HALB]]>
<![CDATA[<400> 443]]>
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
100 105 110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
115 120 125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
130 135 140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
145 150 155 160
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
165 170 175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
180 185 190
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
195 200 205
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
210 215 220
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
225 230 235 240
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
245 250 255
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
260 265 270
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
275 280 285
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
290 295 300
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
305 310 315 320
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
325 330 335
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
340 345 350
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
355 360 365
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
370 375 380
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
385 390 395 400
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
405 410 415
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
420 425 430
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
435 440 445
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
450 455 460
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
465 470 475 480
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
485 490 495
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575
Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585
<![CDATA[<210> 444]]>
<![CDATA[<211> 585]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> HALB變異體1]]>
<![CDATA[<400> 444]]>
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
100 105 110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
115 120 125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
130 135 140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
145 150 155 160
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
165 170 175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
180 185 190
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
195 200 205
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
210 215 220
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
225 230 235 240
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
245 250 255
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
260 265 270
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
275 280 285
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
290 295 300
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
305 310 315 320
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
325 330 335
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
340 345 350
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
355 360 365
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
370 375 380
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
385 390 395 400
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
405 410 415
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
420 425 430
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
435 440 445
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
450 455 460
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
465 470 475 480
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
485 490 495
Tyr Val Pro Lys Glu Phe Asn Ala Gly Thr Phe Thr Phe His Ala Asp
500 505 510
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540
Lys Ala Ala Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575
Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585
<![CDATA[<210> 445]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-L1]]>
<![CDATA[<400> 445]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 446]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-L2]]>
<![CDATA[<400> 446]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 447]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-L3]]>
<![CDATA[<400> 447]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 448]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-H1]]>
<![CDATA[<400> 448]]>
Ile Tyr Ala Met Asn
1 5
<![CDATA[<210> 449]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-H2]]>
<![CDATA[<400> 449]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Ser
<![CDATA[<210> 450]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的CDR-H3]]>
<![CDATA[<400> 450]]>
His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe Ala Tyr
1 5 10
<![CDATA[<210> 451]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的VH]]>
<![CDATA[<400> 451]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 452]]>
<![CDATA[<211> ]]>109
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的VL]]>
<![CDATA[<400> 452]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 453]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F6A的VH-VL]]>
<![CDATA[<400> 453]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 454]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-L1]]>
<![CDATA[<400> 454]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 455]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-L2]]>
<![CDATA[<400> 455]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> ]]>456
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-L3]]>
<![CDATA[<400> 456]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 457]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-H1]]>
<![CDATA[<400> 457]]>
Lys Tyr Ala Met Asn
1 5
<![CDATA[<210> 458]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-H2]]>
<![CDATA[<400> 458]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Asp
<![CDATA[<210> 459]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的CDR-H3]]>
<![CDATA[<400> 459]]>
His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr
1 5 10
<![CDATA[<210> 460]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的VH]]>
<![CDATA[<400> 460]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 461]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的VL]]>
<![CDATA[<400> 461]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 462]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H2C的VH-VL]]>
<![CDATA[<400> 462]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 463]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-L1]]>
<![CDATA[<400> 463]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 464]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-L2]]>
<![CDATA[<400> 464]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 465]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-L3]]>
<![CDATA[<400> 465]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 466]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-H1]]>
<![CDATA[<400> 466]]>
Ser Tyr Ala Met Asn
1 5
<![CDATA[<210> 467]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-H2]]>
<![CDATA[<400> 467]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Gly
<![CDATA[<210> 468]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的CDR-H3]]>
<![CDATA[<400> 468]]>
His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp Ala Tyr
1 5 10
<![CDATA[<210> 469]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的VH ]]>
<![CDATA[<400> 469]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 470]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的VL]]>
<![CDATA[<400> 470]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 471]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> H1E的VH-VL]]>
<![CDATA[<400> 471]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 472]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-L1]]>
<![CDATA[<400> 472]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 473]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-L2]]>
<![CDATA[<400> 473]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 474]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-L3]]>
<![CDATA[<400> 474]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 475]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-H1]]>
<![CDATA[<400> 475]]>
Arg Tyr Ala Met Asn
1 5
<![CDATA[<210> 476]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-H2]]>
<![CDATA[<400> 476]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Gly
<![CDATA[<210> 477]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的CDR-H3]]>
<![CDATA[<400> 477]]>
His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe Ala Tyr
1 5 10
<![CDATA[<210> 478]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的VH]]>
<![CDATA[<400> 478]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Arg Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 479]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的VL]]>
<![CDATA[<400> 479]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 480]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> G4H的VH-VL]]>
<![CDATA[<400> 480]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Arg Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 481]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-L1]]>
<![CDATA[<400> 481]]>
Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 482]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-L2]]>
<![CDATA[<400> 482]]>
Ala Thr Asp Met Arg Pro Ser
1 5
<![CDATA[<210> 483]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-L3]]>
<![CDATA[<400> 483]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 484]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-H1]]>
<![CDATA[<400> 484]]>
Val Tyr Ala Met Asn
1 5
<![CDATA[<210> 485]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-H2]]>
<![CDATA[<400> 485]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Lys
<![CDATA[<210> 486]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的CDR-H3]]>
<![CDATA[<400> 486]]>
His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp Ala Tyr
1 5 10
<![CDATA[<210> 487]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的VH]]>
<![CDATA[<400> 487]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 488]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的VL]]>
<![CDATA[<400> 488]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Ala Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 489]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> A2J的VH-VL]]>
<![CDATA[<400> 489]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Ala
180 185 190
Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 490]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的CDR-L1]]>
<![CDATA[<400> 490]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<21]]>0> 491]]>
<br/><![CDATA[<211> 7]]>
<br/><![CDATA[<212> PRT]]>
<br/><![CDATA[<213> E1L的CDR-L2]]>
<br/>
<br/><![CDATA[<400> 491]]>
<br/>
<br/><![CDATA[Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 492]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的CDR-L3]]>
<![CDATA[<400> 492]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 493]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的CDR-H1]]>
<![CDATA[<400> 493]]>
Lys Tyr Ala Met Asn
1 5
<![CDATA[<210> 494]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的CDR-H2]]>
<![CDATA[<400> 494]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Ser
<![CDATA[<210> 495]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的CDR-H3]]>
<![CDATA[<400> 495]]>
His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr Ala Tyr
1 5 10
<![CDATA[<210> 496]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的VH]]>
<![CDATA[<400> 496]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 497]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的VL]]>
<![CDATA[<400> 497]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 498]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E1L的VH-VL]]>
<![CDATA[<400> 498]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 499]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-L1]]>
<![CDATA[<400> 499]]>
Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 500]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-L2]]>
<![CDATA[<400> 500]]>
Ala Thr Asp Met Arg Pro Ser
1 5
<![CDATA[<210> 501]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-L3]]>
<![CDATA[<400> 501]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 502]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-H1]]>
<![CDATA[<400> 502]]>
Gly Tyr Ala Met Asn
1 5
<![CDATA[<210> 503]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-H2]]>
<![CDATA[<400> 503]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Glu
<![CDATA[<210> 504]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的CDR-H3]]>
<![CDATA[<400> 504]]>
His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe Ala Tyr
1 5 10
<![CDATA[<210> 505]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的VH]]>
<![CDATA[<400> 505]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Gly Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 506]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的VL]]>
<![CDATA[<400> 506]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Ala Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 507]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> E2M的VH-VL]]>
<![CDATA[<400> 507]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Gly Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Ala
180 185 190
Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 508]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-L1]]>
<![CDATA[<400> 508]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
1 5 10
<![CDATA[<210> 509]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-L2]]>
<![CDATA[<400> 509]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 510]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-L3]]>
<![CDATA[<400> 510]]>
Ala Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 511]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-H1]]>
<![CDATA[<400> 511]]>
Val Tyr Ala Met Asn
1 5
<![CDATA[<210> 512]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-H2]]>
<![CDATA[<400> 512]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Lys
<![CDATA[<210> 513]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的CDR-H3]]>
<![CDATA[<400> 513]]>
His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp Ala Tyr
1 5 10
<![CDATA[<210> 514]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的VH]]>
<![CDATA[<400> 514]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 515]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的VL]]>
<![CDATA[<400> 515]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 516]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F7O的VH-VL]]>
<![CDATA[<400> 516]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 517]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CDR-L1 ]]>
<![CDATA[<400> 517]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
1 5 10
<![CDATA[<210> 518]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CDR-L2 ]]>
<![CDATA[<400> 518]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 519]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CDR-L3 ]]>
<![CDATA[<400> 519]]>
Val Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 520]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CDR-H1]]>
<![CDATA[<400> 520]]>
Ser Tyr Ala Met Asn
1 5
<![CDATA[<210> 521]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CD]]>R-H2
<![CDATA[<400> 521]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Gly
<![CDATA[<210> 522]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的CDR-H3]]>
<![CDATA[<400> 522]]>
His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp Ala Tyr
1 5 10
<![CDATA[<210> 523]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的VH]]>
<![CDATA[<400> 523]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 524]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的VL]]>
<![CDATA[<400> 524]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 525]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12Q的VH-VL]]>
<![CDATA[<400> 525]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 526]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-L1]]>
<![CDATA[<400> 526]]>
Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
1 5 10
<![CDATA[<210> 527]]>
<![CDATA[<211> 7]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-L2]]>
<![CDATA[<400> 527]]>
Gly Thr Lys Phe Leu Ala Pro
1 5
<![CDATA[<210> 528]]>
<![CDATA[<211> 9]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-L3]]>
<![CDATA[<400> 528]]>
Val Leu Trp Tyr Ser Asn Arg Trp Val
1 5
<![CDATA[<210> 529]]>
<![CDATA[<211> 5]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-H1]]>
<![CDATA[<400> 529]]>
Lys Tyr Ala Met Asn
1 5
<![CDATA[<210> 530]]>
<![CDATA[<211> 19]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-H2]]>
<![CDATA[<400> 530]]>
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Asp
<![CDATA[<210> 531]]>
<![CDATA[<211> 14]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的CDR-H3]]>
<![CDATA[<400> 531]]>
His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr
1 5 10
<![CDATA[<210> 532]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的VH]]>
<![CDATA[<400> 532]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 533]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的VL]]>
<![CDATA[<400> 533]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 534]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> I2C的VH-VL]]>
<![CDATA[<400> 534]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
<![CDATA[<210> 535]]>
<![CDATA[<211> 125]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12q的VH]]>
<![CDATA[<400> 535]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<![CDATA[<210> 536]]>
<![CDATA[<211> 109]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12q的VL]]>
<![CDATA[<400> 536]]>
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30
Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45
Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
85 90 95
Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<![CDATA[<210> 537]]>
<![CDATA[<211> 249]]>
<![CDATA[<212> PRT]]>
<![CDATA[<213> F12q的VH-VL]]>
<![CDATA[<400> 537]]>
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp
100 105 110
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val
130 135 140
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
145 150 155 160
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn
165 170 175
Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly
180 185 190
Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
195 200 205
Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
210 215 220
Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe
225 230 235 240
Gly Gly Gly Thr Lys Leu Thr Val Leu
245
Claims (32)
- 一種雙特異性抗體構築體,其包含結合至目標細胞表面上之人類CDH3的一表位簇的第一人類結合域,以及包含結合至T細胞表面上之人類CD3的第二結合域,其中人類CDH3的表位簇內含在人類CDH3的胺基酸位置291-363 (SEQ ID NO: 36)中。
- 如請求項1之抗體構築體,其中第一結合域結合至內含在人類CDH3的胺基酸位置291-327 (SEQ ID NO: 34)的一個表位中。
- 如請求項1之抗體構築體,其中第一結合域結合至內含在人類CDH3的胺基酸位置328-363 (SEQ ID NO: 35)的一個表位中。
- 如請求項3之抗體構築體,其中第一結合域也結合至內含在人類CDH3的胺基酸位置404-440 (SEQ ID NO: 390)的一個表位中。
- 如前述請求項中任一項之抗體構築體,其中第一結合域也結合至獼猴CDH3,較佳結合至食蟹獼猴CDH3。
- 如請求項1、2及5中任一項之抗體構築體,其中第一結合域包含含有CDR-H1、CDR-H2和CDR-H3的VH區,以及含有CDR-L1、CDR-L2和CDR-L3的VL區,其是選自由下列組成之群: a) 如SEQ ID NO: 149中所示的CDR-H1、如SEQ ID NO: 150中所示的CDR-H2、如SEQ ID NO: 151中所示的CDR-H3、如SEQ ID NO: 152中所示的CDR-L1、如SEQ ID NO: 153中所示的CDR-L2以及如SEQ ID NO: 154中所示的CDR-L3; b) 如SEQ ID NO: 159中所示的CDR-H1、如SEQ ID NO: 160中所示的CDR-H2、如SEQ ID NO: 161中所示的CDR-H3、如SEQ ID NO: 162中所示的CDR-L1、如SEQ ID NO: 163中所示的CDR-L2以及如SEQ ID NO: 164中所示的CDR-L3; c) 如SEQ ID NO: 169中所示的CDR-H1、如SEQ ID NO:170中所示的CDR-H2、如SEQ ID NO: 171中所示的CDR-H3、如SEQ ID NO: 172中所示的CDR-L1、如SEQ ID NO: 173中所示的CDR-L2以及如SEQ ID NO: 174中所示的CDR-L3; d) 如SEQ ID NO:179中所述的CDR-H1、如SEQ ID NO: 180中所述的CDR-H2、如SEQ ID NO: 181中所述的CDR-H3、如SEQ ID NO:182中所述的CDR-L1、如SEQ ID NO: 183中所述的CDR-L2以及如SEQ ID NO:184中所述的CDR-L3; e) 如SEQ ID NO:189中所述的CDR-H1、如SEQ ID NO: 190中所述的CDR-H2、如SEQ ID NO: 191中所述的CDR-H3、如SEQ ID NO: 192中所述的CDR-L1、如SEQ ID NO: 193中所述的CDR-L2以及如SEQ ID NO: 194中所述的CDR-L3; f) 如SEQ ID NO: 199中所述的CDR-H1、如SEQ ID NO: 200中所述的CDR-H2、如SEQ ID NO: 201中所述的CDR-H3、如SEQ ID NO: 202中所述的CDR-L1、如SEQ ID NO: 203中所述的CDR-L2以及如SEQ ID NO: 204中所述的CDR-L3; g) 如SEQ ID NO: 209中所述的CDR-H1、如SEQ ID NO: 210中所述的CDR-H2、如SEQ ID NO: 211中所述的CDR-H3、如SEQ ID NO:212中所述的CDR-L1、如SEQ ID NO:213中所述的CDR-L2以及如SEQ ID NO: 214中所述的CDR-L3; h) 如SEQ ID NO: 219中所述的CDR-H1、如SEQ ID NO: 220中所述的CDR-H2、如SEQ ID NO: 221中所述的CDR-H3、如SEQ ID NO:222中所述的CDR-L1、如SEQ ID NO: 223中所述的CDR-L2以及如SEQ ID NO: 224中所述的CDR-L3; i) 如SEQ ID NO: 229中所述的CDR-H1、如SEQ ID NO: 230中所述的CDR-H2、如SEQ ID NO: 231中所述的CDR-H3、如SEQ ID NO: 232中所述的CDR-L1、如SEQ ID NO: 233中所述的CDR-L2以及如SEQ ID NO: 234中所述的CDR-L3;以及 j) 如SEQ ID NO: 239中所述的CDR-H1、如SEQ ID NO: 240中所述的CDR-H2、如SEQ ID NO: 241中所述的CDR-H3、如SEQ ID NO: 242中所述的CDR-L1、如SEQ ID NO: 243中所述的CDR-L2以及如SEQ ID NO: 244中所述的CDR-L3。
- 如請求項1、3、4及5中任一項之抗體構築體,其中第一結合域包含含有CDR-H1、CDR-H2和CDR-H3的VH區和含有CDR-L1、CDR-L2和CDR-L3的VL區,其是選自由下列組成之群: a) 如SEQ ID NO: 279中所述的CDR-H1、如SEQ ID NO: 280中所述的CDR-H2、如SEQ ID NO: 281中所述的CDR-H3、如SEQ ID NO: 282中所述的CDR-L1、如SEQ ID NO: 283中所述的CDR-L2以及如SEQ ID NO: 284中所述的CDR-L3; b) 如SEQ ID NO: 289中所述的CDR-H1、如SEQ ID NO: 290中所述的CDR-H2、如SEQ ID NO: 291中所述的CDR-H3、如SEQ ID NO: 292中所述的CDR-L1、如SEQ ID NO: 293中所述的CDR-L2以及如SEQ ID NO: 294中所述的CDR-L3; c) 如SEQ ID NO: 299中所述的CDR-H1、如SEQ ID NO: 300中所述的CDR-H2、如SEQ ID NO: 301中所述的CDR-H3、如SEQ ID NO: 302中所述的CDR-L1、如SEQ ID NO: 303中所述的CDR-L2以及如SEQ ID NO: 304中所述的CDR-L3; d) 如SEQ ID NO: 309中所述的CDR-H1、如SEQ ID NO: 310中所述的CDR-H2、如SEQ ID NO: 311中所述的CDR-H3、如SEQ ID NO: 312中所述的CDR-L1、如SEQ ID NO: 313中所述的CDR-L2以及如SEQ ID NO: 314中所述的CDR-L3; e) 如SEQ ID NO: 319中所述的CDR-H1、如SEQ ID NO: 320中所述的CDR-H2、如SEQ ID NO: 321中所述的CDR-H3、如SEQ ID NO: 322中所述的CDR-L1、如SEQ ID NO: 323中所述的CDR-L2以及如SEQ ID NO: 324中所述的CDR-L3; f) 如SEQ ID NO: 329中所述的CDR-H1、如SEQ ID NO: 330中所述的CDR-H2、如SEQ ID NO: 331中所述的CDR-H3、如SEQ ID NO: 332中所述的CDR-L1、如SEQ ID NO: 333中所述的CDR-L2以及如SEQ ID NO: 334中所述的CDR-L3; g) 如SEQ ID NO: 339中所述的CDR-H1、如SEQ ID NO: 340中所述的CDR-H2、如SEQ ID NO: 341中所述的CDR-H3、如SEQ ID NO: 342中所述的CDR-L1、如SEQ ID NO: 343中所述的CDR-L2以及如SEQ ID NO: 344中所述的CDR-L3;以及 h) 如SEQ ID NO: 349中所述的CDR-H1、如SEQ ID NO: 350中所述的CDR-H2、如SEQ ID NO: 351中所述的CDR-H3、如SEQ ID NO: 352中所述的CDR-L1、如SEQ ID NO: 353中所述的CDR-L2以及如SEQ ID NO: 354中所述的CDR-L3。
- 如請求項6之抗體構築體,其中第一結合域包含選自如下所述VH區組成之群的VH區:SEQ ID NO: 155、SEQ ID NO: 165、SEQ ID NO: 175、SEQ ID NO: 185、SEQ ID NO: 195、SEQ ID NO: 205、SEQ ID NO: 215、SEQ ID NO: 225、SEQ ID NO: 235,以及SEQ ID NO: 245。
- 如請求項7之抗體構築體,其中第一結合域包含選自如下所述之VH區組成之群的VH區:SEQ ID NO: 285、SEQ ID NO: 295、SEQ ID NO: 305、SEQ ID NO: 315、SEQ ID NO: 325、SEQ ID NO: 335、SEQ ID NO: 345,以及SEQ ID NO: 355。
- 如請求項6或8之抗體構築體,其中第一結合域包含選自如下所述VL區組成之群的VL區:SEQ ID NO: 156、SEQ ID NO: 166、SEQ ID NO: 176、SEQID NO: 186、SEQ ID NO: 196、SEQ ID NO: 206、SEQ ID NO: 216、SEQ ID NO: 226、SEQ ID NO: 236,以及SEQ ID NO: 246。
- 如請求項7或9之抗體構築體,其中第一結合域包含選自如下所述之VL區組成之群的VL區:SEQ ID NO: 286、SEQ ID NO: 296、SEQ ID NO: 306、SEQID NO: 316、SEQ ID NO: 326、SEQ ID NO: 336、SEQ ID NO: 346,和SEQ ID NO: 356。
- 如請求項6、8或10之抗體構築體,其中第一結合域包含選自如下所述之成對VH區與VL區組成之群的VH區及VL區:SEQ ID NO: 155+156、SEQID NO: 165+166、SEQ ID NO: 175+176、SEQ ID NO: 185+186、SEQ ID NO: 195+196、SEQ ID NO: 205+206、SEQ ID NO: 215+216、SEQ ID NO: 225+226、SEQ ID NO: 235+236,和SEQ ID NO: 245+246。
- 如請求項7、9或11之抗體構築體,其中第一結合域包含選自如下所述之成對VH區與VL區組成之群的VH區及VL區:SEQ ID NO: 285+286、SEQID NO: 295+296、SEQ ID NO: 305+306、SEQ ID NO: 315+316、SEQ ID NO: 325+326、SEQ ID NO: 335+336、SEQ ID NO: 345+346,和SEQ ID NO: 355+356。
- 如前述請求項中任一項之抗體構築體,其中抗體構築體呈選自以下組成之群的形式:(scFv) 2、scFv-單域mAb、雙功能抗體(diabodies)或任一前述形式的寡聚體。
- 如請求項6、8、10、12或14中任一項之抗體構築體,其中第一結合域包含選自如下所述組成之群的胺基酸序列:如SEQ ID NO: 157、SEQ ID NO: 167、SEQ ID NO: 177、SEQ ID NO: 187、SEQ ID NO: 197、SEQ ID NO: 207、SEQ ID NO: 217、SEQ ID NO: 227、SEQ ID NO: 237,和SEQ ID NO: 247。
- 如請求項7、9、11、13或14之抗體構築體,其中第一結合域包含選自如下所述組成之群的胺基酸序列:SEQ ID NO:287、SEQ ID NO: 297、SEQ ID NO: 307、SEQ ID NO: 317、SEQ ID NO: 327、SEQ ID NO: 337、SEQ ID NO: 347,和SEQ ID NO: 357。
- 如前述請求項中任一項之抗體構築體,其中第二結合域結合至人類與狨(Callithrix jacchus)、獠狨(Saguinus Oedipus)或松鼠猴(Saimiri sciureus) CD3ε。
- 如請求項6、8、10、12、14、15或17中任一項之抗體構築體,其包含選自如下列所述組成之群的胺基酸序列:SEQ ID NO: 158、SEQ ID NO: 168、SEQ ID NO: 178、SEQ ID NO: 188、SEQ ID NO: 198、SEQ ID NO: 208、SEQ ID NO: 218、SEQ ID NO: 228、SEQ ID NO: 238,和SEQ ID NO: 248。
- 如請求項7、9、11、13、14、16或17中任一項之抗體構築體,其包含選自如下列所示組成之群的胺基酸序列:SEQID NO: 288,SEQ ID NO: 298、SEQID NO: 308、SEQID NO: 318、SEQID NO: 328、SEQ ID NO: 338、SEQ ID NO: 348,和SEQ ID NO: 358。
- 如請求項6、8、10、12、14、15、17或18中任一項之抗體構築體,其包含選自如下列所示組成之群的胺基酸序列:SEQ ID NO: 379、SEQ ID NO: 380、SEQ ID NO: 381、SEQ ID NO: 382、SEQ ID NO: 383、SEQ ID NO: 384、SEQ ID NO: 385、SEQ ID NO: 386、SEQ ID NO: 387、SEQ ID NO: 388、SEQ ID NO: 389、SEQ ID NO: 422、SEQ ID NO: 423、SEQ ID NO: 424、SEQ ID NO: 425、SEQ ID NO: 426和SEQ ID NO: 427。
- 一種編碼如前述請求項中任一項定義之抗體構築體的聚核苷酸。
- 一種包含如請求項21中定義之聚核苷酸的載體。
- 一種宿主細胞,其經如請求項21中所定義之聚核苷酸或如請求項22中所定義之載體轉形或轉染。
- 一種製造如請求項1至20中任一項之抗體構築體的方法,該方法包含在容許如請求項1至20中任一項定義之抗體構築體表現的條件下培養如請求項23中定義之宿主細胞,並且自培養物中回收所生產的抗體構築體。
- 一種醫藥組成物,其包含如請求項1至20中任一項之抗體構築體,或如請求項24之方法製造的抗體構築體。
- 如請求項1或20中任一項之抗體構築體,或如請求項24之方法製造的抗體構築體,其用於預防、治療或改善腫瘤或癌症。
- 如請求項26之抗體構築體,其中癌症選自由下列組成之群:肺癌、頭頸癌,原發性或繼發性CNS腫瘤、原發性或繼發性腦腫瘤、原發性CNS淋巴瘤、脊軸腫瘤、腦幹神經膠質瘤、腦下垂體腺瘤、腎上腺皮質癌、食道癌、結腸癌、乳癌、卵巢癌、NSCLC (非小細胞肺癌)、SCLC (小細胞肺癌)、子宮內膜癌(endometrial cancer)、子宮頸癌、子宮癌、移行細胞癌、骨癌、胰臟癌、皮膚癌、皮膚或眼內黑色素瘤、肝癌、膽管癌、膽囊癌、腎癌、直腸癌、肛區癌、胃癌,胃腸(胃,結腸直腸和十二指腸)癌、小腸癌、膽道癌、尿道癌、腎細胞癌、子宮內膜癌(carcinoma of the endometrium)、甲狀腺癌、睪丸癌、皮膚鱗狀細胞癌、黑色素瘤、胃癌、前列腺癌、膀胱癌、骨肉瘤、間皮瘤、霍奇金病、非霍奇金淋巴瘤、慢性或急性白血病、慢性骨髓性白血病、淋巴細胞性淋巴瘤、多發性骨髓瘤、纖維肉瘤、神經母細胞瘤、視網膜母細胞瘤,與軟組織肉瘤。
- 如請求項27之抗體構築體,其中癌症為鱗狀細胞癌。
- 一種治療、預防或改善腫瘤或癌症的方法,其包含向有需要的個體投與如請求項1至20中任一項之抗體構築體或如請求項24之方法製造的抗體構築體的步驟。
- 如請求項29之方法,其中癌症選自由下列組成之群:肺癌、頭頸癌,原發性或繼發性CNS腫瘤、原發性或繼發性腦腫瘤、原發性CNS淋巴瘤、脊軸腫瘤、腦幹神經膠質瘤、腦下垂體腺瘤、腎上腺皮質癌、食道癌、結腸癌、乳癌、卵巢癌、NSCLC (非小細胞肺癌)、SCLC (小細胞肺癌)、子宮內膜癌、子宮頸癌、子宮癌、移行細胞癌、骨癌、胰臟癌、皮膚癌、皮膚或眼內黑色素瘤、肝癌、膽管癌、膽囊癌、腎癌、直腸癌、肛區癌、胃癌,胃腸(胃,結腸直腸和十二指腸)癌、小腸癌、膽道癌、尿道癌、腎細胞癌、子宮內膜癌、甲狀腺癌、睪丸癌、皮膚鱗狀細胞癌、黑色素瘤、胃癌、前列腺癌、膀胱癌、骨肉瘤、間皮瘤、霍奇金病、非霍奇金淋巴瘤、慢性或急性白血病、慢性骨髓性白血病、淋巴細胞性淋巴瘤、多發性骨髓瘤、纖維肉瘤、神經母細胞瘤、視網膜母細胞瘤,與軟組織肉瘤。
- 如請求項30之方法,其中癌症為鱗狀細胞癌。
- 一種套組,其包含如請求項1至20中任一項之抗體構築體、如請求項24之方法製造的抗體構築體、如請求項22中定義的載體及/或如請求項23中定義的宿主細胞。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15164154 | 2015-04-17 | ||
| EP15164154.5 | 2015-04-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202311292A true TW202311292A (zh) | 2023-03-16 |
| TWI858372B TWI858372B (zh) | 2024-10-11 |
Family
ID=52997289
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111129622A TWI858372B (zh) | 2015-04-17 | 2016-04-18 | Cdh3與cd3之雙特異性抗體構築體 |
| TW105112022A TWI772258B (zh) | 2015-04-17 | 2016-04-18 | Cdh3與cd3之雙特異性抗體構築體 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105112022A TWI772258B (zh) | 2015-04-17 | 2016-04-18 | Cdh3與cd3之雙特異性抗體構築體 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11028171B2 (zh) |
| EP (2) | EP4276116A3 (zh) |
| JP (1) | JP6907124B2 (zh) |
| KR (1) | KR20180023892A (zh) |
| CN (2) | CN107750255B (zh) |
| AR (1) | AR104309A1 (zh) |
| AU (2) | AU2016250023B2 (zh) |
| CA (1) | CA2982682A1 (zh) |
| CL (1) | CL2017002641A1 (zh) |
| DK (1) | DK3283524T3 (zh) |
| EA (1) | EA201792193A1 (zh) |
| ES (1) | ES2945313T3 (zh) |
| FI (1) | FI3283524T3 (zh) |
| HU (1) | HUE061730T2 (zh) |
| IL (1) | IL255076B2 (zh) |
| LT (1) | LT3283524T (zh) |
| MA (1) | MA43197A (zh) |
| MX (1) | MX2017013348A (zh) |
| PL (1) | PL3283524T3 (zh) |
| PT (1) | PT3283524T (zh) |
| SG (2) | SG11201708438WA (zh) |
| SI (1) | SI3283524T1 (zh) |
| TW (2) | TWI858372B (zh) |
| WO (1) | WO2016166360A1 (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102164961B (zh) * | 2008-10-01 | 2014-04-16 | 安进研发(慕尼黑)股份有限公司 | 种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
| IL260920B (en) | 2016-02-03 | 2022-09-01 | Amgen Res Munich Gmbh | Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof |
| ES2905361T3 (es) | 2016-02-03 | 2022-04-08 | Amgen Res Munich Gmbh | Construcciones de anticuerpo de acoplamiento a linfocitos T biespecíficas para BCMA y CD3 |
| JOP20190189A1 (ar) * | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
| CN111010867B (zh) | 2017-05-30 | 2023-05-12 | 俄克拉何马大学董事会 | 抗双皮层蛋白样激酶1抗体及其使用方法 |
| CA3122010A1 (en) * | 2017-12-04 | 2019-06-13 | Coare Holdings, Inc. | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
| UY38041A (es) * | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
| US20200339686A1 (en) * | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
| EP3752630A4 (en) * | 2018-02-14 | 2022-01-05 | Yale University | COMPOSITIONS FOR THE MODULATION OF A TREM OR TREML PROTEIN AND METHOD OF USE |
| WO2020094834A1 (en) * | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| SG11202111329SA (en) * | 2019-06-07 | 2021-12-30 | Adimab Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
| JP7738914B2 (ja) * | 2019-12-05 | 2025-09-16 | アーベル リミテッド | TriAx抗体の組成、その製造方法及び使用方法 |
| US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
| WO2022204516A1 (en) * | 2021-03-26 | 2022-09-29 | The General Hospital Corporation | Humanized mab107 |
| CN117143231B (zh) * | 2022-10-14 | 2025-01-14 | 赛洱生命科学(哈尔滨)有限公司 | 包含干细胞外泌体的药物组合物及其制备方法 |
| WO2024196664A1 (en) * | 2023-03-17 | 2024-09-26 | University Of Washington | Dna vaccine targeting overexpressed antigens in colorectal cancer |
| WO2025077833A1 (en) * | 2023-10-11 | 2025-04-17 | Suzhou Neologics Bioscience Co., Ltd. | Antibodies targeting tim-3 and pd-1 and uses thereof |
| WO2025122927A1 (en) * | 2023-12-06 | 2025-06-12 | Integral Molecular, Inc. | Antibodies directed to claudin 18.2, including bispecific formats thereof |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US556A (en) | 1838-01-09 | Machine foe | ||
| US462837A (en) | 1891-11-10 | Indicating device for water-tanks | ||
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US5013A (en) | 1847-03-13 | Improvement in apparatus for the manufacture of malleable iron | ||
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| EP0320015B1 (en) | 1987-12-09 | 1994-07-20 | Omron Tateisi Electronics Co. | Inductive data communicating apparatus |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2105984C (en) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Cloning and expression of renilla luciferase |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| WO1994010308A1 (en) | 1992-10-23 | 1994-05-11 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
| CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| AU718138B2 (en) | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| CA2271717A1 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
| JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| US6809175B1 (en) | 1997-10-15 | 2004-10-26 | Prof. Dr. Wolf-Georg Forssmann | Cadherin derived growth factor and its use |
| AU765703B2 (en) | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
| US7254167B2 (en) | 1998-10-30 | 2007-08-07 | Broadcom Corporation | Constellation-multiplexed transmitter and receiver |
| JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| CA2445611A1 (en) | 2001-05-31 | 2002-12-05 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
| US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
| CA2847885C (en) | 2001-11-30 | 2022-03-22 | Amgen Fremont Inc. | Transgenic animals bearing human ig.lambda. light chain genes |
| US8486859B2 (en) | 2002-05-15 | 2013-07-16 | Bioenergy, Inc. | Use of ribose to enhance plant growth |
| WO2004110345A2 (en) | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| US7904068B2 (en) | 2003-06-06 | 2011-03-08 | At&T Intellectual Property I, L.P. | System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| EP1703348B1 (en) | 2005-03-14 | 2010-10-13 | Omron Corporation | Programmable controller system |
| KR101203328B1 (ko) | 2005-04-26 | 2012-11-20 | 화이자 인코포레이티드 | P-카드헤린 항체 |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| US8234145B2 (en) | 2005-07-12 | 2012-07-31 | International Business Machines Corporation | Automatic computation of validation metrics for global logistics processes |
| BRPI0604215A (pt) | 2005-08-17 | 2007-04-10 | Biosigma Sa | método para projetar oligonucleotìdeos para técnicas de biologia molecular |
| EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2007122396A (ja) | 2005-10-27 | 2007-05-17 | Hitachi Ltd | ディスクアレイ装置及びその障害対応検証方法 |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US7919297B2 (en) | 2006-02-21 | 2011-04-05 | Cornell Research Foundation, Inc. | Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase |
| CN101432303A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗cdh3抗体的效应物功能来损伤细胞的方法 |
| US7574748B2 (en) | 2006-03-07 | 2009-08-18 | Nike, Inc. | Glove with support system |
| US7990860B2 (en) | 2006-06-16 | 2011-08-02 | Harris Corporation | Method and system for rule-based sequencing for QoS |
| US8430938B1 (en) | 2006-07-13 | 2013-04-30 | The United States Of America As Represented By The Secretary Of The Navy | Control algorithm for autothermal reformer |
| KR101146588B1 (ko) | 2006-08-11 | 2012-05-16 | 삼성전자주식회사 | Fin 구조체 및 이를 이용한 핀 트랜지스터의 제조방법 |
| CN100589507C (zh) | 2006-10-30 | 2010-02-10 | 华为技术有限公司 | 一种拨号提示系统及方法 |
| US7466008B2 (en) | 2007-03-13 | 2008-12-16 | Taiwan Semiconductor Manufacturing Company, Ltd. | BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture |
| KR101773696B1 (ko) | 2007-04-03 | 2017-08-31 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 cd3―입실론 결합 도메인 |
| WO2008124858A2 (en) * | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| CA2687117A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| US8209741B2 (en) | 2007-09-17 | 2012-06-26 | Microsoft Corporation | Human performance in human interactive proofs using partial credit |
| US8464584B2 (en) | 2007-10-19 | 2013-06-18 | Food Equipment Technologies Company, Inc. | Beverage dispenser with level measuring apparatus and display |
| JP5675363B2 (ja) | 2007-11-29 | 2015-02-25 | シェフラー テクノロジーズ アクチエンゲゼルシャフト ウント コンパニー コマンディートゲゼルシャフトSchaeffler Technologies AG & Co. KG | 特に駆動機械と被駆動部との間の出力伝達のための動力伝達装置 |
| US8376279B2 (en) | 2008-01-23 | 2013-02-19 | Aurora Flight Sciences Corporation | Inflatable folding wings for a very high altitude aircraft |
| US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8435749B2 (en) * | 2008-06-30 | 2013-05-07 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies labeled with radioisotope label and uses thereof |
| EP3375790A1 (en) | 2008-10-01 | 2018-09-19 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| RU2477176C1 (ru) | 2009-03-04 | 2013-03-10 | Ниссан Мотор Ко., Лтд. | Катализатор нейтрализации отработанных газов и способ его получения |
| US8463191B2 (en) | 2009-04-02 | 2013-06-11 | Qualcomm Incorporated | Beamforming options with partial channel knowledge |
| JP5723270B2 (ja) | 2009-05-01 | 2015-05-27 | 国立大学法人 東京大学 | 抗カドヘリン抗体 |
| US8748380B2 (en) | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| JP6007420B2 (ja) | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | 親和性成熟に基づく抗体最適化方法 |
| WO2011071541A2 (en) | 2009-12-11 | 2011-06-16 | The Scripps Research Institute | Cadherin modulatory agents |
| WO2011080796A1 (en) | 2009-12-28 | 2011-07-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
| JP2014015396A (ja) * | 2010-10-29 | 2014-01-30 | Perseus Proteomics Inc | 高い親和性を有する抗cdh3抗体 |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2012089373A1 (de) | 2010-12-30 | 2012-07-05 | C. Rob. Hammerstein Gmbh & Co. Kg | Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren |
| CA3019531A1 (en) * | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| CN110272484A (zh) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| US9127061B2 (en) | 2011-06-24 | 2015-09-08 | Perseus Proteomics Inc. | Anti-human P-cadherin (CDH3) recombinant antibody |
| ES2659764T3 (es) | 2011-08-23 | 2018-03-19 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| EP3330283A3 (en) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
| GB2512156A (en) | 2012-11-08 | 2014-09-24 | Novozymes Biopharma Dk As | Albumin variants |
| EP3424952A1 (en) | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
| US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| CN105246764B (zh) * | 2014-01-29 | 2017-06-23 | 日本精工株式会社 | 电动助力转向装置 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| JP2017520575A (ja) * | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
| US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
| CA2991799A1 (en) * | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2016
- 2016-04-18 ES ES16716617T patent/ES2945313T3/es active Active
- 2016-04-18 EP EP23166533.2A patent/EP4276116A3/en active Pending
- 2016-04-18 MA MA043197A patent/MA43197A/fr unknown
- 2016-04-18 JP JP2017554264A patent/JP6907124B2/ja active Active
- 2016-04-18 FI FIEP16716617.2T patent/FI3283524T3/fi active
- 2016-04-18 CA CA2982682A patent/CA2982682A1/en active Pending
- 2016-04-18 AR ARP160101060A patent/AR104309A1/es unknown
- 2016-04-18 TW TW111129622A patent/TWI858372B/zh active
- 2016-04-18 CN CN201680035008.9A patent/CN107750255B/zh active Active
- 2016-04-18 WO PCT/EP2016/058482 patent/WO2016166360A1/en not_active Ceased
- 2016-04-18 CN CN202210971153.5A patent/CN116063541A/zh active Pending
- 2016-04-18 AU AU2016250023A patent/AU2016250023B2/en active Active
- 2016-04-18 US US15/566,444 patent/US11028171B2/en active Active
- 2016-04-18 SG SG11201708438WA patent/SG11201708438WA/en unknown
- 2016-04-18 PT PT167166172T patent/PT3283524T/pt unknown
- 2016-04-18 KR KR1020177033397A patent/KR20180023892A/ko not_active Ceased
- 2016-04-18 LT LTEPPCT/EP2016/058482T patent/LT3283524T/lt unknown
- 2016-04-18 IL IL255076A patent/IL255076B2/en unknown
- 2016-04-18 SI SI201631692T patent/SI3283524T1/sl unknown
- 2016-04-18 MX MX2017013348A patent/MX2017013348A/es unknown
- 2016-04-18 SG SG10201909308X patent/SG10201909308XA/en unknown
- 2016-04-18 PL PL16716617.2T patent/PL3283524T3/pl unknown
- 2016-04-18 EA EA201792193A patent/EA201792193A1/ru unknown
- 2016-04-18 EP EP16716617.2A patent/EP3283524B1/en active Active
- 2016-04-18 TW TW105112022A patent/TWI772258B/zh active
- 2016-04-18 DK DK16716617.2T patent/DK3283524T3/da active
- 2016-04-18 HU HUE16716617A patent/HUE061730T2/hu unknown
-
2017
- 2017-10-17 CL CL2017002641A patent/CL2017002641A1/es unknown
-
2021
- 2021-05-03 US US17/306,051 patent/US11926666B2/en active Active
-
2022
- 2022-05-20 AU AU2022203450A patent/AU2022203450A1/en not_active Abandoned
-
2024
- 2024-02-01 US US18/430,415 patent/US20250092133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7668256B2 (ja) | Dll3及びcd3に結合する二重特異性抗体構築物 | |
| US20250092133A1 (en) | Bispecific antibody constructs for cdh3 and cd3 | |
| CA2991672A1 (en) | Bispecific antibody constructs binding mesothelin and cd3 | |
| JP2023134497A (ja) | Muc17及びcd3に向けられる二重特異性抗体コンストラクト |